<SEC-DOCUMENT>0001193125-13-162909.txt : 20130419
<SEC-HEADER>0001193125-13-162909.hdr.sgml : 20130419
<ACCEPTANCE-DATETIME>20130419161945
ACCESSION NUMBER:		0001193125-13-162909
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20130628
FILED AS OF DATE:		20130419
DATE AS OF CHANGE:		20130419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		13771815

	BUSINESS ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>d524974dpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML><HEAD>
<TITLE>PRE 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>SCHEDULE 14A INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) of
the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed&nbsp;by&nbsp;the&nbsp;Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Filed&nbsp;by&nbsp;a&nbsp;Party&nbsp;other&nbsp;than&nbsp;the&nbsp;Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only&nbsp;(as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167;240.14a-12</FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="6"><B>GALENA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Name of
Registrant as Specified In Its Charter) </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of
Person(s) Filing Proxy Statement, if other than the Registrant) </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box): </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of each class of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fee paid:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials.</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount Previously Paid:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing Party:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date Filed:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g524974g01c85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon 97034 </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April <U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2013 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Stockholder: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You are cordially invited to attend the 2013 Annual Meeting of Stockholders of Galena Biopharma, Inc. to be held at the Multnomah Athletic
Club, 1849 SW Salmon Street, Portland, Oregon at 9:00 A.M., local time, on Friday, June&nbsp;28, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The notice of annual
meeting and the proxy statement on the following pages cover the formal business of the Annual Meeting. At the Annual Meeting, management also will report on our current business and operations and will be available to respond to questions from
stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whether or not you plan to attend, it is important that your shares be represented and voted at the meeting. I
urge you, therefore, to return a signed proxy card or vote by telephone or over the internet, so that you can be sure your votes are properly counted, even if you plan to attend the meeting. Information about voting procedures can be found in the
proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">I hope you will join us. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely,</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g524974g01c85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon 97034 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>To Be Held On June&nbsp;28,
2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notice is hereby given to the holders of common stock of Galena Biopharma, Inc., that the Annual Meeting of
Stockholders will be held on Friday, June&nbsp;28, 2013, at the Multnomah Athletic Club, 1849 SW Salmon Street, Portland, Oregon at 9:00 A.M., local time, for the following purposes: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect two directors to serve until the 2015 annual meeting of stockholders; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve an amendment to our Amended and Restated Certificate of Incorporation; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve an amendment to our 2007 Incentive Plan; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve, by non-binding vote, the compensation of our named executive officers as disclosed in this proxy statement; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To recommend, by non-binding vote, the frequency of future stockholder advisory votes to approve the compensation of our named executive officers; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are pleased to take advantage of Securities and Exchange Commission rules that allow companies to furnish their proxy materials over
the Internet. We are mailing to many of our stockholders a Notice of Internet Availability of Proxy Materials instead of a paper copy of our proxy materials and our 2012 Annual Report on Form&nbsp;10-K. The Notice contains instructions on how to
access those documents and to cast your vote via the Internet. The Notice also contains instructions on how to request a paper copy of our proxy materials and of our 2012 Annual Report on Form 10-K. All stockholders who do not receive a Notice will
receive a paper copy of the proxy materials and of the Annual Report by mail. This process allows us to provide our stockholders with the information they need on a more timely basis, while reducing the environmental impact and lowering the costs of
printing and distributing our proxy materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only those stockholders of record at the close of business on April&nbsp;29,
2013 are entitled to notice of and to vote at the Annual Meeting or any postponement or adjournment thereof. A complete list of stockholders entitled to vote at the Annual Meeting will be available for examination at the Annual Meeting for any
purpose germane to the Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All stockholders are cordially invited to attend the Annual Meeting. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">April <U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ryan M. Dunlap</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Secretary</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g524974g01c85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon 97034 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Meeting of Stockholders </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>To Be Held on June&nbsp;28, 2013
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROXY STATEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This proxy statement is furnished to holders of common stock of Galena Biopharma, Inc., a Delaware corporation (&#147;<B>we</B>, &#147;<B>us</B>,&#148; &#147;<B>our</B>,&#148; &#147;<B>Galena</B>&#148; or
the &#147;<B>company</B>&#148;), in connection with the solicitation of proxies by our board of directors for use at our 2013 Annual Meeting of Stockholders to be held at the Multnomah Athletic Club, 1849 SW Salmon Street, Portland, Oregon at 9:00
A.M., local time, on Friday, June&nbsp;28, 2013, and at any postponement or adjournment thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Notice of Internet
Availability is first being mailed to our stockholders on or about May __, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors is asking you to vote
your shares by completing, signing and returning the accompanying proxy card. If you attend the Annual Meeting in person, you may vote at the Annual Meeting even if you have previously returned a proxy card. Please note, however, that if your shares
are held of record by a broker, bank or other nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder as described in more detail below under &#147;What are the voting rights of the
holders of Galena common stock?&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE
ANNUAL STOCKHOLDERS MEETING TO BE HELD ON JUNE 28, 2013: </B><B><I>This proxy statement, the accompanying proxy card or voting instruction card and our 2012 Annual Report on Form 10-K are also available at
http://www.edocumentview.com/GALE</I></B><B>. </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTIONS AND ANSWERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is a proxy? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
proxy is the legal designation of another person to vote the stock you own. That other person is called a proxy. If you designate someone as your proxy in a written document, that document is also called a proxy or a proxy card. By completing,
signing and returning the accompanying proxy card, you are designating Mark J. Ahn, Ph.D., our President and Chief Executive Officer, and Ryan M. Dunlap, our Director of Finance, Controller and Corporate Secretary, as your proxies for the Annual
Meeting and you are authorizing Dr.&nbsp;Ahn and Mr.&nbsp;Dunlap to vote your shares at the Annual Meeting as you have instructed them on the proxy card. This way, your shares will be voted whether or not you attend the Annual Meeting. Even if you
plan to attend the Annual Meeting, we urge you to vote in one of the ways described below so that your vote will be counted even if you are unable or decide not to attend the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What is a proxy statement? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A proxy statement is a document that we are
required by regulations of the Securities and Exchange Commission, or &#147; <B>SEC</B> ,&#148; to give you when we ask you to sign a proxy card designating Dr.&nbsp;Ahn and Mr.&nbsp;Dunlap as proxies to vote on your behalf. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is in this proxy statement? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This proxy statement describes the proposals on which we would like you, as a stockholder, to vote at the Annual Meeting. It gives you
information on the proposals, as well as other information about us, so that you can make an informed decision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Annual
Meeting, stockholders will act upon the following matters referred to in the attached notice of annual meeting and described in detail in this proxy statement: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the election of two directors; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposal to amend our Amended and Restated Certificate of Incorporation; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposal to approve an amendment to our 2007 Incentive Plan; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposal to approve, by non-binding vote, the compensation of our named executive officers as disclosed in this proxy statement; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposal to recommend, by non-binding vote, the frequency of future stockholder advisory votes to approve the compensation of our named executive officers.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, management will report on our current business operations and respond to appropriate questions
from stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who is entitled to vote at the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only stockholders of record at the close of business on April&nbsp;29, 2013, the record date for the Annual Meeting, will be entitled to
notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. These shares include those (1)&nbsp;held directly in your name as the stockholder of record and (2)&nbsp;held for you as the beneficial owner through a broker,
bank or other nominee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is the difference between holding shares as a stockholder of record and as a beneficial owner? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of our stockholders hold their shares through a broker, bank or other nominee rather than directly in their own name as the
stockholder of record. As summarized below, there are some important distinctions between shares held of record and those owned beneficially. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder of Record</I> &#151; If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., you
are considered the <I>stockholder of record </I>with respect to these shares. As the <I>stockholder of record</I>, you have the right with respect to these shares to grant your voting proxy directly to us or to vote in person at the Annual Meeting.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Beneficial Owner</I> &#151; If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial
owner of shares held in street name and your broker or nominee is considered the <I>stockholder of record</I> with respect to those shares. As the beneficial owner of these shares, you have the right to direct your broker or nominee on how to vote
these shares and are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote these shares in person at the Annual Meeting unless you receive a proxy from your broker or nominee. Your broker
or nominee has provided voting instructions for you to use. If you wish to attend the Annual Meeting and vote in person shares held in street name, please contact your broker or nominee so that you can receive a legal proxy to present at the Annual
Meeting. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What does it mean if I receive more than one proxy card? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It means that you have multiple accounts at our transfer agent or with your broker, bank or other nominee. Please complete, sign and
return all proxy cards to ensure that all your shares are voted. Unless you need multiple accounts for specific purposesd, in the future it may be less confusing if you consolidate as many of your transfer agent or brokerage accounts as possible
under the same name and address. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What constitutes a quorum? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our bylaws provide that the presence, in person or by proxy, at the Annual Meeting of the holders of a majority of outstanding shares of our common stock will constitute a quorum for the transaction of
business. On the record date, there were [&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>&nbsp;] shares of our common stock issued and outstanding, exclusive of treasury shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of determining the presence of a quorum, proxies marked &#147;withhold authority&#148; or &#147;abstain&#148; will be
counted as present. Shares represented by proxies that include so-called broker non-votes, as described in greater detail below, also will be counted as shares present for purposes of establishing a quorum. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What are Abstentions? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An &#147;abstention&#148; occurs when a stockholder sends in a proxy marked &#147;ABSTAIN&#148; regarding a particular proposal.&nbsp;For
purposes of establishing a quorum, shares that stockholders abstain from voting in person and shares covered by proxies received but marked &#147;ABSTAIN&#148; as to any or all proposals count as present at the Annual Meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abstentions will have no effect on the outcome of the vote regarding Proposals 1, 3 and 5. As to Proposals&nbsp;2 and 4, however,
regarding the approval of an amendment to our Amended and Restated Certificate of Incorporation and the approval, by non-binding vote, of the compensation of our named executive officers, respectively, an abstention will have the same effect as a
vote &#147;AGAINST&#148; the proposal. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What are the voting rights of the holders of Galena common stock? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each share of our common stock entitles the holder to one vote on all matters to come before the Annual Meeting. The following voting
rights are associated with respect to the proposals: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 1 regarding the election of directors, you may vote &#147;FOR&#148; or &#147;WITHHOLD&#148; with respect to all or any of the nominees.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 2 regarding the approval of an amendment to our Amended and Restated Certificate of Incorporation, you may vote &#147;FOR,&#148;
&#147;AGAINST&#148; or &#147;ABSTAIN.&#148; If you elect to abstain, it will have the same effect as an &#147;AGAINST&#148; vote. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 3 regarding the approval of an amendment to our 2007 Incentive Plan, you may vote &#147;FOR,&#148; &#147;AGAINST&#148; or
&#147;ABSTAIN.&#148; If you elect to abstain, it will have no effect on the outcome of the vote on this proposal. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 4 regarding the approval, by non-binding vote, of the compensation of our named executive officers as disclosed in this proxy statement,
you may vote &#147;FOR,&#148; &#147;AGAINST&#148; or &#147;ABSTAIN.&#148; If you elect to abstain, it will have the same effect as an &#147;AGAINST&#148; vote. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal&nbsp;5, the advisory vote on the frequency of holding future advisory votes on executive compensation, you may vote &#147;EVERY
YEAR,&#148; &#147;EVERY TWO YEARS,&#148; &#147;EVERY THREE YEARS&#148; or &#147;ABSTAIN.&#148;&nbsp;If you elect to abstain, it will have no effect on the outcome of the vote on this proposal. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How will my shares be voted if I am a stockholder of record? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If you are a stockholder of record and do not vote via the Internet, via telephone or by returning a signed proxy card, your shares will not be voted unless you attend the Annual Meeting and vote your
shares in person. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you vote via the Internet or telephone and do not specify contrary voting instructions, your shares will
be voted in accordance with the recommendations of our board of directors. Similarly, if you sign and submit your proxy card or voting instruction card with no instructions, your shares will be voted in accordance with the recommendations of our
board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If I am a beneficial owner of shares, can my brokerage firm vote my shares? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner and do not vote via the Internet, telephone or by returning a signed voting instruction card to your broker,
your shares may be voted only with respect to so-called routine matters where your broker has discretionary voting authority over your shares. Brokers will have no such discretionary authority to vote on any of the proposals, because such proposals
are not considered routine matters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We encourage you to provide instructions to your brokerage firm by returning your voting
instruction card. This ensures that your shares will be voted at the Annual Meeting with respect to all of the proposals described in this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What happens if a director nominee is unable to stand for election? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
board of directors may reduce the number of nominees or select a substitute nominee. In the latter case, if you have completed, signed and returned your proxy card, Dr.&nbsp;Ahn and Mr.&nbsp;Dunlap can vote your shares for a substitute nominee. They
cannot vote for more than two nominees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Is my vote kept confidential? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proxies, ballots and voting tabulations identifying stockholders are kept confidential and will not be disclosed to third parties except
as may be necessary to meet legal requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What vote is required for the proposals? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following votes are required with respect to the proposals: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 1 regarding the election of directors, the two nominees receiving the greatest number of affirmative votes cast, known as a
&#147;plurality vote,&#148; will be elected. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 2 regarding the approval of an amendment to our Amended and Restated Certificate of Incorporation, the affirmative vote of the holders
of a majority of our outstanding shares of common stock is required. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 3 regarding the approval of an amendment to our 2007 Incentive Plan, the affirmative vote of the holders of a majority of the shares
present, in person or by proxy, and entitled to vote at the Annual Meeting is required. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposals 4 and 5 regarding the approval, by non-binding vote, of the compensation of our named executive officers as disclosed in this proxy
statement and the frequency of future advisory votes on executive compensation, respectively, the affirmative vote of a majority of the shares present, in person or by proxy, and entitled to vote at the Annual Meeting is required.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An automated system administered by our transfer agent will tabulate votes cast by proxy at the Annual
Meeting, and the inspector of elections for the Annual Meeting will tabulate votes cast in person at the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What are the
board&#146;s recommendations? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recommendations of our board of directors are set forth together with the description of
each proposal in this proxy statement. In summary, our board of directors recommends a vote: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<I>FOR&#148;</I> election of the directors named in this proxy statement as described in Proposal 1; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<I>FOR</I>&#148; approval of the amendment to our Amended and Restated Certificate of Incorporation as described in Proposal 2;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<I>FOR</I>&#148; approval of the amendment to our 2007 Incentive Plan as described in Proposal 3; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>&#147;FOR&#148;</I> approval of the compensation of our named executive officers as disclosed in this proxy statement as described in
Proposal&nbsp;4; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#147;EVERY YEAR&#148;</I> for the conduct of an advisory vote on the compensation of our named executive officers as described in Proposal&nbsp;5.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can I attend the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You may attend the Annual Meeting if you are listed as a stockholder of record as of April&nbsp;29, 2013 and bring proof of your identity. If you hold your shares in street name through a broker or other
nominee, you will need to provide proof that you are the beneficial owner of the shares by bringing either a copy of a brokerage statement showing your share ownership as of April&nbsp;29, 2013, or a legal proxy if you wish to vote your shares in
person at the Annual Meeting. In addition to the items mentioned above, you should bring proof of your identity. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can I vote my shares
in person at the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares held directly in your name as the stockholder of record may be voted in person at
the Annual Meeting. If you choose to do so, please bring proof of your identity to the Annual Meeting. Shares held in street name beneficially owned may be voted by you if you receive and present at the Annual Meeting a proxy from your broker or
nominee, together with proof of your identity. Even if you plan to attend the Annual Meeting, we urge you to vote in one of the ways described below so that your vote will be counted if you are unable or decide not to attend the Annual Meeting.
Attendance at the Annual Meeting will not cause your previously granted proxy to be revoked unless you change your proxy instructions as described below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>How can I vote my shares without attending the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whether you
hold shares directly as the stockholder of record or beneficially in street name, you may direct your vote without attending the Annual Meeting. You may vote by granting a proxy or, for shares held in street name, by submitting voting instructions
to your broker or nominee. In most instances, you will be able to do this over the Internet, by telephone or by mail. Please refer to the summary instructions below, the instructions included on the Notice of Internet Availability of the proxy
materials, and if you request printed proxy materials, the instructions included on your proxy card or, for shares held in street name, the voting instruction card provided by your broker or nominee. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By Internet</I> &#151; If you have Internet access, you may submit your proxy from any location in the world by following the Internet voting
instructions on the proxy card or voting instruction card sent to you. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By Telephone</I> &#151; You may submit your proxy by following the telephone voting instructions on the Notice of Internet Availability you received
or by following the telephone voting instructions on the proxy card or voting instruction card sent to you. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By Mail</I> &#151; You may do this by marking, dating and signing your proxy card or, for shares held in street name, the voting instruction card
provided to you by your broker or nominee, and mailing it in the enclosed, self-addressed, postage prepaid envelope. No postage is required if mailed in the United States. <I>Please note that you will be mailed a printed proxy card or printed voting
instruction card only if you request that such printed materials be sent to you by following the instructions in the Notice of Internet Availability for requesting paper copies of the proxy materials</I>. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Can I change my vote or revoke my proxy? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You may change your proxy instructions at any time prior to the vote at the Annual Meeting. For shares held directly as the stockholder of record, you may accomplish this by granting another proxy that is
properly signed and bears a later date, by sending a properly signed written notice to our Corporate Secretary or by attending the Annual Meeting and voting in person. To revoke a proxy previously submitted by telephone or through the Internet, you
may simply vote again at a later date, using the same procedures, in which case your later submitted vote will be recorded and your earlier vote revoked. Attendance at the Annual Meeting will not
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
cause your previously granted proxy to be revoked unless you change your proxy instructions as described above. For shares held beneficially by you, you may change your vote by submitting new
voting instructions to your broker or nominee. All written notices should be addressed as follows: Galena Biopharma, Inc., 310 N. State Street, Suite 208, Lake Oswego, Oregon, 97034, Attention: Corporate Secretary. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Where can I find the voting results of the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will announce preliminary voting results at the Annual Meeting. We will publish final voting results in a Current Report on Form 8-K filed with the SEC within four business days following the Annual
Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If I am a stockholder of record, how do I consent to receive my Annual Meeting materials electronically? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders of record that choose to vote their shares via the Internet will be asked to choose a delivery preference prior to voting
their shares. After entering the access information requested by the electronic voting site, click &#147;Login&#148; and then respond as to whether you would like to receive proxy material via electronic delivery. If you would like to receive future
proxy materials electronically, which we urge you to do, click the applicable button, enter and verify your current email address and then click &#147;Continue.&#148; Stockholders of record with multiple Galena accounts will need to consent to
electronic delivery for each account separately. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>TABLE OF CONTENTS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_1">PROPOSAL 1 &#151; ELECTION OF DIRECTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_2">EXECUTIVE COMPENSATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_3">PROPOSAL 2 &#151; APPROVAL OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_4">PROPOSAL 3 &#151; APPROVAL OF AMENDMENT TO 2007 INCENTIVE PLAN</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_5">PROPOSAL 4 &#151; ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_5a">PROPOSAL 5 &#151; ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE
COMPENSATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_6">STOCKHOLDER PROPOSALS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_7">OTHER MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_8">Annex A</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc524974_9">Annex B</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_1"></A>PROPOSAL 1 &#151; ELECTION OF DIRECTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors currently is comprised of six members divided into three classes of two directors each. Each director serves for a
term ending on the date of the third annual meeting following the annual meeting at which he was elected and until his successor is duly elected and qualified. The terms of the current directors in Class I, Richard Chin, M.D. and Rudolph Nisi, M.D.,
will expire at the date of the annual meeting in 2014. The terms of the current directors in Class II, Mark J. Ahn and Stephen S. Galliker, will expire at the date of the annual meeting in 2015, and the terms of the current directors in Class III,
Sanford J. Hillsberg and Steven A. Kriegsman, will expire at the upcoming Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is information
concerning Messrs. Hillsberg and Kriegsman, the nominees for election as directors at the Annual Meeting, as well as the directors whose terms of office will continue after the Annual Meeting. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;of&nbsp;Directors</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">III</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer, President, Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">I</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">III</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">I</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current Nominees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that Messrs. Hillsberg and Kriegsman will be available and able to serve as directors. In the event that either is unable or unwilling to serve, our board of directors may reduce the number of
nominees or select a substitute nominee. In the latter case, if you have completed, signed and returned your proxy card, Dr.&nbsp;Ahn and Mr.&nbsp;Dunlap can vote your shares for a substitute nominee. They cannot vote for more than two nominees.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Class III &#151; Term Expiring at the Current Annual Meeting </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Sanford J. Hillsberg, J.D.</I> (64)&nbsp;has served as the Chairman of our board of directors since 2007. Mr.&nbsp;Hillsberg has been
an attorney with TroyGould PC since 1976 and is a member of the firm&#146;s Management Committee. Mr.&nbsp;Hillsberg was a founder and until December 2007, served as a director and Secretary of ImmunoCellular Therapeutics, Ltd., a publicly-held
clinical-stage biotechnology company focused on developing immune-based therapies to treat cancer, and its predecessor company since February 2004. Mr.&nbsp;Hillsberg served as a director and Secretary of Duska Therapeutics, Inc., a publicly-held
biopharmaceutical company, and its predecessor company from 1999 until January 2006. He previously served as a director and Vice President of Medco Research, Inc., a then publicly-held pharmaceutical company. Mr.&nbsp;Hillsberg is a member of the
Board of Governors of Cedars-Sinai Medical Center and has also previously served as a Commissioner of the Quality and Productivity Commission of the City of Los Angeles. Mr.&nbsp;Hillsberg holds a B.A. degree from the University of Pennsylvania and
a J.D. degree from Harvard Law School. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Mr.&nbsp;Hillsberg is highly qualified to serve
as a member of the board because of Mr.&nbsp;Hillsberg&#146;s extensive prior experience in founding and serving on the boards of a number of pharmaceutical and biotech companies as well as his expertise in legal and other related matters pertaining
to the operation of publicly traded pharmaceutical companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Steven A. Kriegsman</I> (71)&nbsp;has served as a director
since 2006. Mr.&nbsp;Kriegsman has been a director and the President and Chief Executive Officer of CytRx Corporation since July 2002. He previously served as Director </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and Chairman of Global Genomics from June 2000. Mr.&nbsp;Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of
alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Advanced Tissue Sciences, and Maxim Pharmaceuticals.
Mr.&nbsp;Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr.&nbsp;Kriegsman is a graduate of the Stanford
Law School Directors&#146; College. Mr.&nbsp;Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. He served as a Director and is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. (NYSE, the
company since has been sold). In February 2006, Mr.&nbsp;Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate
Award from the Muscular Dystrophy Association. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Kriegsman has been a guest speaker and lecturer at various
universities, including California Institute of Technology (Caltech), Brown University, and New York University. Mr.&nbsp;Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS
Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the California Health Initiative, and the Palisades-Malibu YMCA, the Carlthorp School, Loyola High School of Los Angeles, and the Westmark School.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Mr.&nbsp;Kriegsman is highly qualified to serve as a member of the board because of
Mr.&nbsp;Kriegsman&#146;s experience as the Chief Executive Officer of a pharmaceutical company and as a director of a number of pharmaceutical companies, his experience as an investment banker for pharmaceutical and biotechnology companies and his
expertise in financial and other related matters pertaining to the operation of publicly traded pharmaceutical companies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE NOMINEES FOR ELECTION AS CLASS III DIRECTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Continuing Directors </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a description of the directors in Class I and Class II, whose terms of office will continue after the Annual Meeting.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Class I &#151; Term Expiring at the 2014 Annual Meeting </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Richard Chin, M.D.</I> (46)&nbsp;has served as a director since 2009. Dr.&nbsp;Chin is a physician with extensive expertise in drug and
biologics development. He has overseen multiple investigational new drug applications and new drug applications/biologic license applications, and has authored several textbooks on clinical trial medicine. Currently, Dr.&nbsp;Chin is the CEO of
Kindred Biosciences, Inc., a private veterinary biotechnology startup. From 2008 until 2011, Dr.&nbsp;Chin served as a director and CEO of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation.
OneWorld Health is engaged in developing drugs for neglected diseases in impoverished countries. From 2006 to 2008, he was the CEO and President of OXiGENE. From 2004 to 2006, Dr.&nbsp;Chin was at Elan Corporation, where he served, among other
roles, as Senior Vice President of Global Development. Dr.&nbsp;Chin also held various clinical and scientific roles for Genentech between 1999 and 2004, including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half
of the clinical programs at Genentech. Dr.&nbsp;Chin began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director. He received a B.A. in Biology, magna cum laude, from Harvard University and the equivalent of
a J.D. with honors from Oxford University in England under a Rhodes Scholarship. Dr.&nbsp;Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California. He currently serves on the Adjunct Faculty of UCSF
Medical School, and serves on the Board of Directors of several biotechnology companies, including Immunocellular Therapeutics, Ltd., a publicly-held clinical-stage biotechnology company focused on developing immune-based therapies to treat cancer.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Dr.&nbsp;Chin is highly qualified to serve as a member
of the board because of Dr.&nbsp;Chin&#146;s expertise with drug development, his experience as both an executive and director of drug development companies, and his scientific and academic qualifications. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rudolph Nisi, M.D.</I> (81)&nbsp;has served as a director since January 2009. Dr.&nbsp;Nisi has held various positions at New York
Westchester Square Medical Center (NYWSMC). In addition to having been on the Active Staff in Internal Medicine/Cardiology since 1963, Dr.&nbsp;Nisi was also Director of Medicine since 1975, Chief of Cardiology since 1975, Chairman of Medical
Critical Care Unit since 1975, President of the Medical Board from 1977 to 1978, Chairman of the Board of Trustees since 1983 and from 1976 to 1978, Chairman of the ER Committee since 1984, and Vice-President of Medical Affairs since 1993. In 2011,
Dr.&nbsp;Nisi retired as Chairman of the board of directors at NYWSMC and now currently holds the position of Vice Chairman. Dr.&nbsp;Nisi was the Chairman of the board of Medco Research Inc. Dr.&nbsp;Nisi has also served as an Attending Physician
at New York Hospital, a Clinical Assistant Professor of Medicine at Cornell University Medical College and an Assistant Dean at Weill Medical College of Cornell University. Dr.&nbsp;Nisi has also served as a director of Tempra Technology, Inc., a
thermal research and development company, since 1997 and on the boards of Touchtone HMO and New York Presbyterian Hospital. Dr.&nbsp;Nisi holds a B.S. degree from Fordham University and a Doctor of Medicine degree from the University of Rome Medical
School in Rome, Italy and is a fellow in the American College of Cardiology. Dr.&nbsp;Nisi is also a graduate of the Director&#146;s college at Stanford University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Dr.&nbsp;Nisi is qualified to serve as a member of the board because of Dr.&nbsp;Nisi&#146;s prior experience as a practicing physician and owner of a hospital, his
prior experience as a director of a number of pharmaceutical and biotechnology companies and his medical and academic qualifications. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Class II &#151; Term Expiring at the 2015 Annual Meeting </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Mark J. Ahn,
Ph.D</I>. (50)&nbsp;has served as our President and Chief Executive Officer since March&nbsp;31, 2011 and as a director since 2007, and served as the President, Chief Financial Officer and director of our former RXi Pharmaceuticals Corporation
subsidiary from September 2011 until April&nbsp;26, 2012. Dr.&nbsp;Ahn is also an adjunct Professor, Biosciences at Creighton University. He brings more than 20 years of experience in the biopharmaceutical industry. Prior to joining Galena, starting
in 2011, Dr.&nbsp;Ahn was Principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies and an Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. He previously
served as Professor and Chair, Science&nbsp;&amp; Technology Management, Victoria University at Wellington, New Zealand. Dr.&nbsp;Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to joining Hana, he served as
Vice President, Hematology and corporate officer at Genentech, Inc., and held positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Dr.&nbsp;Ahn also serves on public and venture capital-backed board of directors for Access
Pharmaceuticals, Mesynthes and ScribesSTAT. Dr.&nbsp;Ahn is the author of over 50 peer-reviewed journal articles and books. Dr.&nbsp;Ahn received a B.A. and M.B.A. from Chaminade University; and M.A. from Victoria University. He was a graduate
fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr.&nbsp;Ahn is a Henry Crown Fellow at the Aspen Institute. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Dr.&nbsp;Ahn is qualified to serve as a member of the board because of Dr.&nbsp;Ahn&#146;s extensive prior experience as both an executive and director of a number of
pharmaceutical and biotech companies and his scientific and academic qualifications as well as his expertise in financial and other related matters pertaining to the operation of publicly traded pharmaceutical companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stephen S. Galliker</I>, CPA (66)&nbsp;has served as a director since 2007. Mr.&nbsp;Galliker served as the Executive Vice President,
Finance and Administration, and Chief Financial Officer of Dyax Corp., a biopharmaceutical company focused on advancing novel biotherapeutics for unmet medical needs, from 1999 until his retirement in July 2008. From 1996 to 1999, Mr.&nbsp;Galliker
was the Chief Financial Officer of Excel Switching Corporation, a developer and manufacturer of open switching platforms for telecommunications networks, and was Excel&#146;s Vice President, Finance and Administration from 1997 to 1999. From 1992 to
1996, Mr.&nbsp;Galliker was employed by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Ultracision, Inc., a developer and manufacturer of ultrasonically powered surgical instruments, where he served as Chief Financial Officer and Vice President of Finance until 1995, when he became
Ultracision&#146;s Chief Operating Officer. Mr.&nbsp;Galliker is also a director of Mitomics, Inc. Incorporated, a privately owned medical device company. Mr.&nbsp;Galliker was also a director of Osteotech, Inc., a medical device company, until its
merger into Medtronic, Inc. in November, 2010. Mr.&nbsp;Galliker is a Certified Public Accountant and received a B.S. from Georgetown University and an M.B.A. from the University of Chicago. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Mr.&nbsp;Galliker is highly qualified to serve as a member of the board because of
Mr.&nbsp;Galliker&#146;s extensive prior experience as the Chief Financial Officer of a pharmaceutical company and as a director of a medical device company, as well as his expertise in auditing and financial and other related matters pertaining to
the operation of publicly traded pharmaceutical companies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Meetings of the Board of Directors and Committees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has a standing Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, as well
as an ad hoc Strategy Committee. The following table provides information concerning the current membership of our board committees: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Audit</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nominating<BR>and&nbsp;Corporate<BR>Governance<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Strategy</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hillsberg is the Chairman of the Strategy Committee. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Galliker is the Chairman of the Audit Committee. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Kriegsman is the Chairman of the Compensation Committee. Mr.&nbsp;Kriegsman served as the third member of our Audit Committee until October 2012.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Nisi is Chairman of the Nominating and Corporate Governance Committee. Dr.&nbsp;Nisi was appointed as a member of the Audit Committee in October 2012.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The functions of each of the committees are described below. During 2012, our board of directors held
seven&nbsp;meetings. Each director attended at least 75% of all board and applicable committee meetings for which he served as a committee member. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Directors are encouraged by our board of directors to attend the Annual Meeting, and all of our incumbent directors attended the last year&#146;s Annual Meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has determined that each of Dr.&nbsp;Chin, Mr.&nbsp;Galliker and Dr.&nbsp;Nisi, the current members of our Audit committee, is &#147;independent&#148; under the current independence
standards of the Nasdaq marketplace rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;). Our board also has determined that Mr. Kriegsman, who served as a member of the Audit Committee
until October 2012, is &#147;independent&#148; under these standards. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee assists our board of directors in
fulfilling its oversight responsibilities relating to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the quality and integrity of our financial statements and reports; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the independent registered public accounting firm&#146;s qualifications and independence; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the performance of our independent auditors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee reviews our financial structure, policies and procedures, appoints the outside independent registered public accounting firm, reviews with the outside independent registered public
accounting firm the plans and results of the audit engagement, approves permitted non-audit services provided by our independent registered public accounting firm, reviews the independence of the auditors and reviews the adequacy of our internal
accounting controls. The Audit Committee&#146;s responsibilities also include oversight activities described below under the &#147;Report of the Audit Committee.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee operates pursuant to a written charter, which is available on our website, <U>www.galenabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has determined that Mr.&nbsp;Galliker, the chairman of our Audit Committee, is an audit committee financial expert. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee held five meetings during 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Audit Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee&#146;s primary duties
and responsibilities are: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appointing, overseeing and, if necessary, replacing the independent auditor; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assisting our board of directors with oversight of the preparation of our financial statements, our compliance with legal and regulatory requirements,
the independent auditor&#146;s qualifications and independence and the performance of our independent auditor; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparing the report the SEC rules require to be included in our annual proxy statement; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">resolving disagreements between management and the auditor regarding financial reporting. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee provides assistance to our board of directors in fulfilling its oversight responsibility to the company&#146;s
stockholders, potential stockholders, the investment community, and others relating to our financial statements and the financial reporting process, the systems of internal accounting and financial controls, the internal audit function, the annual
independent audit of our financial statements and the ethics programs when established by our management and our board of directors. The Audit Committee has the sole authority (subject, if applicable, to stockholder ratification) to appoint or
replace the outside auditors and is directly responsible for determining the compensation of the independent auditors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Audit Committee schedules its meetings with a view to ensuring that it devotes appropriate attention to all of its tasks. In discharging its oversight role, the Audit Committee is empowered to investigate any matter brought to its attention, with
full access to all of our books, records, facilities and personnel, and to retain its own legal counsel and other advisers as it deems necessary or appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of its oversight of our financial statements, the Audit Committee reviewed and discussed with both management and its outside auditors our interim financial statements and annual audited financial
statements that are included in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K, respectively. Our management advised the Audit Committee in each case that all such financial statements were prepared in accordance with accounting
principles generally accepted in the United States of America and reviewed significant accounting issues with the Audit Committee. These reviews included discussion with the outside auditors of matters required to be discussed pursuant to Statement
on Auditing Standards (SAS) No.&nbsp;61 (Communication with Audit Committees), as amended and as adopted by the Public Company Accounting Oversight Board in Rule 3200T. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">BDO USA, LLP (&#147;<B>BDO</B>&#148;) currently serves as our independent registered public
accounting firm and audited our financial statements for the year ended December&nbsp;31, 2012. BDO does not have and has not had any financial interest, direct or indirect, in our company, and does not have and has not had any connection with our
company except in its professional capacity as our independent auditors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee discussed with BDO, which
audited our annual financial statements for 2012, matters relating to its independence, including a review of audit and non-audit fees and the letter and written disclosures made by BDO to the Audit Committee pursuant to Public Company Accounting
Oversight Board (United States) Rule 3526. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit and non-audit services to be provided by BDO are subject to the prior
approval of the Audit Committee. In general, the Audit Committee&#146;s policy is to grant such approval where it determines that the non-audit services are not incompatible with maintaining the independent registered public accounting firm&#146;s
independence and there are costs or other efficiencies in obtaining such services from the independent registered public accounting firm as compared to other possible providers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Audit Committee reviewed initiatives aimed at strengthening the effectiveness of our internal control structure. As part
of this process, the Audit Committee continued to monitor and review staffing levels and steps taken to implement recommended improvements in internal procedures and controls. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Taking all of these reviews and discussions into account, the Audit Committee recommended to our board of directors that the board approve the inclusion of our audited financial statements in our Annual
Report on Form 10-K for the fiscal year ended December&nbsp;31, 2012, filed with the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Respectfully
submitted, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Committee: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker, Chairman </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee is authorized to review and make recommendations to the full board of directors relating to the annual salaries
and bonuses of our officers and to determine in its sole discretion all grants of stock options, the exercise price of each option, and the number of shares to be issuable upon the exercise of each option under our various stock option plans. The
Compensation Committee also is authorized to interpret our stock option plans, to prescribe, amend and rescind rules and regulations relating to the plans, to determine the term and provisions of the respective option agreements, and to make all
other determinations deemed necessary or advisable for the administration of the plans. Our board of directors has determined that each of the current members of the Compensation Committee, Mr.&nbsp;Kriegsman and Drs. Chin and Nisi, is
&#147;independent&#148; under the current independence standards of the Nasdaq marketplace rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The executive officers of
our company are responsible for maintaining the employee compensation policies for our company. Included in this role is to ensure that the policies are sufficiently attractive to retain our company&#146;s existing employees and to incentivize
prospective employees. It is also the responsibility of the executive officers to make recommendations to the Compensation Committee regarding compensation adjustments for our company&#146;s employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee operates pursuant to a written charter, which is available on our website, <U>www.galenabiopharma.com</U>.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee held three meetings during 2012. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Corporate Governance Committee assists our board of directors in discharging its duties relating to corporate governance and the compensation and evaluation of the board. Our board of
directors has determined that each of the current members of the Nominating and Corporate Governance Committee, Drs. Chin and Nisi and Mr.&nbsp;Galliker, are &#147;independent&#148; under the current independence standards of the Nasdaq marketplace
rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The principal responsibilities of the Nominating and Corporate Governance Committee include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identifying individuals qualified to become members of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting, or recommending that our board of directors select, the director nominees for the next annual meeting of stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and recommending to our board of directors a set of applicable corporate governance principles; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing and evaluating our board of directors and its dealings with management and appropriate committees of the board of directors.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Corporate Governance Committee also established a policy under which stockholders may
recommend a candidate for consideration for nomination as a director (which is discussed in greater detail below under &#147;Stockholder Recommendations of Director Candidates&#148;), articulating expectations to each director, reviewing practices
and policies with respect to directors, reviewing functions, duties and composition of the committees of our board of directors, reviewing policies with respect to significant issues of corporate public responsibility, recommending processes for
annual evaluations of the performance of our board of directors and Chief Executive Officer, reporting questions of possible conflicts of interest of board members and overseeing the maintenance and presentation to our board of directors of
management&#146;s plans for succession to senior management positions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Corporate Governance Committee
operates pursuant to a written charter, which is available on our website, <U>www.galenabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nominating and
Corporate Governance Committee held two meetings in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Corporate Governance Committee has not
established any specific minimum qualifications for director candidates or any specific qualities or skills that a candidate must possess in order to be considered qualified to be nominated as a director. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Qualifications for consideration as a director nominee may vary according to the particular areas of expertise being sought as a
complement to the existing board composition. In making its nominations, our Nominating and Corporate Governance Committee generally will consider, among other things, an individual&#146;s business experience, industry experience, financial
background, breadth of knowledge about issues affecting our company, time available for meetings and consultation regarding company matters and other particular skills and experience possessed by the individual. The Nominating and Corporate
Governance Committee does not have a formal diversity policy, but it considers varied backgrounds, experiences and perspectives in evaluating candidates, nominees and fellow directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Strategy Committee </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Strategy Committee acts as the primary contact between management of the Company and our board of directors with respect to developing
and implementing the Company&#146;s long-term strategic plans and, together with management of the Company, reviewing and making recommendations to the board of directors with respect to the material terms and provisions of prospective strategic
transactions, including financing transactions. The current members of the Strategy Committee are Drs. Nisi and Ahn and Messrs. Hillsberg and Kriegsman, with Mr.&nbsp;Hillsberg serving as Chairman. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Strategy Committee met six times in 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive
officers and directors and any person who owns more than 10% of our outstanding shares of common stock are required under Section&nbsp;16(a) of the Exchange Act to file with the SEC initial reports of ownership and reports of changes in ownership of
our common stock and to furnish us with copies of those reports. Based on our review of copies of such forms we have received from our executive officers and directors and any greater than ten-percent beneficial owners, we believe that during the
year ended December&nbsp;31, 2012, all Section&nbsp;16(a) filing requirements applicable to these reporting persons were met in a timely manner, except that the reports of one transaction by each of Dr.&nbsp;Mazanet, Dr.&nbsp;Schwartz,
Mr.&nbsp;Hillsberg and Mr.&nbsp;Dunlap were filed late due to administrative oversight. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Ethics </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted a Code of Ethics applicable to all employees, including our principal executive officer, principal financial officer and
principal accounting officer. A copy of our Code of Ethics is available on our website, <U>www.galenabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Assessment of
Compensation Policies and Practices </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012, the Compensation Committee reviewed the company&#146;s compensation policies
and practices for all employees, including executive officers, and determined that our compensation policies and practices do not create or encourage the taking of risks that are reasonably likely to have a material adverse effect on the company.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Leadership Structure and Role in Risk Oversight </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Currently, the positions of Chairman of the Board of Directors and Chief Executive Officer of our company are held by separate individuals, with Mr.&nbsp;Hillsberg serving as Chairman of the Board and
Dr.&nbsp;Ahn serving as President and Chief Executive Officer. Mr.&nbsp;Hillsberg, an independent director, has served as the Chairman of the Board since 2007, and since 2007 we have continuously had a separate Chief Executive Officer. The Chairman
of the Board is appointed by our board of directors on an annual basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board currently believes that this structure is
best for our company, as it allows Dr.&nbsp;Ahn to focus on the company&#146;s strategy, business and operations, while enabling Mr.&nbsp;Hillsberg to manage our board of directors and serve as a liaison between the board and the company&#146;s
senior management, led by Dr.&nbsp;Ahn. Additionally, our board currently believes the separation of offices is beneficial, because a separate Chairman can provide the Chief Executive Officer with guidance and feedback on his performance and the
Chairman provides a more effective channel for our board to express its views on management. This structure can also enable Mr.&nbsp;Hillsberg and Dr.&nbsp;Ahn, and the other members of our board, to be better informed and to communicate more
effectively on issues, including with respect to risk oversight matters. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board does not believe that a formal policy separating the positions of Chairman of the
Board and Chief Executive Officer is necessary or desirable. Our board continually evaluates our leadership structure and could in the future decide to combine the Chairman and Chief Executive Officer positions if it believes that doing so would
serve the best interests of our company and stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation in Compensation
Decisions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no &#147;interlocks&#148; as defined by SEC rules with respect to any member of the Compensation
Committee. Mr.&nbsp;Kriegsman (Chairman) and Drs. Chin and Nisi are the current members of the Compensation Committee. None of Mr.&nbsp;Kriegsman and Drs. Chin and Nisi have ever served as an officer of the company or acted in such capacity.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transactions with Related Persons </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee is responsible for reviewing and
approving, as appropriate, all transactions with related persons, in accordance with its Charter and the Nasdaq marketplace rules. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Policies and Procedures for Related Person Transactions </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transactions between us and one or more related persons may present risks or conflicts of interest or the appearance of conflicts of
interest. Our Code of Ethics requires all employees, officers and directors to avoid activities or relationships that conflict, or may be perceived to conflict, with our interests or adversely affect our reputation. It is understood, however, that
certain relationships or transactions may arise that would be deemed acceptable and appropriate so long as there is full disclosure of the interest of the related parties in the transaction and review and approval by disinterested directors to
ensure there is a legitimate business reason for the transaction and that the transaction is fair to us and our stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As noted above, our Audit Committee is responsible for reviewing and approving, if appropriate, all transactions with related persons.
The procedures followed by the Audit Committee to evaluate transactions with related persons require: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">that all related person transactions, all material terms of the transactions, and all the material facts as to the related person&#146;s direct or
indirect interest in, or relationship to, the related person transaction must be communicated to the Audit Committee; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">that all related person transactions, and any material amendment or modification to any related person transaction, be reviewed and approved or
ratified by the Audit Committee, as required by Nasdaq marketplace rules. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee will evaluate
related person transactions based on: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information provided by members of our board of directors in connection with the required annual evaluation of director independence;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pertinent responses to the Directors&#146; and Officers&#146; Questionnaires submitted periodically by our officers and directors and provided to the
Audit Committee by our management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">background information on nominees for director provided by the Nominating and Corporate Governance Committee of our board of directors; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other relevant information provided by any of our directors or officers. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with its review and approval or ratification, if appropriate, of any related
person transaction, our Audit Committee is to consider whether the transaction will compromise standards included in our Code of Ethics. In the case of any related person transaction involving an outside director or nominee for director, the Audit
Committee also is to consider whether the transaction will compromise the director&#146;s status as an independent director as prescribed in the Nasdaq marketplace rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of our related person transactions will be disclosed in our filings with the SEC in accordance with SEC rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since 2011, the company has retained TroyGould PC as outside corporate counsel. Sanford J. Hillsberg, the Chairman of the Board of our company, is a senior lawyer with TroyGould PC. In 2012, we expensed
$399,932 in cash and $135,000 in our common stock for services provided by TroyGould PC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Independence </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rule 5605 of the Nasdaq marketplace rules requires that a majority of our board of directors be comprised of independent directors. In
addition, the Nasdaq marketplace rules require that, subject to specified exceptions, each member of our Audit, Compensation and Nominating and Corporate Governance Committees be independent and that our Audit Committee members also satisfy
independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;). Under Rule 5605(a)(2) of the Nasdaq marketplace rules, a director will only qualify as an &#147;independent
director&#148; if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered
independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, our board of directors, or any other board committee: (1)&nbsp;accept, directly
or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. For purposes of determining whether a lawyer
is eligible to serve on an audit committee, Rule 10A-3 under the Exchange Act generally provides that any partner in a law firm that receives payments from the issuer is ineligible to serve on that issuer&#146;s audit committee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has determined that all our non-employee directors, including Mr.&nbsp;Hillsberg, are &#147;independent&#148; as
that term is defined under Rule 5605(a)(2) of the Nasdaq marketplace rules. Our board of directors also determined that each of Drs. Chin and Nisi and Mr.&nbsp;Galliker, the current members of our Audit Committee, and Mr.&nbsp;Kriegsman and Drs.
Chin and Nisi, the current members of our Compensation Committee, satisfy the higher independence standards for Audit Committee members and Compensation Committee members established by the Nasdaq marketplace rules and SEC requirements. In making
such determination, our board of directors considered the relationships that each such non-employee director has with our company and other facts and circumstances our board of directors deemed relevant in determining independence. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Recommendations of Director Candidates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The policy of the Nominating and Corporate Governance Committee is that a stockholder wishing to submit recommendations for director candidates for consideration by the Nominating and Corporate Governance
Committee for election at an annual meeting of stockholders must do so in writing to the Corporate Secretary. Such recommendations must be received at our principal executive offices not less than 60 days and not more than 90 days prior to the
anniversary date of the immediately preceding annual meeting of the stockholders. The written recommendation must include the following information: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a statement that the writer is a stockholder and is proposing a candidate for consideration; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the name and contact information for the candidate; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a statement of the candidate&#146;s business and educational experience; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information regarding the candidate&#146;s qualifications to be a director; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares of our common stock, if any, owned either beneficially or of record by the candidate and the length of time such shares have been
so owned; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the written consent of the candidate to serve as a director if nominated and elected; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information regarding any relationship or understanding between the proposing stockholder and the candidate; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a statement that the proposed candidate has agreed to furnish us all information as we deem necessary to evaluate such candidate&#146;s qualifications
to serve as a director. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to the stockholder giving the notice, the written recommendation must state the
name and address of the stockholder and the number of shares of our common stock which are owned beneficially or of record by the stockholder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any recommendations in proper form received from stockholders will be evaluated in the same manner that potential nominees recommended by our board members or management are evaluated. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Nominations of Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our bylaws specify the procedures by which stockholders may nominate director candidates directly, as opposed to merely recommending a director candidate to the Nominating and Corporate Governance
Committee as described above. Any stockholder nominations must comply with the requirements of our bylaws and should be addressed to: Corporate Secretary, Galena Biopharma, 310 N. State Street, Suite 208, Lake Oswego, Oregon 97034. Such nominations
must be received at our principal executive offices not less than 60&nbsp;days nor more than 90&nbsp;days prior to the anniversary date of the immediately preceding annual meeting of stockholders, provided, however, that if the annual meeting is not
held within 30&nbsp;days before or after such anniversary date, then such nomination shall have been delivered to or mailed and received by the Secretary not later than the close of business on the 10th day following the date on which the notice of
the meeting was mailed or such public disclosure was made, whichever occurs first. Assuming that next year&#146;s annual meeting is held within 30&nbsp;days before or after the anniversary of this year&#146;s Annual Meeting, nominations must be
received between March&nbsp;31, 2014 and April&nbsp;29, 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Communication with Board Members </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders who wish to communicate with our board members may contact us by telephone, facsimile or regular mail at our principal
executive office. Written communications specifically marked as a communication for our board of directors, or a particular director, except those that are clearly marketing or soliciting materials, will be forwarded unopened to the Chairman of the
Board, or to the particular director to which they are addressed, or presented to the full board or the particular director at the next regularly scheduled board meeting. In addition, communications sent to us via telephone or facsimile for our
board of directors or a particular director will be forwarded to our board or the director by an appropriate officer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Beneficial Ownership
of Galena&#146;s Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables set forth information with respect to the beneficial ownership of our
common stock as of April&nbsp;29, 2013, the record date for the Annual Meeting, by: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any person known by us to be the beneficial owner of 5% or more of our common stock, including any &#147;group&#148; as that term is defined in the
Exchange Act; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each current director and each named executive officer identified in the &#147;Summary Compensation Table&#148; under &#147;Executive
Compensation&#148; in this proxy statement who was still serving in such capacity on April&nbsp;29, 2013; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all of our current directors and current executive officers as a group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with SEC rules, and generally includes voting or investment power with respect to
securities. Shares of common stock subject to options, warrants and convertible securities that are exercisable or convertible within 60 days are deemed to be outstanding and to be beneficially owned by the person holding the options, warrants or
convertible securities for the purpose of computing the percentage ownership of the person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise noted, the information below is based on the number of shares of our common stock beneficially owned by each person or
entity at April&nbsp;29, 2013 and the number of shares subject to any options and warrants granted to these individuals that are exercisable within 60 days of April&nbsp;29, 2013, which options and warrants are indicated by footnote. The percentage
ownership is based on 83,104,736 shares of our common stock outstanding on April&nbsp;29, 2012. An asterisk (*)&nbsp;denotes beneficial ownership of less than 1%. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:89pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount and Nature<BR>of&nbsp;Beneficial&nbsp;Ownership</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn,&nbsp;Ph.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">815,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark W. Schwartz,&nbsp;Ph.D.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">817,469</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rosemary Mazanet, M.D., Ph.D.(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ryan M. Dunlap(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin,&nbsp;M.D.(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">337,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">472,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">848,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">867,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi,&nbsp;M.D.(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">516,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group &#151; 9 persons (10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,821,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 715,545 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 354,781 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 16,562 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 462,500 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 712,500 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 862,500 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 512,500 shares of common stock underlying stock options </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 4,102,513 shares of common stock underlying stock options. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers of Galena Biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Set forth below is information
regarding our current executive officers (other than information relating to Mark J. Ahn, our President and Chief Executive Officer, which is set forth above under &#147;Continuing Directors&#148;). Each officer&#146;s age is indicated in
parentheses after his or her name. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Mark W. Schwartz</I> (57), our Executive Vice President and Chief Operating Officer,
joined Galena in April 2011 as part of our acquisition of Apthera where he had been the President and Chief Executive Officer since January 2010. Prior to joining Apthera, Dr.&nbsp;Schwartz served for five years as President and Chief Executive
Officer of Bayhill Therapeutics Inc., a company developing an innovative DNA vaccine platform for the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
treatment of autoimmune diseases, where he completed a successful partnership with Genentech for the development of the company&#146;s type 1 diabetes vaccine. He had also served as President and
Chief Executive Officer of Calyx Therapeutics, Inc., as well as positions of increasing responsibilities at DuPont, Trega Biosciences and Incyte Genomics. Dr.&nbsp;Schwartz is on the advisory board of BayBio, is a past board member of the
Biotechnology Industry Organization (BIO), and is on the faculty of the San State University in their Master of Biotechnology Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Ryan M. Dunlap </I>(43), our Director of Finance, Controller and corporate Secretary, joined Galena in July 2012. From June 2008 to June 2012, Mr.&nbsp;Dunlap served as Senior Manager, Business
Assurance of Moss Adams, LLP, where he provided assurance and consulting services with a focus on technology and life sciences. From 2007 to 2008, Mr.&nbsp;Dunlap served as Director, Financial Accounting of Vestas American Wind Technology, Inc., a
private company that engages in the sale and service of wind turbines in North America, and is a subsidiary of Vestas Wind Systems A/S, a public company that engages in the manufacture and sale of wind turbines and wind power systems globally. Prior
to that, from 2005 to 2007, Mr.&nbsp;Dunlap served as Senior Manager, Business Assurance of KPMG, LLP, where he provided external audit and business advisory services to emerging and established public and private, and international and domestic
entities. Mr.&nbsp;Dunlap has also been the Project Lead, Corporate Audit from 2002 to 2005 of Nike, Inc., where he planned and executed several operational and financial internal audits of various regions and business units. Mr.&nbsp;Dunlap is a
certified public accountant and holds a degree in accounting from the University of Oregon. <I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rosemary Mazanet,
M.D., Ph.D</I>. (57). Dr.&nbsp;Mazanet has served as the Chief Medical Officer of our company since February 2012. She is a life sciences investment professional and executive with management and extensive drug development experience. She has been a
partner at Apelles Investment Management, LLC since 2009, and the President of Rosemary Mazanet LLC, a private consulting firm in the life sciences, since 2004. Prior to that, Dr.&nbsp;Mazanet was a General Partner, Director of Research and CSO of
Oracle Partners, LP, a health care hedge fund. Dr.&nbsp;Mazanet received her M.D. and Ph.D. from the University of Pennsylvania School of Medicine (where she is a Member of the Penn Medicine Board of Trustees and Executive Committee for the Health
System), and trained in Internal Medicine at the Brigham and Women&#146;s Hospital and Oncology at the Dana Farber Cancer Institute, both in Boston. Dr.&nbsp;Mazanet led Clinical Development teams in Oncology and Infectious Disease at Amgen, Inc.
from 1993 to 1998, and has also served as the CEO of several life sciences companies including Breakthrough Therapeutics, LLC, and Access Pharmaceuticals. She has served as a Director for numerous public and private companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_2"></A>EXECUTIVE COMPENSATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary Compensation Table </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the compensation paid or accrued during the fiscal years ended December&nbsp;31, 2012 and 2011 to Mark J. Ahn,
Ph.D., the only individual who served as our principal executive officer during the year ended December&nbsp;31, 2012, and to our two other most highly compensated executive officers who were serving as such as of December&nbsp;31, 2012: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principle Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<BR>($)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation<BR>($)(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D. (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">447,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">367,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,007,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">670,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,148,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rosemary Mazanet, M.D., Ph.D.(5)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President and Chief</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medical Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">274,875</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">185,000</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,245</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">317</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">729,437</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark W. Schwartz, Ph.D. (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">205,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95,920</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">693</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">651,613</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President and</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Operating Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235,673</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,177</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">224,264</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">213</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">568,327</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents year-end bonuses that were accrued at December&nbsp;31, 2011 and paid in January 2012 and year-end bonuses for 2012 that were paid in December 2012.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown reflect the grant date fair value computed in accordance with FASB ASC 718 for the indicated year, adjusted to disregard the effects of any estimate
of forfeitures related to service-based vesting. The assumptions we used in valuing options are described more fully in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and in the footnotes to
our financial statements incorporated in our annual report on Form 10-K for the year ended December&nbsp;31, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown consist of life insurance premiums paid by our company. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Ahn became President and Chief Executive Officer effective March&nbsp;31, 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Mazanet became our full-time Executive Vice President and Chief Medical Officer beginning in April 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Schwartz became our Executive Vice President and Chief Operating Officer effective April&nbsp;13, 2011. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amended and Restated 2007 Incentive Plan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For information regarding our 2007 Incentive Plan, see the discussion of Proposal 3, below, in this proxy statement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding Equity Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows vested and unvested option award grants outstanding on December&nbsp;31, 2012 to each of the named executive officers in the summary compensation table: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable<BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Securities</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Underlying</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unexercised</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Unexercisable</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Price</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expiration</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D. (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">05/23/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/10/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/18/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/15/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/14/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/13/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">274,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/31/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/31/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/12/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark W. Schwartz, Ph.D. (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/13/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President and Chief Operating Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<BR>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000<BR>37,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;<BR>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,500</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.72</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">09/07/2021</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/12/2022</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rosemary Mazanet, M.D., Ph.D.(3)<BR>Executive Vice President and Chief Medical Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<BR>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,500<BR>18,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;<BR>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,500</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131,250</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.72</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.73</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/12/2022</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/13/2022</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Of the stock options shown, all options with an expiration date through January&nbsp;13, 2021 relate to Dr.&nbsp;Ahn&#146;s stock options granted in connection with his
membership on our board of directors prior to his appointment as our President and Chief Executive Officer. All such options were fully vested as of December&nbsp;31, 2012 and have an expiration date of ten years from the date of grant. The stock
option grant as to 400,000 shares with an exercise price of $1.38 was fully vested as to 100,000 shares on March&nbsp;31, 2011 and vests as to the remaining 300,000 shares in 12 equal quarterly installments beginning on June&nbsp;30, 2011. The stock
option grant as to 225,000 shares with a price of $1.38 is a performance based grant which vests as to (i)&nbsp;50,000 shares upon our common stock trading at a minimum closing price of $3 for 30 consecutive trading days, (ii)&nbsp;75,000 shares
upon our common stock trading at a minimum closing price of $4 for 30 consecutive trading days and (iii)&nbsp;100,000 shares upon our common stock trading at a minimum closing price of $5 for 30 consecutive trading days. The stock option grant with
an exercise price of $0.72 vests in 16 equal quarterly installments beginning on April&nbsp;12, 2012. Each of these grants has an expiration date of ten years from the date of grant, in each case so long as Dr.&nbsp;Ahn remains in continuous employ
through the vesting date. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock option grant with an exercise price of $1.28 vests in 12 equal quarterly installments beginning on July&nbsp;13, 2011. The stock option with an exercise price
of $1.00 vested immediately on September&nbsp;7, 2011. The stock option grant with an exercise price of $0.72 vests in 16 equal quarterly installments beginning on April&nbsp;12, 2012. Each of these grants has an expiration date of ten years from
the date of grant and is subject to Dr.&nbsp;Schwartz remaining in our continuous employ through the vesting date. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock option grant with an exercise price of $0.72 vests in 16 equal quarterly installments beginning on April&nbsp;12, 2012. The stock option grant with an
exercise price of $1.73 vests in 16 equal quarterly installments beginning on July&nbsp;13, 2012 and has an expiration date of ten years from the date of grant. The option grant is subject to the employee remaining in our continuous employ through
the vesting date. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employment Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mark J. Ahn, Ph.D. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into an employment agreement
with Dr.&nbsp;Ahn under which he was engaged to serve as our President and Chief Executive Officer. Dr.&nbsp;Ahn&#146;s employment agreement provides for a three-year term expiring on March&nbsp;30, 2014 (the &#147;<B>Term</B>&#148;) and that
Dr.&nbsp;Ahn was entitled to receive an initial annual base salary of $400,000. However, Dr.&nbsp;Ahn&#146;s base salary was subject to reduction to $350,000 if we failed to complete a financing transaction with net proceeds of at least $5 million
by September&nbsp;1, 2011, and was subject to increase to $425,000 upon our completion of a financing transaction with net proceeds of at least $7.5 million by September&nbsp;1, 2011. Our April 2011 underwritten public offering satisfied this
financing criterion. Dr.&nbsp;Ahn will also be eligible to receive an annual performance bonus, the amount of which shall be determined by the board of directors in its sole discretion upon the recommendation of the compensation committee thereof,
provided that the amount of such bonus shall in any event be not less than $100,000 for each year of the Term. Pursuant to the employment agreement, Dr.&nbsp;Ahn also received a signing bonus of $100,000 and was granted a 10-year stock option to
purchase 100,000 shares of our common stock at an exercise price of $1.38 per share. The option was fully vested and immediately exercisable upon the date of grant. Further, Dr.&nbsp;Ahn was granted a 10-year stock option to purchase 525,000 shares
of common stock at an exercise price of $1.38 per share. This option will vest and becomes exercisable (i)&nbsp;as to 300,000 shares in eight equal quarterly installments beginning on June&nbsp;30, 2011, (ii)&nbsp;as to 50,000 shares upon our common
stock trading at a minimum closing price of $3.00 per share for 30 consecutive trading days, (iii)&nbsp;as to 75,000 shares upon our common stock trading at a minimum closing price of $4.00 per share for 30 consecutive trading days, and (iv)&nbsp;as
to 100,000 shares upon our common stock trading at a minimum closing price of $5.00 per share for 30 consecutive trading days, provided, in each case, that Dr.&nbsp;Ahn remains in our continuous employ through such vesting date. The option will vest
in full and become exercisable as to all 525,000 shares upon the occurrence of a &#147;Covered Transaction&#148; as such term is defined in our 2007 Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The employment agreement provides that if we terminate Dr.&nbsp;Ahn&#146;s employment without &#147;cause&#148; (as defined in the employment agreement) during the Term or if he terminates his employment
for &#147;good reason&#148; (as defined in the employment agreement) then he is entitled to: (i)&nbsp;continue receiving his then current annualized base salary and medical benefits for a period of twelve months following such termination (the
&#147;<B>Severance Period</B>&#148;) and (ii)&nbsp;continued vesting for his option for the duration of the Severance Period. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mark W. Schwartz, Ph.D. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into an employment agreement with Dr.&nbsp;Schwartz for a one-year term expiring on April&nbsp;13, 2012. Dr.&nbsp;Schwartz was entitled to receive an initial annual base salary of
$225,000. Dr.&nbsp;Schwartz&#146;s base salary was subject to increase to $275,000 upon our completion of a financing transaction with net proceeds of at least $5 million and to $300,000 upon our completion of a financing transaction with net
proceeds of at least $10 million during the term of the employment agreement. Our April 2011 underwritten public offering satisfied both of these financing criteria. Pursuant to the employment agreement, Dr.&nbsp;Schwartz was granted a 10-year stock
option to purchase 40,000 shares of our common stock at an exercise price of $1.28 per share. The option vests and becomes exercisable in 12 equal quarterly installments beginning on July&nbsp;13, 2011, provided, in each case, that Dr.&nbsp;Schwartz
remains in our continuous employ through such vesting date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;23, 2011, we amended our employment agreement
with Dr.&nbsp;Schwartz to extend the term of the employment agreement to September&nbsp;23, 2013 and to increase his base annual salary from $300,000 to $350,000. On March&nbsp;11, 2013, we further amended our employment agreement with
Dr.&nbsp;Schwartz to extend indefinitely his employment agreement following the expiration of its current term (<I>i.e.</I>, September&nbsp;23, 2013) on an &#147;at will&#148; basis and to provide that the employment agreement may be terminated at
any time after March&nbsp;11, 2013 by us or Dr.&nbsp;Schwartz, with or without &#147;cause&#148; (as defined in the employment agreement). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The March 2013 amendment to Dr.&nbsp;Schwartz&#146;s employment agreement further provides that in the event we terminate Dr.&nbsp;Schwartz&#146;s employment without &#147;cause,&#148; he is entitled to:
(1)&nbsp;continue receiving his then current </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
annualized base salary for a period of six months following the termination; and (2)&nbsp;continued vesting under his option for the duration of the term of the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the employment agreement, if, in connection with a change of control of our company during the term, Dr.&nbsp;Schwartz&#146;s
compensation, benefits, title, or duties are reduced, or if Dr.&nbsp;Schwartz is required to relocate more than 50 miles from his current residence, then Dr.&nbsp;Schwartz shall be considered terminated without cause, in which case he shall be
entitled to the benefits set forth in the preceding paragraph. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rosemary Mazanet, M.D., Ph.D. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into an employment agreement with Dr.&nbsp;Mazanet for a two-year term expiring on April&nbsp;18, 2014. Dr.&nbsp;Mazanet
is entitled to receive an annual base salary of $375,000. Pursuant to the employment agreement, Dr.&nbsp;Mazanet also received a signing bonus of $50,000, and was granted a 10-year stock option to purchase 150,000 shares of our common stock at an
exercise price of $1.73 per share. The option vests and becomes exercisable in 16 equal quarterly installments beginning on the first quarterly anniversary of the grant, provided, in each case, that Dr.&nbsp;Mazanet remains in our continuous employ
through such vesting date. Dr.&nbsp;Mazanet&#146;s employment agreement also entitles her to a target performance bonus of 25% of her base salary in our board of directors sole discretion upon the recommendation of the compensation committee
thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;11, 2013, we amended our employment agreement with Dr.&nbsp;Mazanet to extend indefinitely her
employment agreement following the expiration of its current term (<I>i.e.</I>, April&nbsp;18, 2014) on an &#147;at will&#148; basis and to provide that the employment agreement may be terminated at any time after March&nbsp;11, 2013 by us or
Dr.&nbsp;Mazanet, with or without &#147;cause&#148; (as defined in the employment agreement). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The March 2013 amendment
further provides that in the event we terminate Dr.&nbsp;Mazanet&#146;s employment without &#147;cause,&#148; she is entitled to: (1)&nbsp;continue receiving her then current annualized base salary for a period of six months following the
termination; and (2)&nbsp;continued vesting under her option for the duration of the term of the agreement. Additionally, if, in connection with a change of control of our company during the term, Dr.&nbsp;Mazanet&#146;s compensation, benefits,
title, or duties are reduced, or if Dr.&nbsp;Mazanet is required to relocate more than 50 miles from her current residence, then Dr.&nbsp;Mazanet shall be considered terminated without cause, in which case she shall be entitled to the benefits set
forth in the preceding sentence. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Use of Compensation Consultants </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities. Neither
the Compensation Committee, however, nor our board of directors utilized compensation consultants in establishing executive compensation for 2012 or previous years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2013, our board of directors considered whether to engage a compensation consultant on behalf of the Compensation Committee or our board, but decided against doing so based on our
directors&#146; own extensive experience in the life sciences industry, the relatively uncomplicated nature of our executive compensation program and cost considerations. The Compensation Committee and our board of directors may reconsider the use
of compensation consultants from time to time in future years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the discretion of our board of directors, each non-employee director may be paid such fees for his services as a director and be
reimbursed for his reasonable expenses incurred in the performance of his duties as director as our board of directors determines from time to time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth a summary of the compensation paid to our non-employee
directors in 2012: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>or&nbsp;Paid&nbsp;
in</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Awards&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Awards&nbsp;($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All
Other</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin,&nbsp;M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">229,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi,&nbsp;M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts included under options awards reflect the grant date fair value computed in accordance with ASC 718 for the indicated year, adjusted to disregard the effects of
any estimate of forfeitures related to service-based vesting. The assumptions we used in valuing options are described more fully under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and in the
footnotes to our financial statements contained in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2012. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our director compensation plan, our
non-employee directors received the following cash compensation for service on our board of directors and committees of our board during 2012: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $20,000 for each director, payable quarterly, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $10,000 for the Chairman of each committee of our board of directors other than the Audit Committee, payable quarterly,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $20,000 for the Chairman of the Audit Committee, payable quarterly, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $40,000 for the Chairman of our board of directors, payable quarterly, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,500 per board meeting attended by the director, such fee payable for meetings attended in person or telephonically,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,500 per Audit Committee meeting attended by the Chairman of the committee, such fees payable for meetings attended in person or
telephonically, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,250 per Audit Committee meeting attended by other directors who are members of the committee, such fees payable for meetings attended in
person or telephonically, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,250 per all other committee meetings attended by the Chairman of the committee, such fees payable for meetings attended in person or
telephonically, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,000 per all other committee meeting attended by other directors who are members of the committee, such fees payable for meetings attended
in person or telephonically. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historically, independent directors have also received an annual grant on
options. On January&nbsp;12, 2012, Messrs. Galliker, Hillsberg and Kriegsman and Drs. Chin and Nisi were granted an option to purchase 50,000&nbsp;shares at an exercise price of $0.72 per share. These options will vest and become exercisable in four
equal quarterly installments of 12,500 shares each beginning on the first quarterly anniversary of the grant date. These options have a ten-year term and are exercisable for two years following termination of service as a member of our board of
directors, unless the director is terminated for cause, in which case the options are terminated immediately. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reimbursements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our directors are reimbursed for their expenses incurred in attending board of directors, committee and stockholder meetings, including those for travel, meals and lodging. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax and Accounting Implications </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deductibility of Executive Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of its role, the Compensation Committee reviews and considers the deductibility of executive compensation under Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended (the
&#147;<B>Code</B>&#148;), which provides that corporations may not deduct compensation of more than $1.0 million that is paid to certain individuals. We believe that compensation paid to our executive officers generally is fully deductible for
federal income tax purposes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting for Share-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We account for share-based compensation in accordance with the requirements of FASB ASC 718. This accounting treatment has not
significantly affected our compensation decisions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEPENDENT PUBLIC ACCOUNTANT </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>BDO currently serves as our independent registered public accounting firm and audited our financial statements for the year ended
December&nbsp;31, 2012. BDO does not have and has not had any financial interest, direct or indirect, in our company, and does not have and has not had any connection with our company except in its professional capacity as our independent
auditors.<I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit and non-audit services to be provided by BDO are subject to the prior approval of the Audit Committee.
In general, the Audit Committee&#146;s policy is to grant such approval where it determines that the non-audit services are not incompatible with maintaining the independent registered public accounting firm&#146;s independence and there are costs
or other efficiencies in obtaining such services from the independent registered public accounting firm as compared to other possible providers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect that representatives of BDO will be present at the Annual Meeting, will have an opportunity to make a statement if they so desire, and will be available to respond to appropriate questions.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Fees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fees for 2012 and 2011 billed to us by BDO for professional services rendered for the audit and quarterly reviews of our financial
statements filed by us with the SEC were $257,500 and $235,600, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit-Related Fees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit-related fees for 2012 billed to us by BDO for professional services rendered in connection with certain registration statements and
various financings were $144,390. Audit-related fees for 2011 billed to us by BDO for professional services rendered in connection with certain registration statements and other filings related to the acquisition of Apthera, Inc., various financings
and the spinoff of our former RXi Pharmaceuticals Corporation subsidiary were $172,400. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax Fees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fees for 2012 and 2011 billed to us by BDO for tax compliance, tax advice, and tax planning were $9,650 and $10,500, respectively.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>All Other Fees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as described above, no services were rendered by BDO for 2012 or 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pre-approval Policies and Procedures </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is the policy of our Audit Committee that all services to be provided by our independent registered public accounting firm, including
audit services and permitted audit-related and non-audit services, must be approved in advance by our Audit Committee. Our Audit Committee pre-approved all services provided to us by BDO for 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_3"></A>PROPOSAL 2 &#151; APPROVAL OF AMENDMENT TO AMENDED AND RESTATED
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATE OF INCORPORATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under our Amended and Restated Certificate of Incorporation, there are currently 125,000,000&nbsp;shares of common stock and 5,000,000&nbsp;shares of preferred stock authorized for issuance. On
April&nbsp;24, 2013, our board of directors unanimously approved an amendment to our Amended and Restated Certificate of Incorporation, subject to stockholder approval, to increase the shares of common stock authorized for issuance by
50,000,000&nbsp;shares, which would bring the total number of common shares authorized for issuance to 175,000,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The text
of the amendment is set forth on Annex A to this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purpose and Background of the Amendment </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;29, 2013, there were 83,104,736 shares of common stock outstanding (excluding treasury shares). In addition, as of such
date, approximately 22,478,109 shares were reserved for issuance under outstanding stock options and warrants, and 2,024,437 shares (excluding the additional 4,000,000 shares that will become available for issuance if Proposal 3 is approved at the
Annual Meeting) were reserved for future issuance under our 2007 Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accordingly, as of April&nbsp;29, 2013, we
had only approximately 17,392,718 shares of authorized but unissued and unreserved common stock available for issuance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive
ratably such dividends, if any, as may be declared from time to time by the board of directors out of funds legally available for that purpose. In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled
to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. The holders of common stock have no preemptive or conversion rights or other subscription
rights. There are no redemption or sinking fund provisions applicable to our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purpose of the proposed
increase in the number of authorized shares of common stock is to make such shares available for use by the board of directors as it deems appropriate or necessary. For example, such shares may be needed in the future in order to raise additional
capital or to make contingent milestone payments to the holders of our outstanding contingent value rights, or in connection with possible acquisitions of other companies or businesses, technologies or other assets, or strategic relationships with
corporate partners. We have no present agreement, arrangement, plan or understanding, however, with respect to the issuance of any such additional shares of common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If the amendment to our Amended and Restated Certificate of Incorporation is approved by the stockholders, our board of directors does not intend to solicit further stockholder approval prior to the
issuance of any additional shares of common stock, except as may be required by applicable law or the Nasdaq Marketplace Rules. Holders of our common stock as such have no statutory preemptive rights with respect to issuances of common stock and are
not entitled to dissenter&#146;s rights with respect to the amendment. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS
VOTE &#147;FOR&#148; APPROVAL OF THE AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_4"></A>PROPOSAL 3 &#151; APPROVAL OF AMENDMENT TO 2007 INCENTIVE PLAN
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended and Restated 2007 Incentive Plan of Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) (the
&#147;<B>2007 Incentive Plan</B>&#148;) was originally adopted by our board of directors on February&nbsp;23, 2007 and approved by our stockholders on June&nbsp;19, 2007. The 2007 Incentive Plan was subsequently amended by our board of directors
with the approval of our stockholders to increase the maximum number of shares of common stock available for issuance under the Plan from 2,750,000 originally to 12,500,000 at present. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;24, 2013, our board of directors unanimously approved and recommended for the approval of our stockholders an amendment to
the 2007 Incentive Plan to increase the number of shares of common stock under the 2007 Incentive Plan by 4,000,000 shares, to a total of 16,500,000 shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;29, 2013, there were 9,346,533 shares subject to outstanding options under our 2007 Incentive Plan and only 2,024,437 shares were available for future issuance, without giving effect to
the amendment that is the subject of this Proposal 3. No employee, director or consultant has been selected to receive an award under the amendment subject to this Proposal 3 and no term or condition of any such award has been determined.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believe that the grant of options and other stock awards is an important
incentive for our company&#146;s employees, officers and directors. Our board anticipates, therefore, that our foreseeable needs under the 2007 Incentive Plan will exceed the number of shares of common stock currently available. For example, we
expect to hire a number of new employees in connection with our commercialization of Abstral<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, which we acquired
in March 2013, and to grant stock options under the 2007 Incentive Plan in connection with new hires. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The board of directors
believe that our 2007 Incentive Plan is in the best interest of stockholders and our company, as equity awards granted under the plan help to attract, motivate, and retain talented employees and non-employee directors, align employee and stockholder
interests, link employee compensation with company performance, and maintain a culture based on employee stock ownership. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
complete text of the amendment to our 2007 Incentive Plan is attached as Annex B to this proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of our
2007 Incentive Plan is set forth below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The purpose of the 2007 Incentive Plan is to advance the interests of our company by giving stock-based incentives and other incentives to selected employees, directors and other individuals or entities
who provide services to us or our affiliates who, in the opinion of the Administrator (as defined below), are in a position to make a significant contribution to the success of our company and our affiliates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Administration </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2007
Incentive Plan is administered by the Compensation Committee of our board of directors or by such persons to whom the Compensation Committee may delegate such administration (collectively, with the Compensation Committee, the
&#147;<B>Administrator</B>&#148;). The Administrator has full authority, consistent with the 2007 Incentive Plan, to select who will receive awards, to determine the type of awards to be granted, as well as the amounts, price, terms and conditions
of any awards, to issue shares upon option exercises and interpret option agreements. The Administrator has the right to determine any questions that may arise regarding the interpretation and application of the provisions of the 2007 Incentive Plan
and to make, administer, and interpret such rules and regulations as it deems necessary or advisable. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Participation in the 2007 Incentive
Plan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employees, directors, consultants and advisors who provide services to us and our affiliates, who, in the opinion of
the Administrator, are in a position to make a significant contribution to the success of our company </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or our affiliates are eligible to participate in the 2007 Incentive Plan. However, only employees are eligible to receive so-called incentive stock options, or &#147;<B>ISOs</B>.&#148;
Approximately 17 employees and directors and approximately two consultants and advisors who provide services to us currently are eligible to receive awards under the 2007 Incentive Plan. The maximum number of shares for which awards may be granted
to any participant in any calendar year is the total number of shares of stock then available under the 2007 Incentive Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Types of
Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Administrator in its discretion, may award (i)&nbsp;stock options, (ii)&nbsp;restricted and unrestricted stock,
(iii)&nbsp;stock units including restricted stock units, (iv)&nbsp;performance awards, (v)&nbsp;stock appreciation rights, (vi)&nbsp;securities convertible into stock or otherwise based on stock, and (vii)&nbsp;cash awards, on such terms and
conditions as it determines. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rules Applicable to Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No awards may be made after the tenth anniversary of the date the 2007 Incentive Plan was first adopted by the board, but previously granted awards may continue beyond that date in accordance with their
terms. Unless the Administrator expressly provides otherwise, awards may not be transferred other than by will or applicable laws of descent and distribution, and generally only the participant may exercise an award during such participant&#146;s
lifetime. The Administrator may determine the time or times at which an award will vest or become exercisable. Without limiting the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an award, regardless of any
adverse or potentially adverse tax consequences resulting from such acceleration. Immediately upon termination of employment of an employee, the unvested portion of any stock option will terminate and the balance, to the extent exercisable, will
remain exercisable for the lesser of (i)&nbsp;a period of three months (90 days) or (ii)&nbsp;the period ending on the latest date on which such stock option could have been exercised without regard to this provision. The 2007 Incentive Plan
provides exceptions for the vesting of options upon an individual&#146;s death or if the Administrator determines that the termination of employment resulted for reasons that cast discredit on the individual. The Administrator will determine what
will happen with respect to an award granted to a participant that is outstanding upon the cessation of the participant&#146;s service relationship with our company, including disability, death or retirement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Options </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Administrator will determine the exercise price, if any, of each award requiring exercise. Unless the Administrator determines otherwise, each stock option will have an exercise price not less than the fair market value of the stock subject to the
stock option, determined as of the date of grant. On April&nbsp;18, 2013, the closing price of our common stock as reported on the NASDAQ Stock Market was $2.27. A stock option intended to be an ISO granted to a person who owns (or by application of
attribution rules is deemed to own) more than 10% of the total combined voting power of all classes of stock of our company will have an exercise price equal to 110% of such fair market value. Awards requiring exercise will have a maximum term not
to exceed ten years from the date of grant and will vest, either quarterly or annually and all within four years of grant date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Effect of
Certain Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a consolidation, merger, sale or other disposition of stock in which our company is
not the surviving corporation or that results in the acquisition of all our company&#146;s then outstanding common stock, or sale of substantially all of our company&#146;s assets or a dissolution or liquidation of our company, the Administrator may
provide for the assumption or substitution of some or all outstanding awards by the acquirer or survivor. If the holders of stock will receive a payment upon consummation of the transaction, the Administrator may provide for a &#147;cash-out&#148;
payment with respect to some or all awards or any portion thereof, equal to the excess, if any, of (a)&nbsp;the fair market value of one share of stock times the number of shares of stock subject to the award or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such portion, over (b)&nbsp;the aggregate exercise or purchase price, if any, under the award or such portion (in the case of a stock appreciation right, the aggregate base value above which
appreciation is measured), on such payment and other terms as the Administrator determines. In the absence of an assumption, substitution or cash-out, each award requiring exercise will become fully exercisable, and delivery of shares of stock
deliverable under each outstanding award will be accelerated and such shares will be issued prior to the transaction on a basis that gives the participant a reasonable opportunity, as determined by the Administrator, following exercise of the award
or delivery of the shares, as the case may be, to participate in the transaction as a stockholder. Any shares of stock so issued with respect to an award, in the discretion of the Administrator, may contain such restrictions as the Administrator
deems appropriate to reflect any performance or other vesting conditions to which the award was subject. All such awards will terminate upon consummation of such transaction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Equitable Adjustment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a change in the outstanding common
stock resulting from a stock dividend, stock split, recapitalization, or other capital change, the aggregate number of shares available under the 2007 Incentive Plan, the number of shares available for individual awards, the terms of outstanding
awards, including stock option exercise prices, will be appropriately adjusted by the Administrator. The Administrator may also make adjustments in other circumstances if it determines that the adjustments are necessary to avoid distortion in the
operation of the 2007 Incentive Plan and to preserve the value of awards; provided, however, that no such adjustment shall be made to the maximum share limits, or otherwise to an award intended to be eligible for the performance-based exception
under Section&nbsp;162(m) of the Code, except to the extent consistent with that exception. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the Administrator&#146;s obligation to exercise its discretion consistent with qualifying awards for the performance-based
exception under Section&nbsp;162(m) if such awards are intended to so qualify, the Administrator may at any time or times amend the 2007 Incentive Plan or any outstanding award for any purpose which may at the time be permitted by law, and may at
any time terminate the 2007 Incentive Plan as to any future grants of awards; provided, that except as otherwise expressly provided in the 2007 Incentive Plan, the Administrator may not, without the participant&#146;s consent, alter the terms of an
award so as to materially and adversely affect the participant&#146;s rights under the award, unless the Administrator expressly reserved the right to do so at the time of such award. Any amendments to the 2007 Incentive Plan shall be conditioned
upon stockholder approval only to the extent, if any, such approval is required by law (including the Code and applicable stock exchange requirements). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Certain Federal Income Tax Consequences </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following discussion
summarizes certain U.S. federal income tax consequences of the issuance and receipt of options under the 2007 Incentive Plan under the law as in effect on the date of this proxy statement. The 2007 Incentive Plan provides for the grant of ISOs and
NSOs, as well as other awards. The summary does not purport to cover federal employment tax or other federal tax consequences that may be associated with the 2007 Incentive Plan, nor does it cover state, local or non-U.S. taxes. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Incentive Stock Options </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An optionee realizes no taxable income upon the grant or, for regular tax purposes, upon the exercise of an ISO. However, the exercise of an ISO increases the optionee&#146;s alternative minimum taxable
income by an amount equal to the excess (at the time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price and this increase may give rise to an alternative minimum tax liability. With certain exceptions,
a disposition of shares purchased under an ISO within two years from the date of grant or within one year after exercise produces ordinary income to the optionee (and a deduction to our company) equal to the value
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the shares at the time of exercise less the exercise price. Any additional gain recognized in the disposition is treated as capital gain for which our company is not entitled to a deduction.
If the optionee does not dispose of the shares until after the expiration of these two and one year holding periods, any gain or loss recognized upon a subsequent sale is treated as a long-term capital gain or loss for which our company is not
entitled to a deduction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonqualified Stock Options </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, in the case of a so-called nonqualified stock option, or &#147;<B>NSO</B>,&#148; the optionee has no taxable income at the
time of grant but realizes income in connection with the exercise of the option in an amount equal to the excess (at the time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price; a corresponding
deduction is available to our company; and upon a subsequent sale or exchange of the shares, any recognized gain or loss after the date of exercise is treated as capital gain or loss for which our company is not entitled to a deduction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, an ISO that is exercised by the optionee more than three months after termination of employment is treated as an NSO. ISOs
are also treated as NSOs to the extent they first become exercisable by an individual in any calendar year for shares having a fair market value (determined as of the date of grant) in excess of $100,000. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity Compensation Plan Information as of December&nbsp;31, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of Securities to<BR>be Issued Upon<BR>Exercise&nbsp;of&nbsp;Outstanding<BR>Options, Warrants<BR>and
Rights<BR>(a)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-Average<BR>Exercise of<BR>Outstanding&nbsp;Options,<BR>Warrants and Rights<BR>(b)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of Securities<BR>Remaining Available<BR>for Future Issuance<BR>Under&nbsp;Compensation<BR>Plans
(Excluding<BR>Securities Reflected<BR>in Column (a))</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by our security holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,672,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,702,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by our security holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">TOTAL</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,672,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,702,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#147;FOR&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVAL OF THE AMENDMENT TO OUR 2007 INCENTIVE PLAN </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_5"></A>PROPOSAL&nbsp;4 &#151; ADVISORY VOTE ON EXECUTIVE COMPENSATION
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#147;<B>Dodd-Frank Act</B>&#148;) entitles
our stockholders to vote to approve, on an advisory or non-binding basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with SEC rules. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please refer to the discussion under &#147;Executive Compensation&#148; for a description of the compensation of our named executive
officers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are asking for stockholder approval of the compensation of our named executive officers as disclosed in this
proxy statement in accordance with SEC rules, which include the compensation disclosed under &#147;Executive Compensation,&#148; the compensation tables and the related narrative discussion following the compensation tables. This vote is not
intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the compensation policies and practices described in this proxy statement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This vote is advisory in nature and therefore not binding on us, our Compensation Committee or our board of directors.&nbsp;Our board and
our Compensation Committee, however, value the opinions of our stockholders.&nbsp;To the extent there is any significant vote against the named executive officer compensation as disclosed in this proxy statement, we will consider the
stockholders&#146; concerns, and our Compensation Committee will evaluate whether any actions are necessary to address those concerns. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Vote Required </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
affirmative vote of a majority of the shares of our common stock present in person or represented by proxy and entitled to be voted on this proposal at the Annual Meeting is required for advisory approval of the proposal. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE
OFFICERS AS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DISCLOSED IN THIS PROXY STATEMENT PURSUANT TO THE COMPENSATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DISCLOSURE RULES OF THE SEC. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_5a"></A>PROPOSAL 5 &#151; ADVISORY VOTE ON THE FREQUENCY OF FUTURE
ADVISORY VOTES ON EXECUTIVE COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Dodd-Frank Act also entitles our stockholders to vote, on an advisory or
non-binding basis, on how frequently they would like to cast the advisory vote on the compensation of our named executive officers. By voting on this proposal, stockholders may indicate whether they would prefer that the advisory votes on named
executive officer compensation take place once every year, every two years or every three years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After considering these
three alternatives, our board of directors believes that conducting the advisory vote on executive compensation every year is appropriate for us and our stockholders at this time. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Vote Required </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of a majority of the shares of our
common stock present in person or represented by proxy and entitled to be voted on this proposal at the Annual Meeting is required for advisory approval of the proposal.&nbsp;Our board of directors will consider the outcome of the vote when making
future decisions regarding the frequency of the advisory vote on executive compensation.&nbsp;This vote is advisory in nature and not binding, however, and our board of directors may decide that it is in the best interests of us and our stockholders
to hold an advisory vote more or less frequently than the alternative that is approved by our stockholders. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF
DIRECTORS RECOMMENDS A VOTE &#147;EVERY YEAR&#148; FOR THE CONDUCT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OF AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED
EXECUTIVE OFFICERS. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_6"></A>STOCKHOLDER PROPOSALS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any proposal that a stockholder intends to present in accordance with Rule 14a-8 of Exchange Act of 1934 at our next Annual Meeting of
Stockholders to be held in 2014 must be received by us on or before January 16, 2014. Only proper proposals under Rule 14a-8 which are timely received will be included in the proxy statement in 2014. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_7"></A>OTHER MATTERS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Expenses of Solicitation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will bear the cost of soliciting proxies in
the accompanying form. In addition to the use of the mails, proxies may also be solicited by our directors, officers or other employees, personally or by telephone, facsimile or email, none of whom will be compensated separately for these
solicitation activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have also engaged Georgeson Inc. to assist in the solicitation of proxies. We will pay Georgeson
Inc. a fee of $7,500 plus certain out-of-pocket expenses and flat fees of $6.00 per completed proxy solicitation call and $4.00 per telephone vote. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Delivery of Proxy Materials to Households </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some banks, brokers, and other
nominee record holders may be participating in the practice of &#147;householding&#148; proxy statements and annual reports. This means that only one copy of this notice and/or proxy statement may have been sent to multiple stockholders in your
household. If you would prefer to receive separate copies of a proxy statement or annual report either now or in the future, please contact your bank, broker or other nominee. Upon written request to us at Galena Biopharma, Inc., 310 N. State
Street, Suite 208, Lake Oswego, Oregon 97034, Attention: Corporate Secretary, or by telephone at (855)&nbsp;855-4253, we will promptly deliver without charge, upon oral or written request, a separate copy of the proxy material to any stockholder
residing at an address to which only one copy was mailed. In addition, stockholders sharing an address can request delivery of a single copy of annual reports or proxy statements if they are receiving multiple copies upon written or oral request to
us at the address and telephone number stated above. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Miscellaneous </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management does not intend to present any other items of business and is not aware of any matters other than those set forth in this
proxy statement that will be presented for action at the Annual Meeting. However, if any other matters properly come before the Annual Meeting, the persons named in the enclosed proxy intend to vote the shares of our common stock that they represent
in accordance with their best judgment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_8"></A>ANNEX A </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment to Amended and Restated Certificate of Incorporation of Galena Biopharma, Inc. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;III, Section&nbsp;A of the Amended and Restated Certificate of Incorporation of Galena Biopharma, Inc. shall be amended to
read in its entirety as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>A. Classes of Stock</B>. This Corporation is authorized to issue
180,000,000&nbsp;shares, of which 175,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;<U>Common Stock</U>&#148;) and 5,000,000&nbsp;shares shall be Preferred Stock with a par value of $0.0001 per share
(&#147;<U>Preferred Stock</U>&#148;).&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc524974_9"></A>ANNEX B </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment to Galena Biopharma, Inc. Amended and Restated 2007 Incentive Plan </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reference in Section&nbsp;4(a) of the 2007 Incentive Plan of Galena Biopharma, Inc. (the &#147; Plan &#147;) to the maximum number of
shares of &#147;Stock&#148; (as defined) that may be delivered in satisfaction of &#147;Awards&#148; (as defined) under the Plan shall be 16,500,000 shares. All related Plan information also shall be amended accordingly. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g524974pc_001anew.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g524974pc_001bnew.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Using a <B><U>black ink</U></B> pen, mark your votes with an <B>X</B> as shown in this example. Please do not write outside the designated areas.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="6"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g524974pc_001cnew.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Electronic Voting Instructions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>You can vote by Internet or telephone! </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Available 24 hours a day, 7 days a week!
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Instead of mailing your proxy, you may choose one of the two voting methods outlined below to vote your proxy. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Proxies submitted by the Internet or telephone must be received by 1:00 a.m., Eastern Time, on June 29, 2013. </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR>
<TD VALIGN="top">


<IMG SRC="g524974pc_001d.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vote by Internet</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.63em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="1">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Log on to the Internet and go to<BR><B>www.envisionreports.com/GALE</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.63em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Follow the steps outlined on the secured website.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g524974pc_001e.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vote by telephone</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.63em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="1">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Call toll free 1-800-652-VOTE (8683) within the USA, US territories &amp; Canada any time on a touch tone telephone. There is <B>NO CHARGE </B>to you for the call.</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.63em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Follow the
instructions provided by the recorded message.</FONT></P></TD></TR>
</TABLE> </DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>
 <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>THIS PROXY IS
SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>GALENA BIOPHARMA, INC. AND MAY BE REVOKED BY THE STOCKHOLDER PRIOR TO
ITS EXERCISE. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g524974pc_001f.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS 3">&#113;</FONT><B></B><B>&nbsp;&nbsp;IF YOU HAVE NOT VOTED VIA THE INTERNET
<U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. &nbsp;&nbsp;</B><FONT STYLE="FONT-FAMILY:WINGDINGS 3">&#113;</FONT><B></B><B> </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#000000"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff">&nbsp;A&nbsp;
</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Election of Directors &#151; The Board of Directors recommends a vote FOR the listed nominees.</B></FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nominees</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>FOR</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>WITHHOLD</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">01&nbsp;&#150;&nbsp;Sanford J. Hillsberg</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">02&nbsp;&#150;&nbsp;Steven A. Kriegsman</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>

<TR>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#000000"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff">&nbsp;B&nbsp;
</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Issues &#150; The Board of Directors recommends a vote FOR the following proposals.</B></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>FOR</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>AGAINST</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ABSTAIN</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>FOR</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>AGAINST</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ABSTAIN</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proposal to approve the amendment to our Amended and Restated Certificate of Incorporation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proposal to approve the amendment to our 2007 Incentive Plan.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-family:Times New Roman" SIZE="1">4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proposal to approve, by non-binding vote, the compensation of our named executive officers as disclosed in the proxy statement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1">5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proposal to recommend by non-binding vote, the frequency of future stockholder advisory votes to approve the compensation of our named executive officers.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EVERY YEAR</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EVERY</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>TWO</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>YEARS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EVERY<BR>THREE<BR>YEARS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ABSTAIN</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="24"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>6.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="23"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting and at any and all adjournments or
postponements thereof. The Board of Directors, at present, knows of no other business to be presented at the meeting. </B></FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>

<TR>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#000000"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff">&nbsp;C&nbsp;
</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Non-Voting Items</B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Change of Address</B> &#151; Please print new address below.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Meeting&nbsp;Attendance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Mark box to the right if you plan to attend the Annual Meeting.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:1px"><FONT
SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>

<TR>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#000000"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff">&nbsp;D&nbsp;
</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign
Below</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%"><FONT STYLE="font-family:Times New Roman" SIZE="1">Please sign exactly as your name(s) appear(s) hereon. All
holders must sign. When signing in a fiduciary capacity, please indicate full title as such. If a corporation or partnership, please sign in full corporate or partnership name by authorized person. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Date (mm/dd/yyyy) &#151; Please print date below.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Signature 1 &#151; Please keep signature within the box.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Signature 2 &#151; Please keep signature within the box.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="5">&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g524974pc_001gnew.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g524974g01c85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974g01c85.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0Y^4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````40```&\````&`&<`,``Q
M`&,`.``U`````0`````````````````````````!``````````````!O````
M40`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"^(````!````;P```%$`
M``%0``!J4```"\8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!1`&\#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*25#J'6^F]/<VJ^T&]^C,=GOL<3]&*V^[W?REQ_UA
M_P`8EU;CA],:UEX=^EMD/#(/\U_HWV_Z3_!U_P`O_!I3O_6'ZUU=(NKI:&$A
MP-YL<0=GYS,>IFZVV[^7M^S,_P`):L'+^NV?U*P8W3V_9:['!C7<VF3M'N^C
M7_8_[<7'=5Q/M&_K.(7.8]V[,I<2YU3W'Z0<\N?9C6.^A9_@_P":M_,]2Q]7
M\EM63]J=QB5V9`_K5,=94/[5PK:DI]9Z+EC-Z<S(!W,<^UK''4EC+;*JG?\`
M;;&J\L+ZD#9]6,&EQ'JU,_2LD$M+R;FM>/S7>G8QZW4E*22224I))))3_]#U
M5))))2DDDDE/"=1^KC.C];NS*<<9.!U5CZ=A+IJOL]S6^I6YMK*\MP]!CVO_
M`,-Z:Y?(K^K!,MQLC"=_P5@N9_VWD!EG_LPO8+:J[JW5V-W,=H05YI]:^@8V
M#U2RW(R/2QLEQLIK8POL(.MC1N].ANUY_P!-O_X-)3GX3^ET/%F+U.L/`(->
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M4*<OIN;;A9;2R^EVUP[']US/WF/_`#%WGU/^KS<G/RLOJ%8MQ\6JO`JIL`<Q
MSF!EF7N8[VOV9/\`TUN?6CZI8W7;,7)$5Y6-8R7GA](<'6TO_L[G5K9PL1F'
MBLQV&=LESN[GN)?;8?\`C+'.>DI+7774P5UM#&-$-:T0`/(!22224I))))2D
MDDDE/__2[3(^NO3ZLS(P\?"S\]^(_P!*^S#QGW,;8/I5&QOY[5/#^MC<O)KQ
MF](ZI4;7!OJ78KJZV_RK+;'!K&M5#ZB_T_ZS_P#IVN_($#KW5OKIT6W&R;[L
M!^%EYU6*VFNNPV-9:YT?I'N:UVVMOTMJ2GM%B='^M_1.L]2RNFX-CG7XDDEP
MAKVM=Z3[,=T_I:V6>W<@_73JN5B=/KZ;TP_Y7ZN_[+A`<MG^DY)_=9C4^[U/
M\'^C7)]5Q>H=$IZ;E=(Z)E5#ZN.?NRG&K;?C'=]L]5E5CKOT_P#/_0_1;WI*
M?1.I9]'3<#(ZAD;C3BUNMLVB7;6C<[:-%/#RJLW#HS*9]+)K9;7NT.UX#V[O
M[+EA_67.Q^H?47J&=BN#Z,C!LLK</!S)U_E-_.6A]6__`!.]+_\`"='_`)[8
MDIT++&55NML.UC`7.<>P`EQ7-U_XP>A6L%E%6;?4[Z%M>)<YCA^\QVQ;?5O^
M2LW_`,+V_P#4.7(_5C'^M5WU6Z0>CYF+BXXQ@'-OJ=8\OW/EVYKF-:W;M24]
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MJ=5^K&;797UOIV);CMJ<6^H]EM3_`+$]OOV[O<RK^<V?S?Z1)3__T^WS_J-]
M5>HY=F9EX#7Y%QW6/:^RO<?WG-ILK9N4<3Z@_5+#R:LJCI[1=2X/K<ZRUX#A
MJU^RVQ[-S?ZJI.Z[U07VN]<!M>?]F##Z&WT_M`QOH;_MN[T_^#6_UK+NP^GN
MOH(%@LI:"1.C[:JG_P#0>DIF_I6!9U*OJEE6_-IK-55KBX[&.,O].O=Z3'O_
M`#K-GJ*TYK7-+7`%KA!!U!!5'KF7=A=*R,F@AMM;1M<X2!)#=T?R=RJXV9<W
MJN/BC/9G5756N>`*P6FLU;'33^]ZCOI)*;%'U>Z1C])LZ-3C[>G7![7X^YY$
M6:VM:XOWL:[=^8Y97_C;_4L:#I__`(-?_P"EEI]9R<VJW#IQ'/:;WO#_`$VU
MN=#6.L]OVES*_I-1>DGJ)QW_`+1!%@M<*BX,#C7IZ;K&T.?5O_JI*5T[HO3.
MF8)Z?A4BO$.Z:BYSP=_T];7/=[EC#_%Q]56B*Z;ZV=F,R;PT?U6^JC7=;ZFS
M!ZC:S&<\XUM[*\@&L,:*W.:S=6ZQMKMD>[]&MO+RJ<3&LR;S%=32YQ&IT[-'
MYSG?FI*:71OJ]TOHC;6X#'M]8@V.LL?:3M^B`ZYS]OTE9/3,$]3'537^O"G[
M,+I/\T7>MZ>R?3_G/=]!9_0^KY65=9BY['5WN:+J=U3Z@6F/6H;Z[*_5^R6.
M8QUK?ILMJ3]:S<ZC+KKQS:*A1;=:**Z['^QU3?H7N;_I/\'[TE.EFX6)GXMF
M'F5-OQ[F[;*WB00@7=%Z;=TD=&LJ)Z>VME`I#WM_1L#6LK]1CFV[=K/W_>GZ
M/D7Y/3:+\AP?98"[<W;!;)]-WZ,OKW.KV;]BR+>M]69@9&VH'(:+K:LC:?2%
M-1?._P#-^T,<ST?2_/\`4KO_`-*DIZ&JJNFIE-31756T,8QH@-:T;6M:/Y*J
MNZ1TYW5&]7]&,]E9I%[7.:36=?3L8UPKM;_QC$?*R:L3&LR;C%=32YQY.G9O
M\IRQ>G]<SWU95>52[[8VEV5BU.JLJW`#WXK&V5A]SL:W97ZM3?TGJUI*?__4
M]`;_`$__`*X?RK0R?YH_%O\`U07RTDDI^ILC^8L_JG\BH],_G7?U?XKYG224
M_4UG\Y7\3^1$7RJDDI^HC_1[OB_\JED?S0_K-_ZIJ^6TDE/U(_\`I%7P=^0*
M1_GA_4/Y6KY9224_4F+_`#1_K._ZHIC_`$9_P=_%?+B22GZER/YK^TW_`*IJ
M:S^D5?VOR+Y;224__]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`
M#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!
M`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@`40!O`P$1``(1`0,1`?_=``0`#O_$`'\```("
M`P`"`P`````````````)"`H%!@<"!`$#"P$!`````````````````````!``
M``<!``$#`@(&!@@'`````0(#!`4&!P@`$1()$Q0A-C$BM!5U%D$CM7:V"F&!
M,G,D=!<W1U>'&"@X&1$!`````````````````````/_:``P#`0`"$0,1`#\`
MO\>`>`>`>`>`>`G_`.0;Y5:MQA<J;2V#>B.G2%C@'NH.[[8GL;)#2W`%=R5;
MR.C5Q"4N]XT.0CE"&0E'#)G2HLYRI/Y4'1A:D!36M?-GNW4UD:9ES7"GQ2K6
M^P1M9@I8K@LAK,TI,/D(V/*M,MCGBZDH^<.""*4:FLZ0,/M(^.'J(A8^XOUM
M+<>>JYI+.06EH65N^W0E5E7+@[MU*4FC;EI%#HTD[=J**J.G;^GUEBLJH8QC
M**'$PB(CZ^!*?P#P#P#P#P/_T+_'@'@'@'@1.W_MKG'FV3B:KH=^;.M)LBS5
MK5<CIK9:XZI97LB;Z44VC:5"`XE&Y99P((MG#P&K1980(57W#Z>!6^^0;_,0
MW"LR#K$N48FLP.D,+`D6\7Y5VPOS2@-XB2$'-$:G%H:HV*\R)D/IS*K,9")A
MDA.U;.WSPZBT<%<#JC)BZ,2R]Q8XO-25>L4XWE^C\[FY^1LMLQ*_VJ4%`)UA
M,3\E)6>Y8G<I=<I(N7=*KO(5ZL2*DU#*"Q>R(=>X#TQC3]'4UN343.RP7.-2
MWI$BY?J).+'DN>6.X4&.$!**8&F=$CXAF03![?>X#\!'T#P+NOPC-TX/XRN6
MZ.^=L`N%*I"R-XKJ4BR=S52F+G-2NEQ$1:6+9=9S!3KVH76-D#,W94G2:+U,
M5"%$WIX#7O`/`/`/`/`__]&_QX!X!X!X%4'HOXZXKB;M;1MIIF1M=CYJ[GHN
MDY(>N2DO>DI?%^C-(1;3$5!)7&J3\/?:[5.B)J/=52.D6,HV.Q>648]91-J9
M!%T"'+]7/C*<.OKQN&]'<V2)`]BA\QUN%W*GM3D$?Z[^2=?B:S<7($-^/TAN
M28@!?03F$?<`;[BDWS%GDPVL>2=U9PQFT6<A'2--Z`RV_P"2KV"OS3):*G:K
M.@C&ZID,]`V")=*M)!B]L)6SE!4Y#`8@^O@3&I'QW5NNX7U'UGA5#)T#CEXJ
M=+@Z?S1B]@-N+]S:X;5:AHMCS*)L>?S=R>7#)'%BHT&+YR9XG8FM2>R3)R07
MK8KAZ"JN'>YNN>&.HK)K<DXN25QO=F5EN@<XTIC)P8ZJ$E*/I>5+;HN68)/(
MFQ@^E'2["33;E<Q[A<_M`R"KANL'Z*G)G6^0]DY1$:KDLN*J*Z2"%GJD@=%.
MST>>,E[W$#8V21S_`$EB&`PH+D]S=XB'U43&*(^@2?\``/`/`/`__]*_QX!X
M!X!X&`M%7@;I`2E7L\:WEX*8;_;/V#CW@50I5"+(+(K)&3<,WK-RD19NX1.1
M=LNF15(Y%"%,`4>?E:X#S?`NH+G;M&UQ>B9%L-EE;WG51I=!L-RT.19R2J$A
M<8Q@XERTW*H=A!6:16:H@K8UY%LR4:K&CU"')[P7/7K3S+ELJK(XWAE=<RB1
M2$8:!OR\7MMY:JD`H'?1L!)PT/CD$X5.3ZJ)R5AS(L#C_52!A*4_@=VZ(W*^
M2W$E^I;Z[V5[8;=B;[IUN)IJ2^[CH.H=E<S85G;R..5U[X[]TN&%[^V*@"2:
M39TH)/U1_`.(\'6SY0-O+&0F.,MSZ$IZ#P8S[+0*B3<,@ACN#*"X92#G9X>U
MYG5DG?L/]3ZJK0#B7U$?<`"`7$.`^'-_QZ[1.LZE4>=\7F748=M8Z]A25UB9
M2P-5"&`(2VUN$LZ&'E;E<&!<IF$6X%!4H&0.F;]8`=+X!X!X!X'_T[_'@'@'
M@'@'@*9^8'EVR=2\]4^H5>A2&@O4]0KL2_1@2M#6V@Q=P(YKR.NU%)TLQ2DG
MF=V1S&N9F/7<HM9"HJ3*/JD[%D\9A^>?T%3-6Y<V:^8/L4(ZKF@YY.N868:"
M"YV,@FF;W1L]`.UT6QY2NV!@9-VP=%(4KAJJ0X``B)0"V;\0?Q[1VI[QO>S]
M'TN)NV9XKD^9<-TG.;M!QEEH%JM=,KU+N'1#N8KLXU<QD]'5?:6[@K5-9!5J
M64=.Q.`NF8&(%K*"K\#5H>.KU9A8FO0$0U391,)!QS2*B(QFB'HDTCXYBB@S
M9-D@_P!E-,A2E_H#P,OX!X!X!X!X'__4O\>`>`>`>`>`>`GWY/?B7S/Y!;%@
MVIHJQ=2V7&=(SQ9]9W;999I=L4979A+7K/)]!NFK]TLWBUGCZ$5.0P(OS';G
M$B#Q91,&7XIE4/BN95C.89<S\L.G)2$U-*HE0=6>X6>8D+3>;@_1(8Y4Y*X7
M*:?2;D`,)07=G`!]`#P.I^`>`>`>`>`>!__5LW:'\UG/]5V/8<5S/FCY!.JI
MO!+LXS/6+7R;Q[H>UY[3](CVC=W,T.2M<0HR0+98,CHA7*0)BF!A]4SJ%_6\
M#:\B^5Z,V+3*3F$9\>/RM45Y=IYG!IW/7>)+9EV9U9)P)CNIZZWVW6&/@JY`
MQC5,ZRRBAS+*>T$FZ2[A1)%0&OB/H`B/Z`_$?]7@+#X^^7GBON7H[=N7<!N5
M@F='P9&2D9%Y,P2$34M(KT%<'U"LEMR";"4=JW>J5RVM",W3X&[=$3ND#(BL
MF<3E":/2&]4?EO!-=Z-TM*<6S[$Z!9-(N25:8(2E@/7:K&K2DH6'C7+V.;OI
M$6J!OI)'71*<WH`G#]/@;'CFI5G<LBRW:J4233IVO9U2M/J9)IJFQF"5N^UN
M-M,&259(N'B+.2+&2J0+I$55*FK[B@<P!ZB&WV.PPU2KT[:[&_1BJ]68:4L,
M]*.`4%O&PT*Q7DI1^N"1%%119L6QU#>TIC>TH^@"/X>`E""_S!?"]QBF]ESW
M/^XM*I4D+D\!?:#PYT;8J99V+9RLT&5K\VA2$TW\<HLW.!3B4A@$H@8I3`(`
M$ZN/>]LI[;/>ARO.>CJ:TST((LW(;O@6A8>S?.;%^]#,&=9'0HN'7L[E!*'5
M.[^R(L1D4R/US$%=$#AA=9^2WDG"NT\GX+UZ^N*!NNY9S&Z+E2MAC#-:%;B3
M%OLM+B:8UN!5U&T?>I66J;P6C-XDV1=@5-)%=1TLDW.$H]UV&I<\XCL6_P!]
M)+*T3#\LT#8+HG`,T9&=4J6:U*6NEC+"Q[ATQ0?2QH:%6^V1.NB55;VE$Y`'
MW`'QA&QU+HG#\;Z`H"<LE1-RRO/M@I2<^S2CIU.I:74XFYUPDU'H.GR#&6+#
MS2(.$2++$26]Q0.<`]PA!GOOY=^,?C8NF*4+INT6V-L&XO%S0J=0JQ[.UIM6
M9SL%6WVA:*N5^R_EJCM)BP(H_<D*Y<+'35!%!44C``,S^]9_9_O'[IO]A]M]
MY][]9/[7[3Z7UONOK^[Z7V_T?U_?Z^WV_CZ^G@?_UGO?!B!B;W\Z`&`2F'Y>
M-^,4#^H?JF9Q9DQ_'T'VB00$/]`_AX'*^[NK?FDX3MF'ZC?](X'LF`;MW+CG
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M1514`%$S``2_^-L0_P#SOX._$/\`Z;<R?TA_Y+4KP.I]8B`\L=+@`@/_`,?]
MD_`!]?\`PZL?I^CP*[GQDY_\IMR^+CXYW?$O1G)N+9:SYABFDU"[5C-SU"Y3
M5S&\759_+I2D-98&,BH0D2=F@@U*DJK]5)94Z@@H1-,+$_,M>Z'JV-56'ZLT
MG/\`5]W25G5KI<LMIKN@4%\FO8)-6O-:Y5Y*1EY-DE&U@[)!RHNY4.X>D65+
M[$SD3("$NO.7<1[*^?TW//0M+97G,[S\&UD3?QRYSM)2&EVG<;%2$MM4FF_M
M?UJXUIX?[B.D6IR.&JP?@(D,<A@C9V5T/TK\9?&/9O`'>\S:-OYZV+CWJC*^
M"^_AC5Y![)3<WA.APV><N=7'8M"%B]E.D5!I#640%M9O4!4'ZI'9VP/7^-V[
MU3,_B"X+T:]SC&LTF@_'#R_=+A8Y-04HZ!J]7YGI$Y/S+]0`,8C.,BF*JZ@@
M`B!"#Z`/@5V,N8:SVB?JGY"]B^-?H;M*G?)KGEUPKGBMU.TX?6UN;>#:K)&@
M:`U%'5[]45830]BL[12Y"M$I.2-%V31^B[`[OT\"0'QR;9TKMOQ2?(%\3^Z4
M_0*K\B7'_)FPX3"46=F:NCJ5\S[5\-N#?F6RP;HEQ-".)QFQEX^"4=IRYHY!
M5*/66D"F=B8@?__7M*[U\&_Q8=,:Q<-PV+DZ!GM0T"0++W:S0&B;%G@6>:^B
MF@M.2\+G.AU2O.IQZ1(!<O1:?<NU/518ZAQ$PA@\G^!+XEL2TJD:]GO(4$TO
MV<62+N%)EK)IFV7]C`VJ#<D>P=A;UJ_:59JPXEH1^F1PS679JG:N4R*I"50A
M3`$_)KEC!K)TC2^N+#0D9WH'.,]G\NSV]2\[9Y%&C4^U/#O+.C4:@[FE:179
MZQ`H9N^F6D:E,NF`_9J.C-?ZGP.\/V#&58O(R39M9"-D6KAC(,'K=)TR?,G:
M1T'3-VU7(H@Y:N4%#$43.4Q#D,("`@/@0]I/Q]<B9SRG<^(*9D:<)RQ?HZ^P
M]CR!*Z:$ZA#0VG.WS^[PT)*/K8ZLM5AYE])N5@:Q;UFW:JKJ';D2,<PB$!T_
M\M[\,:1"))<=?323*4B::>_=.D(F0@`4A"$+M`%(0I0```/P`/`9-SKQGS5R
MCAKKFO",R:T_$7R]I7?4.0L-NN[%Z:[%.2TI/9&_3]GG';2835,11!1T9$"&
M$I2E*(AX"RVW^7(^+&+2%E7,WW6I0B:KA1A6ZKUYU%"5V'2<N%7)V</$M=8!
MNP9$56,)$R?@7U\"?'&OQ[<Q\&,+PQYVKUWC3Z*\AGEJD]`UC3-;F71:^@^0
MB&#&5TNTVAY#Q;09-RI]NT,BFJJL)U`.8">T.RK\TXFXZ59=?K4E(W1,?BKG
MG=GHO[[L95DL<>79/17--_ETLN%2.DK<DBO?O#,!D`$/I@N"7]7X&S[-B^4]
M#YA<\7VZA5O3,MT&%<0%OI=KCTI&'F(UQ[3@!DS^U9F_9.$R.&CMN=)VR=))
MKMU$UDR*%#EEOXRYQO7*$?Q!8Z"[7Y@B\TI6.M,RC;QH-?+_`-,<]CX2(J]-
M<V^OVJ,O;V(;Q->:M715I10\DV(=)X9=-98J@2$JM6K=&K%=I5.@HJL5&H04
M36*O6X-DWC(6OUV!8(1<+"Q$<T(DU81D7'-4T$$4RE(DD0I2@``'@<+?<B<\
M2'4,'V>?.T6?3$#G+W(T-1A[#;()]+9L_=KR"E0MT#"SK"IW>*;2*_W+4)E@
M^49N$D54#)G01,0/_]![LGW9U`SO5\?$U!DUAJQWTZY^8UF1:\QA4O\`IHWZ
M]C,2!D\@27)/IA],'I+TX$<LX90QY#V.`$6@**@#<NS]6N.*\_R^A4-TS8V5
MGHN!5Q%=^Q0DFQ8O0=^S#/;*F9HX`4C++5NTNTTC_I25,50OZQ0\#Q[>UFW8
M9RKLNJT-_&Q-MJ5>8KPLO,,49.-AUY.PPT&O,.F#E5)HY+$LY-1R4JP_0]Z0
M"H!B`8HA'_,]BN<=U/D>4-^M:CTY4M'S';K)8V$5!9,TDJ9)YR^R@M;DDGV8
M_162;RQ+D^04(]*=)02%%/T,0?`Z+V-HNSU2S\Z4K&9*W1S_`$^\7B*L04&L
MY/9[<XB:QFECMC=.,;;-/UJEMD"R48D9PH=V1?Z("5(IC#Z>!T?D]YT6[H%I
M_P#<JS?-K0UTVX-*.XFV.?1=JE<L2_=IJC*6^,RRQVFBL+"NJH[(HFQ=>WZ"
M:1CD*H)_4(-6_M?IB"P[L>WPN)6FR*XYIO3=6IFQ1\MBK2D5Z$S*VV"(KCF8
MJ$UH,9>)DM78QY`?>R(67>F2,*15?<7U!H6J:=4<8S:Y:I?)!1A4Z)7G]BFG
M#=NH\?KH,D1.E'Q,<@!G,M.2SD2-6+-$#+O'BR:*13**%*(00X=ZVU+5KC;L
MIZ(KEAJ&BR-;C-ASA*PXWJ6+MGU2E"QS;1\NA&>IU.J/[U(\[6Z781SZ?9IB
MWE(V=BG!B)KG<D*'W]G;7MF>ZS3*UFTCK;6GM<%U_7+PUQ',,DU*]KFHMNR^
M&9+(U_49N'</F2$?;'G_``D*1Y).7!D@*@8`$0"2G'M^O.I<V99H6BRL/.VB
MVQ$G,C.P:M76935?<V*8_DN8<?R5+SU20F9.F%CUY%".>+M&\@HNDF(%(!0!
M==L[8ZSA<$V$&-(BU]0A6F_:E0-C"J2I\F98)DUDNS205LH`0\238JW)UQK7
M$H07(!)%EF$X4JC8DHT9@VK4]+JN.9O=-3N[X[&JT2N2-CF5T43NG:R$>W,H
MFPC&2!3N)*8E7/L;,FJ)3K.W:R:*93*'*406)S[W)NLW6=^KFK9W9%=YA<5M
M/2&&9],8CM>1.+@S95P[JQ8'`Q5TH<;9]+G,9OKJ+AG<Y!LG:DTSGXY9)J#D
M54O`_]&X!'?]^O\`U`D?[1=^!+[1_P`JN?XI6O\`$\-X'N7[\DVO^[\O^P+^
M!%GFK\TS?\!#]O:>!*><_,5,_P"?E_[%=^!MO@<=4_(6A_Q:[_MSWP-DT'\M
M-O[R4S_&$'X'C-?GRA_\K;O[/B_`R+O\Z,_[I2_]KPO@8;+?RLY_O-</\2R?
K@>HI_P!MK)_"+A^U2O@9K0/RN'\=IO\`BZ"\#UK#^?<^_P!S:_V%EX'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g524974pc_001anew.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974pc_001anew.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2@!D`P$1``(1`0,1`?_$`+H```$$`P$!`0``````
M```````&!PD*`04(!`(#`0$``04!`0$`````````````!0,$!@<(`@D!$```
M!@(!`00%!PD%"0`````"`P0%!@<!"``1$A,U"10T%18V(3$S8V07&/!!(E(C
M4U1E-U&1L6)&88'A,L(DQ"6&$0`"`0,"`P4%!00'"0`````!`@,`$002!3$R
M!B%!81,'(D)B,Q11P5(T%?"!(T-QL7*"PD0(D:%3<X/#)#46_]H`#`,!``(1
M`Q$`/P"_QQ2CBE'%*.*4<4K5/CZRQEF=)#(G9N8F%E0J7-X>798G;VQL;D90
MSU:U>M5&%)TJ5,2#(AC&+`0XQUSGE2&&7(E6"!6>9R`JJ"22>P``=I)KR[I&
MADD(5`+DGL`'C4=,\\V+3.`P!'-W";OBIR>C78N,5MB*O#39S\E:W%4W)'[,
M.?R&MSCT5D`DV%+<X.H41*U$:`\GMA%C'-J],^BO7O56Y?I^!C(N.FG7D.Z_
M3I<`E?,74'=+V9(]95@5:U:5]1O]07IKZ8[6<[J#+9\XJ2F+$NK)>UP"8VT^
M4C6]EI2@([5O3S:;[7%[7P93,11',)/&4G?43`-T`[+$<3>WJ3,\4/=5("$Q
M>75U#$5:D82@=R`H9>`B'UR+,1ZD]"IZ?]0-L*9/U9B5%>73H4S>6DDBH+DZ
M4\Q%!)N3>X'"I;T9]29_5?H>'K:;#^@BRYIC#"7UN,=)7AB>1M*C7(8W:RC2
M%TV)XUV+S7M;6HXI1Q2CBE'%*.*4<4HXI6.OYN*5RG<VZ>NE&K7AEE]C,!LG
MC[0LD$DCC4Y(E:R(1UN^1QD<[6X/"UP9A0YZ!$>Z')LFF#`40`XXPLH>;[!Z
M>=3]0XOZEC0&+:2P432@JDCMRQPBQ>>1NY(E>P!+:5!8:WZF]5.D>FMS7I]I
MCE]3.I88F/:21$7GER&OY>+#&.UY9WC`N`NIF56K&[:^;W-/,'363K;J5.'7
M7$A2O0BIR:O665"+8LYM">!QKF3O+RA&HIE=,%N"3XDY%'`P)826G<1IA*2Q
MI^BNF/15>BL?'ZHZ@@7<W12<B%0Q.*IM::-5/_D",7$\9%])8QA])#:(W;_4
M+M?4V^Y'16).=KCFM'C93,`LTG!HY'8?P!(2!#)V68`2%==TKD0E_F3?,7MB
MFB>2$6&DD3@SRAME@7'WO*EQ*X2%Q;Y$6[9&ZY?@.6,EGX/R(W)GSYS\F>=7
M[!GX7T4,V&T7Z>8PR%+>7HL""NGV=&GM%N[NK@_U9Z1W!=VGQMP65L_S2&U@
MZRQ)OXDGM/B:O)>3@ZA6R?=QC)&++355FT[K['S!9S@E8"B:0BL4F2EO[6<9
M/3BL9:[&G#!C(<'J<XSGM9SSY^^M,[9F7@;I)\W.3)RV\!DY,C1`_9:%8P`?
M=`[J^IGHKL\?3G2L73<0M'MV/BXH\6AQXQ,?WSM(2?Q$U.)S2-;CHXI1Q2CB
ME'%*.*4<4HXI2+L:#MEEP.8UZ\N,C9VJ:QIXC#@ZQ!_<XK*6Q*\H3D)J^/21
MF/3.3*\(PG=XG4%#P(LP.,YQG'4.;K!RY=OS8LZ%8VDAD5P'4.A*D&S(P(93
M;M![JH9..F7COC2%ECD0J2K%6`86N&':#]A'"J8EWZG0_46C+(U9VDIV86PS
MQ"^S)Z7=,#M:259++PJN?(#ONBGTE4A;91&Y<^5W(&AS8W-L=4QR=I<SB%!&
M,8<`'&=M=&[Q/ZE;Y#O&R[FN#G#;@L>-)`D\,$L36R8T4LCQB1&CE5XV#2(&
M5OEV'"OJD4]#=@D$NR)N>Q9NY%<K(6=X,EHY%UXS-(J.KJCK,A212J2%"`3)
MJ,9A<>\OQM4_^BN;8JG3`Y^5NM2KHS;3`3GK\@<RNLWZ-/X4P/SF99#3,8QU
M[.<\V]%G>H.RR6S</;MQB7WH)WQW(_Y<Z.E_#S1_37.F9M'IMZBP:]JSMPV?
M-?W<F%,B*Y[O-A='`OP/TY/VBI):$U=K[?NSZ>G$)N^G+*M*H)A!W:66E'54
MN;`VK5,+<D*S$9N*.S6(Q5]%9$6;FT!;8\D`6FKVTH2!Q%G)2=4#5O6'6F!T
M=@9C;=BYV%CYL,H;"EC6T,\BD>?BR0R2QB)V:\L3%`'(EBYG0[S]/?3?K;J!
M]OVGKB7`W&'!GB.+ND,_MRX\;`_29D,Z13O*$!$$JH[!08I>$<@XWD]L;W:K
M;?E[!UC65S5K"8$N?HY"ESW$G=W@-CPYYE;E*9J\3]?'1ND0?U-RRQ>K?7+(
M%@S49BE.6G-+]!3B!>;#LW0?5G2QZ>WC(PY\O("-(%=5EA=4"1K$'M(OD(%C
M7V;-9BP(=@<C]2NH?4#I#JB/J?I['RHL#'#*MT9HI$+EG\RQ*-YS$NPU=A*V
M(*(5NI:$[^51O;5Y,HBAA,9LAA2)"[)JU<M*.>8JXF![O*]O%G!9CS$W!0$7
MHBX`,?NC@EG!R#G)OJ3Z8;[Z;[F,?.4R[/,2<?)4'1(..EN(251S(3\2DJ;U
MT1Z2>LG3/JQM32[:P@Z@Q@!E8CG^)$>&M;V+PL>60#L/LOI<6KO/FM:V]1Q2
MCBE'%*.*4<4HXI6,XZ\4KG+:O7&);3T;8U-R<M$D.F,5<F5DDYK>4M711W-.
M1.32\H>T(H[.$#ZTHU)A(3`!/]'"$6?FSC*>B^JLSHOJ7$ZAP[L<:8,R:BHD
M0@JZ$]VI&9;V[+W%85ZA]%[=ZA='9W2.XV6'+ATJY4-Y<BD/%(`;7*2*K6N+
MVM5""T66B=9K,EM8N>OKM+K6K][4L,B?-G%*9V1)G1+CH):PTU$U">#!:UH!
M`4H#G9?(P'IC0&!QC`L=/HSLL65UIMT&]YFYJNS9*!TBP;H"I[I,J2\Q8=H<
M1I!8@@WKY5]0[M-Z8;C/TSTYLY7?<9BCY&X`2N&TV)BQDM`JGL9#(V4K*0P-
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MC`_B<$'[+5T!OWIQZL[MO4J]&MDX.*LC`2-*T,9LQ%^(+"W<JL#QMWFVGIKH
M';-,R&/V9L%=<0M*QV9,J((412J(FP+TX%I'=*$JJS`-;;-']$=G/4TDXHDL
MS(0Y%@6<=<<]]>^J^P[[M4O3_2FUSX6URL"QDRIG4Z3<$8NIH$8=S`DBYM:M
MB>F7H/U/TWU%!U=UQO6-N.[X^O0L6#!&ZZA8AL[0N3(I]Y"JJUA>]A:5?'S8
MYHNNH*SQ2CBE'%*.*4<4HXI1Q2CICBE5H?-U\GV:WI$[CV+I609E-MQEXQ-X
M)6A;*%*\.U?B9"U5BU@4_87'&2==[UDJ7Z*%#)(&@$M5-8!&$G)<)^C/2/UA
MAZ:R<78-U7R]FE7RY9-5PLNJT<VFWL#1:.:Q(;2LIL5;5SUZP^B^-UQBR[SA
M!6Z@B[8^P`M';VHBWO$-=HKVL&:/M&C3%WY(.FBO9Y77,DG+28?6$2V'<KTL
M!&X)#@$/!^O3".&4Q#UY"DGLYPOMFP9`XJ4QF/E+C0P#Q@73FQ/6WKG]*\W&
MQ7MGO@#'BL1[/U3!\AP0>Z&*-`1WS#QK$O0WTV3;,7SLA`%?,$LGQ#&!6%3<
M=\DKL1]D?;Q%7H<?+U_/_P`><7]M=95GI^7Y?-Q84HXI1Q2CBE'%*.*4<4HX
MI1Q2CBE'%*0L%K.OZR3/:*OH;'H8CDDD?)@^I8\V)VPATDTE<5#N_/*HI.``
M!+'5T5FJ#<XQC`CC1BZ=19SF[R]PSMP9'S97E:.-474;V1`%51X*``/`"J$&
M-!C(4@145G+$`6!9NUC_`$D]II=<M*KT<4HXI1Q2CBE'%*KZ>8W$GW93S6?+
MYTPD]QW[7%"3O7+;6W)?'J!N:<T:]R.=5^IKQ#$7)YE5>.C,_KD;*E=E02DH
MS_1^T>,0@YSGBE<D7E$O*\T#NY&GN:RO.H4@JV9UJL<9ZYVWY@=BZS*9`_O+
M**+,4DL$+T.MI$V+7IP2(EJ02DQ,8:;Z*9VLB$7E2IR/,AW-*TFU(F=Q1ME%
M-K@EBF/U+K+6*<&3'6UMB;65@C520I`C"()Z@DY^6A7..`=!DM2%49CKD&,9
M4J#+RL-J'#3K=J/Z`WEYA$2WM3[E5D5;<4LD%U16U'RI]X(4C`1LYKZ(#*]N
M)\7KJ68$6ZPY*;@DD(D1R4@&3AGYPI4BOF!6%/XOYJ?D<0N,SB7QV&V/9&\2
M.Q(DR2%T;(U/$D<UG3O$>33%F2J"D$C(87;JJ1A5`,PF/SDP'07R\4J;+\OR
M_OXI55O=N9R.RO-+VPKVVK]\PN-:^ZQZ?:P3B"4YY?C]-D<]>YY=%C2N/2%^
M5PVMV%VDLQ,"0@(R><9V2$",G(QYP$..*5V9Y7]15+)+)D]PP6Q_.+7&UPAS
M'_=#S$9%;\:K]T5S!&I#ETC<(L%I8P3!S94208<J>R<2@$I#GIWH@9"I3;>9
MJ^[LJ_-&T)@.E%X@K6?9U9W"M,FN)L8X+J)O9TKJ14H-)6=PL2-22-&U2-N=
MU25(_I0#<F%68!21UQ@P.5*9[S"?,R%?WE3;/G0D^R-2]U-?K2U.B>P]`+I$
MJB]T4@^OVU%+,3F:W/;&>B'+ZIGC.O4%M$F:Q":WUI59#GNQC-3@4JP'M#LA
M6NH6NEN;,6^YB;*]IJ".\U?QE=D3@Z";T^`-,;921Y#A9(Y8]G)FQN3]<94+
ME91>.G:XI53O4?>>T]/-P-=[HW%W@AUD'>9U*Y!7VV.HBJ[(I*%?EVWG+755
M+M48_%Z\(>1/<(BS)"5?N5,^^3IPHGG(3EO:.P5C"E70>G^/]N?F^?\`OZ\4
MJ,#=CR]["V.V#UZVPH':=]U7V`U[A5JUHS28BJX5<4;D,%MX4;/D;<YQ29GH
MB$KFD51DD:562=C(0FF!$`7Z.<*5RG=7E/;O[60@%+;6>:N_VA0CS+Z_D\^@
M$9U%IJN7J5)J[F[#/VEH235E>53@P!4/T;2]X<62:+`,9_1%\W%*D#M;2%GN
MO<76W9RQYVO?8-J=$YF93E!F,B7W5179.$ONXLO"0O`UHSWU^CD$$<V,R,Q-
MW+>:K.5EF8.R'HI39;E>59K;M%39D'@$4@NKUN1J<PBUZ=V(IJJX&S6)4]J5
MY(DDBC<L:3$+6U>U21C)-2K41YV"%:528$>.O9SA2M!O)Y>5M;96!I->%=;8
M*==[ZTN56H[1V>M=.1:QV>4/MPU^QU[+UJF&RIY(;&Y,)I;UGHY.1J,%>F_(
M+M$@'Q2MQ1^K'F-02UH;+;D\S[-XUFRKE9\LJG\(505YB9(CFM>D2H<S..O*
MEY8LI')02J[U.`0A]QW><=D>>*4U&Q7EQ[4.^[4UWATLW6C6M,\MFDH#2-JQ
MFQ-<V*^H\\,U9O;T\Q9UC8ETTARJ/+<C?#`*@9RH"9@&,XSCKTPI3[ZN4/YD
ML"L[WCVNWZK+86L2&%R3$5O`M18W2C@JD:K)!;<[.,S3V%+U^6YK*P:/T0D@
MK)YH@=LSL!R$2E.A8.GS?/=Y-<MUC9RO;7/7NF[TJ%)`2F9*H;Y.ENU=!EJI
MZ5/8U8%3<>PBA(,`*`28$_OL]1`[/02E<T^9EY0>N_F5M<8>Y4YOE07G"5<=
M)CUY5Z465(W6&,LP9)DLJRQ6O"E"BL6MW-W8R513>XC'AM<RREB40!A,`<I3
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M8:84:N48'@/4``?+G9'2'26V;WLLNYYWGF9<Z.`*A8`*Z,Y8Z,?(8M<``$(+
M7[2>RM?]4]3[EM&ZQX&'Y*QMAR3$NJDEE=5"C5/``+$DD%CP[*=V2["2IHTD
M)V92-,=.F)M"QBU?8H@NPHO[<>XNT/:I"7@PQ(\B:"U3@,)7:$`_)>`]K/7K
MR'Q.G<2?KD]+N\@PAN$D&KV?,TH[*#WKJLO;Q%^%2N1OV5%T:.HT2,Y9P4FT
M^UHU,BL1W-IN>R_;:E5LA;\@J2COO$CYL5;WE7)Z>C/M>9%JC8C&D]F69"8(
MZR=\)3.C*><VQANE!RW(!+4H!=QC!AP`=H6+7IG9\;>-]_3LD3-"L60^F*WF
M.8(9)5C2ZL`SE`M]+$7-E)[*NNH=UGVK9OKX/*$QEQTU27\M!--'$SM8J;('
M+<RCL[2!2/H.[Y3.;=M*L7F?5!:S5"X!5\W;)Q4*!0VH"5TZ?K-9'.*O:;,Y
MGZ,2YM)@B964,"LDS):WH(GI@`Q7?4&QXN!M&+ND&/F8DLV1/$T60021$D#+
M(A\J$V)E92"I%T[&XBK/8MZR\W=LG;9I\3*AAQX9!+`"!JD:961AYDHN/*#"
MS`V;M'`TS,[V1VA.NNZH!3]?-LM057+JICS0VXKQ<Y(7]/,&&.2&3FR:S#[;
MBZ.('MB!V4#*R4PN`"BR2\BP:(SL8G,'IGI9=BP=QWG(:&3+AR'9O."E/+=T
M31`,>0R!BH!O*ER3:UKU$9O4/4K;QF8.TXZRQXLL**/*)#^8J.Y>;SD$>D,>
M$3VL+WO:NE=C;JE-,9I@<6A2J?G6+<;;7;K'6OT7$A,:%L)G$D/61T3D[LC0
M%Q1JHR2(>51^"O1>]QC&3,@YC'36R8N]_6C+G&.N-A&97:^C4)(DL^E6:Q#G
ME%]5NZ]9%U#O&3L_T9Q83D-D98B9%MJTF.1[K=E6X*"^HVTW[[5Y-<KREESO
M%[(I5!55>YJ^TT\%9F!W]$S)<M9L"A\IPND(FQX?&<2M4LD)N2?13NQA-@O`
M@X'VLY]=2;'A[)!@28F0N3]5BF5F6^C5YLB:4NJM8!!?4.:]NRU?FP;UD[O+
MFIDP''^FR1&JM;7;RHWNVEF6Y+FUCRVOVWIFXENQ[P[(YKX]A,3TI*)-(*GK
MBQQ1">HTSS;$*(&I>#%$W7-95;N,0F:TAR9X]Z"L,5*'2/J,9[85:;&)K,Z'
M.-TS^HK(#O<423S0^9$2L$O8MH@WG"2,%))M2Z529>!1JA\7K'ZCJ'Z`I;9Y
M)'@BET2@-/'VM>0J(C'(0\<6EBS/$W$,M;G;78ZQ*5FM71N&-9JEFD\-M^;3
M)R:*I?[DD[4UUHFAYY0VF&1^>P%6I2FAD9HE`RSE:C.2RP%$"$+.<4>D.F]N
MWO`R\K.<+-%/CQ1AITQD9IC(/:D>*4`^P+7"KVDENRJO574.X;/FXV-A*3#+
M!/([+`^0X$/EVTQI+$2#K-[$GL``-+V`7;.9#ITCOZ0MD223H^F7^Q1(&96)
MUAQK@@8W1V9S2S&UW=3?9CB0E(./3E+E!J?O1DX.&,';S';CLF#C=9MT_CO*
M<`9J0W8:9+%U5N95%Q<@,5`-@VD`VJ_P=YS<CI(;[D+$N:<-I;*;QW"LR]H8
M]AL"0&)%R-1(O3+5OM];TUL/7:#/].D0<,N(>V2['AW]LB:BI^160K`8&VD7
M(8$Z691->VEA<E#J;V@)D:Q,D$'"_P!)+3SFY='[/A;=N6?CYIG\DJV,JZ=7
ME&?R6.2O&.0'V`@[2RLX_AZ2T1M_5>Z9F=M^%/B>2)@RY#'5I$HA\U1CG@Z$
M>T7/8%95Y]05?[9[02:DE<4BE8Q!18-@N"%VL&01U'$)],C$E81#H)U2E)J]
M:7A<U3"P7+.&:,FKPE-PU^#S#1"+2FAS'](=+8V^I-E[I,,?;U98D<R117GD
MOI-YF4-'$/XDX2[A-(`NX-7O5'4F3LSQ8NVPF?/96E9`DLEH8^8?PE8K)*UH
MX=5E+:B20I%/U]^-;_<G^(3W@3_=;[@?>5[?[(OAGV1[8[7HWT_M'N?V7HW3
MOO2?V/9[S]'F/_H6Y_KG_P`[Y9_5?J/)T_'JT\>&F_;JX:?:O:IS]:V[]&_7
M_,'Z9Y'FZO@TZO\`;W:>-^SCV4G;G]:8?Z!?0K/ZT>M_2D>`_4?O?\W9Y<;'
MRO\`^PXC\MPX>]]WA>K;>.>/\AW_`)CCW<GW_NIW'/X<4?#_`(87XG\-?1`]
M8_EGZO\`EZ<B(/S*_,YO=Y^/=XU+R_ES\OD][D_?X?=7CFOP:^_"/A9GQK\&
M?,#QS^5_K?[N>L+\['\[G_E_,[^7XJ\9GY-_E<O\SY?][X:0E,^&/7]%_$$W
M]%_#/5L>-_;_`-W]5R0WOYL?YWE/YGFX^YX?;XU8;/\`)?\`)\1^7Y?[WC]G
MA>G/;O$GWP;UE)X=XGZ@3X[]J_<_4=GD7)\M.?@>/#B>7P^WQO4I'\R3DXCA
MQX#F\?L\+5EU^G9?!O%P>+?3>IK?!/YM^K]3WG/R'D?GY/=_M#G^'[[5^2<R
M<G-W_P!!Y?B^Z]?+7ZX^>"^)!\+]<]22>._S/]7ZCL<]3_+C^9R^]PXGD^'[
M[TBYGY.;W>/*.;Q^ZU:<KX=C_P`%^),GT7P[XF3\/_S+^"^U=GE3_,R?.Y7_
M`+7*>?P_'\-ZHGY"?)YU_L\?<^+\/Q5NE/CC5X-ZFY^L^.?\R+PK[%_%?[>[
MY0C^2W/Q7AR]_-X_A_?5P?FKR\IX\W=P\/M_=6C8?@S'P5ZL[^`?!?KB[YOL
MW\9]=WO*^1^<_G>[S_,X#]E\+50@_*?RN5N3Y?$_[OQ?OK:C^FC?P_\`./Z7
MZ7PX?PU_U?9NO*2\DG/]W'W_`-N-5?\`A\G[#W/VY:]!/CKAX3X6T_0>/>MN
M_B/\J_A/K/2.&^0O/S-QY>"\OQ?B\--!\]N3D7AS<6X^'X?'52=_T5_H3Y__
D`(KQ7_'_`,OE?_/?S_\`N<O]7^&K7_)?Y?C_`-/F_K_Q5__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g524974pc_001bnew.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974pc_001bnew.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C0%``P$1``(1`0,1`?_$`.,``0`"`@(#`0``````
M```````("0$'!08"!`H#`0$``00#`0``````````````!@0%!P@"`PD!$```
M!@(!`@,%`P8%#@\````!`@,$!08`!Q$2""$3"3$B%!4605$7\&&!,B,8<9%"
MUYBAL<'1X3,D)=4F5Y=8&:+3-)15EK;6)V>'ISC8*1$``0,#`P(#!`4$"@P'
M$0```0`"`Q$$!2$2!C$3010'42(5"&%Q@3(CD;%"4J'!T3.3TR06%QABTE,T
M=)34)9755I;P@D-CHT2EX7*2LG/C5#55=>4V1H:FUAG_V@`,`P$``A$#$0`_
M`/OXPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3"+56X]B/-7T1_:XV"2LLN5_"P\-"N)/Y*T>RL]*M8E
M@F_E@92)XYD59T!E%2MUC%*`\$$<K+&V;=W`A>[8PU)-*Z`5T'C6GT*;>GO$
MX.:<HBP=[=.L[`Q2RRS-C[SF1PQNE>61;X^X\AONM+V`DBKAU47I_N[O\-17
MUG1T]`.YFGEVVZV1"GV4JW8Q,;J)U&H32]5ERTM=2SNY()$#-TEF\>7W!`QP
MYYRZ,PUM)/V3.X1R"/MG9U,H-`X;QMI34@GZEFK%^@O%<CR:+"OY!=LQ^0^%
MMQ\PQX<^63*-D="+F+S8\LV/MT>YCYSJ*-7<I_N;LU=O-KB7FMXY6A5YQL"'
M9V=O=#&L<E8-?T6-O#UJO5#ULC5C&/V\AY";CYBJ<IR=1DN!`,Z8\5%);LD;
M*X3N##MVZ!KWE@(=NU.E:;5'<5Z-8?+<:L;ZWS$K>473+&5]L;3^3QP7UY)9
ML<+D7!<^1CH^XZ/L-!!H'U"X<.YC:I&2T,XT]4T]E*VRGP47`$VBZ4JCF)N%
M:>6EI+/;6-#(]9NFK!D8AVI8Y4HJF#A7I\<Y?"K2O<$S_*ACB3VQNJQP;0-W
M^TUK4?4J[^AS@[KAN0BY!?NX>VPNIY9SCFBY;+:W#+9T3+;SI8]CI'@B0W#2
M&@U971=IH'==6K=;ZA1)>))7+/<J)0KA%1QIZ.>K+N;B:_%?1S-LJ$>^D&5>
M&A*^:[12,!@<I]2:>==SAY88'W#';HV2/:30@>[LH?$`G=H/HZJR\I]#LO@L
M#?\`)<?<&\PN.R=[:RO[$C`UMH+(L>]PWL8^?SK=L3WBG;?1SE+/G+.L&IA%
MCD/RYPB`(#A%G")A$PBQR'WX1.0PBSSA%CD,(G(??A$Y#'T(G(81.0PB<AA%
MG")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+HVPJ#";,JSZHV%24;Q
M[U9BZ3>0K]2+EH]_&/$7\?(1K]$ICM7;1VW(<AN!#D/8.5%M<R6LPGBIO`(H
M14$'0U'U*1\4Y1DN'9N//8IL+[J-KVEDS!)%(R1A8^.1AIN8YKBTBJT?+]HF
MMYJK)5-U8-EILE3W4;"_:W9XA,71#8:K1:WM+>_*W$TLUESLD^HO2GT@'`"'
M.5[<S=,E,P;%7W:#;4-V5V[172BR38^O7,,?FW9V"TPQN`+3L1NLV&*T-B'"
MU=:LK^$Z(/=0U=4ZE=FD.VN@2MQG[A(/KB[&Q%LIGM85LKKZ0;O[=76M5GI=
MA"`D4K64>0K,B?F@I[@\F`.1'.IN4N&0-A:&#;MH[;[U&N+@"?8"59[7U@Y3
M9<?M<!:18^/RAMPRY%NWS3F6L[KF&)\U:NB9,XNV[=10$T"X8G:O221#A@-O
MVJK+K6&%L:-S6O#H]R8.J_%N(6*9,9KX7]A%MHMTHCY/EB!@,/(\YS^+W&\.
MV0[-I;MV#::FI)%>I(ZJO?ZV<C=?LNAC\(VP;:36YM!9M%H]L\C9I7OAWZRN
MD:U^^NA&@HM@1.CM:0Y-=F0K3)U*:L;)-*=9)%!N\L[!N1D^8G14GE4/F"R+
ME.27,J0#E(HHH)A#G*9]_=2&6KR&2FKFBNT]#TZ>`U47O_4KF60?EA)>21V6
M;>77=O&2RWD<7L>"(`>V"TQL#33<&M`!HH.>J)"2<WK+7",7;-J5)5&\.E5'
M>J;+>:S*.4S0ZQ?(DW5%K5E>N&)1]XI%DTDNL`$#<^&7_B<C8[J7>R%_X8_?
M&M<!KX;W-U/31;*?)9D;/&\QS$EY882_:[&M`;D[>SN(V_B@[HVWMQ;L#_`E
MCG.IU%-52=^']N'V;G[Q_P#6UW#_`,U63D7$']PL?X.+^,7HR>5X(C_Y=]/?
M]%X'_6:GYZ;E5GX;N(<.Y+8?<):6XT:<2^6[-OFU[%7"J&6:B#@L==*+7HCX
M\GL(?XCS2\CTE$,CW)YHWXP-9';,/<&K&1@]/:U[C3[%JW\WV<QF0])VV]IB
M>*64OQ.$]S'66,@N-`ZK>Y9WD\NP_I-+`TT%2%?F']@/',>+R[_,LX1,(F$6
MF=\[NJ7;SKB0VA=VLV[KL7*U^*=HUYA\SDP4L4RSA6ZZ;/S415;-57H*KB`\
MD1(8W`\<978^PFR5T+6`M$I:XZZ#05_:_*L@^F'IMGO5CE\7"N-OMH\M-!/(
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MFJ>290:U.SR=;>I3<<,<[>)L4DW#*Q1C4RBBKNM6%FKYT>Z``*Y3*;I_5$,7
MN/GL'LCFVG>P$4-0*]6D^UO1P\%\Y_Z9\C]-\A98W/FW=/?V<=PPPR=QC"\E
MKX)'4`;<0/&R>+4QN(KU"Z#K3NMINRFLK-M:U;8.GLJQ.7!E<I-"+<0;N%KK
MP[*30DCQ4D^<5JPD%,54XY^1%PHAR8`Y`2A476'FMML9>QTY>&[!6M3TI4#<
M/:1HI3S#T.Y!P^:#'37MA<Y^2]AM'VD;I&S-FN&;XS&)(V-N(#7:Z>$OC:^@
M.A!/H-.\G5+B$TM-NVMIBT=W[&-JN$:/X@J3ZMW#X=TNW87!`KD_R=-WY*0%
M4Y4`/B4Q-P`B(?3A+L/G8TM)MXNX2#U;XEOMI^TJJ?Y>^<1Y'D6-A?93OXWB
M!DIG,EJRXM-S6N?:NV_BEM75;[I_#>!4A<8Z[SZ2M;[!0ZQ1MA6ZU0&TG^IA
MCHV.BV*,M-QE0971U*P[^6E63-Y7OE;T"$<`</,7(8@%'CG.8P<_:;<2R1LA
M=")*U)(!=M`-!H:CIX=560?+QR./`VO)LUD\588.ZPC,GW)))'F*&2Z=:-BE
M9%$][)^XPDQD>ZPAQ.M%L72W<C0M[)S)Z@SL3,\!$1<K*H3T:1BLU-(R%ABE
M8_A-RY35=Q\E6'22HD,9(W24Q#F*8!RFOL9<8_:)]I#B0"#6M`#^9P*B7J)Z
M0<G],G6XS[[21MU/)'$89"\.V,@E#]6M(:^.XC<T.`<*D.:TBB];2G<2PWA\
M*]@:-:8:NR,8M+1E@FGM8%%XV3<BV3`T7'3K^99J+B`F*"R!.`#@W`^&<K_&
MNQ]6R2,=(#2@W?G(H?RKO]1?2:Z]-M]ME,G97&6BF$4D$++FK'%NX_B20LB>
M&]#L>:]14*1N6Q8D3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(JM/5.VK<=4ZRUI)4W8]0UN[E+P\8NY"W[>L>H&S]LE"KN`9LI2MP%@
M<2ZY5"@<S=0B9"D#K`PB'&2GBMM#<W$HFB=*&L%*1M?37Q#B*?7[=%NM\DO!
M\!SCF68L\_B;_+V\&-8]C+7%P91T;C,&ESX[B>!L32-`]I<2?=(`-52"/>-O
M+C_Y3:4_IM;2_FWR<_"K(Z>3D_Q>/^V7I$/E\]-_]BN2?[H8W_+U8'Z:7<'L
MW9O<8M6[9NW6^P(GZ$GWWR*K]R5WVI*%=-U6?DO`J]@I\*P\A(%#=;@%P.ER
M'!3=0\1[DEA:VV.+XK=\3][=3$UG6M02T_530UU]BU7^<3TGX?PWTC&7P7'<
MOB[[XI`SOW/'[/&QEK@ZK?,P74SP20-K-FUVM2*"OT"A^7Y>(9CY>5ZSA$PB
M81:@W5J:-W/3VU,F)`T?%IVJJV*0Z6R3HLBSKDRVDW4.H14Z9$T99!$R!E/$
MR8'Z@`1#C*NPO'V$_>8*NV.:/"A<"*_96OV*>>G7.KST\Y`_D&/B$U\;&Y@C
MJXMV/GB=&V4$`U,3B'AOZ1%"0%$H.P&#<,6S2P;,D[:D>3@7,TM98&,?A.Q%
M:V6TO,'6'B1W(H'@XF'8(PK9,P'Z&I.H>1]W+S_..0.+HX@PT.W:XBA+"TN^
MLD[C].BSQ_6GR<%R^?%8:&PD$$[81;S2,[,MQCW6<URTAN[O2RO==R.%-TAV
MU`U6\JOVYM=?U;==&US;/HNG[56DI&IQ43#,D5=7S=DB%8RU/*ZZ172,^:O7
MG0]9MU`(5@X`Q2")#`!;?-DW7,T$]TSN30T#B3]\--6AP\-*@GQ'58RS/JW/
MRG-\<Y+RVQ^(Y[!MCCN9997D9&&WE$ELV=I!V.8RL,L@),[*%P#A4XU7VO5+
M2-N?3NN)^QP]<FM?0U)L5:F)^>M:CY_6#G1JUE:3EJF9AY$+PD2Y7:)LT`(S
MZ%0$$RB7Q^WF6FOX!'<M:Z02%S7!H;0.^\VC0`:FAJ==%]YOZTYWU(P,6-Y=
M:VEQF+?*RWD%Q%#!;!C+D`W-NZ&VAB9*)I6LE=*^LNYM"X@Z:97[(YJ==60;
M+M.*1;62&-5IR0H6O(^@6:\U9]/LY:6#8DS!S()S\^X8-/A4'R2+=1N9118G
M2)N@*X9Z.,-$4+MS7;@'O+VM=0@;`1H*ZENH/0K(3/F/Q^-@LQA\).Z:SN!<
MPLO;]]];V=RR!\47D8IH:P0->[N/A<][7AK8W5`W+VISL+K"TC-A5=@6:LUE
M](2-J@H)^H_NCRI[`D:'*4@]QB;);9F4FE7+8ZS%^FDLJ<J;AD`%$I3^[\CY
M%,&-[T37R@!I(HT.8'AVTM:`*?>&@U!^A=.-^9[,Q6EL<WBK.\S4<<=M-,P,
MM&75BR]CNQ:2V]K#'"&N`F@<YK071S:@ENO*0O8]2&U@JTI8)MI=8NOS4/87
ML!8:[&R+&>F(_6C2@OI%Z1RLX2(XE'Z*LF8>@P)J+"F7W0`<XOS]P8WL8TQO
M<TM!:XB@+R\`?4*-^D"JHLC\R7))L5>V.*MGXZ\NK>6!D\$\D;X8GY!]\R-A
M:UI+8HRVW&H+FL#S[Q(6PFNAK14=IRUPU5<J?2J98H*CUR=UXIKY!TBSB:9\
MU232K+^-G(=*$^.;3"G("U5(13@_2/B&4KLC%-:-AO&/DN&N<X/W]2ZGW@0:
MT(]O116;U/PN>X3!@.<8_(9'D5I=7D\-^+YS2^6[[9)N(Y(93-L=$W42-<6U
M;4+@^W#MCE=`.FC5.7U=+0K"&=PR<E":B85384JFH\%VW6L5R:SKU26.4P\K
M`*!06.`&]T0SLRF59D@7$3"0NK0R%S!]`;04_*KCZN>LUEZI0R3O@S5OD9;A
MLICFRC[FQB(;M<(+1T+!%IHSWSL%6ZJ8?5_!_'_;RRK`.JP"A3?JF*;CV])@
M']'ASA?7-<W[PHL]0?IYXXY^W[OX<=!5?$`P<\?;[1#GQ#^$/;A.HKX)U!X^
MSP_.'Y_[6?*A*'JO+/J)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*O
MOU!ZA]84"C,QGZ)7@:VU=P+B]S@P;)?F,6("#)<*?</.=>/(D\I+@H<]8^P9
M%QN8P7+SMD<2RGN"IZ^(W-_.MI_E4SPP'*,G<>5R=WOL&MVV4/>>W\0'<\>;
MM=K=*`[G:FFWQ54'X'_^9O;N'_J&I_,:&3#SQ\8KG^#_`/.K>7^D?V8;EU?\
M!_\`C*F;V)ZU^E-W+2H734L\`U"7;_`4FUC,S'"BC<WG'9CK2J?X*00]XWQ7
M(#_('[+'G[LS6`88YFC>-7-H/_'=^9:]?,US`9STW;9''9VUI?Q.WWEKV8M`
M=-_Q"Z]X^`[73](*Y4,A*\^%G")A$PBB!WO)"KHX!6;RSJ&2V3JM>U(0R4FN
MY/4TKU"GL7GH1'^,%F`1H'%<J8#RD`\^&7K`$#(>`D[4FVM/O;#MZZ=>BSW\
MMSPSU*/;?`S(G$9(6QF,;6BZ-E*(*&7\,/,E-A=^E2FM%7UM"-!:7A'M$^85
M[MI<[ZKSFO*W2K7RR4Y%R35M@1MD@E56;IC9PJ+JP^2FCUF(V^8\J$+QDBLW
M48YL]'93R[@[:6M=^^-VC<?=W4K7J::+:KA5X8[&YMN3=J[]8F<7G;.+2YLK
M>[<WXE`;:-UR]K[?S38-SG`!TG8HUQJNX;31@S1&MI6"=-9U.,UM+Q%8J\=0
M=DPE6O<\6PJOS-M03D=)+3VL]CDD?+2*M))N"*$,0P""8'SIM.Z'RQR5:3("
MYQ<PN8*4'<%*/93]4CQ5AX1)DA?YBQR;'VKILQ%+<7,E[CYKFRA,`9NRL,D8
M@R./[>YVRW=&YI#@07EJYMR$^UM=JG-T0-H-I@NV]L.QB9LMEDH:,OKRI4$M
M(<7-.OIN9-[2$D?C&Z2J"*S4C[S#]'4(9P!C=$R.R<SSW9C%1M!+-S]VVM`'
M=#3J1356N(XN;"6.,]/+FQ'J(<#C&]V'R\<TEDRZO3>"S,Y;&V\<>T]S7N;(
M8=K=VT%=>KB6\U%:YLZC4RX5\VN-2;(^6ZP"=LLI7=G4A[>13&/BW=H1:2S5
M\O##\PKA7*9'3<4B)&Y3-QG9)\/`?:W$C']V9E9-K06/##J0VH(!T?30]5=\
MM)Z:,;=\,Y+D<?=-R^>Q_<R)AMXY\=>,LZ]R1MN71.8)1V,@8W&-X<YX]\56
M8Q[O265U7M9E0[=*:_TC5J15;$QEYV5AY6Q0=XCUR[Q&1I"R)E[0_B(*<8@V
MY$%$)")-Y8CR;#V6##-9ND8VYG>YP(`(:6G\*C_T07`U\"')>V_IE8QYS@UQ
ME+"'E/)+Z\N;=\4,<T4$UG(WX-LO`0VWCEFAF[GZ+X+H;AH*=Q2U"K3:AM23
MH]3F86Q#WD5B,K[IJ><4.&ND-@4URV;M2*.5O\T$DC*G5`@>3Y/7SX`(9T><
M$\\+;A[71^2<3T^_L=K_`-]T^U1YW/6\ASV$LN27]O<8C^CZYDG8X0@>?=8W
M;7%Y#1_*B=H;N]X.VT%2NNFC!-7H2/JL/L9'NKC[!?W.XG[@MA!8U;?,[8,\
MO9I)41A).J2S19F6"2:'.J0?A_)`IB&SMWD2N=*Z+X06L[8&WJ-NW:.H<-=U
M?IJKLR\`RMS=9R?$.]#Y;.Q;BF-,%!<,?:]EMM&/QH[F-PE-ZZ4!I_%[A<'-
M7?>V:'W+2-M:'UM<TKG.4B"[?YZ>JU^EEY!T+MI/C5E3T:]KN%#B>Z4J2!9-
MNNL`'<QRJ?'OI*B--E'V4]G<7,';;<.N0',%.HW>^RGZ#AU`Z.!]JBWK)D/3
M[DO!.3\PX\['6W)+KE,,%S91!C=KX/,@7MD&C2TO(]CGL9I'<-?^B]@'%;3&
M^V2O7MW#+V>1GU+[W70LHG'&D3FCDHJO#":_CCMFAR&;MS0Z+=5L`=(JF5$Y
M!ZC<YSL_+12QB0,$8BMS4TUJ:O-?KJ#^15W"AQC$9;&6^0;90XMN,XS-&9!&
M.X99^]?2;GCWG"5SVR=0T-#74`HI-Z5ITYV^Z)L5DGH:JR-B;U)"RF8:]KL]
M%NI4\96$56T;(1\O,33IY.JOBF(91,R8'$_B7GG+7?3QY+(,BC<\1[]M7D$"
MKNH(`THL->HW(,9ZJ^IUIA\7<7L6*??.MP^^G@D;$)+@ASV2111-9"&4(#@:
M4^]10KB:/W"_3CG3&Q6]NIDKL^WZZW!!WNN6*5L;V`N<I/.W-_3=ODBIIQ;6
MOS0Q[A.,,/PQF8>4`&*)\OKYL:9?/6Q8]L3'QN80!5H'N4'C4;O>ZUU6Q=_R
M3TI^+L]1.)/L,A8X7'W^*FLKB"*W9-:1P-;9%C'$F5\\/?8;@?B"8A^A#5VB
M4<=P#ZJ;FVFC%6*F[ZU3MF#KT`B5F_FJE:6,C'0=,LLI'0H*E;S%-GHV0^<(
M$)P=D[2`.H!(?GI;\.;+!:58_'RPEQ-0'`@ES03U#FD;3[059K&+TKML[Q[@
M[Y[7(^F&<P4T\Y+V0W5L^.2:[MHY)J;HKN"1GE'EVDL3JT(<VDM:=75]7;VU
MOK:N24O+PB^B+@[NKN6=.'[R5EH.YU<8*SR[I<ZGER;I_9)0A"E$H'(Y4``Z
M42]-FGD%WCY;J4`/%PW:`-`"UU6CZ!M;^3Z5@CD&6BYKZ99?F&7AMX,DWD]J
MVT;$UL;8XIK2X$UO$T`5C:RWMB2:T=&TDATAW2^RS+`J81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PBJ/]71*<6U/JT(1KL5TL%^=BN77&Y:=IB0*F,&
MX`HOY:YPTRTEVG7^JW1(10A^#B(@'&3'ANT74P?VPT1C[\;I!U\`TBBWN^0U
M^,9SK-G)R8B./X4RGG\5=Y9A/>'W(K26)T3O;(YQ:1[M*J@SX+80>/R?NE_3
MWVZ+$/\`L+F0=UO^O:?XK)_;KU%[_%/&XX3_`+FYG_+59+Z6#>UI=S3DTRPW
M8V:?A]8.%-@=SFLMMP/7YS+H`M6J58B94'H_R'`J^6EX]0#SD9Y9V_AGN&`_
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MO[$>PL(:`7MDKM=0D4T'19IY#Z)8#AU[G;CD.0OW<;QHL)+26*U:V:\ML@7=
MB<PS2-[0VL)+"2212HZK\('NAV5>$93Z'UE6%I:H4FPSUR@)VXOV:P6:KVF4
MK4I6("6;0+AHY06"*,LW>+I)D."I"G(00,(),3:6YK<RO`>]H:6M!]US00YP
MJ#X]`N>3]%N'<:E@'),S>ML+_(P06D\-JQX\O<VT5Q'<SQ.F:YI'=V/A8XD;
M7%KG#;7:]\WXM7M)5;<U3I4C;&%I0H,BE'GD6,26&A+M)030TG+.ESF,)8U"
M:`WE-TUE%E"](``<F"DM\=W+]]E/(&%A>*TK4M!T`^FGM%%!^,>EL>6]1K[T
M\SF2BL+FQ=?,+^V^4S36<<SQ'$UH`_$,--SW-:UIJ230&1P>(>W]/W^&6L+$
M:SQ_#GU$X_A_CPB<81.,(O0:14:P<R+QDQ;-'4LX3=R:[=(B2C]TD@FU3<.C
M$`/.6*W1(3J'QZ2@'V9R<]S@`XDAHH/H'7\ZJI[V[NH8K>YD?)#`PMC:XDAC
M2XN+6UZ#<2:#2I)7O\!G%4J<8HB<!A%QR4/%H2CV;18MTY:1:,6#Z0*F'Q3E
MG&J.U6#913VBBU4?+&*7V<J#G(O>6!A)V`DT\*FE?S!5;[^]DLH\=)*\V,4C
MWLCK[K7R!H>X#VN#&`GV-"Y+.*I$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A%6QZE5[TY1-=:]>;E,T)$/[FZ;1'Q6S(W60#(DB%EE>F3D:G;4Y$0;
M%$?)*DD8`][KX#C)-QBWO9[B5ME7<(Q7\,OTK]#FT6W_`,GG&?4#D_+,M;^G
MPD-]%CVNEVXZ3(G890!6..ZM3'[U/?+G#PVJG(>XKL7X\5H;^EK5A_J?@KDT
M&/SU>I_@'?QJ]`_Z)?F8_5N/]V+C_6ZG-Z>>VNV6Z[]6A]3*QYK5]%S;H0:[
MXA=C'-'HJM?BO\WH_7%57`I14+^W^*$J?AR0>><L'(K3*0X[?=_O6\?\D6=:
MTUWN_)35:S_-=P/UDX[Z7-O^=B7X)\1A;[V%FL!O(=M_'DO[ENM#[G;!=^L*
M*\T/R_+\V01>:OYUG")A$PBUKM+7%'V?6V\'L5HC)5.)G8:WR,6^42+"R*E6
M=EEFB%B;N"':R$$FY0*JX;K`**H)AUAT@(94VEU/9RF6V)$SFEH/B-PH:>-?
M8?I4NX7R[DO"\P[)<2D=#G9[::UCD8#WF"Y;VGN@<TAS)BUQ:Q[#O:7>[JHJ
MVO4':Y7G$'LR%VM^"<=9GKF9JS[6MU@J;5)`[R`90TPO6&#-HK#"C+Q;%%1X
M=LGPJL0%C#U#SEXAO<M(UUI)#WRT4<'L<YPU)%2=="=*].BS?@^?>M>6CN>'
M9'!_SCN[.-L5RS(6<UW<L#)WRQ-N'N<):Q2/>V(2'W6'M@;=%X6757;%"#48
MTVZY77T;.T-6N)1,)M%K$-]CU"9GWDH^DII\KY[R7/-S4NX!=^FNF=07!R`<
M/``17F5D#W]@2N;)NJ8Z['!H%`/"@`TI]*Y8?G'K/DO/W@XY!E;RVR8G,LV-
M=*['W4,#(V1PL%&1"&&*/9`YC@W8UQ:?&2&RHS4D7K)&G7J7A:9KT2UV)CB+
M2[>":))UY['RD+'Q[E90O)$#Q"7NEYY2(//AR.6NT?>NN^]`TON?>)TJ?>J#
M7\JQ#P^]Y[>\R=R'C4%QD>5UGED+8G3N)G9)',^1H!^]W7:D"CB/%;@:N6[Q
MNB[:+HN6KE)-=LX;J$50705(51)9%5,QB*)*$,`E,`B`@/(91D$&C@0X=:]5
M`IH9;>5T$[7,G8XM<UP(<T@T((.H(.A'AT7[Y\76F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%5?ZJD9*R6L-:$BKD--.E>
MG9E7/T70+K\:4T*L4$!9W]HZ9,O+-[P*-P!4?U1]W)5Q1S/,R[FEQ,8_2<VF
MO]CU^T+=KY(;RQL^9YEU]C_B#78Q@#?-WUGL/>&NZQ<U[Z]-KZM'4:T5'/TK
M;_LWD/\`J&[;O\C9.P^.O[T[^$E7I/\`&\`?_IK_`+:S_P#&JPGTS82?8=QR
MZ\CLWZL;!0Y\@Q0:NT_4/VAEFG2N,K2(]M-?LA`1\OJ!(W/O`/`9'>3N8<:*
M,+3W&]7O=X'P=HM4OG'R6*NO2)L5GAO(R_$X/Q/B.5NM*/T$5X]T/O?K4W-\
M.J^@P/[7MS'B\JUG")A$PBT%W)UW8ETU3+47616B,_=Y*%J\A,2"G2TKE4DY
M)`MLG54?,2,],U@R+$(W*;J7,H!0^T<N.+EMH+L7%U^]QAS@/UG`>Z/HJ::K
M)_H_EN)\=YQ!R;F?<=BL;#+<QQ1CW[BYCC=Y:`&A#-TQ83(11@;7P4-*?J?<
M>DK;0HI_KE3:=#U?,[+9TQ2E-8*-CVM/V)!Q#N&KC.NRC[_%4=3IELNQZC',
M)D1*H'N^&7J>\LK^*1[9.S<RM9NWEQJYA-7;@-2X4/["V%Y!SGT^]2<'D[^U
MR[<+R?-6^/?=B\=/)(Z[L9I6S3OGC9^(^[A<R:@``<"WKJLUC4NT]=MIF#DM
M)EOGXA:NN,"Q@&<G`K4VC2-HOECFV5(E9=Z=,6L!&1LR0YW#=$Z?6*@)E\"B
M'*:\M+IS9&S]OMRM-2#N>&L`+@!XFE*'[5\S7.^$\LF@R5ER/X9\*S=K,^=T
M<XN[R.VLH(7WD43`=TTDD1#6/>'4VEYU*W9M2M;/IVE-.TBJ4E79-SAXB(IT
M]>FK2(F9:BL4*LE$V*VP,9/K(IR4Y*$3,W:]9^DAE.M4#%`2C;[26TFOIYI9
M.U;N)<&&H#SNJ&DCHT=2L<\(S'#,_P"HO(.29O(MP_'YYY;N"R<^6**]>ZY,
MMO:S20`F.&,D/DH*D-VL()J)0ZQ@(ZJZ\IE<B(N4A8V%KD5'LXF<5*O,L$6[
M1,@-Y18BJQ%)`@@/FB4PEZQ'I\.,M-U(Z6Y?*\@N<XDD=/L^CV+#',\I>9OE
MF1RU_/!<WEQ>2O?+""(I"YQ.Z,$`AA_1J`:4KJN]9T*,IA$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB815K^I7M#9^K=<Z^D]7
MMIAQ)25S<,9,L-8M.5Q<&)(E98@JN-RQLE#N$Q7`/<9E*X`?$1Z.0R3\6M+2
M[N967=-H8"*MD=K7_FR"/MT6WWR><+X9S3EV6LN:.MV6<6.:^,S6^5N&[S*`
M:-Q,D<K33QE)C]@W*G'][WN[_P"BKW_K0[%_^ZN3;X+B!U,?\'<_VR]!?Z!?
M0;^[XO\`T;S+_*5.GT\]_;[V3OU>N['96A"NA2YE\"DO=.V6?:?'(+-@0#X'
M4D)'VHJ@E,/!Q4^&#^6`B(9'^28['VN/$MN6]TO'1LPT^N0EO[:UG^:[TM]+
M^(>EK<MQ"2Q=EOB,+/PK3D4#]C@[=[^4FDMJ:"H#>Y^J>JO,#^[_`!_W<@2\
MU%G")A$PBTUOS:C'2^IKAL%VL@DXB62;.#262<.@>629<HQ,`R38LTEWK]5>
M4=I_L$2&55`!`H<CR%;CK1U]>,MA7:3KX4`J2:^&GCT"R!Z7<(NO43G=AQ2!
MKG13RE\Q:6MV6\33).\O>6L8!$UWOO(:TD$Z*(NK.X?9VY2ZAI["Y0D#;EWN
MU:UM*PL*,]*U>V/7S&+=1DG`5NS.(V4BZY8VTF1VW%P4#KH#[H\>]EXN\;:6
M7>F,;G0TC+`7:@/K4%S:@D4IIT*SSS?TGX9Z?.S_`""ZQ]S=8%D>-N,;`^\8
M7,@OGR-DCGN+=LD<D]NZ,QOV&C'_`'JG19I^\-V['CK,Y:W>FTYQ0-;7.<>3
M"U3)(5"V3E/NUDK_`-1F4<3J+F-J4DP@0\PJ:YS(*><)5#`F'/V:PL+5[08Y
M'B65K0-U'-#FM-.AJX5TT'@%\S_IMZ<<2NK.*?&Y#(197,6D+(FW19=6L-U:
M6\_EZ-A+9+J-\VA<P![>V"T%Q(WA<MD[(F=#TS8U`%O$6^Q41M>`I2,.VL%L
ML#M:K(S2=8JL3)2T*@X51?N2&=G44ZDV9#\=)A`P6^WM;6/(/MKCWH6R;=U:
M-;[U-SB`?#I]*QMQ[A_#\;ZG9'B7*=]QQ^TR;K/S9E=!;0-%R8C<7,L<4K@"
MQI$0:VCI2WJ!0[OU5<4]@ZUHMW3<L7GU35H6:6<1I52,#NGK%%5X#4B_*R:*
M;L3E`IA$2\<<CQR-#=P^7NI(-1L>1KUT.E5CCFW'W<5YAD^-N9)&+*^FB#9"
M"\-8\AFXMT)+:&HI6O0=%W_*=1=,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3"*M[U)-3Q&VM=Z^C)>FZ[N:<5<G3]!KL:PZV
MKK!D=2(6;G<,'.RA^7+O#IF$HD;_`+;H$1'W<DO&;MUK<2N:^1@<P#W&O=76
MNH9K^5;=?*#SF_X-RS*WECD,MCW3X]K"ZPM[^X>\"4.#9&X_\1K`=09/<J*#
M54\_N8TK_07VOC^;\4.U/Q_X633XR_\`NUS_``4_[BW]_K!\C'7DG-:?^[>2
M_N*<GI\]NM<UAOM:S1FL=*U)U]%S<>65H5UT=/SH)NE6HJ-A8Z],,^5FL"0>
M8<>$`Z0ZOLRP\CR#[JP[9DF<-[=',E:#2M-7^[45T^O1:V?-5ZM9?F?I>W#W
MF9Y%?1?$87F*]L\Q!#5H=1V^^'9W"IVMKOU-/%7A!D$7FVLX1,(F$73+PA3B
MP2D]>6L>XA*4NG=OB))$JZ$4^K1%)!K,HIF`?\.C1()T1`!,"G'3[W&=UN9^
MYVX">X\;=/$'0C[?%7[C4F?=DQB^-OE9D<BTV=(SM,C+@B-T3B/T)-`\'3;U
MTJH9WJZ]HFP8K6NT9#6TWM)UNALXL-.<5*@6.:MDJR@(AO'/)*4CV)6<C&I1
ML1Y;94'($,!`!,2CP`9?+>#-6KY;1LK81`=KMSFAH))(%34&IJ13ZUL-QKCG
MKUQ6^S'"+;,6V$AX[(V"Z;=7UO#;1/GE<]D<4C]T<ADEW2-[9(K5U1JN/N%T
M[,)%:BO'NKG]QC6.O#R<=*5G6LY+UNDZ^CK"[8OFUO2CTDF\,PB)]DY%TT<H
MG.F=%4QR#XB/*"#.,$@;*&/,E""\!SGT!&VO4D$4(/B%58'CWS#6L>3@MLW%
M87DN7[<D=QD(8KB\OGP->QUJ9"72OE@?&(I8W-#FN8UKAHI%;P>=O_X/.MA;
MD3K;[5%1AR7!&9<-UG39G&?`@9LZ@OEA1?*'?L50232;!RNF?HZ1*.6S'MR7
MG?+66X7KSMI]-::U_+JL3>FMOZJ?S_9Q3T^-W'SB_N#:F$$-<^3?[S9NY[@[
M;QN+I/N.&ZH(6Z:S\F&NP1ZXV09U]2'C581HV;%9-V\4LS15CT46A2$!LF1J
M<H`3@.GV<912]SNN$IK+N-?KKKK]:QYF1D1E[IN7>Z3*BXD$SG.WN=*'D/)<
M:[B7`ZUU7.9UJVIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB815*>K>VMKS56K4JBGL0[H+Z],[_#O4]6VR^(@6#7$OS&+M+A
MNVBVIE/`JZ0B<Q_='PR7\/?#'=2F8,(V"FZ1S/'P(Z_:5O5\B%Q@K?F^;?GC
MB1;_``M@;Y[)W.,97O#][DMFN=(ZG5C_`'0/>&JH7^1[J#Q\KN>_H8:@_P`H
MY/\`S-GXL@I_A+UZ>?$?3KQ=PP__`';E?XM6/>EM';'9]S+A6TH[I+%GU_8"
M`:^=NU`U?!E<><S,F/U+7'BTB+LP<@FWZ?+4X'JXXR,\JFMY,92)L8>)&])7
M2'Q\#^S^PM2/G7N^(S^C;685W'3>C*P'^19Z^R,U*/K_`">X8&;?UGUJWPZK
MZ,P^W[_M^_\`LYC=>2"\L(F$3"+3&^-:S6W=?KZ]BK(>J,;!-UXEKE&Z8GD5
M:>QEFTA8(J)4`!!K)3#5H#=-8?!(%!,//L&LQ]U'97/F7MWEK7;1X;J$-)^H
MFOV+(7ICS#'<"Y4SE=_9B^N;2VG-M$XTC%T^)S())17WHXG.WN;U=M`^E1N@
M^V?:&KKTTL>N;)`VJ!A;/L"QUV*OSV4)*,3;.A8I*R-',E'-A148,K%'&<M$
M4DDRD05%/P$.<NLF4M+N`QW3',E<QC7%E*'MD[30^UIH3XG59=R7K)PSFO&7
MXCEMG=663N;*Q@GELFQ]M_PZ:4P.;&]U0]T$G;E>YSBY[0\U"Q`=M^Y->HRY
M:59J'(35YI%BA;=8)YC*IL(BV6FWR]EDIV%KK<RA7L0T;R_DMV:BZ?49$#'-
M[Y\2Y2RN2#,R0,C>TM`(J6M:&@%W@=*DT7W*>KOI]RN2`\BL\G%C<9DH);6"
M!\1?+:VUK%;QPS7#@"R5SHM[Y6L=0/(8/=:NS[M[2%MGZ*J6G:ULN?IAJ%1Y
M*JPCY..BY./FW2U(6IL>[LL;(MW)%"-"*F5(9(2J(BH<2#SP(=-AF!:Y!][+
M$R022!Q%2"/?WG:0?L-59O3CUWCX;ZF7_J!E\-:Y`93)1W,S#)+&^%HO!=R,
MMY(W-(+B`TA]6N#6API6LI*#7GU1HU/JLG+J3\C6JQ!0+Z;5;HM%)9U$1C5@
MO(':MRE0;F=J("?H(`%+SP&6JXE9-<22L;M:YY-*DTJ:TU6%>49:VSW)<AG+
M.`6MI>7L\S(0XN$399'/;&'.]YVT.I4ZFB[=G2K$F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%73ZC+?6+C7M!)M!6VI1A;
M@Y-'?241J67=F??*50.#I';=CKD4DW!'G@S111QU>`EZ>1R2<9\V+B3R@9NV
M:[C(-*^';:3^5;:_*/+S.'E>4=PMM@;TX]O<\U+DXF[.Z*;3B[>XE+JTTD:U
ME.AKHJAOE?:']CK=/_4GLL_3[=I?=DTWY@?HP?\`A77\6M]?/^O7BSCM/\+Y
M=_JU3<[`F>A$-[+J:W<;&4L/T;,`8EIK?;G%1GP`JMO/$'.K;M/V85P-P!2B
MA\.(?KF#PRP\C=D3CP+H1=O>.AF)K3_G&AO[-?H6M_S2W'JA)Z9-9R]N'&*^
M(Q?WM/GI)-]'4]W(V<%MMIU/<[@_1!%5=D'\''@'Y<?9[,@J\Y5G")A$PBT)
MW*7^8UWJ.P257CY:6N4^XBZ32HZ";HN)5W:;>^2A8P697#EFU25:`X.X\Q55
M-),$>HQ@`!RX8NV;<WC6REK86@N<3T#6ZFOU]--5D_T>XMC^6<]M+3-36\''
MK5LMY=R3N+8FVUJPS2;]K7N(?M$>UK7.=NHT$E5ZP-Z>/7NI-1]P6P=A:Y+K
M>5VE6[9,6N[-:5:+:S90,1-ZPMUIF("4=PRTK.PSPZP-F[M<A5DQ*/)@$N21
M]OM$UYC(HI3*(RT-:7-;4D/:T.`-`1U('[:VMRG&K>VML[SSTJQ6*R[LQ!C;
MBVBMK-UW;VKWSRPY&UMHIXVRB*&9C6=Q\3'%C@=!0K\(^\DEVJDIM_=]]IJD
M+IVTRFI9QO:UJY9;>V:;$L3"G6X:MY""=LM4E&MVB9$#-5!=(^684N%N<Y.@
M[9V64$3PZ9HD&W<UM6`N;6IVM!KK70^.B[+OC;L?,++@7&\9D&7'(+:/*0NM
MA/;VKG6$#[NU\SN)MK6.0RN+Q(WM/W`/K&I#;[F=DR.E-!N9K9-<T_9I4D+.
M;"-9Y"R5AC-2;*EGDI.IGF:TCYT0HXE#G,)%%D0,*727K,'0-MQS+9M_<".)
MTT(J&;0UQ`+Z!U''73_NK%'I?CN'6GJ+RF&PP]WG\+`Z6&Q\M';W+X8GW8CC
MN1%<&DH;&`-S6.H'5=M!W*7VGK(YN&K:!:'D'+UMS.56'D%8.>7.ZEXXR[1,
M?)?.E"E4<JF`.L%#`4QRF`1`!$0RRWL0@O)(FN:\->14=#KX+`G/L1#@.:Y3
M"V]S!>0VU]*P30@-BDH\ZL:-&CPVC1I!`T"V1E*HBF$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%4UZM%$&^:KU>Q!:GH@SO
MKQT(W#5YMH-C=4&NF`,HWZMJ01;@!$!,OYBW43DO2'/5DOXA<.@NIB-]3&.C
M]GCXZ&JWF^13DPXSS7-7.V_=W,6QG\ER/PUPI,#[\GE;GN-T^YM90Z[CT5#@
M=N?`^#W2?Z>T4W\]'V9/OB<G@9*_^6=_:+TX_I:!T[?(O]Z!_JE6-^EWJ3Z)
M[F'$S\5K97JH%A:G3JN@QUQ)CYRS(2F"Q?B-:/V!>@>M#X7]KX>^7CQC7*KM
M\^,V.[E!(W4R%WMZ@M'Y]/IKIJ5\Z?.QR+T=;C]N7'^=('UN<WY^/0/K_)_(
M6WO&NCQ)[NONFNGT6!^7M_/F-UY++.$3")A%U"]6V(H5/LETG`YC*O$NYER0
M.D55A:)&.@V0$P&*#EVX$J28C_+4#.VWA?<SM@B^^\T_+^T.I^I7WC&!O^4<
M@M..XS^_;V=D33K0;CJYU-=K6U<[Z`5%-+NGD;?7M0/:#HYY;KEM-&V*2-%L
M-PK=3D:"]HZ+;ZCAK))/64JU/.QRKDB0MTR]0#XB(!EX^$LAFF;<7`9!#MH]
MK2X.W]"T5!H>M5G!_HE9X#+9^VY3R6.PX]A#;=N]@M;BZCO67A=Y>6WC8^)P
MAD#2X2.-/H)7X&[K9.PNF(T+0TG=FD/3I2TW\'-KKD%/T56O6)_79ZLLH%ZQ
M=GLDTP<Q2ZJ1$%VZ;@GE=)@%0./HQ+8@?,7`C+I`UGNN(?4`AQ(/N@U`Z&GV
M+N'H?:8F&4<HY/#C9[C(1VUC2VN)H;T3P,G@N'S,>P6\+VRL:XO8]T9WU!##
M78.UNY2GTFBZ\MD=$M;A^*B*+ZD1LK-Q-2CWS`89.P+O9";GB+,HP6\6L4P$
M,0YSJ&Z0X`#&"FL\7//<R0.<8^UHX@%Q!K30#4ZJ)<&]'L_R/DV6P=W._'_!
M'.9>210RW4C']XP-9'#!1\FZ4$$@@!HKJ:`R'K<N6?@(:<*S5CRR\8RD08KJ
MM5U6@.VZ:P('79+.&:XI`?CK2.9,X!R41`0RVR1]J1T=:T)'_"NJQ3EK$XO*
M7&-,C93!,^/>T.`=M<1N`>&O%:5HYH<.A%5S6<%;TPB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(JXO4AV$^UYKR@2#'7A-B'
M?7%PS/'GU'#;>!@4(E94'@1$U:ZHC%]0AT>>154P\]/2`>.2;C%LVYN9&&0Q
M496O<,==>E0UU?J6W'RA\4MN5\LRMK<Y8XEL6/:X2#*2XO?64#9W8;:Y=+UK
ML+6@4W;O!4_?O.V#_9A;C^;]R6@^/_O+DT^$L_\`2C_C3_XM;]_T,XG_`&S=
M_O?>_P"J5.'T_-T2M^WRO!O=+)4%(E+F7@3I.V^K:J,84EFP`S^IX?85F=F!
M?D1^'^&`JG'(G#CC+#R.P9;X\2MG,AWC3O.D\/86-_+71:V?-1Z>6/&/3!N3
MM^1.RDAR$+>R<_<Y*E0[W_+RV-LW3]?N$M\&FJN\#(&O-\+.$3")A%JO;VJ8
M/<]31H]G>R2%:5L5=FIV.CEO(+9(^ORB$M]-21_UODLJX:IE=%((&.D'2`AS
MSE797DEC.;B$`R[2`3^B7"FX?2%->!<XR7IYG7<DPL<+\RVTGA@DD%?+R3QN
MB\Q&.G>B:YQC)T#C4@T6CV_:+%5.WJ6W5-VE-==,[9+%'P"$3'SD'$2=T@X^
M&M[Q@A)'%?XB=<1J;Y05%#@#OD0#I'C*\YE\T'9O8VR':`75()#22VM/94CZ
MEDJ7UYO<Y@6X'G&-@R];:W@?.Z5\,TL=I-)-:M>Z,;=L+9'0M#6C\*@K457@
MW[2C03)6.I6V;A50FJ9)5"Y32+"%?VFQ*S=CD+--VA*6<M@0BK)(O)19/SDV
MYDTDN@"$#H+GTYELCM\\+'EKPYHJ=K:-`#:>+0`#2O5?9?789.Y%WR+!6%[Y
M?(QW5I"7S,MH!#;LMX;8Q-=NDMXV1M=M<\.<[<7.]XK8%W[>:[8H/6$979$U
M5>:>:N(ZBO%(N/L31E%O:T-1?,GL5+IG;/A4ANGH4$2G36(!N1#DHTL&3DBD
MF=*-[9S5XJ6DD.W`@CIK^513CGJOEL3DLU>Y>+SUOR![9+UHDD@>^1EQYICV
M21$.926M1J'-)'6A&U=>TB(UM2*O0H$[M2&J<,RA(Y1^N9R]5;,D@3*JY7-P
M)UE#<F'V`'/`````927-P^ZG?<24WO-310KE?),AS#DE]RC*B,9"_N7S2!C=
MK`YYK1H'0#I[3U.J[EG2H^F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A%6KZENC%MZZXU["(:UE-EFAKFZDQCHLEU45CBJQ"
MS87JH4K96LWH)GZNCE9RY3Y'P3`?>R3\7OQ87$KS,V(%@%3LUUZ>^QX_(!]:
MW!^3KU+C],^7Y;)29B'#"YQS8^Y(;,!Y$H=M'G,?D&5%*G;&QW]D1H::O]W<
M_P#]E.W?\WWY_P#:X,FW\YFG_K<?_1?Q"]"?ZV5K_MQ8C_C83_\`65.WT[^T
MMUI7?R]O6T;/:]3-2IJ+^?R2.TB-Q,Z6:F^"`UQWIL2)\Q?R_``CP5\/=4+X
M\Q_D>7;?8[M"=DGOC0%E=/'W8F'3Z_'6JUD^;'UV@]1O2QN`CY+:Y9_Q&&7L
M1G&EWNAWO_R7#6$M!7^[[?:PZ4O1#\OT^/Z,@2\T*U6<(F$3")X8T*)A%CP_
M-CZT3P_-A$\/S83JLX1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81.0
M^_")A$PB81,(F$3")A$PBI_]827?P^IM4K,;-]-'5V"](HX_!ZR[A%P0(%P<
M$0BJT<B\1TF#J^(5Y(?CH#Q$,F/#(P^ZF!:''MC_`)01CK[3U_X>"WY^0+'V
MN0YWG&75IYL-Q3"&_%;?%;?QFBO=N*MEKTV-U'WN@7S\?7%@_P!*YOZ#NUO^
M-S(GEA_<Q_C+/W5ZI?S:Q7_L3_\`,,9^XK,/2BLDK+=T+AN\O`V%$->V,_P)
MNVJ\:H'J*LR$JP6>P*&8#Y8F_P"3\=:H#[OL'(ORR/MXO[@'XC=>\U_M\!^?
MP^U:<?/)A["Q]%62VV-\H_XM;C?_`#@L\EX/T\M`-^OZ_1IZZ$!?2J7[?Z^8
MS7CVO+/B)A$PB@;W&[UOFN.ZCLYUG!S;")HVV7NS_K])XV8"=XA5V575B")2
M#Q%0S$A7$JIU>69,Q^H`Y\,M-_=RV][;0L($4CG!WU``]5LSZ1^FG&.7>B?J
M!S+*6\DW),%%CS9%KGT8;A]P):L:X!Y(C;3<UU*'13><3<*U,<CJ7BVYD_(\
MPJ[]JB9/XHW0VZP45*)?B#^"?/ZX^`<Y<G2Q,-'N:#])'BM<XL;D9@'003/!
MW4+6.-=HJZE!^B/O>SQ5)MX[U=^0.T=F5II;HEG7ZMWP=ONG61W4#%*'1UU?
MT$E[+&*.U$4$R'6X-TNC@=5(GL,''.1FZR-[%<M;O`C-R&D`#[OU_LD^"]&>
M+_+QZ693B.'R=UCYY,I?>FN<RK@V:4!V0LMWEY-H<20W3\)H:UQ&H-5:?W%;
M!>T/0FYKG4IJ/:6RL:CV#;ZLX$S-Z))&`K,F_82*;%43IOVS5\@F)PZ3)C^J
M/MR_W5RR*%Q:]HE+'%NHJ:#J!K6GVK2?TAXG!RGU3XYQS/6TTF"O>06%I<MH
M]E8Y[F.-\9>`"QSF%U-0X=1T45)?N'V4;TXAWM&V6/#<@:.C;H>4081903GW
M;!)4K]2$6*Z9)-UUN>"F3\L?'CC[+5#D+B3!B^:0;@LKKIX]?V-.E5FVP])N
M(-^;P^EU[://`AR66T[6^4U@:\C8)@6O+@W0G=NJI:Z\ORT[I&CVB6G8QQ;Y
MC5M>FY)1%>/3.O9W=.82TEY3)$PI$5^.<"?R2E$"@8`Z>.,NHN6NMQ('-[A9
M74TUI7I]O18'Y1QF/'^HN1P]E:SLP,&:GBC!:^C;9MT^*.KCK38VFXG4@ZU5
M-?;KWO=SUO<:(2NUYBGAKMWA[)U;8RJ5J"2(\UY!5Z/?P\8D>/:L08NFRK@Q
MS.`Y5-_*\`XR-0Y:\DCA=NU?<;#IX"F[]NAT7H/ZN_+GZ-\<@Y-/Q_$S1QX[
M@./R,!;<S$QWT]Q)')*1(^3N-<&AO;T:.K1XJS+OAW/9=6=K>V]@ZCL\4WOE
M7@D7\(\0/$3`,UUG)$T5UV3HCQL=`X<A^T)TB`#P(9>\C?=JS=-:.8Y[2.A!
MH*ZG1:<_+;Z?8;FOK5A.*\\LYI.-7=PYDS'=V+<`PD@/:8W`C^Q=525J-I9O
MZ=6Y>8F8P'SB!KRLPN=XS033EI*+:+J)JE!0J;99PX5-T)^`CSP`97-GB[0D
M>YH``J20*5]OL6'<YAKBWS]W8V%O/Y9MS.(FACW$Q1R.`+>I<UK0*NU^D]5`
MC5G<ILJ?L/J(1=@LL2X#0MHLC'4K0T?',UXYG&T21G&Z"HI]"LV"4BV*83*%
M,;I\!$0'+1!D)9+F\@<[]Z`V=/$'I[>GBMI>>>C?$</A_27(8NSF8WE&/MY,
MF[?*\/>^]9"YVIVQ!T;J`-+?;H5RU4[B=BR'IU,-\2%BBB[@?Z/?7EN^7:1P
MIJS:,<+DSQ"$(#1NX;M5%"\D`G07D`-^?AYZZ^!^8>6MOBPTZ&I::5'V:GV*
MW9_THXA9?-G+Z:VUG.?3Z+DL=FYC'OJ(7O#0PS.+BTNUH2ZIUIT4B^UW:#[8
M?;MHV[WNPQ3BZ7;6E-L,\J8\?&'?3$[&(K++(QJ1TR(%>.Q."9"%`O("!0\.
M,N5I=L=9QRW$C=[FBI)`Z]/92OU+$_K=PJTXGZO\GXQQBUF9QW&9F\@A;1\G
M;AAE(:'/().UM-Q<?I*K%C.\GN*?[0:UKZOCQA4>_>P:3?(IUZ$37#6C2MG?
MLH4RQVZJAETWA.H7!2%<=/M,(>.1Z+,73[E]N75(NPP:#[M"3T`Z>TK<S(_+
MUZ467"W9CR#Q?2>EUOEV$SSG_.#KC9)-3>!0MT$=2P?JU5V"EDKJ)>I6>A4B
MBHLB!E)1B0!5;F(1PD`F7`!40.H4#E]I1,'/'.2OO0TKO;3ZPO.6/$Y64TBM
MKAQH#I&\Z.KM.@Z&AH?&AHJZ=2]PFU)_U!>XO35HM#(^GZ)KNKV&I1AV<.U"
M/D)%ZZ3?NUY=)JB]60,@0G2"RPD#GD!'[+5;WT[\G-;RD""/ITZ&E#7Z?8ML
M^=^E7",5\J_$_4##63QS_)Y6>&ZD#I7%\;&`L:(B\L::UKM8'>U;"T)OFX7+
MN2[P:-<I^,)1-162B1-)!4D='H,F\_`B_=@N_P#+24=J.')@Z3*+&^XH!G.W
MNY1>W#9W-%HS;M)(%*^'V]03]2BOJ?Z88'`>D'`>2<?M)CR?.VE[+=[>X]SS
M#,&-HS<X-#16H:QOTU6K^['N7V;KK?E#HVO+5&M*O-Z%WI>)!!&-BY0[JS4E
MC'*0C@DBN5UY1(]=<_6B!.DXCP?GV!3W>0E;?=BW>-GEW/'0BH-.M5-/0GT<
MXAR_TORG)^4V,DV4MN48:S8XRRQ%D%V^03-,8+0[NM:`'$U;2HI52N[6MI2F
MQ^W#2&PK],1?U=>-;0%GFUA.TC4W;]TP(XD7+=F!DB)H$,/)N@H%('W9<K*8
MOM8WSN'=<W7H*GQT6#/6CAEEQ+U9Y)Q?C-O,,#C,O/;Q"CG[&,>6L:YWO5.F
ME7$GVE19]2#N>V)H&H=O$YINS0[9Q>>Z#6NL+<H+..GDG58LGQHRD8'F%<@Q
M=J)D3.50G2J7PX\!RGO[QS-C;5S3()0'`$&@I4@]::?4LX_*'Z,<3]4LYR['
M^H%E<21XSA60R-J-TD);<6^SM2Z%F]@)<"#5I^Q6'3EA8,H68=M)6-^*;,Y8
MK0/BVJ@C*,6;A<6H)>:'FN43)\F2_6``'D`RMGGCCA<0YH<&N(U'@*_L>*U,
MQN)NKC)6]M/#,(9)(]U6N'X;W-&ZM*[2#H[I["J;-,]Y>^KQZ>&_MW2EVA7F
MX:7*79&IR+:"A6)FC.&G2,F8JP9O.9NP;MS&+UF3,!O:/(Y'+'*W$N,GNI7@
MRM-6Z>&GA]J]`O47Y??3'C?S7\8]-;#&7$7!KZ*S\W&Z>:1KI)8=[]LU6O:'
M.H0T.!%:#12B[G^XC86M.Q='<%-LD>UV>2GZ[DW<@LPC9(R#RQMF!G[M>(4\
MEJD#DZQQ)RF!0$?=+E9D+^2VQC9FO`N"6`D:TK]&JPWZ,^DO&>9?,P[@&;LI
M).'G(WT;(M\D0<RW<_:QLPJ[W0!4[B?UBITP%GC'<1"F?S<5\U<0T6\>H'?,
MTG`+N8Q)ZL=1KYI3I=11,IP)0X(`C[`R\,GB]UKGM[FT$BHKJ*UIX?D6LF5P
M]W;Y"=MO;S"R%Q*QAVN((;(6@!U*.(T;H3K])4/=O;ZNE=[Q.U?5%6GXS\.M
MF5;:DQ<4T$V#P7SJIJUU.-\N2,DX.U2;_,E14*F<@B/M'PRWW5W,V^MV6[FF
M!Q=OU%`*=:^T>S]Q;`<!],N.9;T"YOS7.6LO\[</>8Z*T+C(W8VY$YDK&'-#
MB[MMVES'>-.JUZZ[DMDH^J/!]O/U=#ET7+=K,CL9O$?"PXF>7IM;646D\;SW
M'QQR@R7$H(%4%,PCSQR&//#XH+;>WL]K=3Z21K7H>N@T^U2VW](>'2_)5>>J
MIL+@^IMMS6*Q,NZ;W+-]M)(YCH*]O[S*[RP.%.M"MC=G^^+CLZ;[F(S9%AC%
MD===P=BU]2_-2CXI5.`9M&J[./,9)-H60<)F7XZ^#'$!#D1'QSEC[J5[IA=.
M'NRD-Z#3P'751#U]],,%PW'</O.(VDS79;BL%]=T,DM9GN<U\FI?VVFG3W6C
MV*-<9W7;J1[4.^_9LS;XY*\:;V)N2`U>^7BX1)*-CZJ_<I5QB#`K=%O+.$6R
M8<@MYJB@_K#E.<A(ZTN9-X#HW.#32G3ZZU^P+,<OH=Z=7'KGZ7\-L,?,[C7(
ML5BILC&V2:LC[EC>^\O+G.C#G&M6%K6CH`K)-`VV:OFC]276R+INI^UZ\J5@
MFG2+<C5)Q*2L*S>/5DVR8F30(HX6,($`>"^P,N&-G==6$-P_[[XP3]H6H'JE
M@+#BWJ3GN-XMI9C;#+74$3:EVV.*9[&#<=74:`*G4]2MO96J!)A$PB81,(H#
M=_<8WDZ)24G%FF:P1.UN%`=0U3V%;EW!OEBI?)5::[G(1^U3`!Y\QP<Z//@!
M>KQR0\=>63R'8UYV#JYK::^UX(^P+:'Y6[R:RY/DG16=O>.=8M&V6YL;4-'<
M&H=?PS1N]E&`/\:T55_TI%_;MB^<?;_X+=SH_P!3\0<EW>?U[,?\+#_:+=PY
MV\I_ZCQG^E^._P"0J8G8[!L8W=*RZ%ZM%C.-3EB?`2^N=T59F4HJH"*WS2^V
MN9@A4((>"?D@L;GW3`'AEDSTCGV`!C:SWP:A\;OV&M!_:]JU^^9/)W-YZ=MB
MEQEE:-\]$=\5_B+E_1VG;LK:&:AZ%Q<6BFH*N$#G[?Z_/WY"UH&LX1,(F$5;
M7?\`=C]F[P%M</*O=V=)?T*)O#%-XX^8`JJK:UZHHF9`\>=)5+R4X`X&-U`(
M=8<!EDS&-FR&WM$#:UW4TJ32FOLT-5MS\K?S'8;T$^+6^<QLF2L,I-:/<UO;
MT%L+@$$2-<""9A04_1U6J-O^G%LG9%=W!!L=U/8A79)M!*P[Y-U+$/5EM1(,
M&\N9IT*F6Z9\&AC\%.`"8_)N1\<H)L%<R%^U[:%D;:$D@[*&I\:GVUZ+(/!?
MF^XGQ'*\=R4W'8YV85V:[S"V*ETW*.D=&'Z4_`WANH.C?=("]';'IG6W8#?;
M*4;LB/BW.QMWZPVXB],@Y.HV3UY7?E`QRH*)KG(X>K!U@H0P=///W@/RXP=W
M*Q[8WL;NFW#Q!%*&OC7V+GP;YP^/\8N<++D</+/!B>-9#%[0YHJZ^G[O=;MV
MBD8THX&M*'1=U?\`I\W.2JVHJV[VJJZ5UYVS[7T7,2CQ64<GL$IL5)9)O/+M
M3K>2X+&`M[5NLW!>`#*HXF?9$-S`Z*!S=!H7'IJ=0/;3JH_;?-;@+7/Y_+18
M)K+7+\PQF9CB9VV"!E@6ET+7!NYIDH?N%HUJ5P;7TYKL2N[`KJVRV!H^U]K%
M(T!',Q1D3,F,W52R(.;,HR15;L_+?_%$Y`J?F>[XC]_"#"S,;VGEHC[&S0G5
MU:_=.E*^/7V*XR?-GQD9;%Y=F'G-Y9\VO,W*\NB[CX;DLV6X>6N>2S:=7.+=
M>BX_5?IO;#U_!:>A5MOG4_#K<9=F31VCB6%O/Q1*77ZN%:%!=0RA69E8@ZGE
MB?R@`P>'W=%MA+Q@B[KVU9(YQZNT=3H3^D*:$_4JOFOS><5Y5E.0Y$8"C<M@
M!C[<.$>Z"3S4]QYBK0UN\"4-KM)TZKC-8^F):Z#%T1HOL:)>+TSN(V=N?J:M
M'B(/(Z^U].#;QA5%_/.BZ8"F!Q,4`#@>`'D`'/C<#<C:-S12<N)J?>;0!H(Z
M`Z:CI]JK^9?.;@.2W65E@P\[(LEQ/'XJCW,=LELK@SNEHT-!:\F@K7VD+6%3
M])+:4)$]P41)[T2E6&W]00NNH:->#./F,+*1TLO*+33E-RZ$%%#`H"13$`#=
M//(9S@P,T?<#G-#'1Z4\7`UUTT;^4J79KYZN$Y*]XKD;?C+X;_!YZ6^GE:86
MOFBDB$8A86L'B-QWU%0`%O#8OIT["O%>VO#H[</'#?[_`*0MD0B1S,)-8!GJ
MB)>1T@U0!FJW$OSY5T"AR``@;RP`P\\"'R;!W$['L<64?*QVM3H!1U?`_144
M\>JQOQ+YM.+\7R&"O/@1F.)QF8MI'$0[YW9.5DC"XN8[2!K"T'K[VFE:\<GZ
M:MW;]Q-SW*EM5$8*WQ^QFCZL)).FI'A[S3V]:;+2`%(=-VK$*MQ4*<XF/TJ#
MP(>//%V!N#D77;71B/PT][[I`!/UZJNE^<'C4WI%8^GAP;_BMC+8/9<.<U^S
MR5TZX<(ZZL[P<&N#?=]T$M*YASZ<]O-6]6UYMLALFA0.V*]:&63(#]-HZE+:
ME')H6#X)0R[-8K(&8^)B>9X\@/CG9<X.XD#1')2D!:377<34@::"O4BA(ZJU
MP?-I@_B^8R5QAW$97F5GFC7MDAEKO)@W!H<-Y=71VWVK6DOZ6&Q'MQU/-,]T
M$9PNN:%I&IJQC<\XS!Z^U8_D'4C(%0:.TFGDS";HI>@2`/AP/L\>$V!GEEB.
MYNT!N_V5'6C>ATZ$U/7HIG8_.QQ&TP.<L'\<<_)Y?*9>Y$CNR_9%DF,:R,N>
MQTA,1:37<>NBVRS].^SLM@1UM)?(A1HT[K);N(7148+E76CY2K*07R$HH@F;
MXQNY,!P5.<P"7^+.YN&F;*][BPAUP'U%1HT4%?:?MHH'/\U>"GXM+A/AETV>
M3A$6#%)&EK9([D3&>C@:->W0L:!JM`2GI0;E?ZCK&MT^X=\C*U_:.\+VM9B/
M)H'4A';31:(0\6X$ZBJYS5_RC'`!,*8&*'2`#XA03<=OIK=D(=&US)'N%"2/
M>(.GLK0@CI319;LOGF].[7U!O^9/XFQ]A>X3#V7E7-AV,?C2XRRMH``9Q1E?
MO;2:GP6V+1Z:E[FY_?\`.1^W$8M[N#26K=71TJV3DT)B*E*"\;.9"8</$U^1
M3F"MQ`>D!-^T'D..0&LN,)/*9*%GOQ;0=1M.E10>%16NI4$P/SA\6Q.-XKC[
MC`OFML!R3(Y&2%QB=#)%>,<V.)K2VH,6[QT]T4UU7K;K],Z\;/JVYX>$VR%5
MD=J[#TI=%'S(\FW7!KJV%+&2$6\=,SHJ&2F50Z^"EX\/'$V"GEMWQ[F%[WL^
M\*C:T4-?:2?R+YZ=_.-QSA>;P&1R&`\];8/%9>U8QQ90OR,O<CE:'!U#"-/>
M+NNBY2J^FY<8M.B%F]E,)1Q3:)W"4]1VH@_<*27XT2X/8]05'!A=I(0;8H%,
M7S1ZA'@H!P`YQ^!S%I!V?O+X^IZ%U6Z@#3Q/UZ*FR_S>\?N'Y8XS$3PP9/*8
M*[[8=&UL?PF,MDHUH#"Z9Q-#MT`J=25W&1[";R>OZ9A8C9I8Y#6':Q=.W]TQ
M3._(Q?SEECR-&-N2*F(&ZX\Y/`1`%0+[!RI?BKEW8]YA,4+FGJ*N(^CP49L?
MF:XP,CG\ADL,Y\^9YM:9L/';+VV]N\N?:.J*4DK70;:]0M"1/I0WA#6U;I,S
MMUO+NX#N8U?OHSMW\V>D<MJ%"_+'D*FH_6<K-SR*P^8`EX`..!$>?"FML%<V
M]L&A[.\9@YU=1M`I0'J7==3X464LC\\?'9^67W(;#C[X8KGA^2PK&M=&S:Z]
MF$C)B(VM:X1MT+2#4G2E%OEIV%[#;VVN69QMA1^A$=SFR]YN8QTO)&*I7;S`
M?*&=03,4X-C(QJP>9TG2%+@W@`#SSW1869C*/<TO[SW?\5X\?IZ5'0K&ES\S
MG#Y\%>8>+!"&:XX;C\.V5@C!%Q9S=Q]V:@N#I&G;5K@[34T4:]=^DEL6BU?<
MU7-N)A(1VT-;S]+8QYF[M.-AI*9MREE"7,T333*<P(*_#F$O!^"`/(AX!;X.
M/7T`E.Z-VYA:!J.M*`D>&BR_S+YZ.&\JSG'L\WC\\.0PV8@NY)`]G<GCAM!;
MB,N.[7<WN`G3WB*>*WU;/3NN=EJ^^:JMLY%5AN"MZ<@HI%TFZ695,VM6+!E(
MJLVBY7``G+"S\P`*(>(^/CXYW.X]<'N['1AKVQAH)<:;*5K](IH1K[5C;"?-
MKQ[$9KBV;CPSV7/'[W+3RN86MDNOB#WOC:]XI^][]IJ.@TTT7&%].783?N<D
M]ZMMLD&"?.WB_P!+G<3?][7H$G4$$R)&<*L$`1=/2K"`)B40+X``AQG=\#N!
M=27!<TN<2![=M#X]>M*"NB[7?-KQ6Y]'(?3*YP3AD(8V!MR!"2'"]CN7N!V!
M]2UA:#NK4ZU"]77?IL7RI0.G8V8VZ,Q-:NI.^ZH-D6&07?O%-P?"C'NVRBIR
MKHF@S(<\F.8?=#I_,L\'<P0MCED:2"\FG0EWW?L'U]=54\Q^<#C'(<WG[^QX
M^(,5FK_"7'EQVVL;\*W=QK@!0]\$UH`-37Z=1V[TEMG6?8&HKPEO!.->:XT3
M2M0/GR17XS,P\K5E9SC^<._(4BH)R*;$""GR!A%0>H1X\::7C]V\0L:8]C-N
MZM3J#X#V4^DJ=<>^>;A&"XOG^.GCDLT67Y/=Y6-CG1]J*.XMWPLM]A!![9?4
M$U`#!MI4K=MH].F]2DR]DX+:"<"60[K%.X=\1B=\@,A$F9Q[;Z7=``'$WF&9
MB)O>\OQ]@^P.R7`W3Q2-[6_CN?KK[II]%:Z:+&N&^;'C=KCQ997#.N#'PAN"
MC+MA,<H<]WFF].F[0$$]>BU_M;TL[[L2@VNG,-O-Z^-IWYN/;;P&B;X&;F)V
M;&.V#&'D4!$Z+P\.JX!7@4^@3!X<#XXN\#=3AY88Q(ZX+P:GI2@Z4^T>(4PX
M'\Z_%N(<FL\[=8&2\99\7Q6+;O,>]LF.D9(^6-P#2P2[2VH=N`ZDJVO4-*<:
MXU;KR@.W23YS3*=7ZRN]1*!$G:L+&MV!W"9`(F!"K&0ZN.D..<DEE";:TC@-
M*L8!ITT]BT1YWR&+EG-,KRB!KXX<A?SW#6N-7-$TCGAI.M2-U":ZK8V5*B:8
M1,(F$3"*MSU)/W*?P]U]^^Q]4_1OU@[^COI7ZZ^*^H_E*OQ/Q/T'_A_P_P`N
MZO[]^RY]GCDFXQ\<[\GP/M]W8-V[92E=/OZ=?9JMO/E`_K%_SKRO]7'R7Q_X
M>SS7F?);?+]T;=OG?<W=RGW/>^RJIZ__``&^S\7^?S?O%<_HX\<F9_I`I_U?
M_H5O^?\`^I%-?@'_`&"IR^GO_NL_QX7_`'._Q`_%GZ.F_-^I?Q:^6?3?F-?F
MG1]:_P")OB.KR^GC]KQ^KE@Y%_.KR'^>.UY;>W[O;K7P^YK3K]"UH^:S^NS_
M`$8M_I^^%?S$^(Q?WM\+[GF*.[5?*?C;?O?V/MU5X0<_H_NC_8R"KS;6<(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
-1,(F$3")A$PB81?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g524974pc_001cnew.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974pc_001cnew.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C`$.`P$1``(1`0,1`?_$`.<``0`"`@,!`0$`````
M```````'"`4&`0,$"0(*`0$``04!`0$`````````````!0(#!`8'"`$)$```
M!@$#`P("`P@+#`4-```!`@,$!08'`!$2$Q0((0DB%3$C%O!!46$7=WBX<3)"
M0S0E-38WMSB!D:&QP='Q,R1U=K93)B<8*%)R1'2UID=7ATAHF#D1``$"!0(#
M!0(&#0@&!@L!``$"`P`1$@0%(08Q$P=!42(4"&$R<8%"(S,5H5*R<[,D-'2T
MM19VMI&QX6)R-74WP=%#-E874V-4)54X\)+2@]-$A"97=R@)_]H`#`,!``(1
M`Q$`/P#^R_RM\N6GB]-X&AG5$=W0V<,AOZ"@X;V!"#"N'85Q_81DUDU8F3^:
M$4*QZ72`R`@)N7,=N(S&)Q"LJE]27`CDMA7"<YF7>)?#KW2CT#T-Z#O]:<=N
M?(LY-&.&V\2B]*5,*>\P%W#;'+20ZWRY5U5D+X2IUF(9M/N,1U8AH&7/B61>
M!.8KQ[D\$"7!FB+9._1>6))*%%08%0JJL67%IR&7`"E6%Z40(3I#SD&=LJ>6
MI/.`I>6B=)UH+8GQ[>9P[)>V.AX/TCW>:R%U8)SS39MLW?8ZHVBB%&Q<QC9>
MESQ(.?60(1J4\D@J-8*8RP][L$3EJVTZK(X.E((UOK.#K&5ZK?F,@2/+FFW+
MU5!H=%*L-A<#73(]<YP,7N0'B!4_VPW[W::[1+B^>%<LN?(E/EI)^VTG+XHW
M+?WH9OMBX+(9M6Y6+E%A>9BWH%DM%?U1:BY*P3<JIY\Z$@@\OWB5<(]>2O=5
MB\=2K:+4PA*RW<9,C<<]=.]L68%4D,F9*QS\WZ9ZRX$R:2F.S.Q1WW$KL$^>
MZ8G-]M=HKN4E0N`)-%?N'62$+EQ[:Y3[)3[8L;/]$-[NVP7?)W(S;T89R_I-
MDM<PWC\??\H$7"=2+\-5RD"T5TR6$C8L3^YI'91H-UO*>')&$+3:QE*RGC3W
M9H_-($QIDESCP[,KHM;9E;*3)VX.P.)#E0`W3^LVYC9N=L+MWDL\X$+<2B=)
MTJ35/WCPX>WV<(B-[^C:[V7NC&[:7N!JX5D+W&VX<%FI`;.0QZ;X**?,+J#0
M5RY5`K(K\$Z8B*^^\9#T9&=54P#+2/R/"4SF4P%R*Q:]PC$7R0HPU_D-1<=-
M5P=@+D'.QBE*;ATQ$.0Y;6S%O"8N`!SDM^YWIKGJH?!+[,;[MC__`#]OMR.6
MR$[J89%SN-G$S\@M5)=LD7O/_*DS"0OE\N8)(JK`,A8.P^XE'0%`0O1L3R+I
M->WW.IA&%N#1)0IZA68"QG?=R,"<IBORSH(@GP`4Q2$VY@-L&"WMI;EP6.<`
M0A*ITGY2BF4I]DI\>V.4XKTF7F4W2K;`SC*%)L+2YYGE5$'S=P^P$4\\'P<F
MLJGXJI2!$S![+W>HAY;DZH7`TL0ZF4,_XT!]^4%B<H*X)KLO8'$OT/LH4PIV
M8L4*1$>>[43\A.KML.:K9SB6><;@?1M+E1_TI`E[W9]GV1TJX]!%_;X$YT[H
M8(&%PF0H\BL:9E]IA+57F?\`Y<N5%<OG)2"43F)8RK[E,=C!M=G"F()&9^QV
M*C9/,4ET:,`?I%PXZR[\E`PUQV+904FW8=?BH`&'K=,0^K'#M]LJN$I5S@*G
M*)4S_P!IRY^\)]\M.Z?;&B[&]'MWO1W'-)S[5N+_`#8QTS:*643RJ<7SI>80
M%":N=1-)D**IFJ->PY[H\7EW-D7AI'"TI`K29,?*!85;RQD$D?MYB>\Y3(4T
M<G7&JA_EB5*,Q-LL'5,X!4.($$AK][M)=G8F^+Z5`5^&@_(<2WQGVU5<.R42
MW4'T57FP^G+_`%!7N-FZ0R;[YA-DMLGR63LL:?G#<*`YAO`\/":0V6S,JJ&%
MF_=@B85>AHFP=*N!N]S84Y,0OC%/Y<=_3)2X`_/_`-6%.Z*D2,%#IAP$1-SY
M>G$2=I+)5\^)I23[G<92][M[_;$CCO0U?9!K*.#<K"!C,<NZ/XBL\P(NV[4H
M'XR*22Y75XAI3+68VC#WN=1F6\/R^6DL-2<"C%,L:O302EV92"SC\HF3)G'*
M:02"=<:IIC$J0XNS#TQZQ5`3#@("<:+W:B[.]%F7PJ=8G3+W$!?"KMG+[,XA
MNH'HQO-A]0+?8CFXF;E;[N01SQ9K0$^0Q[-^307U$\T.\H"KP$5F8,A%=H]X
MF(K4E-QY\`RSP8:M8HL0JDR*P1%P7*%TF*<FTZ9JD<$QA317<&/R-W`'X`5/
MCR-DM;,6Z0/,`$E8^C^T35]MV\/9WF-UPOH`O\Q9VUV-TL-BXO,FQ+R"U4_5
MUHU=E4_-"?.#G+`D*"FJ:IR%@YCW#X^(K%"LAL3R"Y+R>XE(S"WM$C1OV2R4
MQQV83K#!&!UWZKX'8;%3Z92],>0CSU@-[;4X\XWS0"W3K3]L@KX5=DI=L<JQ
M_I0N;_-93#_7K2%8T6A*C:K(<\UCUWXTYWAH".69E51-8E[L01%>[[$2CZKL
M@P+*H_::NYRL!%/RA,3]H&%<FNL<+M1)]DR=8U@4:BZ*?<O;`;IB57;GK-_8
MY="E%\>%38]SC6FJ?O=GV9=G".FWWH'O[*UO;D[H85Y.[PS$O(+%?UOCTWX5
M/S6G("N41(\PBN:/=B3/(7W-HW`3[,3-QAN3M`XDF'L4LHA=F<2$Z+)O3G`N
M$BJ5Q^+`J@6X`XCU1#H#ZCS#CCX[:Z\@AE8>">:F?NSE[VGO"?N_^G;IW2CT
M:WG5*VV_<-;A9LAGK=#H!LUN\FI5VFDR?17+RIU%(\8X4S.1Q9[D\;D[)URQ
MLEB"1AU*A>,B4H\NI<VCY-\I0,<ER`>0*R+76QVY9-,>T*D*A^D;ZP3&#X=4
MW.V5VUJB[+P(4E!E3+WET<:CPXS[8Q-[>D"[V9LW'[O<S[-PB_QMA=AH6BT%
M`OK_`,B$5E]05RS\Z54BH>$!/O1%TY[N43"RM6BS8(EG!K+0<HWLJQ<@L$@9
MIXTP\MEM6-,0:L<5E)A%+L"J@)00,/5$IP^#66G9KBT*7Y@"AQM/N'6MSE_;
M=DY_8C=,;Z#K[(V5[>C<["/)93'613Y%9K.0RHQ8<GYD2#1//*9&H?-U)/BB
M3Z-[E$;=<2Q^5$\/R,<D_>8V9A"GNC-RJG^43'MLOJ:@O@KR!3!$IU86I@Z0
M=8RX'#@!1*.&]MA;-V;8/`F2S.G[5:4<*CQJG[)2UC3-R^CV\V[OMW8ZL^RZ
MXTWD%<[RBT@^0OK:R(HYY^E-R'0:C0$4F954(=6]X2'1G96$_('+F-%94P?C
M`[C\H3``65S35I"RH3`)!5!X$KI&(I'0Y"+D3<@.GMQ'-.S'`E*N>/$VZKW.
M'+-/VW;W]G='06_0%?N8QC(_M3;R?PF8R(3Y%>@Q-RBW+1/FM2^5U!<I-RD4
MKXBP$_[AL?"1U-D38HD'06ZI05J*D6W-$3,"3<YD2%!B8XP)^Y.V''YE!.`$
M`W=`7B`IB)L!&VEK6M(>$T+*?=/8$&?'2=4OBCE>,]*%WDKS(6@SK2/(7SUL
M2;51KY+-@Z5@<X4A7G@FDS(+9,_%)-DO$;R&;^5?CYCW/36J.*0A?FLLZ3K#
MJ81GEXL(J>E(,2'E4&$8D[ZQHT5`$$$^('X[#MN,9F<:<1DG,>I8<+9'BE*<
MP#PF>_O,<AZ\=)W>A_57*],'[Y&2<Q:VDFY2T64N<UAMZ8:4MPIES*??5.4]
M)R%D=1D<AAI"&D(:0AI"&D(:0AI"&D(:0AI"&D(^,?NT?SZ\`_TB[!_5K8=;
MIM$'E7WW@?=1^AGH5_W;ZH_NBS^L&(I1E7^9F/\`]%#QU_Y5\M?\VI^S^E<_
M.W_NK>/1>Q]=Q967_'&>_2-KQ5[PV_I=PS^;#P4_K??:D,R1R[CX;G[A4=H]
M0?\`N%N+_&=Y?JI$9KR:$/M=&^O_`-SM;_6>\F=58G1E7YHK\`Q&#T<_N!_]
MS+C^'-O1(_B8`CX_YNV]?^R[RH_65DM8.2_+V3V>8:_!F-.ZY?YI[:_QK;7\
M/MQ3SR`_@=__`$';K_7]8]3%B-/_`*Q/X&._]+M7L7+_`/)-I^HV(^B61/3Q
M^C]__G'FG^K#'H?X]0=M_>1/_4-_A%QY.VKKU3>E_P"`8?\`6-]%$X,!_+`W
M'[P^5?N#[#_].+?J;>_(Q^;6GW8CTOD]=@N2_P"!]C?K"UBV_EE_)V;Q_P#Q
M/4_P>&,D`_XM0V-]QH]GF3^DQPCH5^6;<_?@?Q8W$=^%_P#;AJ7XF_CUO^+_
M`,(V=M9^;(&WU`][WZ0U&W>H?_RV7W]K._Q1AHTB^`/?8#]/_C=`_P!25KU4
MU[SGWM7W<;%MP@V>Z!V_LV]^M[:)4\-/[&UP_P!Q^,WZSEUUCYO^^V_[3_X!
M,:3ZA/\`S!X_\ZW#_#MG%4\I?SGO'YL?$P?[GY;+AJ2M=2)?;O?<1W#9/]RX
MS_&-S_JBUCZ'W/UQ;@#;U^LS-^LQ!Z@;?\LN/@:_`*CR=M\$;UW3/[7$_P`/
M/106I_R_BK\VWG;^M%+ZF3]"Y]]MOP(CU%G_`.[<U_C&S/X<:BT/N+_RWYE_
M\83G_L_"_P#FU&[>^@LOO?\`\6.,^DG7'=/?S!G[O+QL7BA_:BS/^?;R/_5N
M*.J,H1]4M?>F?PT0W7+_`"6V[^[.`_7\57O7\[L5_C\>_*K;_P#35[J89U;=
M_.&/TD1VS;()P6<E_P`5[;_BM,6DP1Z^(M<_WSXT?X?'?+>H>]!^MB.VE[\*
MW'%^IO\`GW=_F^X?U[BXIB^_G[;OTLO!7^JJPZG)CDM?FMU]V(]"VP/[*6/[
MC[S_`%DQ'T,OW\W,+_FAH8_^_/D?K7F/IG_ORON68\I[8US&X?\`'[W]#P$?
M2[V@?_YW^.W^ZK=_S]:=:MO/_>2Y^%/W"8\=^OC_`,V.[?O]K^A6T?2S6KQX
M\AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(^?GG%XJW_`,E+'XQ2](E:Q&-\,97E
M+S9R6)T_;JO8E[4)2!20B"L8]Z5=Z#MZ41*J*1.&X\A$-AV#!95C&MW*+@*/
M.:"1+O!GKJ)?#K'JCTV=;MK='L/O/'[D8O7G=Q8-JSM_+I;(0ZBZ;>*G2M:"
ME%*"`4A1G(4]L5ZNOM^Y?L=?J\4RL=$27A<(XHQLZ.X?3)4SS=%ALY1TJZ1$
MD2H8T>X6R6Q%`P@"@E26Y%*(%`TK;[CLFG5*4ERDON+X#@LM$=O&2#/VR]L=
M6VWZJ-@8?*7M[<6>3+-QN/)WZ0E#4PU>NX9;23-WWTC'O!8]V:D2)FJ4-8!]
MKO/.+;UCZS3]LQJ[8U2G>-E?D$XV0GU7"[S#U\<V>QJ-2N(-`@H/&"P$:"8P
M"=3T.!`]=9.1W387:'4MH<!<+LI@:!:2!/7O.LNR.@]4/6GTQWKMG*X7%V&8
M;N+[(;@?07&V`D(RMDFWMPJE]1FA8FZ`"`GW2KA&0R_[8N=+_.,Y*(M6-VR#
M?,45D`Y7\A/$4&&89CR_D%5L4$(-4/F!H>_LTRAOP[A-4!-Q`IC566ZK"W;*
M5I=F6"C0#B6VT=_":#\4NV,;8/K,Z9[6Q;EED+',+<5M]VQ%"&".:O$XJQ"O
M$\/!S;%U1[:%-D)F2!MN#?;DS5C;%^1J7.V3'KB5MM-S578Y>.D)M=FD[R+F
M![?85=THO"-E4T$(=P4CCB0YB+[E+S*`''%N]Q6#]RVZVERE+J%G0#1*)$>\
M=9\#\?;$#U*]6_3K>&]<1N+&V>638V&0Q#[@<;82M2;'%)LG@D)>4*E.@EN9
M`*)$TDTB!<G^TGY#71O9THRX8L1-,^.-@Q$V[R3L28%L,KD^6NC9VH*5?6$L
M42,?$3,<.2H+;@!!+\0R-ONW&M`5(=GY@+X#@$!/>/A`]D=/V9Z[.D^WG;)=
M[89M0M]W,915+=N?F&L<U9J0)OIFYS$%0&B:)&JK06JMG@%EV=Q<UI32Q41.
M31OF0;.===[,@S%A:Z=5J]'I%.6),J#E%W"*F4#CQ!,Q=A$=P"+9W%9HNS<%
M+E/+2G@.*5*5/CW&.(83U2;#QN]5[C?M,F;)6+L;8)"&JPNVNKE]P_2@4J0\
MD)UG4#,`:FMT=[47D`TOB-G4MV,#,29J\I<C"D63L/<?)LV5*<@JPV`HP'#O
MV+N3(9X7EP(0HB0QQ]!D5[LQRF.6$.U<EA'`<6E`GY7;V?9E'8;OUQ]*W]LJ
MPR;#->9.W=MV$^6Q3SL1=,O7*OIYT+2V0R93)E4$B)QSA[=V9LDLLCH05DH#
M92VX//C:-"1?S2)4ILWC\\Q6#AV="%<BG'#8'`+<RE.H#7XN'/X-8%IN*Q82
M@+2Y-+U1(`.G-"])GC3V=_;*.9]-O5CT]VA<8ES)V>46FQW&+]SEMLJ)9^O$
M9*E(+R9N<A-,B4IYFE5/BC5?'[VTLX8J\C83+L_:<<NZ['(XK3791;^=4E3#
M1\%Y)QG*"FFXA4&P@XG;@V51W4#=LFH)N)@`HY&1W187>,59MH=#JBYJ92\;
MJ'!V]R2#[91.=5/6)TWWOTCN=AXJRR[>7>.2(6XAD-CSF9Q^1;F4O*5HS:N)
M7X=%E($Q-0UVR>UWGB7<8Q5;6O&A2TS(D7;9+K2$^45H]ECR:J:B30"P1^;H
MTA(D,4#"4O2`1WW]!K3NFP25D)<`4@IX#M5/OB6Q'K2Z86#69;=L<P?K#$N6
MK<D,>%Q=^U<@JF\))H;(F)FHC21F-SP![;N:\68!GL63]GQX\GY2,P^S;O(Q
M_.*1A%:!F*PY!F!54<0R#@".8>6320V3-NN!@-Q+L8;>0W/87>13>(2X&P73
MJ!/QMI0.!EQ$:_U4]7O3G>_5*UWMB[++(Q;#V564N(9#DK[%,6+4@ETI)2ZT
MI2YJ'@D1-6D0G<O:6\A[#,V2096_%B2$M3\&P#7N).Q`H5YC;(L_;9PZQ"5X
MX%0<1\FF1L8#")U>0&*0``PY3.[<:W(E+QD7-)#Y2:4ZU:]YTTEI..B[>]=7
M2C$X^SM;BPS:G&,AF'U2;8D49"P8MF9$OB:DN-J*Q(`)D05$D"U5@\!<N2M,
MQ?7F]BHQ'M+/D$THJJ]F.W7"U9@C;_'@S,6),H?HQ#,R:O,"[+B`!N7<VHQG
M<-FV^ZZ4N4N42$A/PM%!GKVDZ>R.(8SU0[#LMPYK+.VF2-OD18AL!#52?+8I
MRR74"Z`)NK"DR)\`),CI%9(/VH/(*,DZ6]6MV+SI5VI>2<"]*23L(G4=YAS(
M^R%6U$-Z^4ID&<.Y*F[$>)B.`V(!R_%J1_:S'\M:`ET5+95P'^S12>WO^Q'9
M<GZY.EEY99&V:L,T%W=]M]Y$VV)!.*Q2+&X"OG^*G4E30D:D2*B@Z1,GE?[<
M.:LYR.?G=5L^/6">4YZ2E($LT^FT3LV[QKC]%(DEVL,Z!)4IZJX$>GU`#D3\
M([8F)W+96+=NEU+A4TD`R`_K\-?ZPT^&.?=#O5ST[Z:VNUF,W995U>$M6VWR
MRAE04I"KXDMU.IF/QE$JI$R5PTGE<)^WAF7'&9L@9#FK)07,-:LDY9N$>VCW
MTTH_1CKUB4*'%).2+0Z"172$L'46*4YBE0]2F$WPZMWFX[.XL$6R$N<Q*$"9
M`EX7*N_NX?9C"ZD>K'I_N_I]BMJ8ZSRB+^QP^,M%J6AD(+EEE/.N%)2ZHTJ:
M\*"0"5\0!K$+V/VJL_3$[2Y-O;\8D0KN+<TTEX1:1L(**2F1<`KXLAEVX$@C
M%%DUGE05<"(E.#;U*4Q_@U(-[MQZ&UH*'?$ZVO0#@A[F'MXD?%..AX?UN]+<
M?C<C9O6&:+EWFL1>(DVQ(-6&;&2=2KYX>-3`*6Y3!<T40G6)GQI[=V9*=@N*
MQE)66@KS;&0Q`Z5=-7TT>-%.@8JO-'EP(HI#IKB=Q*69!1#ZL`,B0XFXFV*.
M!<[DLWKXW*4N44N#@)^)Q"AV]R3/7C*.>[P]6/3S<'4U_>5I995.,<:RJ0E2
M&0X#?9*SO&B0'2GPMVZTKU]\I`F)D5_<>TSY!JV2;F"W#%H-I/-_C;DE$GS*
MQ`L6$P]2I2N6-JJ'V?$H2#UX^*9H4!%,R>XG,00V&1.[L<4(30[-++R.`U+B
MICMT`[8ZFUZZ.E*<-;8Y6/S?.9VWG\>H\MB7.RMVV^PH?/SH0E!YIE,*T2E0
MU%I;/X#Y<FHF@,6UBHQ%JK1:Q67XK/)D$UGT+9,LS#E5J)8HXG;G;WIH4@G`
MIA.FKN``!>44WN&S0XXHI7):U$:#@4M@`Z]Z28XIAO5#L/'WV5N7K3)%N^R=
MQ<(DAJ80ZQC&DA4W-#59.DRG(*1J9F5O?!#`=N\8?%7%6#[U(P<K::.RG6TJ
M_K:SQQ"N%).SS,T@9DJ_:LG9BE;2)"FYI$^,!VW#8=0VX,BSE<N]?VX4&5D2
M"I3T`'9IV1P3U-]4<%UGZWYSJ3MEFY8PF2<94TBX"$O)#=NTRJL(6M.JFR1)
M1T([8MYJ&C@L-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(11_P`OO+E_XP63QY@F=-;6LF;\B2M&<N',FK'F@4XZM/IX
MK]`B:*H.U%#M03$AA*`%-OOOZ:G,-B$91NX4M9266PH2`UUE(QZ1Z!]!K;K1
MB-V9.XR"[%6V\2W>)2EL+#Q<N$,4*)(I`"JIB9)$I1"61?<6DZ+6H*?3QFTD
M#S&*L=9(%L>;52*@K>8'+TTI%@H"!N9&!L8$("G[L'8C^X]9&VVTBX=4WS3X
M7EHX?:EL3X]M?V(Z/M'TE66YLS<XI69<:%OG;_'U!D*J%F]BV@Y*K0K&14J7
M9R@/E&48X.]U>9R]=*-5%\0Q\*E<*C@2S'=I6)PZ49*9GMCJM.6I4SMB%5)!
MD0!4AA$!5$1`=M7[[:;=HAU27E*+:G0-./+!(^,RC<>I/HAQ^PMN9+.-9YVX
M587^;MPE3"4A8Q-JFX2HFJ8+Q-)^U$B)QD,@>Z7+TJSQ->3Q*P?%D\E0%!%R
M>PK)&23F<HY5QV:1`A6Q@,=%+'!'($WV$SD2[_#N*WVFV^T7"\1)HK]WC)MM
M<OY5R^(QC[5]$]AN/"OY56>=;4SAWKVGD`S+.-QM_P`N=6@4;\MS[`W5\K3/
MXG]R^6R/C*^9`<8M81BM-JF4[,G'(S[AP1]^3O+C_&;=J==1LF9'YF@T!T<P
M`()G,)0W`-QL7&VFV;A%N'5>-Q*9E/VR*O\`09>R416^?1S8;1WEB]K-9MU]
M&0OL;;EPLI!1Y[%HR"E!(49\M2BV!\I,E&1TB'\F^\!.8_2L*J6%XV1^1X,>
MY@*"EE<H`NNTR-(43Y*;BT-P2.DR!QU0W-R$2[??UGVVS6WR`7E"I\(]WO0%
M3_T1OVS?0+C-U.6B%[B>9\SN5&*/XNDTI58(O>:/%J05T4\)"<XL9-^X7)1-
M&0N!<;M%CK9!OM)[(9M4I2ITRN5Z>3?=7H#N=\:;%,2;;%!/?[^HY&VT*N"Q
MS3(-(5.0^4I0(X]DHY)CO2A9WVYE;?5F'$I&*L;ROE"<[NX?9*)3X(#(5/MJ
ME%>(OW?)N1NK>I&PQ&I$7RKY'8Y%X%E<F,5'!,#.S+:2Z0M``5I\T0":A-^*
M//<!-Z;YZMG-I8+O/.C;*I4_]*0#V]D](ZQ>>@?&VNW5YP;B?*D83`7]/ETR
MGFGF6E-SJX,<V:3\J0!E$V9F]R&6Q7%721;8P82QZKB=QDE)->>7;D=KHX<#
M*01:IDVRADD3+CV@J``B!?CV$?36%:[:1<4E3J@DNTF21I\Y1/C\<<XZ>>D2
MPWO?8^T=S3MNF]SB<>2&`HI2<M]6\P`J$S3\[(R$_#.6L:]@_P!SZ6R]G)CA
M];%+"%0>-,=.AFD[`NY5)]NL0WO)ZA.U%L4O\7K4XK0!Y?&5<3#L)=M7K_:J
M+.P-Z'BHBL2E]HXEO[-4_BB7ZD>C"PV%TU=W\WG';AUM=^GDE@)!\GE++'`U
M53\8NR[PT*`-09QK\K[K$Q'/,>MB8BCE2W>\1=16.-B<`+!*0QY+7<7B8`V^
MM.DK'%0XCL`E,)M]]@T&U&_%-X^%)5P[E4ZZ]O&)2Q]#^/N[?+/G//#ZMQKE
MT`&$^,HOVK.D^+0$+*YCM$HVW$?N9RN3,)RN6E<6,8I:-9XB=!#)SRS@BHY.
MR;*X_5)W!FQ3%^5)1W<E]/K!-Q';;5-YM5%K?ILPZ2DEP3E_T:`O[,Y1`[[]
M'%CLWJ-;[%;S;K[3SF43S2R`1]78YJ^'AJ/TI<Y9[@)ZG2(HMWN]SE9L,E"$
MPQ%NTV,5@Z1*N:S.4SJ'R[<[#5729R=F)"EA4X4JQ!`1%4QQ*(```(Y3&SVW
MAJ\H'YSY(EX$@B6O;&\X'T$8S,XEK(KW$^VXX_F$$>73(#%VC%RDB:IS>+I2
M=/"$@B>LK$27N%23"IXZLI<;-%3WH;V"C7YVJ4K#['9/9X])P4Z&ZW?).1<C
MN`<#!Q^CUU'(VVA3SC1=,FRC67&ILK^Q*4<GL_2E976<R^(.8<`QGDI*Y(\?
MF\<J^,Q5I04\L:ZSG%>(;W>IR5D:<P-AF,2"T4S.-K44+9G)A:*8ARK(XY;L
MR%%H`*$F46'<G,(@*1C<0`0]=2"MGH"5GG*FE;:?='RT!1[>R<A'5\CZ"<99
M6>0N4[B>4;+(X:V`\NGQ#*XQO(%1\>A:*^6!\H"J8.D2AY-^YO+>/K[,K-KB
MMA8_R53:D0BHO/KL_FX$&J`"RI2-CBW$?M(.X!O_`*K\>L;%[7;R"&5J=*>:
MF?`:>]_[/V8TOHSZ-+#JK;[>??SCMI]>6P=(2P%\HGS.@FH5?DXUT][V1G<1
M^Y!)Y-R?D#'RV,644E2;SDJH)R:<ZLN=^E0<;$OR3PR!D"E24D5#=N8H"($#
MXMQ^C5J[VTBWM6[@.DE:4&1'VRZ?L<8C=^>D2RV;LS%;K;S+CZ\EC<?=%LL@
M4&]R'DBBJK4('S@/:=#$.2_NY349+UJ++AJ.5">H66KH98;*N46RF,\'!EY)
MB!>U^,DJN/9"?][+\8;_`$:SD;.:4E2N>?"XVGW>-;O+[^P:QT#'^@['7EA>
M7BMPO`VN4QEI(6X\0R&9.+*YU<6T_/2[3X>&L2O3/<IE;5B""R>IB]BS5F)G
M&$2:*+/+J)HAD+%UJR(JJ5P+<#F&.5KA6Q0V^,JO(=A#;6(]M=#=V;;FG1*S
M,I^U6E`[>T*G&C[A]'UC@]_7.RT9IUQ%O;Y%WF\D`DV&2MK``B?^T%P7"9Z%
M-/;$.+>[Y-IV-_`AA>.$C++V#,8]P-F<`95#,-/?6A:5`@-?A5A3M`2*01V4
M`=Q$!]-9AV:V&PLOGQ-.K]WM;5*1U[8W]'H(QJL2UDSN)X%S`YG(T^7$@<5=
M(MDMDU<'JJBKBDZ:ZQ866]PV3C8&BS(8U:*C<L?P%V.@,VL7LE)J3R9'F8%-
MT/K2(!C\I@-Z"(N1#]SZX"-M)4ZXWS?<<4GAW!!G\=?V(Y58>D^SO<ID\=]<
M.`8_*/V@/)'C#+>/77*>A5YXB79RQWQ!>)O=MFLE6/%L$KAR-BT\B8NJ.0U7
M"=D<N#1BUFRG(XZ/'$*+4H+I-4F(.0/Z")C<1#;UUFW>T&[5+OSQ):<4GAH:
M4!7\I)E'2]]>A'&[.Q&;R;>X7GSB,U=6`3Y<`.BWQK=^'":M"HKY93V`53C:
M\V>Z5,8E4LZ;?$C&9^SV0&])**EA7;=RFOE1QCD7X\&QN!BI(]UQ^CD/'5NP
MVFB\IJ>*:FZO=_ZNN7'XH@^G/HHQ^^DV2G<\[;^;Q2KS1A*J2G&IOZ/>$]5<
MN?<*HW'&ON0RM]A,ORRN,&4>;&"7DBHB@G.K+%E?R#7&$JS8JAS-RBW&PIRX
MK'V`01$G$-P'?6/<[92PXR@.E7-+,_#PYJ2H]O9*0C7]W^D.QVQD<#9(S3KJ
M<T<!,EE*>5]=6CURJ7B-7(+5*>%85,RE*(=RO[N<WC>9G(I+#,=)A#X_S+=2
MK*V5PWZRN*K.G7T&(E*U-L27*?J&.'JF(;``ZSK;9S;[0<YY$W&T^Z/]HF9/
M'L[(W_8_H.QN[L=;9!S<+S/F,IB;20MTF0R5N7RN94-6B*0."N,3G+>XG*1F
M)RY*#&C)94UON-8^5C-K%(!*M@1AF=-WU^WWY/%WO8B7;X2%Y_3Z:P4;90J\
M\J73*A*IR^V=+<OY!..:V/I,L[S?1V?]<N)0+"TN>9R03.YS:\313/Y*4<Z?
M:33PUB=O$#RO>>4#W/+1W3T*D&&<IKXY0,A)'D/GB24:B_"35`Z2?:J"*O'I
MAO\`1OOJ.S.(3BDVZDKKY[59TE+64HYEU\Z&V_1>WVN^QD%7YW%A!?JFWR^2
M2XIOEC4U#2<]/@BZ>H./.\-(0TA#2$-(0TA#2$?%CW:_Z1?`']("S_U=3.MV
MVA]!?_>$_=1^B?H2_P!T^J7[JV_Z>S%+?(/^CFD?HN>/O_(OEGJ?QVMRN7_;
M'_NK>/1'2?\`WNR7[ZYS]-VQ%;?"C^F/"GYJ?!C^M22UF9KZ&Y_MW'W*HZ[Z
MBO\`+_<?^.;R_5J(S>>O3)-4_2-HOZS?E%JO'?DJ_P`U5^`8B/Z6Z;/O0?\`
MA&\_AW;D;]XM>GC;G#\U'DW^M7,A_CU@Y#\O9_.$?@HU;K5_F_MK_'-O?PTS
M%1O)/^!W_P#0DFOUAIW4UC=%HG_VU/X(1WGI!^48O_\`9#/ZA9CZ&7+UP@S_
M`#]YT_J[H.M?9_+S^;-?=KCRC@?\R%?NOAOT^^CY^UH/^V1A^E![AO\`R-=]
M;`[^1'\WM/NQ'J?+_P"7KW[E[%_3;.+H^8'\V,O_`*+#S]4-,/\`'J%QA%#7
MYR?T@QYXZ!_WS@?WU1_%,1WX5?VUX0/OA%^/N_XO_";G#Z?P:S<YI@E3[WOT
MAJ-M]11__G&Y^_YW^)\-&B6?^5\!?GHK7]05GU\3_M/O:OPD;/AO[NW0>S]G
M;C]=V\2OXG_V,[1_NCQ,_63M&K65_OQ']JX_`IC1>N/_`)A+'\XW/_#]M%6\
ML"'V]L/_``SX6?X,Q7O4C9=WW_[@1VK8X/[*VOYWNW]5647^LG]%OCW_`.=G
M#]92(U!L_E=S\+7X%4>6,3_OKNO^SA_X>=B@-/\`YPX@_,_YL?K16#4XY]&[
M]^M_P*8]2Y\3Q.=E_P"/[0_AQB++^Y1_+7F%_P`:./\``?%>^H_;/T=G]Z_T
M.1Q[T?\`]W[!_P`.3_-DHW?Q0'_Q+9Z_/;Y'C_<_[N9/7]CUUC97^ZF/O37X
M:-<ZY_Y.[7';^SN`_7QBH=J]+=C??T_["O*KZ?T*D]337T3GW^W_`$DQWK!_
MW%F/WEVU_%QBTV'O[)E)_P"+_&G]63*&HF\_O-7WMW\,W'$]_@_\]<C_`(?N
M'^(L=%0W7](4]^EGX2?U33FI8Z,-S_[+=?A([RU_NG;?N-O#]:-1?JU_S'P=
M^8:A_P"&Q>26W]_4$W^4O_G"_P"9F/,&#TW)N6?_`!/>_H^`BDOBK_2%XR?H
MS8F_6=L&IK+>Y=#_`*YS\"(]%=;@?V5WG^^63_AUB)1\S?X3DG\_<?\`K02&
MK&$'A;^\'\`(TST]?1X;]V%_PXW$O^.G\S/+3_U?W$_ZWJ7K`R&C]G\-G]PJ
M-$ZMD'<&Q?[>Q/U7=Q43RB_GA=?S#>8']9"&IK'_`),G[^Q]Q'=>BO\`N_C?
MWGVK^KU1=JU?V5T?SL9?_44@-0;7][?^Y1^E*CSK@_\`.Y7^!8O^,WXO'[2G
M\L><WZ3[S_EUIJ`WC[EA^:#^>/-?KM_N_II^YB?TA<?7V7E&$)%R,S*.4V<;
M%,G,B_=*[]-NS9HG<.%C;`(B!$DQ'8`$1^@-]:8A"G%AM`FHD`1X&L;*ZR5Z
MUC[)!<O'W$MH2.*EK(2D?&2(K=_WML7,JE,7.SQN0J/#Q2E9[8MQHTM%/[$T
MN3XL=6I*MLT@=GDF,F[4`NXBFHB`[K$3#4G]37:G@RR6UK-4Z5"2:=2#PD1\
M<==/0C>MQG;?;V&?Q.2R#Z;BHVEXTZAA5HCF7#=PHT<M;:1/Y25\$*48RLOY
M-T2'E+'$*5[)#UU`HG.P-'4>3=(7)RV?H1<DPI2G),9IS#2*X(NCF!%ND8IA
MZ@E#D-",5<+0E06T`KC-0\.A(J[I]G$GNC"L.C6YK^SM+Y%UAVV;E0"PY>-I
M-HE2"ZVN\&O)2\VFML"M:@0*`3*.7_E+B"/C&4F>7EEBOL6V+,23)I"/EI!.
MEU84DY-9PAQ*1"3.[4[=!J8_466`0+\(<M$XF]4HH"4_2I;F2)5*&DOBUG"V
MZ)[^NKQVS0PPDM9NWQ16IY"4&[N9EL)/$MA(K6X!2A)!5J91Y6'E!2Y!>KLT
MJAE%*1M<.I--XM6FF-(QC=0KXT,A-MV\BX%B[M`1RWRXI14*N!!$QB!ZZ^JQ
M+Z$K56U0E4IA7'A.6FM,Q/M$7KGHMN*U1>OKO\*;2QN`RIT7?S;BA1SE,J+8
MK1;<Q'/)"2B<@%1K#7S3Q.8(\)B"RA5%G=DGJV^;6NB/8AQ`'K*D4VG)F=*=
MRJ5K7X]],(-CN4Q6^O$Q>/P"(7E8*\$Z%-+`2""E8-54Y`?UC(Z:::]L33_I
MUWRE3OU?=86_;;LV;A"K6]2ZE\7`<4RTR:05/N(:6XEM01X)&>HB0HGR$I\Q
M5+7<6T!?TXZGN8<LHT=5%XWEUX.<>I(,+?&1YE14?U(T><\B9V40X1R*BPE^
M'B..O&/(>0R5-S6#+Q"4P)E)/"KY,OMI"-3ONE&X,?G;';[UUBC>9!#O+6FZ
M0II+S*"I=JXY*2+JL!@-$:W"T-@ZS$`^:OB7;O)NT>-4Y6++`U]OA/)DO=YQ
M&:2?*+2S&1JTA!)M(P6:*Q2N2N'13&Z@E+P`=AWUG8/+,XQNX0\E2N<V$B4N
M^>OLCJ?ITZZX'HUA=XXW,V=U=O;CPS5FR6B@!I:+E#Q4Y40::4D"F9G+2(%R
M=[>&0[Q5J]`L;U5&:\/A_&>.5UW+>3%)62I%<S5#/GZ8)MC&[1XODUJ=(!^(
M"MU-P`>.\E:;DMF'5.*;64EY:QJ-`LM&7Q4'^6.H;,]6&T]MYJZR=UC+];3^
M?R%^`E3<PW>7&(>0@S5[Z1CG`L\"7$2.AB*,`^UEE3$E[H-JE\C4F39U&F>.
MM;=-V#:8(Y=.\.7-W9)M=`5FA$RH2K58I&VX@8%-^8`'KK(R&ZK2[0Z$-+"G
M%.GLD.8D@=O9/6-XZH^MC9&^]LY3"6&(R+-Q?Y#/7"2LM%*4Y:T3;M`R63-M
M0)<EI3[LS&1R1[7V4+I;(:P,LB4MHWC<I5V^*HN&LN*JK"'RWE_(:[,O3:B3
MNE8_(K9`HB/'JH*>O$2B-5MNNT8:4TIIPS:4CB.);;1_.@GXQ&)M'UH[,V[@
MKC$W&)R+CKV$?L@4J:`"WL7BK`*,U3I"[!Q9[:5I`$P8V3#WMLY+QUBG(5!E
M+[3GLA<*=EVM,WC%"6[1JOD',TADF,=.`7:IJB1G%.RH+`4!'K@/'<NPZQ[G
M<EH[<H?2ARE+B%$&0,DHI($CW\/9$1O_`-8&S]V[WQ.Z+/%Y!NUQ^0Q=PM"U
M-5*38XENP<2F2B)K<25H)/N2G(Z1"65?:)R]?D+,DPR?0F8S?CZ^Q"W%TUFQ
M!*8=Y.DKR635Z3,_\7E8O"HB`;J"J`^G'UU(6F\+*W4E2FG-+@+[/="*=->,
M]8Z-LCUY["VP[9KN\+E'!;;J1E#2IGZ)..;LRV)K'CK05"?AIEK/2+/3OM]Y
M!E,?(5!&\55-XCDG(EU[I1O)=`65RK%9@V;0`*W%3N6J\(<Z@[<1*<NPB.^H
MM&XK9%R7^6L@M(1+3Y*E'O\`;I'&L9ZJMJV6ZU9]S&WRK=6(L+2D*;"J[2XN
M'E*]Z5*DO)2D<9@S[(K1$^T=EQA>F]K4R;0C-4<O^3^1#-DVLWUQC<YUVP0T
M$R*8S/AWL0M+D,Z']H)2CP$1VU)+W?9J9Y0:<GRF$]G%H@GM[9:1V*]]>&P[
MK;2\&C#90.JP.W;&HK9ES,,^PZ\L^.=#H:(;[02*@(GG./MS9'RC#WEA$WJH
MQZ]IPZXQPT%\A*]-O)*80_)<1\X,@U4,++YI_M`\0$_0';;EZ:P+3<MM;TI6
MA=(=K,I3^DK[^,M/ACE_37U;;1V5D,;=W^,OW46>?3?KH+<U-C,?6)0FI0%?
M+^;$]*]9RUC6L!^V5DS$N?H_+DMD&FR<0S8XR:GBV#65(_.>CX7R%C-\8IUF
MI4`*\DKBBX2^+T12.!MC"`:O9'=-K>8Y5FVVL.$KU,I>)U#@[>Y)!^&)KJAZ
MRMF[[Z6/;"L<5D&+YQS(*#BU-%`\YE['((F`HGP-VBVU::K4DC0$QK4O[6.5
MI!]C5RED>D%3I=^B;;(%4;3')TSC\:3%*4;-.+00!PH_D"*ASV+T@'UY;!JK
M]J;.2_FW)J00.'$JGKKW$_'*):P];.R+6VS##F(R-62Q;MJ@A37A6O(-7@4J
M:_="$%)EK7+LUC<\,^VKDK&F")C%$ED"H2$K),<+-4I)FVE2,4SXRRK+WZ2,
M<JK8JW&082)4$=@]%2CRV#UU1>[IMKK("\2VX$`NF1E/YQL(';V$?R1KW4+U
MA;/WAU-M]\66*R#5@RYEU%M:FBL_6.-:LFY244_-K;*UZZI(E,Q#UT]H_+MF
MLDG,M<FT-NW>Q&`H],B[6:,L5;$MYLEIF#G`K,2=.2:3*:;?8=P4*;EL&PCE
M,;OLVAJTX?I=-)>-(2.WX9_%'0-O^N_86'P[-@]ALHMYM_-K,E,REE+.WMF@
M#7.;:VE*7I*DBF9BR\K[?F0']/QG6T[O5B.*..0A?+G;R71>?;#*[/(#/M@!
MN)P[1@V%!3EMNJ.X?#ZZCD[CMTO.NEM<ET=WR6RC^<Z1QRR]5&U+;/YG+KQM
MZ6LGY&A(+<T>5QB[)57BEXG%!:9<$SGK%:8/VC\N1<G2'RV3:&<E8HN?ZL[(
MFUF^3AWEO+\ED2'<(<F8`#>-C7P(.>6QA6+\`"7UU(JW?9E*TAISQ+:(X?(;
M"#\<QI'8<GZ[MAWUED;9&&R@5>9/"7*25,R2G%XINP=!\?O..(K;EH$'Q2.D
M2UY6^VADS/S_`#B[K^0*;"ERE/*R\425;2QS1Z2@T\01?"U;*`)_^KBOJ3?_
M`%A?QZQ<3NBUQZ&$.-K5RD2,I:^]PF?ZT:-T.]8NSNEMMMIC*XK(7"L):AIT
MM*:',(%W,HJ4-/QA/&7NGV1G\,>W/D;&N6,D9`E+W4GS"Z7_`"G;63)DA*`[
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M:5!DJGC_`!+;\?2*293M@6`[Z0L2:Z0B``"29M]C;`."_N:V<O57(;724N#B
M)^-Q*P?Y$RCG^Y?5YM'-]1;K>3.+OTV;]ODVPVI358-]E+6_03)4I(;84A6O
MOJ!&DXA!;VCLN*6>1FPR;0P;O<T^/^3"I"UFP53B\14J1K,O'B(,^(O91V\*
MHW'?@!`'D(#MK/.\;,M)1RG`4LO(XC4N*FGMX`<8Z2WZ\-AIPS6,.&RE;>W<
MYCR:F9%S*7:+AI8\>B&TI*7.TF4@1%E)GV^<@R==Q[#IWBJI+T_'%<ICQ8[>
M2%-T]AI7*K]9VW`&^X-U4[\W`H&V-N@?T]0WC$;CMD.N.<M=+CJE2TX$-@=O
M]0_RQR#'>JO:MEELMD%8V^+>0R]Q=H`4W-*'6\:A*5>+W@;)<Y:26F7;%?<.
M>TYEG&]HQ)-R62J*_;8\Q+2\?R*;-K,E6?259R[)9#<O&@+-"D*R7C7P($YB
M!^L41$./KJ1OMWV=TAX(:<!<<4J1EP4@)UUXSU/LCJ74#UR[$W?AL]CK3#9-
MI[*YV[OFRI3)"&[C%MV*4*DN=:7$5F6E!T,](W#//M>Y/RPI:CQ.1*9&!/Y'
M;71`'S:7/T&2&7G.1!:*]%J<!<#'+@AN&Y>L&^_'UU9QVZ[.SH"VG"$MTGAJ
M>71/C\<0'3'UH;,V,FQ%]B<B\;7$*M%4*:U6K%IL*Q-0\(6FL@ZTGOC>,7>W
M/D:B06:HI_>JB\6R:EY1IQBC1O*`2._+M>(&T0(O.LV*8WR=I$G3=<`'=0X<
M-PUCW.Y;5];"TMN#E<B<R->4D@RD>TG3X(US>OJWVEN;)[=OK7&7[;>&.W"X
M%*;FY]2V;]N\$25(<U3H4W/@`:I&(1S![2^6\C3M@E8W)M%8HR^.,XTQ%%XT
MFC'3>Y2M24_%.E11:&#MHY`@D7VW,)OVH"&LZTWA9L,AM;3A/,:5V<$)I/;W
M\/LQT?8/KJV)M/&VMC>8;)N+8R^'NR4*9D48VV+#B1-8DIPFI'9+B1%@)GV]
M,AR>'28X3O%43DBW6[V87YV\F+,6MH\=8[#35OQ*W%7KMYED+LX[;"W$`#XO
M36"WN:W3>>8+:Z.6E,A*?A>+G\QD/;'+<=ZK]JV?4`[O7C+XV9QUG;\L*;JK
MML\YEE&=4J5-+#8[>8"3IK%A?"KQ4M7C&^\AW5FLD)829CRZMD2'+#)/$C14
M<K%(L`8R'=I)`=T"B0FW)R+L/TZB\[EVLJFV#2%(Y#-!G+76<Q'*/47UOPG6
M:VVFQAK.YM%;?P(L'2Z4GFK#JEUHI)DF1E(ZQ<2YUEK<ZE8ZF\4,BVL,,_B5
M5R!N=`'K<Z)5REY%YBB<P&X[@!MMM_74*RZIAU+R?>20?Y(X!M[,O;=SMIG;
M=(4]:7"'0D\%4*!*?94)B?9.<5T5Q+FZYX_N-.R=?J>Y/)5^!K=<3JU?=,XU
M)6&?-G3VW2POU5WX3,V5L!0:HJ`V:EW`HG$>02?G+%BY0_:MKT6I1J(G(@BD
M2TD)\>)CK*=]=.-O;JQ^X-EXO((2S=OW%P;E]*G"'4*2BU:Y8".4S43S%IYC
MIE,)`D=?<89SNZMV4+*]L6,I<MC8,JU3&\M&V%=%ACEDJB1]CJ4:)N$T6K"V
M)@JXD7[83.Q='*!?JR$*6YY_'AEII"74E)*E$%.J]9+'M3P2#I+VQ*M=0NF3
M.!PN'MK3,VZK1U=Q=J;<8!7?K!HOVUE)*EVQI1;L.`-!L$J\:E$Z+7_"6<JZ
MD5*L<E%F'+>@V"K2U*LL(VE,=2KB09MVL/&*,A`LT2IQC9+M>W[CJ=$A3@//
M?5]S.H=FE35(Y@4%),EB7$]Q4>,Y<?9&S97U'8[-H?L;K#FW95E6+EJ[MWE-
MW[:4+4IUP+^B\RXH\SF<N59*94RCHH_A9-5+(->OA)6H-':]EA+38AB6TXDO
M46]9F)^4CJ%C0JKOMFE-ED+$L@_*Z+S,("8@`4P$+5<9QMZV7;TK(H4D3(\5
M02*UZ:J21,2BYN;U$X[/;4NML*8OW&$V;ULQS5,D71N&F&W+W(234N[:5;H6
MR6S(`R49BHY:V^']CLL'B2-<V.K2\S38R3:V&TST5(+R;:R3=A8V69R#546S
ME%LI8Y1PT4;K)O0.@9-;E])=AH9S3;3KRTI6$.$22")4A)2$*GV#3AK&#@^O
MN(Q&3SMVS9WMOCL@\VIBV8=0EM5NRPNW9L;DJ25"W;"DN(4S)84B7`Z;+4_&
M.R5VD97KJTO#N7F1+/3W31K\WMRD/&P%7G63@S;N%G8RR+5W%$5#Y6B8&0"(
MMQ$4%#@%E[*M.7#+H2H!M*IZ)F2H'XM#\HZ]O$"(C.]9L1EMR8++ML7"&,39
M725*Y5J'7'[EA:0JD(Y14ETI_&5@O'Z8`.H3.ZO(/Q_Z=0?\\><YQSR#Z/N_
MN?ATA''(/[_['^?2$<[A]WXM(<8XY!^/]G[VD(YY!]W^72$-_P!G[O\`1KY.
M$.0?C_O?Y]?80WU\F!"&_P!W^7]C7V$-](0Y!_ETA#?2$<Z0AI"&D(:0AI".
M-P_'_>_R_1I"&X?=_=_S:<>$(;A]_2$-P^[]C?3X(0W#_!O]WX])PAO]W[&D
M(;A]WW?3I"&X#I"..0:^3G".>0:^PAN&D(;AIPA#?2$<Z0AI"&D(J)Y)W+(K
M2P4B@8YMH41_,UK)-\DK(6)8S+A1OCN!1D(^`3;2)#MDVDO+/40=GVZG:D.5
M,2F,!@F,4Q;*;7<W2.8A*T(`G+WR03,:S`&@[X[QT?V]M)_%9'=.[K$Y.UM[
MS'V3=OS7&DA5^\I"WRILA14TTA?*3.GF%)4"!**G(>6N7AKP>0#F69!3"V1A
MC$<4H1+3M?F*^,U9YW;OG8@:54>ENC<3)(`/2^6&`@[G^/4P</9!SZMD>?27
M.9,\*Y!,N'NGX:H[FYT)V&,M_P`K&;=W]HC9+R/UD755<L9$,(M>3]&$&T4`
MI9%0N!4"$FF-K;9"\@TK=!>.\CF'JW*^##7!IE1I3(,CJNPOV#E+C9*RTA3)
MC&K)K2;`C=BLJ4RJ;4QN?(^PA:-KCBRK))9DTW4DMU&1-82E4^/`S/MB$>VI
MTJ7@+GJQ:;?IV]C`[:*QJKM\I?>\ZW:6]PIZ8<!#:U+>0DTJ<`ID-(UF#\I,
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MDS/S=*$J`'VVI(,^P1DW71[IM;7EM@6+!Q3^ZW+PV3RWW`K%)M[)BZ:2E((2
M^"X\4K+FI;0D`S,XG7QUROE"Q7FL!>[0A8X7-E"O^1H"#0B6$<CC@]`O<963
M0,>\:!W4Q'RD39&AS'<B94CELH(#Q/L$?D[.T:MUFW30MAQ""9DUUH*IR/`@
MI/#LE',NK6Q]EXG;-X=LV2K/([<REE8/O%U;AR`O;)RXY[B%>%I;;MNX`&P$
MEMQ`(FF9K\KY*YZ;PL'9"6Z,<+>0AKS'4F)6@6)(_$3FG9494E)ZQ7(47,]W
ME6>BN<KL3`$D0-OJQ$NI(8K'%:FBD@6U)69F;@4V5ZCLDH2F.R.J-]'NE[V1
MN,0<>\E&U19N7;J7EE>43=XU=X4+'NLT7*`@%J1\N3\H3C8#9DSU(SE]Q1"9
M03;VCQOCKM8[-<Y.I0QB94+"OZZYJ\1*,DP*TBF9X2852D5&G34.X(0Q!*&X
M:M^2QZ&V[M;,V[HI2E`4KYN8540>)U`E/LB+'3[IA:8S%[XR.%*L-N]ZS8M[
M1NZ=_P"[.<BX3<NM+)K=4'FD*8#M20V5)5,ZQAW_`)3YH+"DRC%3[#Y5EZ1R
M;1:'29*'9FC\=RU:");4VS*ODB)R$RLHN\74E$5C=)3ZL$P)L.]:<19<SRBT
MFI@(6M8.JPJ=29<!*7AEKQG.,^UZ(]/59`[*OK5T7V!9QU[>WC;J^9?M7'-5
M=VX030R`$(3;*2*D^(K*IB,Y(93S^%IM^`8W+8ENF*(VWY"?9*>4^",:XP$;
M`L9.L5>1CRIA'L-IAPJF_61(511F!./$^YAM)M,<649)3,F'E)0&PH^$DD*4
M#Q.DI>V(VTV3TM.%L.J5W@?_`+=SCUK8HQZ;I[\4?<?6W<7*%D\Q?S24EE"R
M4I=J*IID(L?E3ROB<.XQQ%;YZ")-V3*C:/*QA4IR-K,:FZ3J*]JGW2TU-&,T
M:,VR#,Z;8I@,=PLJDF7U,(A&6F'7>7;S#2J6V9S,BK2JD:#77M[A,QR+9'0R
M]Z@;TSV`QET;;#X1:RX\67+API-T+9A(9:\:EJ4M*G")!"$K6=!(QU9?.B/=
M0DBQQ_0K&_NDIA"8S=3/F8Q[2&7ID=5'SYY8GZRZY#$1@;HBG"KM=@57<&%1
M/='XM9;6`4%A5RXD6Z7PTJ4YU%0D!_:2:@>$M#K&V8;TSW;&29N=U92T:V\Q
MN1K#W?+K4ZF[<ND(0PA*09EZT*KM#FJ4(`0OYSPQ<7%%CG;AC.A6JSQ(0=AL
M=2@9J8B2NFSPC%_(QK=TX13<LS&;*I]103%XB(`40#[VH2\:;8NG&6E5-)60
M#(C0'N,<`WOB,;@-XY3"89_S.*M+]]IIVE2"MMMQ24DI7)0,A(S`UUB0-8T:
MM#2$-(1$V=KS)8RPSE'(,,@W<S-0HUCG8=!V`F9J2S&,<*QH/"EV,+,KWIBJ
M`#N*8#K,L&$W5ZS;N:(6XD'X"1.4;QTSVU9[RZA87:N14M&.O\E;LNE'O!I;
MB0Y3_6HJ"?;**-K7SR&/:+!X]LLP)A<*V96YHY7=5&#%[(P;G'R=IB:H]A"I
MEBDDTK&!TW"Y2@J9@)2AL?XAGQ;XU+*<DMB;*O"6ZC(&NDJGQ]W4#A./2K>U
M^E"<-:]5;G`$X"\`M#C473U#;R;XVSMRATGFDEBE3:"2D/3404Z1J(^6&84X
MM/.*DRQ-4(FV,\52F+21#3L9.0/07DL\N"$SQ^:-WPW!`ADD@.*'R[<@@)AY
MZN_4]D5^1D><4%P.3X"N5,N$J.TZU:\(GO\`D9T_5>GILFW<^OG[%>3;R1=7
M6V@7R&D6I:^C4CRI(4L@*\Q)4Z?#&:@<J>0LK9JM@IQE5$EFR-#X^R,3)J56
MA1D*M"62G3%ALU5B8<4OECE-*>:-TX]9<IE2,#*E/S/Q.%"K3'(;7?\`*^::
M*T45'Q%*@$J)X\)SEVRE$=E-C]*;'#7O4UO!J.'Q#]]8?5QN7J+EZWNFF+>Y
M<=GS`2RIQ3Z$$)+P04!*9B,/!>4.:+)`ES`WL[)K`XFEJ50\A8_/`L$X^_RC
MV,D'=VLK*5/SD(U8YTFXQ:*(@DF(*`H!]PVK7B;%E?DE))<>"U(7,S0`12DC
M@>VHGCI$AE.BW3O#Y,[`=LG7,GGF;R\L;[GK*[%M#B$V=NIK1MP":_,J4"I7
MAIID8,<]Y["<H6.WN0VR\AY(06.+?6K6E6HHC[%"5TG)KY["1#$$Q:3+-E7(
MM--DL]*=0KLQCGY%$"Z*Q^/+;MT&B$VJEI4FHR<I2""3Q!).M.DH^772_I<<
M;D]V,8E:;3:-S?VMQ:FX<HR9M&&>0ZZN=32UON*4\EHI26@$ID=3Z(?R,S79
MBV:5875%@3QNL=+IUXBUJW&F99B=6K+LSCE>9>NQ#KP`H5^(!T5%H(%*_4'<
M1)L4/B\98-4H6V3YI"U),S-NEL+``^5J9:]@BU?](^G.'59V-UCE.G=]I=W=
MFXFX<KQ2;;%M7X:0GW7ZGW2V5.SFPD?*F8GS/V2<I0UYLZ]*N"57KF$J)5LB
M6&OF@F,J&1QL=B?1[B"?OW8=Q$,&L1$+=,[805[E4IA'B40U'XZUM%VZ0^BM
MU]Q2`J9%%*9S'>22./8(Y?TMVALK([9LF]QX]5[EMQY.YL6'P\MHV'E[="TO
M(0CPNK4ZZFI+@(Y:2`)F<5\<^2N;6L5"7=O;6J\3Y#*V&$H]>>0,:3\C\@PS
M+7,5QDFR<H@5>PD)$SBCU9-YN!WA"E`0+Z#))Q=@I18*/';4E1!/S@+1<(/=
MJ):<`8ZLUT?Z</7USMMVP<1?;32P]>/H></UJA>)N,DXVM)FE@EUE+*%-2DT
M23XM1[I',^?QE<@8V99,0;S'CC!97O5CN:M6AU'>5F5`&ES,)7):-$O8PS=]
M!VM5N[69@0_71(<HE]0&A-CCZ&[I34T72FT)2%&3974"H'B2"F8![(Q;7IYT
MM%CB]X7.&4NPW?<XRRM[07+H1C5WWFVGGVG/?>4AZV2MI#M0H6I)!T,<6+R6
MS3!UN4SBTL[%U5KS(W.B4_&CR`9$:TV6C8YHK5;0>83XR4BL1<K@[]!4125`
MR8$X[#N;Q5BMT8\I/.;"5J7,^('WDRX`<)'CQC[BNCW3O)9=GIH]9.(S>,:M
M+V[R"'UE5VVXXH7-N&M6VQ3RPPM,E)(4553$K*8QRW.42M>0+;,EN/;V_C^N
M$P\NXQ+.,DI6JO*>C;.D]C8TB;(9-@HDX2**8%!0ADP$-P$1B[JS;N';=5BB
M@W.@3,D`A5.A.LCI''MY[#QNY\SM5WI_8)Q[NZD\I%GS5N-M7*;HVLT..$KY
M:P4*(424D+["`(SCO<2HGV)E+W8*-/1L)`6"L05@<0DY"6YO%AD"/5-CMP+J
M(."3I6RV),(E5!/=2/=&`ZWU(\]9:]M7'/2PVX"XI*B`4E,Z#X]#]JGQ3[1P
MUC<;OTF;G&XF-L8O)VKV2NK2X>82\R]:J<\BX!?II=$TBW8/FDK5X7VP4M_.
M"F+`8)RI?\C6C,\==:9]C6E(ML+#5ILI)Q<DZ78/ZRPEW17IHQ54$WC9VZ$A
M^8[;_M?0-1N1M+:V985;KK+B"5:$:A1&D^S2.6=3=D[5VCA=O7FW,B,A<9*P
M>=N%!MQM*5HN%M)HY@$TJ2D$2'PZQ9(/HU&1R&.=(0TA$*Y>PG!9<+!.'TY8
M:M,U[YVS8S]:<H-WYH6U1BL':()<';=R@HRFHM<2"/'J(J@15,P'(&LVROW+
M&H4I6A4IA0,II(*2)=Q'^O2.B;!ZC9/89NFK>VM;['7?)6MBX2I2`];.!ZV>
M32I*@MEP3E.E:2I"P4J,1XAX@8J;6#O$5)X*ET6KDV-C/R*5'[1LJ:&/VEJ*
MB=$7Z<HE5@,GL"W2,Z,+@P"J.^LHYJ\+<C3S]17+Q4E593/A*KV3EIPC:W.O
MN]WL5Y9Q-K]>U*3]8!!%UY==WYY=L2%4%LW,E3*:@V`T#1I&.:>(5790HH(9
M$R/]L&LM"OX3)"\LP7MD%'UN&<UB)@&ZRD>+)>))77BK5P51(5'0GZBAA.`"
M%1S3JG9\IKDR(*)>$E1J)XS!G(C[$9;W7S-7&1#CF)Q'[/K8>0]CTM."U?<N
M'DW+KZ@'*TNFX0EULI4`W*A(I,H]S+P]Q7&259&-<6-M58%K4/F%#&3*K6[7
M,T!-=.H66Q$51[US,1)G',YB*D3<'21%0H],`'X<W=J2NH(+JBJ2Y>)(7[R4
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M9"R0DK,Z3+5$P$FGNF`!K_/%EWU`;SN6[PW#-BN\>6\JU>Y9"\>+AE%N\FTD
MJ24K9;;0*PLI*`I)JG&=I?C%5Z)(R<E`VV[)*BW-%5$BDDS4+CVMN[4%SFZY
M61.Q.8L?8)H=G9G'65,V(FB!@*F4=4/Y9VY2$K0W*<U:>^JFD*.O$#AP$]8C
M-P]9\WN:S9L\G8XY385S;H\M8\]<)MO*-7%Q)?OL,_1!%*0X5K()68U<WA=B
MU9O9(YQ*6UQ$/TI%.G19I5,J.,59FV)WR6<TY4C<'*2[ZWI$=B+@RW%,@(`'
M2]!O)SMVDH6D("Q[QE]))-`J^!.FGP\8FAZB=[-NV=VRS8IOFE-FZ<Y1)R(:
MMC9-)NP54E*+4EH!`3,DN>_K'9(^'U*DXQ@V=W*^A+N0LC:^6AM*LVDUDR,N
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MO:N6KBGV'V@7*^:EY:EK*B0XDA"YI``D7)/CY4,BU^APA7TO5G>,E2GH\Y"F
M8N'T,@:O.:D\9*-YEG),)!J\KSU1$P+)F,14"*E$#D`=8MID7K9QQ<DK2[[R
M3.1U"AP(((([/@[8U/9W57/[2RN3R):8O;?,I(O&7JTH>(?3=)6%,K;6VI+Z
M$JFA0FDJ;4"E1$:0Y\.<5.GZ4NY>6]Q,I5[[$_.%)TQGYZ`K5'-5D:0<Q4"H
M!!S`.?F#HI4RF5DTR+[E$.(Y2<W=@4`(HJJE+2NJH+^$2D/ZND;(UZ@=\,6I
ML&&[!&.-UYOE!GP"]%TFY;O`*BKG-4\AHE1";<J;((,Q86BU5.CTZMT]&5DY
MMO68AG"M928426E';2/2*W:F>JHI(I*KIMR%()@*'+CN/KOJ,N'2^^IX@)*E
M$R'"9XRCE&Y<VO<F?O,^XRS;NWEPMY3;0(;2IPU*H!)(25$F4S*<;9JS$)#2
M$-(1K-RJ4%?:C9J19FIGM=MT%*UR;:%5,BHXBYEDLP>IIKIB"B*IFZYN)R_$
M0VPAZAJZR\Y;O(?:,G$*"@?:-1$QM[.Y+:^=L]R898;RUA=-W#*I`A+C2PX@
MD'0@*`F#H1H8K0X\0:J[A5T'&0<B&N$A+/7LMD@DJP2MDI&25<3ICNMKJIL`
M8DB/LND5ND!$@427W7*;JB(ZDQFW0Y,-->7`$D2\((55/C.=6OM&G".Q,]?,
MW;Y%+C6*Q(P#3"$-8\MK-JTXV^;M-PD%=9=\R2XHE12I$FB*!'O)X?XJ)8&+
MTJM@^RK(C1Y^3LTB0U5=V9A5%Z.VMCU,4?F#B3+6W)R&+U@1.YV<"7J!N/PY
MJ[Y13X><=*Y>*DJKI[I5#NX:<(Q3U^WNK$N6I%K]>.%2//A$KE-NNZ3>JMD&
M80EOS"0H&FH-S:!H,8ICX<4R-B$BL[S?T;?%O:PI6<B#)L36>M0]*A)"KUBN
M-#"Q"/=13&O2B[=8%DCG=JG!=43*%*(5JS;RU^)MLL&JI$C25+(4I1UXU`$2
M.G`:1G7/J"W#>7RC<8S%*P#S5P+BPY:Q;W#MV\W<W#ZO'6EU;[:%H*%`-('+
M0`@D'(I^'V,&\E4Q:2%H;5>MM*H#ZC!))&KUME:*B\;UFP64HM@>O91JG)+=
MT)5")O1,3K%'@75'UW=E*YA'-63)<M4A<J@GL`TT[NR,-?7[>;MG?!YNR7FK
MQ=U1><L\^U:O"E5PQ;^*A#:BVCE@I*F9*Y9%1C'-/#3'S)N^43M%V4G6GV>;
MT.S+R;165QG#TZ<>6.L0M9W9@U481LG(+`IW)%5'#8X(G'@4-5*SEPHA-#80
M0:T@:+*@$J)UXR`X<#KQ,9C_`*A=U7#K2566.&,<YZKVW2VH-Y%VZ93;W+UQ
MXJ@MQM"*>44!MP<Q(J)C(&\0<=E6KX-YNW-6#7Y:O=8EM)MTVF49*%M3B]1<
MO<A!KUUY!M<':KTQFYD0.!^D(`F``%(S=UXE4H*M:"1.@%-)"?84R&OP\8PQ
MU]W86KKF6U@N[7S!9NJ;)5C6W;9-FXU:>*E+:K5"60%A4B*YE9)C8KCXV5V[
MSS"=EKC>"*&)\NMC)M*-4F=\KC:P'LT36K$0&7(T9#21A*B*(IK"V$R1C&*8
M1U;8RCENV6T-MRXI)!\"J:2H:\2.^>NO9$3M[K!EMN8MW%V./QI3/F6RU-J*
MK*X4QY=VXMS7(..MZKKJ2'`E82"D1K*WAUC5TXLO>R]L<QT@WE$J;##)H(L,
M7*S5F8W>0>4@J#4BC5V-QC$'Z)G!ENB<G`-R"(:N#-W0""`@+$JE2,UR24R5
M[*20>$3+?J`WBPW9^78L47;2VU7;W+45Y$,VR[-M%W-1"D^5<6RH("*@:CX@
M#'F>^'-&D&3/J6^])3[P]F0OEL;2K-*:R5#W60BY2U05G-V1FI8Z36A&B9`;
M$2.@V1Z1!XF$=5#-/I)DVV6Q30DB8043"2->(F>/$F+MMZ@MRVMPY188Q6+;
M\N;*U4VHLXYVT0XW;/6_CJYC:7G5'F*4%N+K4)@1D'_B!C*6E;2>4D+4\JEC
M9V4K.@C*$2J]7EK@T9L[!88!))`KQM*N$H](6XG4.FT.!Q2*',=4IS5TA"`@
M(#R:9KEXE!,Y`^S4SEQ[8QK;K[O*RLK%-FS8MYNT<MRN^Y4[FY:M%*6PP^2J
ME30*U!P!(+HI"SX1&\57Q^IL)1[_`$J=>S-Z)E4)$N1)RRN45):S)R,(C6S(
MJG8HM6[-NVA6Q$D2(D*!#<C_`+8PZL.Y%]RX;N&PELM2H"1()D9]OMUC6LYU
M3S^3W)B]Q8UNWQBL'R_(,VZ2&K<MO&XF`LJ4M2GE%2RHF8DDZ`1&8>%F-I&`
M+5[K/6^]0(R35^O$3+N-8QKL(6%4A*>F[904;%HKJU'J]\U6$.J>2`'"@F$`
M*&5]>W:7.:PE"')'4`DB9FKWB?>X'V:"-R/J)W?9Y7ZZVY:V&,RG)4A+K*7%
MN(YSP>NBA;SCA`NI<EQ'NBWFT@`$DS1C;$<9C.0M4E&V"RS:UP^SBLH2POD7
MNTA789.#+)(*$;HJ$=2C-!,SH1$045)R``$1U@W5XJ["$J2E(15*GN49R^(_
M8CG6\=^7V\K2RM+NUL[9-ASPWR$%'@?>+Q;4"HBAM:E!N0%*33KI$MA]'W?A
MUAQHT<Z0AI"*,>6*(6.X8XI$Y-S4-4'5)S3<G`0\_*UD[RU4NH)/*PLM(Q#V
M/=K!`J.5I%)`5!2,JW*90AR%$-3V&(;MW+E*4J?YC2=0#)*E>+0B0JT!^&/2
MO0MPXG`9?<F-MK>XSZ,EB;0<UANX"+:[NBBX`0ZA:1SPE+"EA-02X0A25$&*
M0,LBY$4HP9V"RV=_F8MZAL<@T&<E@8_89S@Y>5,@%5([+!IJ2HH$L(O1:]<'
M/UI%`(.PSZK:V\QY"A`L0V5\!.OF@3JXZ>Y*<I=DX])7.T=IHW+_`,L_)637
M3XXQZ_JY+=8O4YA+8/F2GG$-358\H.4%OYM22H3$B1]:BTLDU+`K>U726PG=
M25.Y6J16R/:UWZMJ4Q1.69DW);DIL)9HVN<PS3?K-D7";==1+X"`4>(XRGE&
MV7D5)0F_;J2@4)D$\P#W9:T@T@D:3UC4[K,7J]GWW4]VRQ['47&FYM+9`L+8
M(%L,FS;K)M2SRE&T94IA+BFRM"5>)1.L1]5[U=Y.FI9?=7.T2.2L<VSQWH./
MW!YV6(TFJ5;D6+><4D*NF[)$3RUO)+/"KNW+=9<3M2G*<HI`(9+S#"'S9!"4
MVKJ'EK$A,+3.4E$333(2`(&O;.-HS>VMN66X%;!9Q]BSL_+V.>O;Y/):*F;R
MU*U,A%R4EUA-J6VBAMMQ").*2I)"XSU807<3^(L<*6JYN\?^0%$P_>,QOU+U
M9P=O+?.R>13R(M;">7[JM)65Y7F;-=G'JM$SD0X@0!,.]MY0Y;UU0@7%NXXA
MH4)E2`B6DI*E,F9F8C,RZTSB\]NY%ECF]U;5R>5L\4@65M2BU9:L`W4P&J;@
MVZ'W74.OI=(*RJJ21+"0]FM$A!76U.+?;']BP"RQ6SPFJ-GFTROF\SE6VU]\
M$JP(^(SNAY^(B6S)11^1T?I(^@@)A$:UM-!Q#24(#5P5EWPCL;21(R\,B2=)
M:Q)7^%PMMD\;A&["Q:Q.Z7,DK,#R[)*"SC;5]'+7056@9==<=2&5-BI4R"``
M+*>*\A(M<@X_F`L$[,.LRXJRA=LIGF)^7EF1K?6,IQ4'5GS2/D7KB/K*AV,T
M^8@@T3;IJILR%X"9+?45ETMFV<2$I"6'D);D`#26R5:@`JU`))GJ8Y!UNL[9
MW:V6QYM+6W8V]G,=:8T-,M-+%K<8UUZY0IQM"5W("VF7BMQ3BDJ=4:@%Q5MU
M:+,UJM,L:-[MS>6S\IDQAFV6"TS)@:L:_GB,JT$K'MC/C,Z:=**=J095&";4
M3-S;;]0`-J7#39=<:4A-%M06Q2)3+149_;:^+6>OLCM#&%Q#V<R.(<QE@YC]
MK)Q[F(:\LT*EOX5RY>#B@BN[!<0+PI>4[)8X4^&-S>(*.;/E_&\I:[G6\=>/
MT%E:QX2FF]]LR#E.8B)NG*$?.)E27.[LY:+(2"T:W2?*.4DDUQ34*8P`(8Z9
M):8N4)0JYN5-I=!0DZ$*X"7AJT)D`3*>D0##H9PN!W?96./O-V;KNL8QF&E6
M5L4EIUFZ!0EH-46WG6VTW"ULI;4I2*DD"-6G+U=TJFVR:I;[37[_`)7G<Y4O
M*;A&P2Z25:J,$:O-6ZL=#N'BD955,=(.#"V<MT$54C.3&5.<3!M>0PP7C;4(
M5;LH:4WH/$HU=LIJK/$'N[(FL9MC;B\ZO9R+"RN]K8.UPUWC4J8:)N+I_GJ(
M<=2D.7(OU)`<;6M:5!L!"0`9[E.0[4M]R+A%:S7.%PUC2'R3>:!,(Y#M:3QO
M>8^FP\H>+/8E9LTI-(4=9?YJ@S775314<"*A3)B4H6FW#R&[X(0J]=4A"Q0F
M5)41.D"0J]V<NSOC7L;D'U;8Q/4=NRQUQU!S-QC[*^:-C;%"K-=VZUS.0&>6
MR;P#RRW4(2I:4`((5,Q9;-?D'E#'6*O'9.CPLO9[WEIDT2=RD;5D+I)HDA<=
M.;@_>H5M:PU)J^=3:[$A%3&>$!JW556`AQ3`NHJPQMG=7=R7U!-NR=)DI!FN
MD35)4I3TTU(`[8X]TYZ4[+W;OC=J]R7-O9;9P+BE);<N3:-J+M^FU0@W`8N5
M(2RE9*0&CS'$MMU`+)B%K9Y=YJGB/:`W:5;'U@LGC18\VDE3+!(3=0<1U+D&
MCJBBA'R#Z*&X.K,))>/,1VH<L.F(B0YMSESF,-9-RN55N-IN@U+Y*IJ!"]0#
M3+PG3WNV.B8+H-T[Q:F]TO+O<KB[/>+&(+0!0S=)<NVU(O07&T.>53;3M7P6
MT@W2@`I(\)^C>&%Y]UB/&CNU2Z,]8W='K#N:F4&PM$I*0<P[1==V#<RJXIF6
M,IN;XS;FW'[^M9O0T+QT,I*6@XJ0.LA./)'4)K%L;[S#&$MU6N(;R5PEEE2J
MBVA+JDI35(3D!IH--(DS6+&G0TA#2$09Y,6&<J?CUFJRUM\XC)V$QG<9"+E6
MO\)BG2$(\,25;[E.!5XPHBN41`0`R8#MK/Q;2'LDPRZ)H4ZD$=^HT^/A'2>C
MF*QN=ZK[=P^8;2]C+C,VJ'&U>ZXDO(FTKV.>X?8J4?/1Y684,A6[`RUPN<7A
M>!3?76(=$R):B/F%N/A]&P/4@MBLR>:=MX"0VF4V9W)T$W"@F,02#QUL@=<Y
M",B$(-^J22*$RIYDITREJ/"2!./6#&8R/[*V'4]O'X][J+<E%HZDV%L4+M1E
M2P@^5#7)2I]'XHIT-A90FE*@KQ1&P9"OY:NEF\EIM"N78S(45C6+1-.RHLI.
M@FQ%(R!45ZKW0PSL\B1,)\SL6PN#.2`J"G`..LKRUMS?(4H%F6BLZ#1?,'!7
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M2PLK%6S<U:Y.\R7XNS5:72'60H-W%',MQCJOFVD+2E`=(6DA0CMCGDBC;L0T
M%&WV]U2_(*JX:M>;D5+G85E5+!9+;8QEW3>7/*"_JI+.\9)12S=BLU1,BD"9
M2`;<1I6$%EZX4AOG6RW$M>%/!*4R!'!5(FJ:IF>L4WEO:.X'/[H<L,>C<6U;
MW+6V((M&$@,,6MORDJ:#8;N3;)6JY0X\AU04HJ4HC2/9`3UFFFV09J=LENC9
M+QVMF.ZS@Q\6VV!`KRMS'D%8J7+J2+`TD#>ZJ*5V.0B#N7Y'1Q1)OOU-SZ.-
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M'D;4<?E<QC!Q(*MZ0K&U*1<1R:T>1H*::HJ`(&^+4NEIHN.,E""U;!):\(X\
ME2]3+QS4`9&<X[5987"/Y;(8!=C8OX3:J+5W#J\NQ-3IP%U?%+BTH"KP.73:
M'U(?+H4I(2?#X8S$LFJI9\R8W7MUQ;4;`53SS<\+))7:S(.D+94UL<2$#W$V
MG+%E+4C7)B=>,$6CU=TF*:XIB4=@VH0?FF+D-H+]PMI+OA'NJ"YZ2DF8`)(`
MU'&(^Q4E.&V_N]JPQZ]R;IOL):9<FSMU)5;7*<@A^EDM<NV+[3#3RW64-JJ0
M%A0F8\ESM=LAZ)+9H8W"V1>6;W.9.H]W;)VJ6590=1CXJ,`RS*KKO%(B$7HX
M],S=V@V250,[,8YQ$P"!AIEQ]-B4(-FVE"T^$3*B3H52F:^T$ZRB_M["8&^W
M,QT\NL?8/[$QEMCKRS5Y9L+>NENN:+N0@.O"\\0<:6XI"PT`A("3.V6.[G^0
MRF^79X0DY:J7@TY[)38.0FI6QO$5?R;M+-+5AM-2[N0E%6II)(BW%19041=F
M$/A$-1%RSY]ZRYE*'K@240`G2LI!D--!IP[(X9NW;QZE[@V$G)&VLMQ[E`M[
MMY#+3"2//JMVKE3+24-A7+)1-*$A?*2#,@Q`CSS?SW2<5S60K?1D3G@K50(]
M*.M581HDO9HW*S!9HQ^40<1;+N]298]FRE>NGRO`K^)`Y@*D8ACA(#`XY^[%
MNPX?$E9FDUA);.LR4IU6-`!P5WB.H6_IMZ8;CWO;[4P&24$7-C?.%RVN%7K5
MNYC%A2^:\Y;6B"N^9FRTRDJ+%T4@J6E24FXOC7,9'EK;GLM_NL5;R,+I6D*Z
ME#,3LHR'CW%-BGR[>/$SQUUF+IRY%1(X;<RCR'<1U"Y1%LEBW-NV4$H5.9G.
M2B.X:R$>?NL%AM"QP.USM7'/V"G,=<%\NK"W'5INW$!2Y)3):4I"5#61TTE%
MM`^@/].H>.%QSI"&D(AO,U=PK8:_&)YO;51:OM9QFK$J6IX1@BE-*B9%!-JZ
M%PV5YNTCF352`_!9$3%4*8@CK,L7+YM9\B5AR@SEKIVS^#3X^&L;]T\RO47$
MY5Y?3==\G++MEAT6R2M19&JBI-*A))`4E1$TK`*"%2C&?9'Q]#+`2H1M#+EL
M:D+<$BN&99H:D2/)'`H,21<&W;IPQ2MP6%'J%9;)@;HCMJOG9'R=$W/)U^V5
M4Y\?AU^'7C&;]?=53L8V/.RG[">?JG2OD^:YA<ES955%Z:RBNDO3407(CI*@
M>&J>+;!%H,,6IXJ4MB3J=40F4"1"5O;*]%F!I1.0!RT?M1-TVZ2:I0(D(E3*
M"8B&LHW&;\XEPEWS=&FGR>W24I=\Q\.L;>O=7J$7O>UO77<VK?`L2ED%HETV
MJA-<FRBE2%2J<4I)*E2*C4`8WX]-\=4\B4!_\KH">1HZL(ML>)IKLDY/[+,V
M[DC)2'C4EP0>-&319<&JW34,F0QQ2,'Q;8W/RGE74S=\J5>/NJ[03V&<IB?P
MQJB=P]65[2REJE[*G:+UZ57Y*5EOS*E)*PZX4U(4M01S$U`*(2%@Z1IR%"\0
MDJ5E!DVCL7DI+R<26RCT9-M\M:SK58BS0K]T5\)H9PT<F`S9-`Z)2*&'I@!A
M'>^;C,^8:4HN\\)\&FLC\6LQQG\<;"YNCKVO<6%N7GLT=QMVI&-FVKF*84"%
M4)*/G4J2).%862D"LR`C8EJ5XRA/8B74C,=$GHF.11PX!'C1-P:-;BFX:A7T
M$G14I5!!8051$Y5N*PB8@@H(B-H/Y7EO2+O+)/,T[?:>SVCN]D1+>X^LIQ>?
M:0]EE8M]XG*S0HI#BO"KGDIFVH@%*P"B:12H4@"/94,>^.CF=R0UI4/2',_*
M3<<ZR4U@WA%WJ<PRD#R\>62;MG9C1G"6(=P":14DC..8F*)N6J7[C)I0TI]3
M@;"2$$\)$2,N_3O[/9%C/[LZM-8S#O;CN,DC%,6SB<>IY!2@M+1RE\M2DR<F
MT0@J45*#=(!E*,:C1O%\)+,`(Q.-S2,NUXYD1%VS.*;)4YW9QG&IW0I1"2KD
M#+G,D5'DY#J&$50`=7/,96E@S=I2?FM.WLD>W_5[(RW-R]:?*;?YC^8%K;K_
M`.Z30H36))^94$S=(3)`J*Y-^$>`RC#+T7Q%6I^*FCJ/QBK3HZ64-BLSF4;'
MCW,J\<E</$X]VJ]$\P=\]2*=TFX.L158I15`3`750N,R'WE@NAZ7SFFLAH)]
MTAPEV<(D&]S=>6]P9NX8=S*=Q.L#ZRI;4%I;0FE!<2E$F@A!(;4@(*4DA!"2
M8VS[&^.:MZR4[/&8_6O,O65V^3T'#EFJ[/67R`$D%)Z.7<&:LFL@W(7O%NFF
M9<I2"L8=BZM<_)BW:`+@82N:/[0X2/&<^'V(@_V@ZN-[9P["'LJG;5O>!6.*
M4K"?,(5-L,N)34M2%$\I-2@@E0;`F8T96A^'2^,ZC'N&.+U<9-[2JZJ*KB80
M/&*VMXL"#T&\FK("Z?/7HD!)TDJJ<%$@`BI13``"_P"8S0NEJ!=\T425I\GX
M.``XB0X\-8V1.Y_4$WO&_ND.YI.\EV03=!+1Y@MD@E$VPW2A"9E3:DI!2J:D
M$*),3M>L78\RA76E8O%5B;)7V;AJ_CF#@AT4F#AHB=NV7CEV*K==EQ:K&2^I
M.4IT3F3-N0P@,?;W=S:NEVW6I#I$B0>,^,Y\?CCF6V=Z[LV9E7,SMN^?L\JX
MA2'%I()6E1"E)<"PI*_&`KQ`D+`4)*`,8@^$\.-6@%4Q]4F[)F\;RP<HUNB@
MV<1U<<U5NN)AX$30:UETJS`@[)%;G,`AZB.K@OKXJ\+BRLS''O-7W0!^&)%/
M4?J`\^5(RM^JX=;4UHXHJ4EQ]-RH=I*E7"4ND^\7`"#&[U&MURH5N'K50CVL
M56(=DDTA(]B<ZC-HP#<Z*34ZBBQA;@!_@^(0X_1Z:QWG77G5.ODEU1U)[XUO
M.Y?+Y_,7&9S[JW\S<.E3SBP`M;G`E4@/%IKH->.L;'JW$3#2$-(1X)1M&O(V
M09S"+1S$NF+IM)MY`J2C!>/6043>HO2.-T#M5&QC`H!_A$@COZ:J25)4%(F%
M@Z2XS]D95D]>6]XU<8]3B+]#B5-J;F%AP*!04%.M04`4RUG*6L53-0?#<V*F
M,:=ABXV*"7!1VR55F$3Q)KB<2M%R?-E)`SI5^J@4$%43K"4S4`3,7H[!J7Y^
M<\X5`N^<HD9#6GCP`^/X=>,=M3NGU!#>[EXAW-#?)QX2L!HAWR@\8/*"*0@*
M\:5!((<FL&N9B00IWCU^5>.E@C*"&64:F1O%I`X9A,!52,C,$5FL2"_:F13B
M3&0(N5$509B)`-TO36,7LEY,HFYY.O7NJG/4_#K+O]L:K]?]5SL=ZQYV4_89
M5\2X:5\KS)760IR54RZ`LH*J2Z`HBO6-"3H'ATCB^RQJ4?B\F+C6I-U8U4I=
M$(IM:V:AF[0@RA7_`'3!VQ*L9%JDBJF5)N<Q$B@D8P#D&YS0NDK)=-W09::T
MGCIP,^)GV\=8VE>Z/4"O>EG>.NYH[U%B4VX+1YBK98J4>444K2N06XI:25+`
M4LE8!&Z+4[QO#(..7RL;CPN0XJMMFV-$R.F))$E98)"6,-!QZ3@&[QI'H*G[
M)7IG,B4Y^B8-S:L<[*>6=3-PVI5X^,JNV9/:>W77MC7&]P=7CM/+VS;V6.TW
M[Q2L@:5ELW#AFX'G"DJ2IQ0'-34`HA/,!D(UIK0_$I.JY6;LXW&9:I(3`GRJ
MJA)-S-6LPT>=VB22>`]%6&6:21A5;IH'1*DY,84P`XCJ\JXS)>9J+O/`^;TU
M((UD):Z<9SF.,3#VY^N[F;P;MP]F3FVV)8T*;54II2:26T42=2IOPK4L+*FP
M`LE($LPYI7C$>7PZHYCL<C,1,<5/#)#OFH*J1J)2NTOD2/=\)A!(Y@63,J5;
M9P(J%'JB(C:#^5"'DI+E!/SFG;PU/8?]''2,!G<?6=-AN!+#V7\@^Z3EB$*D
M'%>`\XTS:41X"$E'@\!%``C(7.A>.Q+1CPUZB*,A;&<Z_>8Z3G7:2$FM-OGH
M2KWY8@X=$/(BI)B"X)*`HF5?B)2@;;7QBXR99=\NISD%("Y#20$A/NTT^",3
M;VZ.K*L+ED[9N,FK!N6R$7Y922V&4(Y:.84I(;DW-%22E11,$E,X\"%)\8C3
MF8U$8W'*D[,1[E+,Y#/6BKDD:X2!P]^?H'=&+$(K<"JK&3*C]<4IS#U`*.JB
M_EN6Q,NAL$<KCV<)'M]GLC*<W'UE1C=OMK>RR<9;O).)-"@GF)-*.0H)',(F
M4H"BOPDI3X21&!=T/Q$5IN+VSZ.QB:EL)PZN+U7$F@#%Q/.GH+N2Q[XSX%9=
MPZD4RF<)KJ+%.L4O4`3`7:X+C-<]U22]SRF3DA\F4M1*0TX2^*)5C<_7I.X<
MT];.YH;B=M@,B$MJK2RE%*:T42:2ELD-E"4E*"J@@$QM:=+\;U,C7Y\$7CQ7
M),I67#?(22CABI+'J[UN1.0/,1RK@R+5F\:I$!TJ"1!4(4G5,(`75@/Y1-LV
MF;@M@KP2X5#A(^SL'9V1!JW#U>&T<7:E[+)V@S>)58D)6&Q<(42V&G`F:E)4
M3RDU$)454"<XV;%%:P['T`(?$C&KKX]D5)$BJ,$LE+1<DNZ+VLF60<++NU7Z
MZJ)035!P<YNF!2C\(`&K=V[>KN*[PK\P)<=".T2[OBB%WSE^H%WNDW^_'+Y.
MZFDMD%]):=;2GQ-T)`2$`$U)*`!5-7O3,8ZN>.6#JFDFA`8SJ[!-%Y*OTMV9
MW1RN)J*/!R!N;Q5P<4U(90S0B8B)$6XB1,"`(ZK=RE^Z?G75F8`_D-0^SK/B
M3Q,9>7ZN=2LZM3F4S-ZXM3;:#X@GPLNAYO1`2)AX!TJ'B4N2EDF-KI>/<=4A
M]-KT>`AH-_(H0<?/A$G,"BR5?8"Q@6[Y'KJ%(I'QINFER*4W2V`=P`-6+BYN
M7TI%PHJ2)D3]IUE\)B$W#NO=VX[6V:W+=7%S:LJ><8YO`%]RM]2#(3"W!4J1
M(J[C$@A]`;:QXU6.=(0TA%"?+]W7H:X8SG\@)-ST$M(SA`@K(LSO8Q.[S])!
MK6VJB8HK))R<NU([:,A$`,HNJ"9!YG`!V'"I<6RZU;?E-;1T,C2%^(^T#0J[
M@)QZ>Z!,9;(X#,XK:JE#=!R6'>DVNATV;-Y5<*!F"6VE%IUZ1DE"2M7A22*)
M,H*S%IQL=)1[UOY+?;J$M!45V3@+5^3-+Q_58)NS2)D.Y5@&D"9*)73!42`]
M`K<P=4NP;`IQL/>:JGB^64\137S1I\,_%\&HCTW<9/#G/C=CCK2NCWU8];$I
M6#;?6!S@64<N=(?6_5=(53,LDNI-!F9"C)_%`Y#IV1XI*"9>,L%]B8*[*K5T
MZ%6;9`1Q!/Q%;"3C5HWIA)5Z26*S<G.01:NU"%4,!]M8RVKORR[9RHY9511K
MXJ.8"J1G,A0U`[1&JWF+WT=J9':5Z;ISK)=><>LP'ZKE5B<HP[<<MP.3+;[:
M2ZV`KYQH**`4SC0:E#R+6H,J,XB9%GFBRVCQILN&8YZP<!:VV-85N@H^4C'Z
MC?KL(BOMV\J9^D"A"I)KB50OUH`;(>6E3Y?20;%"7DN&?AYAX3'`J/AE\'LC
M:,[D+2XS[NY67VG.G=G9;@M\LXA:?*JR#RB$!Q(5)QU]2K;D*I45%`*#X#+,
MU)_2$IO#UL*TCFV(,;T;"E>\A3+P:H0\1D&*E\CE%"Z1_P`O_P!HEX.7?LEG
M*JY%!1352,<0``VMO"X*'F9J-ZZXZIGQ:E!"/<,^!$P)<2#*([.6NXUXW<&#
M*WE;^S&3R[^"`>'-=L'&K`U6CE?A:>:0ZAM*"FM27$IU.N(@F96L);8-2,<,
MK=DACB9UXOMGD:N63,Q89>N$HHI3SG;`I"H1;%XV<N`(*'!N=,YO@`!U<<)4
MMM84"PTI?/U'$MI'BUU[0..LXD,E<J>R-ADD/)<P6'=R:=QJ2X.76O%VK8%T
M`J3JG%H<;;*@N:TK2GQ18;Q?G*Q#7:BN6YD85W0,5Y(J>=UA8+MG<?>++F:*
M-1(JV+%:$7>S#A8DJNW!05#)HN14'B14##&95MU=NX#X@X\A36LYH#9K*=>'
MNCVR[XY/UGQ>8R.W,FRX%7+&4SF/N<*`L*0Y9V^)<\ZY:BHA+0'ED+I`"E-T
MZJ1(5E=LF:E0J46E"O59C&:F3G'DY&MHYT68:1$AY#Q<S`$MX%1*XDT3]%24
M2(<RNT:!E0#I:EPI8?62H4N\OD&>A(9(-,^!G))]OMCL=O<7#>?O[TW+:;#,
M#')VZXIQ):4ZC!.-/FUF2$$33;**0G\8(036(W:2?4DECS!9K*UC9;#&3*_F
M",\;FS&".NPDIU_8:8$JSJ#1&.`$).S6%JH\9"D!3ND4E%$A$H#K&0A_E,M-
M33?-*;+Q)D0`E4JM>`!D9\.V->L[7<:L1@,/AUO,=0L-=8MS<"EO26VPAB[Y
M2KI2EZMV["DM/5$AM2D)6`J4M6L<3*+U,]2DHR0E\J4N<\@)_P`A&+)HN[L+
M['TI]F591684;IF<S$9;6*)0CR@90KL$#E1`>!@"ZTI"7N<E0%HXED,S.E8G
M*7<4GCW3$XF<3>V36<&<LGFK?9&1ML&S@EK4E#"+YOS`;#04:6G+59//)"2T
M5I*R*A/<I^8QR-[R-?7Z4(_\<;?$95@,7$;00K0S[*+NBPK.94KS=./Z*#^R
M-D2L6BI`*+EVD9-,14`=6&F[KR[5NFH9-"FRO74(K)%6O!/$]PU/&->Q6/W8
M-L8C:]LJX:ZN6%QC7\D5/2>1CDWKJV@^HKFI%NHEYU)GRVE)6L!)$6#\F+QE
M7&N%_&AG7)1[4(^3391.09Q:Q_8M>*&.Q;)O8"*E;4O7;0,&+BPM4BG`[43/
M'*)&O,HK;C'XNWM+J^NE+DM:9E`":IS<$R$S3/PSEKH"3V1ROHYMK8^\.HF\
MKC+LM7]VR5N6+(8\V'>9DFT/NMVR7[?G4L+400Y)I"R]20W%?I_)N>+@@I4[
M9<K:XI5I\;9@MI7@X`&[1?/SS%\PO`8^CI->$1?)Q%JJ`*S;HAD"'"72!+FD
M`@B,BW:8]H\QE"`\BZ%-1X,UB:R`=2E7A&ONZQU/%[-Z8X!T9S!XZQ3N.RW@
MUY9+S]2DX1.2:#]\XVEXH+MM=%-FVH+(-JJLI607(^J/C\XCG6#\3K14P\GF
M'V`JR:,M(+=P^=BA$-45A=K=LSY+HKIF3-ND00$FVWIK4LBE:;]X+2$JYBM!
MH.)X1XEZILW;'4G.MWUNW:W/UK<DM-BE"9NJ(I%2O"4D*'B,YSG$OZPHT*&D
M(:0B!/*./F9;QQSE&U]L\>S#[%EU;LV4<50TB]%2!>@LR8$2'K'=NVPG32*3
MXA.8`#UU(8E2$9.W6Z0$<Y$Y\./;V2CIW16[QUCU=VU=Y5;;=@WF[12U.$!"
M)/HI6LG0(0J143H`"3'S=?3^)!O]PR,]:Q#SQLE0E("&<-X(3U-_D0<)-XN<
M)&1R;#H!*RB0)QJ:@)`95Z042F%4-M;.&KLVR+4%0R@D3KX@CFS$S.<A[TN[
M7A'KVUQ.^QM;'[2MEOHZOL<I]U)>E=(L/KA3C)<<*ZBVT9W"@520RKF$!!B.
MOD=B-6VV/T8Y\GY#.,AQ%KK34S-?[5-L7$PG)-&CPC[I"X:0#6OG&+4**A2$
M>&Z`@"H@&LKF-!XW,Q]6ALI49^'F<T'APG/7X-8V[ZSQ7UPO=2W6CTJ3B7;:
MX54GRRLB<NVI2**J5/*?'F4FDJ+0YH-`G&T5.8QNA?,<Y`69L$O'ZM0&$ZY>
M'KB'-]DXO)\9BNU1C0;#'G:B@$E6D5U(]\HLF86SMPFBJ(*&*&K+S=WY=VV!
M/UBI3I2)^(H+B2:?8KWAW@$B(3.V&[WMLY?:K3CJNJEW=Y>XLTI=_&G,<YDK
M9Q?(6%547!2E]E*%#F-(4XB:`3&MU:,?,J>UI$]'K'S1;)_#4_X^LRQJR-FB
M\>LXB>+5%6KPS5-2/C*>J=;OTQ.4&@+DZP!S+JX\I)?+Z#^(H2XEXSF"LD53
M':5=G?+3A$OFKVUN-P+W'C'4CIW96N68SBN8#;.7RG6/,A2:B''+I(3R5`$N
ME"N6328YB5ZX-MP[:&+%)''>,JK@Z&\D7ORE5.$B[9$WBT&=-;FB+0J+B6@[
M(N1\[.L4YDD%"+''@(#KZL.<A]E2IW+JW2SJ)TE"?=]B@)`#B8^7Z,P,%G\-
M=.*5N[,WV8=P".:DO.6SME;4JM#5-+3UNDLM)00%K"FTBJ8CW0**+%I?8JTM
M4'$IDVUXSE?%E@$.H>5<TUAY(6.>E?L:H5D!HF/2B73>0,BF9'A'G*<0!/;5
M*_$II;)(2TAP/ZZ5%A(%0^&:9GMC&RCKMR_B[W"K4FQPUCD6MR+YHY8NUX"W
M8:\V*_GG"XE;`4H*F^"F97.+(>2$W3Y#(%_3D!9R5@O.,:A4L&+K1#EZZ>7N
M!R'()ST96')F:O93,?+&9KK"04S`FEU=^!!'47C&WTVS=,TM-NJ4[K\A2!(J
MUU$I@?#*.1](,9N"UVOBE6G,9Q6-S-U=9D!U*$ILG[!LL.7":Q6RMH/(1,*!
M4JB52@(K!*M`<U^HP_8*/K[C-6[N_*`[&+6%XVKB_DK3K&\2N2Z;-,TN@^J3
M19Z5,XK=:/(;8#$`0"70J3JU`@6[H1R-=">0I(HUTDK2?88[/8O\K*WV0YH;
MVOF!9HVZ%N"@W`V]=L(-HDK/**+E2&BH!%+Y$R%$1EYM[22V?,=H?,F:N+\F
MU'R$@O')R,*=:O2MZFGV-$(Q&FLP8G1:2TS;H]V[9JI)IBH"2BI!$-S:MH#Y
M:8:!(O&5LEX3U"!S)U2,R`D@'X8C\;;[B5AMO82V=<3O7#7^">SR.<$W#5DR
MC(%Q5VJL*4VU:K::=2HJ`*D-J$Y".B[,%'M%G:,TC'#W/]9G,M3^6D8Z*=FL
MZN/G<-#_`#M1]))(`L]B[&D1L#1,%C@ZZ!@3`>!MJF%47";A2@,:I+8;F136
M"92$^*=9]TXO;=N4V^Y;;<UP\AOI9>VV,8Q96XD6PODO.\D(;4J2'+<ESFJI
M!;K!614(MSCFPRC:@^961\"1[:6BW)G,SB-*+9`E!SUN@\7L47[N"9$110=I
M*2R#9(PI$X++H"3U,40"$NFTFYLK;(*DK@Y,ZA)<.A)UX3/P&."[MQ-D]NCI
M[M'J@ZMB\0$M90NKF\S:O9%90EY<RI!#1<4*C-"%A6@(,5$;9X\F?R63<C0;
M[*6N]I6FB)5*&9R:>2B2+:1K3MUG!*9F5JA4FR0TRM$^<LF)`ZD?*$!N8RO(
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M>\[;D&^V_P!=T.>V_P"YWU\\5/;3_I_UP'F?+Z5^4J]M%4O_`%:I?'*/+_$W
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MW?'UZOT<>?Q?@U]\>G&79_1!7G)(KYM-)HG5*GMH[)?!I`/EW-YQ['J[!\QV
MZ'/CP].]V^+;I?\`2?N?Q:I->DIR[/Z('SE+<^;1_LYU2]M'9Q[NV/R'RGHL
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MC^+J='Z/O\?Q:^^+3CP]O"/GXQ/Y<Y>WA/\`FG\4X[6_0Z).UZ/;[?5=OPZ/
M'?\`<=/X-M]_HU\,YZ\8H<YM9YU7-[:IS^.>L=VOD40TA#2$<#ML._T;#O\`
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=<^D<VNF9E.<O;*>GPQZ@^[]G[^J8M0TA#2$?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g524974pc_001d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974pc_001d.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)``F`P$1``(1`0,1`?_$`(@```$#!`,`````````
M``````@`"@L!!`4'`@8)`0$`````````````````````$```!`0"!P,&!!<`
M```````!`@4'`P0&"``1$A,4%187&"$)&2(C*#@Y"D%B0QHQ48&A,J(S);7%
MU296EK;6-U>7>(B)2A$!`````````````````````/_:``P#`0`"$0,1`#\`
M<5]\-?"[]G$^W*O1+M332MRG-$_;N.>H(38T6YM7K\!L$A$CH-.T[(5O".E2
M,904%7*)%$Q``@"(CV9"#4.)[VR[)3G"&[;VGA@8P$.9D[9""<H#Y)A)P>;0
M$0^#,<OIX#A\[:=S^;#V?T5MD_<W`;YMD]YL=BY)]VQ8:'<8\=`J[LU<C4'3
M=2J%O%MM0)4E4E231$U"*JR4G3R=-D3IA3CPH<6+#,8T,IQ-HCEE@'0_6$_O
M@B=:F_D#J/Z-^:O$O#:;PYS(X>UF^>%=5NG=^\_/;'H:G+R,M'`>8WO0'\+?
M\/+NOP=16`BS,`L`;_=H>T+LG_N?97]OD3`2>O\`S1_Z_P#\28#3_O%M$R;B
M2S<M^JKXT5*.?;G=2VR'6JA3]0+=,)=:KR%3$U3:;446G4]2G$R668J>>"2,
M,(Q2G$!$,L\!'G&[IRX8#&`M3-B8H&$`,%03P`8`$0`P`*7F`&#M[>W`4\)V
MX?\`25L?UAG?R7@"YL.[N"NV>N^M[>)WW/;RD&_:1TJ0<NH%!.AU/5:I.2M%
M+$M4`(Z6C(2%,S<=05XD@67A&,!81#1-(Y@`,`_IW,O_`#:[=?#J]O[P]MHX
M;W5-\0ZSA;>.P[GU6V[PV?Y'0UFEV99X"\N#;.K;YG$OK<F&EU96Z!:=+2=O
M%L[6(E0N(G)JJ]:-#3*C>"MEREVY>5B8]93T.,KRR9)2TY44G!"4AF.!X9_L
M@"F#8Y<^:?9TD7N\4<L)5EYDU6R@7976!+5@8L:"2%&JQ>ZHS1+9(I(.D<)>
M5D7*"+I_=2:&1@LPL@N@%,>2(;N^Y,LREJ$H2D)HMRETYIBB98\U.%F(%*H'
M6`!+H81I<A!&;F9]M!@9`;41=;HP@[XWMA;SK5>6\)#FV-Q*`;^H5*!`=2KJ
M:N(NFKU:7$HXP@F%)<IN/=_2Y+<)N#"RB%E9>:<<#GC'AZP`EP/&`TV9:UPJ
MZ9Z\+NL5YQZYD)ABWU:=%HZO0K%=YEK=D#CN(WKG%3S.`,^9:&K)9I1J&D!4
M@CEG`CRY8N6G]$!C5=JZAKQ^EWQ9MT=4K@<UNGKD7REYU[IICC?A#C+[_P"Q
MZO9=/6_*Z679E@,OZ5/;[=#X-+U8OJ9X!>E3V>W0^+ZL7UL`O2I\KVZ'QO5B
M^VP&>8C0V.^W<WB>=6'"]N7''%W);J,X.XME.#^4^P?F5L.Z-NWKMWG-U;3J
&_.Z&`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g524974pc_001e.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974pc_001e.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(``G`P$1``(1`0,1`?_$`&T```(#`0$`````````
M``````@)``H+!@<!`0`````````````````````0```&`@$#`@0#"0``````
M``$"`P0%!@<("0`1$Q(*(126UB)8&C$R8B,D%187&!$!````````````````
M`````/_:``P#`0`"$0,1`#\`9![@[W%%\XOLI575O6BA42Z9GLF.V]]MMSNC
MMY(1F-&LO+.F5:8HUECXD9B7E&\2Y643<K)D20,F;TB)RB`5ML"<D7N;.6>S
MS,KJ[EZV1-?JC]E`VB?QNQQOAG%%:E7R`.V,?-V.?0(S2DEV?\T"?,**^+\1
MP["`B##S:/\`O&BQ8RX[I=F8-P<^4=F,7@@*0]A`_P`Z-?!AZ!`?WO+Z/XN@
M7-G7E"]R[Q+W6':[2Y;LDJQN!Y%K49?*4/CO,.,;8I$>$99*L6B`;@R=N60.
M2"J4KDBQ`,`@`!\>@>_QH>YLR[NCJCR&HY'QUC^E;5ZA:,YVVFQC/P/SJ]-R
M8OBF@6>965FJN]$H1B\/9`B/*T;KG3<LU5#=RB4W8``YW]%-K;UR:YNR9$<5
M%HVTI>14J`XQ9EK'TO?V[)ZWCZ%7(!W$WAG75YAFXD(NQ1[@OB#^U"+3Q]^_
MJ%006IN"SV9Q!J3JSQD6.C477C<;+6Q5FS^A@_$,TWQ5%XDQI-T6M4.@5_*U
MC>6YXFK>+O(5J0FA&7EU5VD>JW!44_4F0`](7Y+>;JW:3U[C_",UD+B*VR3K
M1*'M*-IKK++RMFIZ8,78N;\IFD"L'H!%"/\`DBS0D:X-W,101,`]!S^GO_2N
MU&A^4N-[&5#QSL#N%JYLU9\VV/"^;)2/R,SS)BJPU8U&M3;&=C6LD8<EDQQ8
MVJ#M1.*FDE'K)8QTQ.!3%$"IX\.,KD3JMKVALL_Q/UC!T8.@F[5*<$F6^1$'
M67KSD+7J]4ZBXFJL8^R491RQO5OE6;9RU3%53Y83&3<HJ`10H7_]VMIJ9I1J
MCG?:2^&2/`X:QY/6Q*.47!L:P3Z#4S>JU9NN8BA4GEHLKAJP1,8/2"C@HC\.
M@QKFVZT_F7D-;;M[43TE-R-KR\ID3(C^-HM/R0NTC3D6;LXB"QW?W#:DST;!
M1Q6[-G'/U"-"MT2@(_A#H#3KN^>IT:ZQJJ]=77QUG>>[9XG/'IIJH],&)YQQ
M(J1:K9-Y-%)/S1B.2>NFO?356?[$5!`A>@!['>[5QUIW[2W2UJFGT5)U;+\E
M>JF+^KU^EEFJR_DU3OJ[8*147"M5B(V?A5E&SF.9G.R2*IZ2=P*'0;"U5WTQ
MO=>.-UR.UJ/6D\<LM6+ELTYKR#YN9ZDUH-`G+C:Z>:1`!:A)1,E7'D8HKV]`
M+HB;MV^'0"QS]:P9SW'XL-B->=<J@K>\LWF3Q&I`59&2CXD\FUK67J1:)K^M
ME'#1BF#2(AUENQU"^OQ]@^(@'09QGZ93F@_**_\`KV@?<703],IS0?E%?_7M
M`^XN@GZ93F@_**_^O:!]Q=!?AT_TEV7QG[:RW:*7;'CB)VADM']XL3,L;&EX
DARX5O6639_\`]?P(3"#U2&*>:)<HT`4%?Q)><`.8H%-V#__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g524974pc_001f.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974pc_001f.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)P**`P$1``(1`0,1`?_$`+@``0`"`@,``P$`````
M```````'"`8)`00%`@,*"P$!``$%`0$!``````````````$"!`4&!P,)"!``
M``4#`@(&!P8$`@@&`P```0(#!`4&!P@`"1$2(1,4UE@*,146EY@964'4U987
M&%%Q(B.!-F&1H7(SLR1U,D(T=+0:5"4F$0`!`P,#`P0!`@0$!04````!``(#
M$00%$@8'(3%106$3"!0B,G&!0A61P18)\*'1(T/Q4F(D%__:``P#`0`"$0,1
M`#\`_9SG,&8`X^3O[&:JLI1N0?M!2WJ*<R`B:BFK;(T_ZV2"J$)!C2S9Y+FD
M7$4)BM#%3$A5>'-P#I`.J+2#R^:`\1>TU[N+Y]WM5:2B<OF@/$7M->[B^?=[
M3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::
M2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[324
M3E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<
MOF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\
MT!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@
M/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!X
MB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7
MM->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]I
MKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->
M[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<
M7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^
M?=[3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[
MO::2BRJA%/,G-JXHQQ<;(#:WD+>MZLIQ>O&%+V]O2C4SZC$IAFI5+.G5GT$D
MR2G',&5<C0RIR)E<&()C`'$0:2BZ54&\R\M4U1*TAD)M6M:35GIA2EVLU;J]
MIYEM3AY%R:#;RQVT$JW/)HQ@I%7$AS$%4#<#"'2+247A<OF@/$7M->[B^?=[
M3243E\T!XB]IKW<7S[O::2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::
M2B<OF@/$7M->[B^?=[3243E\T!XB]IKW<7S[O::2BYY/-`#Z,BMIL?Y6WOH(
M_P"H*>TTE%\5?_L^H)'77R.VEVZ"?2HNXMU?%!$G^^LK3Y$R?XCII*+QQJ/S
M+0#P'+'9U`0](#3-V@$/Y@,9Q`=1I*+CVC\RSXLMG3\LW:_#-3I*)[1^99\6
M6SI^6;M?AFFDHGM'YEGQ9;.GY9NU^&::2B>T?F6?%ELZ?EF[7X9II*)[1^99
M\66SI^6;M?AFFDHGM'YEGQ9;.GY9NU^&::2B>T?F6?%ELZ?EF[7X9II*)[1^
M99\66SI^6;M?AFFDHGM'YEGQ9;.GY9NU^&::2B>T?F6?%ELZ?EF[7X9II*)[
M1^99\66SI^6;M?AFFDHGM'YEGQ9;.GY9NU^&::2B>T?F6?%ELZ?EF[7X9II*
M)[1^99\66SI^6;M?AFFDHGM'YEGQ9;.GY9NU^&::2B>T?F6?%ELZ?EF[7X9I
MI*)[1^99\66SI^6;M?AFFDHGM'YEGQ9;.GY9NU^&::2B>T?F6?%ELZ?EF[7X
M9II*+D*C\RT(\`RQV=1$?0`4S=H1'^0!&<1TTE%["?\`]GY9(BZ.1NTPN@H'
M%-="W5\ET%`_BFLE3YTS_P"`CII_@B^7)YH`/3D5M-A_.V]]`'_4-/::2BXY
M?-`>(O::]W%\^[VFDHG+YH#Q%[37NXOGW>TTE$Y?-`>(O::]W%\^[VFDHG+Y
MH#Q%[37NXOGW>TTE$Y?-`>(O::]W%\^[VFDHG+YH#Q%[37NXOGW>TTE$Y?-`
M>(O::]W%\^[VFDHKT8\R6[\&4EM%\B+IX5S^*1K<4S%W(IFV5'7$C;P2-WPM
M)&Q]42U+R4TU+`M:*<WO*Z?-"++`X)3YTT3I]H`=011%N5U"+!;B_P"5W/\`
M[IE_\@NI'=%7K5:A-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$4$Y,Y!T9BQ8NXM^J^,\5IZWT)ZP]4Q9B>NJGFGKIO%4W24"D<P=IFZGGW
MS9DW(`&'G6YA`2E'4.[*5K0H'"^]F;\9%WOW%[FW+B8BKTF51T-A5:2NZBMC
M;2UU+/4C.XB(N=45&OXFM;CU^=LND=^H:0;1Z*@"D1N(<1&A%D]RML7:NM!1
M\A7MR;1I4M2D8LR;/)F4N[>HQ.UR+@K5BT3*2O%G3MZ\7/RD3(4ZAQXCPZ!U
M<VEG<W\XMK1A?.ZM`/`ZD_P6W;&V)NWDG<D.T=D6,V0W#.U[F0Q@5T1M+Y'N
M)(:UC&BKG.(:.E3U6)76P`V?K'TM#UG=>@HBB:>J$J)H%W+7=O9U\QU[=)T3
MU='MJW<2#D"MUB&.)4A*F!@YA`1#C[V6*R.1G=;V43I)6?NIV%.G4GH/\5L7
M'O"W*7*V?N=L<>86\RN9LB[\AD(;IATN+#\DCG-C;^II#075=0Z0:%=9W@;L
MW,;3)WT<TE3)+2J\A4JW)>F\JL4HX4,"96)2)5T=Z,EUH\@MNJZ\IN@2!JIN
M(R;K[^V""3\[_P!E.O\`'Q3W[+WMN#.7KOD1W$T&W\D>16U)L3'28-`J9"20
MSXJ=1+K^,CJ'%91:G;7VG+X4HC6]I[81U<4NLY49>M(6[]YU"(/DBD.JQ>-U
MJZ1=,GA$U"F%)4A#\ABF`.40$?"]L+S'3_CWT;HYJ5H?'D>A'N%@.0N-M]<4
M[A=M7D3&76)SS6!_Q3M`+HS4"1C@2Q["01J8XBH(K4$+FCMM7:BK^JJ_HJCK
M4-Z@J2U\C'Q-=1["[-ZE/4$C*(+.631=R-<E:+JJ)('$>J.IR"40-P'HTGL;
MNUABN)V%L4P)83Z@=_?U]4W-QOO;9VW\/NG<V/FL\'GX9)K"22@_(CB<&O>U
MM=;0"X4UM;4&HJ.JDCY.^W2/1^WYQ[V+R=_M6BT=5CJ?$79#HNNWEL:IBZ6A
MJ^82[.!>4PYNY?<T@A,2`-3,H\YF]6K-177!ZEPX*"`"<`$0$!X9F';V:N+8
M7D%M(ZU+2X.%*4'<]Z^B[O@?K#S_`+GVE'OS`;5R=UM":V?<,NF"+XW0QZ]<
M@U2!VENA]:MKTJ`11>S<["39>LS5,%1-SJ9IFCZKJ1-JM%P<G>2]1GQF[WD[
M$Z>D:ULX+%M7G6!U2CD4BG`>("(=.O.SPF6R$+KBS@?)"RM2!TJ.X%>Y'M58
MW8?UZYJY.V_=[IV'MS)9+;UB7-EGB8-&IE=;&%SF_*YE#K;$'EIZ'KT7E7%Q
M!V1K250YHJY$32U)54T:L7KB%D;N7V.Z3:2;5)]'N.=G5SIN=)VT6(H02G'B
M4P:KM-OYJ^A%Q:6\CX"2*BG<&A[GT*R&ROK)S[R-@&;IV1M;)Y';\DDC&SQ"
M,-+XGEDC:/D:X%CVEK@6BA"^^J\-ME*B+?TI=*J*>IR)H.NBJ'HZ?7N[?(4Z
MC316.W76BV2=8GDED6RQ!*H<40*00Z1#B'&F#!9>YNGV<,#W7,7[V]/T_P`3
M6G7^*\=O?6WG/=6\<CL#`[:R-QN[$D"]MVAE;8N:'-$KR\1-<YI!:W62[T'0
MJ:J,VK-KVXE,1%:4/9UK5%*S[8'D/.Q%X+QN6#]N(B'.DH%>E,4Q3`(&*8"G
M(8.!@`=8^XMY[29UO<M+)VFA:>X7+MS[7W%LO/7.U]UV<]AN"SDT303-TR1N
M\$>_<$$@CJ"0O3G-I/;0IJ'E*AJ"R*4-!PK%S)RTK(W@O"U8Q[!HD99R[=.%
M*_`B2**1!$1'_#IU1'')-(V*(%TKC0`=22?0*QQ6*R6=R=OAL-!+=9:ZE;%#
M#&TODDD>0UK&-'4EQ-`HAL]@;LY7_)/'L]1<%70TP80GD8J\-ZTW4:ES<A7B
M[5]6S1SV`Y^@K@I11$1`.;B(:O[_`!&2QA;^?"^/7^VOK[5%>OMW72.2^#.6
M^'G6;>2L#?8D7X_^NZ5H+9#2NAKV.>WY`.IC)#P.NFBZEO,'=F2Z]<3UMK=T
MM355UQ30N`E:=C;RWI%Z0&9P3>*,S+UNBWDTFBH\JAFQU2E'T]`@.INL-E;&
MW;=W<$C+9_9Q'3KVKXKZ5HKC>?`',W'FU+/?&]-NY''[4O@WXKF5@T'6*L#]
M+BZ(O'5HE:PD=NM5G,KMG[4\+<BEK125I$6]QJSBI:;IREOU7O6H_?Q4(D"T
MB]'JJY.BU222'B7K3D%0`'DYN`ZMV6-U):/OF,)M(W`.=Z`GL/\`T6IX_CO>
M64V1D.1[&QE?LK%W$,%S=?I$<<LYTQLZD.>2>AT!VFHU4J%&=8X:[*-OKCM+
M25G!TK3]PGJK5NG3KZ\UZ@60<O>7L;5^\2K96.CG#@3@!2+K)F`1Z>&KNWP6
M7NK0WUO;R.M1_4!Z#N0.Y_D%O>V?K=SIO+9,G(VV-LY.\V9$USC<QL&ES65U
MNC87"21K:&IC8X>*JR'R>-NCP_KC_I"[-Y!`?]("%?<!`=8E<046W<VX]I2P
M]+^V5W+:QM#4Z9R5F@_E[O7IYGCPX<2M&+1M7#AX]<<O2)4TS"4O2/`.G5Y8
MX^]R4WX]C&Z26E:#T'DD]!_-;_QSQ9R#RYGO],\<8JZRV:#"]T<('Z&#^N1[
MBUC&^E7.%3T%2O>MYM>[5]V:5C*WMM:=A65*3!3#'3<)>*\;EHN8AA(JB;C7
MI%6[A$X<ITE"D4(;H,`#KSNK2YL9C;W;'1SM[@]_^/=8C>>RMV<=[@GVKOC'
MW.,W#;'_`+D$[=+VU%01W#FD=6N:2UPZ@E8I3FWGM$U;$7)J"G[<1\G!6A?2
MT=<69;W:O8:-IEU`LU7\R1TZ]M^K7+'-4#F5,CUA2B0P<>(<->\N,OX'PQ2Q
M.$LX!C'JZIH*#W/:JV'-\0<D[=R.#P^9Q-S!EMR0PRXV%P;\ETRX>(X2QNJK
M3(]S0T/TDZ@>QJL;M5A)LO7RG7=+VCIJ"KFH&;`\DZC(*[E^$WC=@01*=WSN
M*P9@0I!#TE-S!KUO<)EL;$)KZ!\<1-`32E?Y%9OD+Z]<U<48B//<C;<O\1AY
M91$R6?X]+I#V:-$CC7^2]NX&'M]<$8F8OCMWW)N=5E+T:W=5)7.#MVZUJ.Z-
M#7'I..(F\GHJSM456\EZ\M_<46#=92.`S]^P<N1*@+8`,42XM<;6S['*_E#9
M/V4M_?2W3M=Q2]?PB,FBT>F#UK`29/[$U2\XD'2UG*=DB*-7*1@`Q5"<1`./
M#5;>R*;=2H31$T1-$31$T1-$7NTQ_F.#_P"YM?\`F!J#V4JT6J$6"W%_RNY_
M]TR_^074CNBUW6YRYQKN[?*\N-5M;OTO5]]<>R-#WDMO&$EB3-#D>.6[(IG;
MEY&M8B4!H_>)-G?8'+KL3E0J2_5J&`NJU"L<!##Z"F'H$W0`CT!Z1Z`]`:(N
M`*8P@!2B81'@```B(C_``#TCHB<!Z>@>CT]'H_G_``T1.41X``"(CZ`X#T_R
M_CHBAG('(.S6*UKIN]605=,+96NIR2IV(FZOEV$U(,H^1JV;9TY3K55G`1DM
M*F-)S<@B@4Q$#$()^8XE(`F`B[-][\VBQCM-5U];\5M'VYM+0:$2YJZM)-E+
MR+&%0G9R+IN)4790,?*R[CMLY--6Y01;J"!U@$P`4!$"*OU:[D>#=N\8[?YE
MUGD71\'C)=27;0%O+KJQM6NXNJIQVK4B*<3'0D?3KNJB/TE:/DP6368)F;]B
M4ZSDX!QBH16YHJKZ;N-1M)7!HF42J&C:ZI>`K6DIYHBZ2;35+51$M)R`F4$7
MB#9X@WDHE\BL0JR::I2G`#E*;B`2BR4I3&X@4HF$`$1`H"/``](CP^P-$6#U
M%<NW5(59;J@JJKJE*=KF[TU*4[:NCI><8,JGN'-0<*[J.=84A!JK!(S9X.`8
MJO'IT4S)-$"@94Y.8G,18C9/(2S>1L/6L_92N&5>P]NKFUC9JM7K&-G8PD#<
MVWZS-O6-*+IST7%+N74&L_1*==`JK13G#JU3\!X.Z*9S%,4>!BF*(@`@!@$!
M$!]`\!^P=$02F+Q`Q3%X<./$!#AQZ0X\?XAHBI=EEN'87X+/:%CLLK[P-F7U
MS&<](4(VF:>KB>5J)G3#B,:3R[4*.IBH@;EC7$PV*8%Q2,850Y`,`&$%:(L]
MQAS"Q@S2HF3N)BO>RB[V4C!RQ8&H'])KR"+ZG)I1L#U",J*GYV/B*B@G+MF/
M6H=J:)$<)@8R1C@4W*164Y#B8"@0PF'@(%Y1YA`>D!`.'$>(:(N.`]/0/1Z>
MCT?S_AHB<!]/`>'IX\!]'\=$7'`>''AT?Q^S1%1G+3<MP4P7F*<IK*G(ZC;5
MU95;`)B#HP\=5=8UDO`BJX0"HWM+4#3U43<-3AEFBQ2/GJ+=LH**G(<P)GY5
M45HK1W<M??RW5*7<LI7M,72ME7#`TE2=;T9)I2\%-M4W"S-R#=PD!54'C!\W
M4;NFJY$G31PD=)9,BA#%`BD42F`1*)1`P>D!`>(?S#TAHBYY#AS\2&_ME,<X
M<H\2%*'$PF#AT``:(H7L#D+9G*2V,5>>P%>1URK83<M4D%%5=%,9F.9/9:D9
MEU3U1LTVL_&Q,F4T7,LE4#&,@4AQ)S$$Q1`PD4S:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M5FZM'T]-0^`L#6"A`I";W+,>6M1MG
M)^6/D&[.@+W340SDTS""+AH-413!0J:G$@KIICPY@+J'=E*VC+<PJJ\P<#=8
M?F#APX#S#Q#@'0``/V:H1:<=VFQ;NJ[5RUZ)JX54F@+=I4DTI6US)T9M2H53
M)5,@B^JV61+_`.N>E8&*BD0>(%Y>/1K?=CY)L-ZW'1Q,^24N+I"*NTAM0T>!
M7JOI?_MT\LV^WN0;;B_%X;'C,9IUXZ[RKV:KO\2.U<66<+O_`!L^0%[R*$UI
MU5D;^1&-M#41:3*?(!NI+.+'T`@WH:`?.TWL3,S-44W%MQB6%)NDU&DQ4,F=
MJF1`X@(I``FX<`'6)QDF7N;F?"XLZ1<RG6X"A`:X]2X=0T>OE<0X?R7.&Z]U
M;C^O_#KQ;0[KS#G7]Q&PLEAAM;F5WS27;"'PV\0>YSQ4!YHWN0J_8?XF).\5
MXV1O+;9LZGI.[M09%VNL]+R182.B9)^JH]HRGYIBZY6I$WJ*A.T-%2B4@#T@
M&LIG<X1F2W'S$1"`022@5)`_>X'OT]"%V3[*?8F2W^P,]EQEG)(\1!MNWVWE
M<S#$9Y)HHP([VX@D95Y+"'?',TU=Z%5YLOD*3%JU6<<]5<='4%D8]O;&1[RU
ML8=!O0="57<V..PM^]B90G5QRT1U,>X?KO"\"=6UXC_2&LKD<5_>KW&QPDRX
MD6Q(D/[WMC-7@CO7J&@>Z[+RAPT_G_D#BC$;>FGR_"<6U99&964.=?W]IBY1
M)D&31&LC9JR1V\<)J=4O3J5GVU26A:$O7ES;R.NK3]PYV5D[;3J,\SG6LFK6
MTF>!F9.M)>%51.8)&.C9N2.D91,1*4`+T].K7>HN;C'V-VZ!\48$@(((T#4T
M,!\$M`Z+4?\`<'.[=V\6<<;TO=O7F%Q-O!DX'6[X'Q"QB$\,5E#.'#_MR201
M-<&NH2:^%O&2$I54C'Z"`H03?[H&`3?[-<X/;IW7RAD!,;@W]Q!HOSI5';F^
M6+-Q+I9&WHL#8ZX=H*MR3&2E)>;=QM2W(A::GJA1B*8G(5TW4.6,0CDA;*]G
M,/6%6-RF`.&NKPW>-S5I!B<?=7,5_':4`%6QES6U<#YKUZ^%]K,+O7B?[`;+
MV_PGQ?O#=>&Y(QVQ_BBA@9):XV>ZM[=TUU!.QP!E=(?D;\@&DL%6DU6$5G4M
M=S=YMQJXR]B[=7DMO1E3QB-RE[@2'99V$M)3K--5C3%$)%*9=N_1:D*YZQ,2
M\.KX<>GAKVM8[6.PQ=I^3+;W;VGX]`Z&1U*N?Y%21_-;5MC!;2Q?&/"6R8=V
MYO;.]\I82NQC<='K@GR]R\B2ZOC4-=&YY,6EU?W5HKM9@PUDZYQXL3^G%J*.
M<W!RK&U=M[;STQ%-%ZNIFB96`8/WTDE(K"=<SZDZ1;D;ATF$HG_B&L!@9,C;
M96Y_,GD%K9?))(T$Z7/#B`*>'.ZK\L?6O*<I[3YHW;_K?<.3CV;QZ,MDLE;P
MRO;9W-]%<21LB,8HT1W=XYTGI72L/R@H,EGKZX46YQWH&G;M7#M;:.Y=/0UF
MJJ*B2DS48ZBDTY2M).2=I*-8J3%^0ZB/6%YG)U#`'2&O?#7/Y^-R-WE97P6L
MT\;C*W]VL'HP`=Q3QVHMDX%W>_DOB7E+>W-.8O=N;+W!N3&7,^:M-1N_S6RD
MQ644;"'RQ?&0U^DTB:T$]"K+[5?LZAB/`QT,^>JR\=5]9IUO"/6JK$M(5@YG
MGSJ6I=BU5_X<;&*J"1`Q?Z5$P`P=`ZQ&]?E.=>^0#XS&S00:ZF:0`XGR?5<+
M_P!P7^]2_8V\O<I#$W&SXVR-C.QXD_,LVV[&0W3WCO)*!J>#U:XEI[*2]P^W
M5>76P\O-15MVCN3JE_#1KUO!L#G3>SS&&G(R7E(AKU8@=5=S'LE!(D'_`!C%
M!/IYN&K+:MW:V6>M[B\($`<14]FDM(!_Q(Z^G=:-]+][;1X]^RVV-T[WDC@V
M_#=2,=/(`66\DT$L,4SZ]`UDCVU=_0#K_I6G9>[T2ZR8?3-G;;5?9Z/=X%W/
M@ZFC9BDG%#*U%/T-0+QT1VG&"DW,\)#SK$I2.@+_`'%!X@(ZWX6,@Q+8[^6.
M=W]RC<TAVO2U\@%*^E6D]/1?2Z+C;(P<%18ODS.8W<M['R]BY[66&\;?BVM[
M_(,86&6KM!F@D),5?TMZ$!2)8NFH"BW&S55M,P3)E455RMUH:J7[!!-!_4D4
M[APEW+68<HE*N_33D'BJW%43"41]/``U:92>6?\`OUO,XF%@C+0>S2*BH\=`
M`M+Y9SF8W1#]G-N9V[EEPN.M\3-:1R.+H[:5D_PM="T_IC)C8UGZ0*C^*FF(
ML<[M!NC6,FYVX54W*J^YM'7LJ.>G:E=BLDQ:-HY9.GX"#:<`(QC(:.>=24``
M.<0XCJP?D6W^R[F.*)D,$,D+6AOKU_4YWDDKEN2Y7M^2OH+NS%8G#8_![;P6
M3P=M;P6K-)D>^0&XN)W]Y)9I&:R3^VM`NAFK:FRU.+59CE9NC5[@9/Y@W/B:
M^F%I9R6H)>@&AI)-Q*5B::71%S2<&Q`AE&B',"91Z?\`P\-3MZ^R$FC+7\GQ
M8>QA+`!T#S2@;3LXGU/^:O?JWR%RAFX\=S9R;DV8;@3C7`S8^$0M-O#D'B,M
MBLA`UVF[GD)#9I*%Q'3]U5NCIB'5IZFJ<I]=ZI)+0,##PJTBL8QE7ZL7'MV*
MCU4Q_P"LRCHZ`J&$>D1-TZY]-()9GR@4#G$T\5-:?R7R\SV2CS.=O<Q%$V"*
M[O)IFQB@$8ED=(&`#I1@=I%.E!T4)9!6@IBX4=$5JK;R$N=<^U3>9J*T%)U+
M,(14#)UB=FHFS:R@/.9D9JNH(%.HH403#IUDL7?SVKG6XE=#9SD-E<T5<&UZ
MD4ZKJO#?).=V;>W.UF9JZP.P]P/AMLQ=VT+I;B*S#P7NBT?K#FCJ&M(U'HM-
MMG\@(O&_#BZ="M)R-H?(.XN2M=6WDZ:DU4(&G;2UK4BZ(U`]B55%"H$HJD(-
M8JR;A,>4552\.G6_7^+?E\_!<N:9,7%9LD#A5SI6-_:#_P#-SNE/"^FG)7#M
M_P`W_9G;^[+BTGRW#6$V+89.*YB#KBYR]C;-=^.R5H!<;V\G!8Z-W72TU73Q
M=I=21QCSXQWL!6=,7)N'+UB:*I_M-71:)ZMIZ8AXR+JVK2RCI5-!:,=+2+L4
MUA'E4.8I.(F'569E#,QC,KDXWPVC8ZN_2?TN#B6MIWKT'3T[JZY]S[++GCA_
MFCF+&7^#V9;8P2W&BSE<+2XAFEEL[0Q,!<)6-CAU,'5K07]@K+84K558'(&"
MQCO98^S-#5_4EH?::WU>VH:('>34)3B2B,]%55(ICQ7>`9N;^[PXJJ@/V"&L
M-N(V^3QKLMCKFXDMVS4>R2M`32A:/'4=/0+A?VDBV_S#PY><\<6;KW/EMGV.
MY/Q<CC\L]P9!/<D.MY;2,_M80X?I_H93U!6Y9$3%62$G'G!0@EX>GF`P</\`
M;K0E\RUK$VEVE/QME<F8>DG1G5*0FX9F%%TV4O#LC**1JJG5BQ\:!?[81[5V
MX6ZOE_IXF-P^W5;>R+:/J5":(FB)HB:(FB)HB]VF/\QP?_<VO_,#4'LI5HM4
M(J?Y]9(TCA_A[?S)ZN#H#3]DJ`EZY["NJ1()Z=8$*WI"ED3'$I1=U95SMC&H
MAQXBHZ#4CNB_GV8C59>S`6[F!&X?>G$/*NS[RZ]T+I0&XUE)=&FH",LY>6AL
MXZT8U';>I89RTJ20GXEO;E5PUE4@D6;8'"C8`#D-R)FGW1;"\EI/)"X[WS#]
MV6^<>7]NT=O6Y=-5;B]0%IKT2='V^IB<+1):C>%F8YFW7>5%2+U"(*V0A>TH
MQ*`N'#D$3N5`4*130TF<@<Y=P2@+(UEF!E#9RUM7;%>/&6=9TQCG=)Y:@*AO
MC4;Z/([JQ!U&,W8T[VB9J0'KXL85FI)$9H-%U#,^=`[_`*(H,PVSTR/K2F_+
M95W>O).KVL!>^N\]K>Y"5+4E<J4U2EWT;8FEJ3M&A>!\Z?,8.JYJ,5:LTFBT
MF<ZRSTP*B)W"ACF5[(NH[W!)JH+);BB$SE3E!449=#>S#%;%N6QSNS14)44Q
M1LQ#*3,/9J@[\W-ETZ(Q_LW4+6/4,I4;!P4&B12&;E4157XO^J*FMU+UWGK[
M:+WC+0W8N-5]>06..?V(M%VPC:[R&;Y85!;BG9R[-..YF@OW%HQL0-T(^$EX
M7J@>`B5$CI-P5/CQ.8P(OT>^8F'ALQ9K=/#_`/FK.A_KO[:8.'^/'4GLB_)3
MD51%6R=+9,;6LK%/"6:VP*;W"<]H)P=$?5#RA+X6BM=(XO0Z'$>5)>CJNO=)
MNR<``H@\*)!'E4*$>R+8!>7(;)NI*YM3C]%W6N]9^UF/>S=B1?.S9;8YM6PP
M=ARUQ4%F:7>S^0M?SEPVPJWZIJ@IM`8I:EVRBB2;=FI_;!10YCJE%EM]\M\Y
M;VW/Q%LO=R[-:T["%VL(?*:4JO%_-VTN&%-7@O6XJFH8&2R`&^M2MBTA=.DZ
M7I.#:S`TA%B#<55EW/4BU!8AE2B^NHF->WVRD\MG>',?*6IJ<N'<RALJ*:K^
M\UFLB8&F;<OT;4L'BM%7%H"N(EJUI*GZIOG%O(^.K1=J8H5``$8B0@E(`OXH
MD[E!EK4.,])-H'*N^=O*OKSS-E=XH'N%2U:.B55`60F>MB6MO(WUL21C75)4
M^+OM3*(>-W,:1RDF8R!BEY=!_FBS&_N1F7^"<1O^V*L7DAD-<^"Q9B,$JFLM
M75[ZUD[VW9L9#Y-+Q:-\JNB*SF6QIE="&AIM15J)B@E%G22=IE(JFHJ=V16E
MQ(KYE;S>5QPQ=L-N.7US.QRF=OZXEX*PIJXV0Z%^XJ*NG*G(LSG)*HXLXHK.
MYZ);M9ME$OSN%Z?[<<K?J6[@B02.]`BRC=X2R"7W=]F!'%IO9!U?,]$9O>Q+
M?(Q.KE;/J"%#0)YT*L3H1%>J3<M.%=F9]E(/!\"(G_M@?0]T55\TL9LS]O7!
M_<ISTJW(B@Z!S7S)OYA:I*.\,XVJ;:VGM-3]&7&C:-;L*5--%CZCG)*JV=2K
M^NU7:0%?)@;KS.#N7!ACJBLQ>JW596ES0P@VRKL;A685%XP7<M)D%D5761%5
M9&M+>7OR!O[&RK5HVL:UOX6.A/8:@Z.8LRS3&GHSLQ!)(F2,"ICMSD>R*FKG
M,7(E/:\R&O`SS<N])W&PBW-*@L?MZWQ1DY>H93<0I:"J.G&5(V*NA3M,*L&&
M1T95+!RZ(I*D15`I&G6F.9)-R54BS*B+[Y.SNT.?<FI?+F_]Q<I<>\X&^1&:
M]G5:JJJFX*@*(HRXQJ7O1A.I9V3E'#6E+84/0$VVG2L54@!TFFJL7E*0B:+T
MJBVX[1EX+DY?/LW,[9VX-?S=A;_Y.U%0^&ENZ@GI=6BJ.QVL,5:AV-:4G2#T
MY&--RMTJD%RM*'22*JNXCA%01,)M2$53,6[L8]8_;QF\HIFE7EJ+376KY[8&
MK;%UCD#-TS2L34V)T?;N3:+QMMY^O%F\2\@(EPV9)3#!@H)W*[0Q3I*F;*@F
M]>J*$+NY7873N&F+=![><-E3CW;++'.&[5(T#;S'"JJ)P[+D34M``V4N@]>9
M(71J&08V<LE4[Y\P.G+P9R2#Q=OV%)DD=HNB2#2G1%0NCLO<T:TVS*<IV)RZ
MO'2=P(??SI'"VD[QT[>S]6*\@K(U%3[LC2C'E[4&<>C?2F(61EQ=M9)ZU%E-
M$015!`&W5(D>G\T6QFXU%RM#[C,5M]7>W+<PK$XUXT8"S625HKJU/DTRHBZM
M\;PSEUJD<5)6UU;N3D>QC+J1]H(195NVIEPW.Q".A"IF;]49WUQ%:GRTB_:=
MH&QKD7X2HKW7R86&4!`K8)$5;WU:IV\&Q2D*W[9S=9R```3FX<`X:D=D6^;4
MJ$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%5#-C&**RZ
MQUK.SCF5&F*F5<0M96OKA)$JSRW]V*(D4J@H*L&13=`&CYAJ"+@`Z3LG"Y`Z
M3<=0[LI5+[$[G5)4<NRL!N&JQV)^4=))$@Y>5N"L>!LE>@(X$F:=Q+375E0;
MTF_8U``=H<1SET@]8*G$IBF+P-JA%+F4]RL3<F+&U):9AFEB[3!JE=P#Y&H3
M7PM+,MD4XB21DN`-4:[9@N5R5+E`P*@`<>/3K+83)#$9)E^YGR!@<--:5J*=
M^J[5]>^6H>#^5;#DB>Q=D8K**X88&R"(O^:)T=?D+'TTUK^TU[=%5W,.D;*Y
M-/+'C3&Y!BO;B+LDP9+Q,>XN3:6I4Y"KF2,<@E4KA!Q<EM'J':DC2]G3515Z
MKK#](\VLU@=R6>'%S\ML97W)-3KTT::_I[5]>M"*KO\`]:?MEL7@FVW6,]M*
M;.7^ZI7MFD;??BF.S>Z1QMFN;`Z0!YE/R.8]FK2SH*+[YF+HNK+-P5-5CNOV
M"F+W4!<IG<BVUW&MT[-Q32'58(@BE3\Q2K2ORL)J-,4/Z06,8A#=/(8.C5+-
MP8N"_=-;V+6XZ6$QR1:JDU_J#B*@KQQGV?X<V[R;=YS;/'5I;<59C!/QN3P[
M[M\SYA([4;B&[?&9():]]`!<.FH=U[5F;=8/1$/=)]DQF%BKD;<&]-6P-7U]
M-3-X;00L(=W2C1ZRIAI&PS*MQ21)#(23@"'`0Y@6$.4``->>0W1/))`W#M-I
M:V["U@!J:.(+B2?-!_@L9R=]Q-Q9+)8"TX+MI]D[-VOCKBSQ\$$YFG#+M['W
M3Y9GMJXS.BC);0T+`:DDE9/CQ1^WYCM>V\5W*4R8Q$;-J\<0Q*#@8R\MJF![
M;P[2.6:3<2T?'K]R5\C..5"JG'JTN42<.G7CEMRWF6QUO8S%]8@=;B:_(:U:
M2*=-/98'FC[:[\YIXKVUQQN&>]?/B&3&_N)9Q(,E,^1KX)GQB-OQN@:"QOZG
M5K7HKT!EWB3QZ<J<93%_\Q1O_:4`,'VE$0K`!`!#^'3K6U^337T-"M4=06GL
MM4U5S%+3.Z/8B2QAGKMIWBD+42-XK0/ZD-*)R(3!:4)6#JO55RTSZR`H@GU7
M*1`A2%(!PZS6[1;KLX8&S1V;!F6P?$)`ZC:4IJT@?NI_SZ^R^A6&^Z>Q<%MZ
MVS^,V'90<\VFW#AH\M'.8[;XC'\)NS9LC#?ROBK^K54O<YQ<6G0O2OW:_'^X
M5QKHS]I-R/&NTE`9"0D/3]]J&_5.S,^2HFD4W19JNXEZM73=5B\E&2/5K&#@
M?IX\W#^G5&,W3;6MI#%?6PGN;5Q,+]1;I)ZT(IU`/967$'W-VMLS96`P_(VT
M6[CWCLR[FN,#?_EOMS;/E<YX9,QK'"1D3SJ8.W3]M>JGVI/V>2-R,0*H@<T\
M98BC,2F;]E!T@ZO;:=\XG"+4VRIEBL:3+7;=-FX:LF)!.845>L,'V:Q<6<<V
MTOX96:KF^()?6FG]1<>E/6I]11<?P?V/NK+9').!R^/_`"=S\C2QR3WC)!&V
M`BY?=2#XBQQ>USY'4`>S2/*\7)QY8.Z=S+?7WL=N"8QV;O+04%-TB,T\NY9R
MJ(BH:6GR@1RPD(]W6R223AF`F%%0`,``8W$.;E,7UPV;MK*SEQF2@_(Q\K@Z
M@<6EKF^H(\^JRG`_V'VEL#8F9XCY7VX=S<8YB[@O/@9<NM9K>[M^K9(Y&-)+
M7]-;21V%#2K729B95.'>+MIT;?)YHXXUI/R4W*57657O+Z6B8'J"J)IPHY?O
M4F!*U<`R:E,IR)I]8<0(`<3".K/.9=V:OC=%@CB#0UC0:Z6CL*^JT7[$\X7?
M/O(;MY/L8\7AX+6*TLK-CS(+>U@:&QL,A#=;Z"KG:6@DF@`4F7GOMBE=JUE<
M6Y99KV"H5_5D$XC8^L*;R(M:SF:>D.9-PRDFBS2MVCD2HND2]:F15,541.3F
M+S<0L\?=ML;V.[=&V5K'`EKA4.'J#7V[>ZT3B_>L''7(&)WM=8ZTRUICKMLL
MEG<L:^"XCH6OB>U[7M_4QQT.+7!C]+M)I14VL?3F/<+5]87(R:W#\:;]UW/6
MO5LS`O2W<LW3C&FZ#<(=E?BFDWK9=1W-2B`<BRQA#B0P@;F,/-K8,EN.WD@C
MM,/;_BVS9OE(U:BY_<?P`]`OTURM]J]LY3;>-V/P3MD;0VE:9\9JX8;E]S)<
MW[7:HZES6AD$3NK&`='`%ND?I6'8]6LQWM+=*V-45WN/XX7'MYCTC5B%@:%_
M5BS40K3'M<NN9V[FI1.N5U))VV:+B@!N4.<I0X<A0`NO?*[J@OK*:&VMA#=7
M>GYWZB=6GL`/0>JV;F;[G[<Y%V!GL#M+:4>$WIO-UH[<%_\`E/F%U^&UH8R"
M(M:(F.>WY*5.DDUU$ERM36-9XI55E/9_(\F:F,#-M:VCZVI96E#7JM.LM,GJ
MUFFU(\3E0KQ,C,K$2<PD%!3G]'$-86WRP@PEQB"RIGD8[57MI-:4IUK_`!7Y
M\VSS1!M_Z_[EX2=CW2S[@R=C=B[$H:V$6;R\L,6@EYDK0.UMT^"J*SMI(3]P
M-S<@:"W=<8Z(J:Y$JZ,N=*L;-3#^-I8SPRL;2C60E+EN!1CXUF!$"@B1(#$(
M'$/LULL6Z\/_`&N'%W./^2&)H_\`)0%U.KJ`=R>O6O=?K7$_=7@D\.8'AS=_
M&)RN"P=NP-!RCX8Y;K126[='%`VLDKZR'67D.)H5MRI[*W%N-@(*-F,OL9YJ
M7CX:+8RLR:_%HVYI>2:,4&[^4%N2L#$0&0=)G5$@"($Y^`>C6BRN8^5SXQIC
M+B0/`)Z#^0Z+YQYFZLK[,7=]C(/Q<;-=2R0PZM7PQ/>YT<6H]7?&PAFH]32J
MJUE/5M@KU.+<UG:?<*Q[LW=.U4NYDZ9G4KX6DFZ?DF[]/JWL74$`K6Z#5\DH
M41$AS\X$'TE$.C69PN6ML<)K>^@;<64[:.;6CA3L6N[A=_\`K_S;M3BV'-[8
MY$VW;[FX_P!PVS8KJ`R?!<1.C-62V]P&N?&0>X;2H[$'JHVL]:W;QIV@Y:$O
MYE%BED/7%6W`GKH5C6-47FM"P3=U=4:31"14BXUK6XD8,@09)E`G.("8!$`*
M`\H7E_NN^ENFRXNMI;1Q-C8QIK1K:TJ2.IZK=^2ON=R)FMW6^5X@?<;+VICL
M-;XJSL[68R%EG;%[HQ+*]M9'ZGN)=0&E`2XBIP>FK`X!4Q2&2=+P&9&,M'/+
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MEU=5K$`YS6_'%!V8T=P!VHO4OGN94]<1>0QYVYG#/)_)VKD%8",K"A>,Y8NQ
MGK)-5JM<BYMT&A'%)=52Z8F=MHQHNZ=/UTR)\A2F$VM77XZ5XL,\:(3$;'6A
M+(1$LXJ20A2R,_6]7NR`D[K6X]5.O6]<5:Y2+_2DI,S*IC%*'`"I%('`.&JV
M]D5HM2H31$T1-$31$T1-$7NTQ_F.#_[FU_Y@:@]E*M%JA%JZWBKQ6WL3@K7]
MP[N8VT!E?;UA5UM8^?LY="K[6T/0TJ,I6<6UB9B;G[R(N*!1&!FS-EVJ;HAE
M57@)%1X*\H@"+1/D'NK7_5L?4I,JMAJM_P!MIV=-!5P7\R'QQ0LIV#UM$C1_
MM`M7M,)44FU]>@Q]6BN8"]JZ@$?Z^355?(11@ENHS04IE`1'8:CO8=5G#!FC
MR9'8H&I@6)::(6`_<RH%.C&MVWL?R]D&IA(48[@).*73I7V19/1&ZI<PMTXD
M]M]AJ3_6P,:Z62@_8O(O&$]SOV?@NR]B@BDH:FSU...?:>S^K%$B^SHGZOJ3
M"/+I7V15WKW=+LXXQ2MRRN9L,V7#"+VNE%+1>U^3&%#3&<*[2E)M6=_3B2D8
M1O;OVG&7]9=N)&+]H.MVDJX"/6AI7V1=FHMT^TSNP]UF]3[#-F0QF?7&IS]:
MO6&26$K"R@7<&#8&I`;@.RP#6CHRX_LR1MZM[4HC)^K^0$/[(AQ5]D70A=U"
MR1K3W4"F]AFQ(6,.-DB7M]0Y(X.$M1UC=-N3'0;H#&T^6D4U^K*E['FE.4ZO
M](L!.(\15]D5Q,A=U7)-6S=:)Y6;#5QQQ^,VA_U#_7W(C'IO:'L83T2,![8K
M5[3"-(D;>TX,>R=L,!1?=0"?]WDTK[(H<JW=3D35-?[VZV&87VR5LC3:>4GM
M7D9B42IOVXE80H4C^O`2E.%DT+,>K/5WJ\\[R0PH=FZHPEZK2OLBC')/=,M:
M[IRP:>7>PU:/V39TQ#NL8OW`Y+86Q\'[#ILXTL"%EEJY@VC61HCL!6G9D8DR
MT8=+JA*00$NE?9%E.86Z=!R5*6M1SVV&J)]B@,+NRG[ILD\/X:G@(G'L1.%K
MW-QX".:'C_5(M>L0BSBV.VZKG().32OLB]#([=/;2%!V*+EGL-4L%LDY6'=X
MS_KKDEB+$T.$LE&1?J(+(*5?`,(1<_J4S'LZ$()TU&O9^!#)@EP5]D7TDW48
MWU'#@389H[V;#+EPO3_+D?B!ZE_?CUX=K&(,%/=B'*_M/#K$D1&J^?TDXZ5]
MD76OKN&Y,7<A\S[?VIV?[HX]Y/U/;ND4\D;S6\OKB54%Z:#IZ,B0E*`D\AZ:
MJ*D72DQ;UU1K%RT*RJLB+)W3KAT1NJD005(JBU<[8V4>2="97T1?/]BEO,B[
MK4QCI7EFK%V@PEK?"BPE)*T>O4[63O%>&<H>TTW6K^X=?/)1$6\Q(MT6S%@9
M<Q5"EY42)P"BW?5SNJW^-?*R"ERMAJN/W)ILJ\#&_P!MLB<<R7K]7&BBA<W]
M%D9JF25HLS]2\OKSU*4Q"MN':>!-37V1?=D9NJY#*VHER9:[#5>C8X9FEQGO
MW"9$XZM[6^T!9UF-%^ME;@TRC2X2_M-V?U8"INN%]U8(\5.72OLBCW,C=0K-
M];*.9;@.PTI^D#BHDO4@Y9Y(8N1=#A5A&_,CZAD;HT\QC6M1=D__`!%B.3)=
M`\2=&A/D(L;)NJ<U,XE'2V&:7]C&U4(IX+`CD7B"6E?;<KAF1N.+!$J;"&>U
M?VPB'*:EP5?"MR#QYQXBK[(J[959^9?7MLSF=;C#?:GBL6*^K&0GX3<0NS#W
M"Q5N74$91LI1U<15P4;VLXUW1HT)<I*'>OG2<]4ZXKL4&[P3I_U'625\(K>X
M2[B^4-I<1L>;78Q;*&0=R;"V\MG"TA;FXM(Y26(JV"KUA!J.F4W6*-2TG3SV
MFYF0J2JTW[M^JS5.B5^JL0!`2"``>B*,<V=TR"D4J$;;BNPU1?*F9ZYMF.7V
M2V(4.ZY4UO\`]F%%/+J04<^69]H#_JD6:AD#'_XI!'2OD(NUD%NHQDACE;=O
ME'L-4:&)2CB`/9_]:,C\/XG'\'*$<Z-37Z8O*HIYA0B:@Q!5^S%B5`ZUKU@`
M!DA.&E?9%C\'NIT">DB'IC89M4%!*9$T`LB%.Y&X5IT;^[(D*7]+A;)Q5.E@
MDL@/9T2^HDTP"?,RX=F**8!I7V19QEQNI/7$U:0<[MAJ$&HFE2K/;&?NLR.Q
M*9S/M2F\8E<A;4MTZ=;/'\AZQ%KUS=B"H'7ZH3IB?DTKY"*9,?-U;(Y.V+`N
M*FPU<(+,^OZM-%_H%D1CNM;3VH-4#X:Z[`>@:85IGU[[5"Y]:@F/7E?]8"X`
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MG):+C:B97\M8W9S\?'R#AHRFVC<],KG0;2K9$JY""<XD*H`<P\.(JGPB\3YK
M.XS]!O*CX@K4]U-*GPB?-9W&?H-Y4?$%:GNII4^$3YK.XS]!O*CX@K4]U-*G
MPB?-9W&?H-Y4?$%:GNII4^$3YK.XS]!O*CX@K4]U-*GPB?-9W&?H-Y4?$%:G
MNII4^$7S3W6MQP!XI[#>5/-P^S(&U)NCH^SV3'[=03Y"*)[T;KF5"E,`AD-L
M,W/]D%DG!4QO%D#CRC"`EP_ZKLCFL*43;MPX?\043E'^(ZBH\(M8CO<?PI4<
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M]76ZP!XEY$A<J`<>/V<H\=14>$6SVSNZYE@2ETT<?]AFZ@4:BDB0HVAR`Q\5
M@12`![/USBD*34:N.CCR&4.8?X#I4>$4HGW6MQP3<3[#>5/-P^W(&U)1X?R]
MDPU(/@(OC\UG<9^@WE1\05J>ZFIJ?")\UG<9^@WE1\05J>ZFE3X1/FL[C/T&
M\J/B"M3W4TJ?")\UG<9^@WE1\05J>ZFE3X1/FL[C/T&\J/B"M3W4TJ?")\UG
M<9^@WE1\05J>ZFE3X1<?-9W&?H-Y4?$%:GNII4^$5[,;\QLIKE95VML_7FW'
M>*R]LJFH&EJZG\AJFNC0,W2%$U7+6ECKBR-LY.G8EDE+/YN`K)XI2"SA%8"J
02C<RY4@0$-02BW>:I1?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g524974pc_001gnew.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524974pc_001gnew.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+P*.`P$1``(1`0,1`?_$`/H```$$`P$!`0$`````
M``````<`!@@)`00%"@,""P$``00#`0$```````````````,$!08!!P@""1``
M``8!`@,$`P@+"P8%%0```0(#!`4&!P`($1(3(105"3$6.4%A(K,7=SAX\%&!
ML3*R([4VMK>1H<'1)+1U=C=Y"G%"<C08*>%5)AHZ\5*B,T.4)37%U6:6)T>7
M6&C862I:$0`!`P($`P0#!P\(!0@)!0`!`@,$$04`(1(&,1,'02(4"%%AL7$R
MLG05-G:!D4+"(W.SM#5U%C=W.#G!8G(SPR0T%Z%20R4)\()CA,1%A;714Y-$
M9%4F5F945V<H*?_:``P#`0`"$0,1`#\`]_&C!A:,&%HP8P/V>[^]HP8C3N<W
M;8-V@U2`NN>+0ZJM=LUA"KP[MK"RDV=S,C&O94&QD(MLX62+W&.5/SF`"\2\
M./$0U)6VU3;LXIF$D*<2FIJ0,JT[?6<;@Z-]".I77R^2MN=,82)UUA1/$NI4
MZVR$M<Q#6K4XI(/?<2*`USKP!PWH'>]MRLCK;LQB+F[7<[J&,Q(X53/`2Z7K
M,U@0$9-1P)V@!$"W`!['/3$W#LTHJQW)"9"U(%(M.9F,J\/=^IB6N?ENZMVA
MC=LF=;VTL[(=:;NY#[1\.I[^K":*^ZA7_1ZJ=N'O.[G,.UO.$?MUE[&X;Y7E
M*'+9)9P!8F1504J4*1PI(2`RB:!F!#I$:*""1C]0W+V!INW:YCD(ST)_NH6$
MZJCB2![O$C%;MG1KJ!=^FSO5J!$2O8[-S;MZW^:V")3I2$(Y95KH2I/>`TBN
M9Q'RQ^9YLXJF&*7GV;R/(-\89!M5BI=6G"5*QK+OK%55%DIMF>-38"];%:G;
MGX**$*0_#X(CJ21M>\.3'(`;'B&D)4H:A0!=-.?U1C:MH\F/F"OG4*X]+;=:
M&E;TM4%B7)9,I@!#$D`LK#A7H5J"AD"2*YTQJ9"\TO9=BZM8GMUSR7(1L'FN
MHFN^/'2=1L;L\Q6RR2T29ZLBW8'58&*^0.3IK`4_`./#@(:RQM6\RG76&FQS
M&5A*^\!0TK]7(X<;4\D_F(WK>+Y8=NV9IZY[=G"'/294=/*D%L.A`4I8"^XH
M&J:CLXXD9![G,.V3-*6WZ)L;AQE%?&D3EM*#-$2"2!J+-G`D=*>)*(`R!583
M!Q1Y^J7B'$-1R[7,;AF>I(\,'"BM1[[T4X^GZQQJ.Y]&.H%HZ=JZJ3HB$[,1
M>';67N:V3XQG-QOE@E=!G1=-)ID<,^Q[VMNU4D]P\/-W%VVD-K,-"SV:$"P$
MPMZM1E@8,Y&+7:G2:&),&<-7Z0\K85#%$W`>'#2C=EN#K<=U*!HDDA!J,RFM
M:YY4Q8+3Y<>K-[A;3N%NMZ%Q-[2'F;2KGM#Q#C"UMNA0*JM!*D*%7`D&F5:X
M&&6_,ZV=8/:XU=Y&R._AD,N4>*R+13HU.Q/QE*G-'$D?(J`S8J"R,L8.U)7E
M.4/2&G<7;%WE\SD-@\I90KO`44GB,7+8?DS\P'4AV\,;2M#4ARPW)V!,K*81
MRY30JML:UC6`/LDU2>PXZ=J\R+:12LVP&WJPY`?M,IV9>FMX>#)5;`N@X6OS
M%C(U@IY-)B=BCWYK)(F$3'#I\_`W#@.O#6W+H[#,Y"`8Z=53J%>Y6OKRTGZV
M&EC\H77?</3F5U6M5J:<V3"3+4Z\9+"5)$):VY'W,K"SH4VL"@.JF5:C!YQA
MN-Q+F*_YAQE0K"O+W'`]A9U;)D:K%R#).$FGHR!6S9%V[02;2(*#%K\3H&.4
M.3M](:8RK;,AQV93Z=++Z24&H-0-)-16HXCZ^-8;SZ1;ZV!M;;^\]SQ4L6#<
M\14FWN!Q"R\TC1J44))+9',1DL`Y^K`14\Q3:BGC:PY9/?WP4:L9E3P%,R@5
M>?%5KD]4"&+"`R[EWE9'E.`]Y*44.'^=IZ=N7424Q"V`\MKF@:A[RND&M?3E
MC8Z?*7UQ7N^)L9-K;_26;MXWMEOQ+%%6X$CG:]>D*J*!LG7ZL;-K\PK:O2]Q
M47M6L-\?-,TS-AKE785HE9G7#96:M8-QA&IIA)F:-3*Y[TGQ.*@%()OA"';K
MPWM^YO6\W-"!X0)*B:BM!6II]0\,\L)63RH];=P])GNMMJMC:^G<>)(DKD&0
MRE09C:N<KE%?,)3I50::FAH,:F/O,7VH90S=/;>*;?WTEE6LN;BTEX%2KS[1
M!!>A@[-9BEDW#)-@J#(&*G*)3B"G+\'CQ#2DC;EUBPA<'D`1B$YZ@<ETTY<<
MZC"^ZO*3URV9TWB]6-P6MIG9$U$1;3PDL*4H3='AB6TJ*QKUIK4=VO>I@M8L
MW485S/AV?SQCZS.)?&586MB,S-JPTFP6;*4DJAK"!8YVW2?+`S*B(E$I!Z@?
M@\=-)=IFP9B;?(2!*5IH`0??&@SK3%%WMT0ZB]/>H$3IANJ&B/O*:F,6F0ZV
ML*$LCD5<0HH&HD`U5W>VF&;7M\FV^TLMN\A"W-XY:[IW\[&X8.:O3*(V1W7#
M+DF".2J-2C#@V.W,7BYY`,/HXZ459+@WXC4@4C`%>8RU`D4]-0"<L3]V\M75
MVR2-V1KC;VT/;):9<NPY[1$=$@`M%)"ONNH*!HWJ([<-2C^8WM-R)F>X8!JF
M0'S_`"?0S7\MEA%*M/MD60XR[Z%Q`DDNQ(R<>&C'K<O(<>MR_`X\0TL_MRZQ
MX:9KJ`&%Z*'4*]^FGZ]1]?$YN7RC]=-I=/('5&^VIMK9MS$+P[PDL**Q<='A
M:MI65IYG,16H[M>]2AQP\9^9_LVR["Y8L%%R1(2D7A*GKWS(CA6I6)D,/66S
MSN"KY%-RP3._,5R/+TT0.H(#QX:4D[6O$1;3;S:0IY>A/>&:J5[#B3WEY,?,
M%L*XV*U;FM#3,W<=P$*`D2F%\V0I&L()2LA'=SU+H.S!LLF[G!=2VYQVZR<M
M3EKA.5@H*QL;.6%E%UUHFQKH-HE<8=)N>3*9PLX*`E%,!)QXCIBBTSG9RK:A
M(\6FM14?8BISX<,:XL_0?J9?>K3W1"VP4+ZC,27F%QR\V$AV.E2G4\TJY9TA
M)-0JA[,:QMXF`R91+APUN<A?S8C^7'P@(26Z0XX\-4E_&N_=U[J"W<$C'[OS
M=;W.7CKU\C7`QO%Z/N'-Y=:CW]:4^O\`4PLGH!U0.RSO\0$?HN+]\C\WG-5^
M4.8&N5HU:J:S3731VUI@)8_\TG9AD^HY9O%-R7(25<PE6VELR(]4J-D:GB(-
M\^/'-G:#=PP(M("H[()>1$#F#T^C3Y_:UYC.--/-@+>44H&H9D"I]S+TXV/N
MKR4^8?9E^L6VMP6=IF[[CF*C0$^*CJ#KR$!Q25*2LA%$D&JB!V8Z==\S/9]:
M<(6K<1#9%D%\4TJ\0V.K!/GJEA17:6N?)&*1;`D8HQ!^NFN670$52$%,O-VB
M'`=>%;:NS<Y%O*!XM:"H#4*4%:^KLPSNWDWZ^V3J1"Z37&TM(WO<;:]/88$I
M@A<9@N!Q?-"]"2"TONE6HTR&>)#Y=W'8EP83&9\DV!:$+EVZP>/:(*47(2`R
MMJL0IEBF"G<D%>Y$<"J7BHKRD+Q[1#4=$MTN:7/#)"BT@J5PR`S/L.-4;"Z1
M[[ZEJO"=H14R56&W/3IM7$(Y<9BO-6-:AK*:'NIJ3V#`XL&^/;A6&>X9],7-
MXV;[7'\9&9F$E>F%1K;V8%(L>DV*FT$TQUS+E#BVZ@%$>W3AJR7!WD!*1_>*
ME&8SH*FN>61[<6VU^6OJ[>9&U(UOMS:W=ZM..VD<]D>(0U4N%55#E4H<G*$]
MF!&V\U790ZPU)9\0R;(FQE$WQCC5]-^I]E!=*WR,4K-M8\(T8_OATU(Y`RG5
M`@IAPX"/$>&GBMK7E,L0^6.>4%8&I/O0=-?KFG\F+Z]Y(?,8QU!9Z7N69G],
MG[8NX(9\5'H8J'4LJ<YFO0"'%!.FNKMI08)4+OYVQ6"JX)ND7>'KBO[D+G(4
M'$KPU<FTC3]GBW)FCUBY04:`K%)I.`Y>JX`A!]P?=TV78;DVZ\RI`YD=`4O,
M9`BHIZ<AV8IUQ\KG6:U7S<VW9MM;3==HVYN=<T>(9/)CN)UH6E071PE.>E%2
M/1@ZRN:L>0F8*E@B1F54<EWBIV*[UR#"/>*)/:Y5EVC::>'D4TA9-SMEGJ8`
M0YP.?C\$!TR1!DKA+N*1_=&UA*C_`#E5(RXXUG!Z=;LN6P)_4Z)'2K9UMG,0
MWWM:042)*5*90&R=:@H(550!`IF<%@OH^Z.FF*/C4?OF<8R>24B[;L(^/:+O
M7[YVLFV:,F31([AT[=.%C%2;MFR"9CG.<0*4H"(CP#64I4M00@$J)H`.TG@/
M=PM&CR)DAN'$;6[*=6E"$(!4M:U$)2E*14J4HD``9DD`8B_1=Z6W;(UPBJ56
M[NOXC9%G#:FR4S7I^OUF]NFQ3JG;4FRS,>RB+*Y.@D91)-NJ8ZR9!,F!@#4K
M(L=SCQU/N-@I1[X!0)2/YZ020/=&-T;E\NO5K:5@?W%>+:GP<-"52VVGV'Y$
M)*B`%3([3BW8Z0HA*E+2`A1`603B4RJI$4CJJG(DFD4RBJJAP(FF0A1,<ZAS
M"4I"$(`B(CV``<=10&-))0IQ00@$K40``*DDY``#B3@/1&X/#,[CRT99B<B5
MMYC6F2=AA[#=D7I3U]G(59YX?-HI/R\4GW=)`>@44>H"RWP$^<P@`O%VV<W)
M1$4TH2G$A033O44*C+B*CT\!C8$_I5U$M>ZX6Q9]IF-[PN###K$,H//6B2GF
M,DHXHU-]_OZ=*>\N@!..!2]TN#;S7KC9XR\-(F,Q\P),79.VM']1DJU"+)*+
MLYN4B[`V8/D(>010,+=P!!36$HE*(F^#I1^TW".ZAI:"I3AHG316H^@%.51V
MCLQ*;BZ*=2]M7>WV69;5OS;JZ6H9BK1*1(>!"5LMN,*6A3J"I/,174@$$@)S
MQW,1;@,59Q+,EQW8CR3VO]Q4F(>2BY.!G&3&6(JM#2YX>9:LGYH::01,=HZ*
M045RE'@;B`@'B;;9D`I\2FB55HH$$$CB*BHJ.T<1B-W[TKWOTU5'.[(@9C2M
M8:=;<;?96MHA+K0=94M'-940'6R=:"<QP.'!7\MXYM5QR#0:];(J5M6*QB"9
M!BFBW.:JK3K`\I&-I5?@""#E6/)UC)\PF3(("<`X\-).0I33#<AQ!#3U=!/V
M5#0T'NY8B;KL3=MDV_:MT7:"\Q9+WS3!<4FGB4LK#;BFT^^*0X=`52BB#0G`
MXQ-NQP=F^87A,:VA_/.$(YU+=]4K%FBX5>-9K=W6>LYR5BV<2\;\_:4R2Q@.
M7X0<0TZFV>X0&PY)0$@D#WR2<Q4`@$D?5&+AOKH9U*Z;6]-QWA":BM*=2UH$
MB.X\EQ8U!"V6G5.H53B%)%#D:'+&:5NRP)D*QR]5J5\;2DS%Q4S.MD@82;=O
M9X2MJ=&PRU)>.&B;6X,85<0(X/'F7`HF*/:40'0_9[A&:#SS9#9('$=TGWH4
M/L2>S53'G<?0SJAM2SQ[Y?K8MFWO/LLJ.MLJCO2!J8:F(2LJB+>34H2^$5`-
M:$4PVJ9O=VY7R\5?&]>N,H-QN:L@A5X:5IEO@E9E2*:'>R7<U9B%8H*$8M""
M=4W,!2!PXB'$.*K]AN<>.N2ZV.0@`J(4DTKPX$G$QN'RW]7-L;;G;NNMO8_1
M^W)09#S4N*\&0ZL(;U!IY:N^HT2*5.=.!P[J?NHP3?,A.,95:]M)*U)KR[1@
M'<I%M#6![7U.C8H^L3[EJC#V)]7URB1XDT65.B<I@$/@CP0>M%PCQQ*>;*6Z
M"O"H"O>E0S*0KL)Q!7_HEU-VQM1&\[U;'&;(4MJ7WVU.L(?%6%R&$J+K"'Q0
MM*=0D+!%.(Q]*YNBP9;<B.<80%Z9/K0WDI*#;F!J^2@9>PPH*#-UR`LJS=.#
MFY^'!(XN&C9=15/IF[!Y#<,.VF>S&\4XW1J@/94`\%%/$`]A.7#TC'B[]%>I
M5BVFC>=TMCC5D6RV\KO(+S3#M.3(>CI47F67:CENN(2DZDYC4*_5KN;PF]RB
M?#S:Z-E+J217@BI`RD`@UK0V;&>N:@VLQFP02]M18)G6-'E<"X`B9_@\2&`,
M&U3DQ!-*#R*:N(KIX:M-=6FO;2E<>'NC74>/LD=0'K<L;<+*7ZZT<X1E*T)E
M&/JYZ8I60@/E'+U*3G0@X/H=@:8#&K\9T8,+1@PM&#"T8,+1@PV[A;(&B56P
MW2T/TXNN5:'?STY)*$.HFQBXQLHZ>NCD3*=0Y44$Q,(%`1'AI5AER0\EAH5=
M6H`#TDY`8EK#8[IN>]Q=NV1HO7>;(0PRV"`5N.*"4)J<A51`SRPTKQF3'..,
M7/<SW.QMX3&T=!QUC>V9=)P=LWA93NIF3]1-)([@J*A'J9A^#Q*!NWT:48@R
MI,L064E4DDIIZ2*U]F)W;73[=V[]Z-]/=O0UR-WO27(Z(X*0I3K>H+0"2$U&
MA0XYGAC8E,M8]AV^.'CNS,#,LM3D97<>O6ICO&=FEIB'?3T8@Q<-BJI"1W$Q
MJRQ#F$""!?3VZPB')674A!U,I*E@Y4`-#4>D&@PC"V)NNX.W>/'AN^)L49Q^
M<A7=5':9=0RXI:54-4.N)00,ZGAAB9OW.8CV\)LULIRLW"LW<:_F1DF%4L4]
M&,(R,-_+WLK(0T<]:1;=L4!,85SDX$`1]`:=0+5-N9_N@2I5:4*@"2>``)!/
MU,6;IOT:WYU84XULEB-(D(>0SRUR8[+BW'/>(:0ZXA3BE<*(!SRXY8[>&L]X
M[SS&2LQCIU.O(^&68(.EYNK6"L`L,DV4=LE6!9Y@P/(-U6Z8FZB('('$.(]H
M:2G6Z3;UA,G3J57(*"N&1K0FGU<1W4'IANWIA,8M^[41FY<A*RE+,EB13EJ"
M5A996O0H$TTJH>-.&#0'HTRQKW"^S[/N:S@.(_2NYK$,6HDV"<?2CYQ)6.'0
MC86(?R3]25JEB"JS4<""*0`1TWFAZ9"&$O5*'.3B7MT_3:IJP3I"4A*34FF2
MQJ!]PCZW#&TH/1O?LY"GO#-L14,QW2XZZAM`:DQ_$LN5)S0IKO$@'2>ZJARP
M]HK+V/9I3'*4?8FRR^6(J0G*$W%)P1:>C(J-0E9)RD0Z8=`K-DZ3$X*"40,<
M"AQ$>&D5P9*.:5)-&5:5^HUH/=S'UL5V;L+==N3=W)<1:6K&^AF:JH(8<=<+
M3:20<]:TJ`TU%$DY##>;;@L8.3O"!,/$4VEZA\<I.G$4^2:2-GFWBK)FWC'/
M2,1VT17;JBX7`03;)I'.J)2!QTHJW2QQ`KRROB*A(%<_1ZO2:#$L]TJWHTAM
M7AVU+<MCL\I2Z@K;C,H"U*<36J5J"DAM&:G%*"4:E&F&=*;O,&Q:=;$+%)RC
MNVEEU(.*AJ_*R4LX1@9:6A9E99@BAUFB48]@W0JBKR<J20J=I1`1619;@K5W
M0`BE22`,P",_6"*8GX?03J5,<F`Q&668'*#SCK[3;22^TT\T`LJHHN(>;TZ:
MU4K3QJ,.B1W%8Q8&QL5-_+2QLLFD_4HL+"OGYGZ$/W$9-ZY$A"@Q9-"OT>8Z
MG#B!^P!TDBV2U\PT`Y--52!35P'K/'$+$Z2[SDB\*<:88%B#?B^<\A&A3VOE
MH34G6M?+71*?1C9OF?*%CJ50B9\MF<'4.X3<OX*L2TY$Q9F30K]^,O)QR*K:
M."/8&ZZ_4$.DD`F-PX:(]ND2D%;>D`>E0234T%`<S4Y"G'".U^EVZ-W0E3;6
M8:$@)*4/26V77-:^6WRFW%!2^8ON(TUU*H!C5G]R&(:\B55>SEDNI),8E!.`
M:JS9G3]\@FZ21:C'==)P=-LJ!U`*83$`!#AQ#AK#=LF.F@30T)SRR!IV^O"]
MKZ0;^NKG+:A%FC*W5%Y09"4-J*5%7,TE(*LDU%#4&M,\=>[YRQMCU60:66=.
MB_C*JG<W$<T8NWK_`,"7EF4&T63;HI")G+R1?$*DAV*G*50P%Y2'$/,>!)D@
M%I/=*]-2>T"OUJ#CPQ'[;Z:[OW6VT_9XP5&>G&(EQ:T(1SDM+>4"HF@2AM!*
ME^]!*4DZE)!;D-N8Q=//7[&.<V!7PJN25FEG1Z[()LXQK$D=&?,7BXD^!,I&
M9J$!J4#*'4#E+Q,(!I1=KF-)"E!(JH)&?$F@%/5F,3%PZ-[UMD9J3,1%'/F-
MQVD\]LK<6Z4Z%H37-HZTJ+AHD).HT`)QT[AN$Q=2(RNRDY-.NE;(QG,UYM'Q
M;Y^^DV#\R14CMVB"0K"N3J@)TAX*EX"'*)@X:\LVV6^M2&P*H40:D"AS[?Y?
M].&6W^E.]=R3)<.VQT:X+ZVGU..H0AM:`:@J4:4RR5[TY&M#7"N6X3&5#F`@
M[!)R:<@6I-[LNDSA9)Z5G7GB[MI'.7IFZ`]U4DG;!9%$A@`QE"<H\O$.(Q;9
M4A',;`TA>G,@9]M/2`*$X-O=*MY;F@?*-J995%,XPTE;S:"M]"4*<2BI&H-H
M6E:R,@D@BN>/G7=P%*LLVQ@FD5>63F0KCZU(NY:FS#")3AHY,QW:SB5.D9DD
MLF8H$!,3\XJ&`H!Q'67;;(::*U%!2%!.2@34\,O^66/=WZ5[CLUN<N<AZV.,
MM3$1BEJ6TMTNN&B`EH$+(^R*J4":G&+#N*Q;6#UKQ26D@;VA)F\:OFL+(.F$
M;'/F\6Y;RLZZ21%.(C3)S+8!55X`!E0`>WCH:MLMW7I`J@T(J,R*Y)]/#!:N
MDN];RF883#7-A*6E2%.MI<<<0IQ*FV4DU=<!:<[J>Q)/#&I.[D,?5N?M5<DV
M-Y+(4]VR9RBC>D3SIBX7?LO$D/"7J#8Z$J0(XBBYS(B8"))'$?P1UENURG&D
M.I*-*Q4=\5RRS'9GE[N%[7TAW7>+7!N\-VV>%N"%K;"IC*5I"%Z#S4*55KOE
M*`%TJI20/?8>$AF#'D8$,=U84`0GJC*WF-=$275;*UB&19+.9%58J8D;@L5^
M0&Z9^51P8#E3`PD,`(I@R5Z@$>]6$'^D:T'UQQ[,L5^+L#=<WQ(9B*YL6>U#
M<22D*$ATK2EL`FJJ%"M935*!I*B`H5;3?<-CE52-(N>S1PO6CQ\^&3J4XQ)6
M6S1N^=E/;#*,^6O]]:QRBC;K\O6)RB7CS%XJJMLK,ITJ%0!10.HU'O<\^-#3
M$R[TGW:A+RFA">#:T(1RY3*_$*4I"2(H"_N^A3B4N:*Z#4'WIQQD=U.%Q7D6
M+ZP2$++P]9DK;*P4]`2T3-L(*+D(.-<NG$8[:D<`<5K(R,F0`$RB2W.`<I3<
M/9M$X44$A2"H)!!!!)J:5']$CW13$@YT0ZAAIF3%BM28,B8W%:>8>;=96\XV
M\XE*7$J*:`1W=2C0)4C234BNRGN?P\[C(Z3B)V0L))>$]8(ME`0,M*R;Z-+9
M5JDLHV8MVPKG5;3;94BB?`#)D1.<0Y"B.CY)FA90M(20JAJ0`#IU>SVC"2NB
M^_V);L.?%:B*8D\AQ;[S;3:'/#B4`I:E:0%,J24G@5+2D'40,?5IN8Q(]"P+
MHS,F$77($;(O.J0$JE"2L2@+<C]:OR)FP(S:L0=T0KM-#F4;CQY@X`(Z\FU3
M$Z04C4I>FE14$\*CL![*\<>'^C>_(YB-N1V/&2Y0CAD/M%YMU6HH#[>JK(="
M"6E+H%BE#F,-^0W;XGC;`M6'#>]A*I6A"H)IEHTZ#9[-N(Q&:328/%$$VSQ`
M8ARFZ%0AA+T3@;2B;/,4V'4\O3H*O?BH`-*D5-,\L2L7H/OJ7:DWEE5L\"8:
MI1/C&=2&DN%HE:`HJ0KFI4WI(KJ!&).IF`Y"G`!`#E*8`,'*;@8`,'$.W@/;
MJ+QIE2=)*3Q!Q^]&,86C!A:,&%HP86C!A:,&%HP86C!CSL?XD'Z+V"OG]2_9
MY=-;(Z:?E21\7^W3CZS_`/"'_73N;Z+G\>B8!V$/TG\@C^H>6?B2Z?SOZK<'
M]-'\F-D=2/R-YH_SI;?:<3'S7[9ZB?4BRA\1-:A('S,<^.H]J<<_=.OX>5T_
M:/;OA,XHDW&^R$VD_6:SU^<I75_M_P`\)GQ9GV#'TSZ2?O[[[^AED_!,X9>_
MCZ.GE;_5:7_7Z1TXV]^5KK\:'P4XLOE=_6UUJ^FP_$F\>@W#'M@HS^[MQ9_/
M"ZUM,^:"_P`X*^VQ\J.H?[@K_P"UFY?!.(E;@/[1?/S^:C$GZATS4S`_P5A^
M^N^U6-[=+?FIY7/SW=/QV5BMKS5?T=\N?ZF>-OYR75GVO_WG\=<QU[Y(ORKU
M;_:%</@X)6Y_VS&"_P"EMI?ZFT[3.V?,R1[CWPG,5'HO_#XW/]YW-^-R\7>>
M6[].3S9OG^JWXMSU2=S_`)!L_P`65]ICYO>;O]VGH7]%Y/MBXIP>^SVSK_>\
MLOC&VKFKYP1OS1]MCZ!Q?WK=L_L%7]OCJ;GO;_8S^?/;_P#B06D;;^K]S[PY
M[%X8]&OX6EX^C-[]KV&[L1]LYG;^F]U?Q-ETXO\`\RF/Z,?[3$OYF_X>FV/B
MVVO;'Q:?Y97LFLY_TQND^]*:JNZ?G?']QC^3'$OG(_?FVS\7VY_9XB/@#]"O
M(,_KSFGX^P:?R_?7W[TW\'&]NJ/Y?\T'YNM'P6<1?V9>V#W:_P"EO@_&M6IN
M\_,^)_U7V(QNKS$?N";$]S9_LBX"/EP_V0>:7]5.8_6LVI#='^)M7QP>PXV+
MYN_G[T4^F[/XMBY7<-_T?RA_,AAO\ZP^J)!^?COWQWX)Q\^>E/\`%-NGTCNW
MX)W'"=^TI0_NL3_L_>Z<)^;O_BG]H,2;7[H"_P!MG_;D8IDV(?11\TKZOM:_
M7)[J\7[\JVG[^?@#'T+\SOZ\>B?TKD?BK>"%M[]C+N8^NOASXC&NFDWY[1OB
M3OV^*KU6_B&;-_9U=?;<,7\>:I_JWET_7'PS^.RUKW:OO[A\4<]AQ\N/)%_7
M=6OH!=?M\5]9V_1/S[?Z^XV_$AM3UO\`?V/^BY\''5'3/\N>6#\V3_[;%5%>
M]D'?OKM4[]G$CJWN?/!'Q-7X08[ANG[^UJ_9S+_\P1BQ;#7T8/).^MS>_P`]
MN]5N=^5[S\43\$XY(Z@_KH\QGT#A_@4XNQR?[5[:U]6#/?Y\JVJ9$^9\OXVU
M[#CYS[,_<;WK]-+)^!DXLX#^$?OZJF.-,1#WZU:XW/:+G"NT1I(R<^]JS=<T
M-$`H,I.P,;-Q4G:X&/*C^55=S579O&Q$R\3*BITP_"U,[>=99O+"Y!`;"^)X
M`D$))]Q5#C?7EAO6W]O]>=M77<[C+-J;G*'-=IRV7G&7&XSZZY!+4A;3A4:!
M&G74:<#B1W-;/K;`8!K-8;UO,,K/VRC(8MQM2&<98K32Y&/0*H2T.X=,Z2]-
M88[8I'-(NE^[]S!,4Q^&($%RBUWIIV0ZZ5LH2E1<6LD)4"?>U^R*SDD=N+=#
MZ.=?;#==TWJ\JF;?@Q(,TW*X3%N,1I;:U4,9+IJF6Y/64AAM',YI4%CN@J$W
MK?4*]?:S-TVVQJ<Q6K&P6BYN*64621D8YR'*Y9K'0.BL"*Y/@G`I@YBB(:@6
M'G([H>9-'4Y@^@]A^IV8YNL-^NVV+Q&W!8GE1[Q$=2XRX`DE"T^]4`H%-1Q&
M61]S%9F');!>%=H>X66RU7X9GA7'FX7*[A6KC#)N8WIPF0(H]/AXJ$*F"+AV
MM8T62;,@@!!<"0QS`4#&"TSFY\Z\QFXBB9SD9OO5H<T'423_`#:U]6.R.H,#
MJ7U$Z];3@;%E2'.HMVVI;$B3SBERKT%WQ;KKU:I2&"\IT\>6%``F@QKXGR!B
M.[$SWNJS/8<>VEW.8^J\-8,*X^?Q630Q9A2#F%I6%;WYK`F?^L%P<RL@=W+K
M)E,S8@CT4.8J1S#ZF1IT?P]H@I<0$N*(=75',=(H2C5P30`)'$UJ>.%-\[6W
MYMQ6U^B'3R)=83,6ZR76;O.0[;OE*[O-);>,)3^CD14MH#45)(=>U<QRA6E(
M9,)>+RQW`;E;5M[FX?=C<+;MNK$M29>LA6*TRQ<I&VMVQIN*G"S1XRI+TCV-
ML#B;;J.U4I)8L<9-403,0177&CFVQ6KDE4-E$I06E6I175-5.<"H9I",LA6H
MKGBQW';>V972O9UDZK1I&QMOP=X26YC4CQ,A=R#D9*Y=R2%(7,04.,-PW`TE
M4=)?"T`J2H8:>W)C.U2^;UZ38\2Y8QBU?[=JM+7S(LNZIMNMBUK5HUL-.VUP
MQJU@FU[%:K(LZ7>,6[?J@4&I4#@F(D)I:Y*:=CP9#;S+JA)4$H`4E.D*3I34
M@42``#[M<3W5R1:[YMCISN*TWVQWI]K=DEN%`:3+BQ1&$V+R8J5R660Q&CA*
M&GEKT_UA=25=Y6/K2IB3A6,9A+;AN!L^Y*A7G9QE0TC&2!H:3>XVF:[CY*)Q
MA(0`UY@R6HA[5)O!8&AUA-Q<(\2%!1(PZR\VE:C.N49,62W.;H<^^%+JL'4>
M_I`KJ'8?01CSN.!#N,E[J/U=VK"VANBV=0;:&W6^<VBX-/SB[<6WP^M8FB,V
MCGB6@"B%T)TK2,.'9W:EF%PV@5R!S/&9G&U8>LZ>1*$>L5E$,##6*3'D3D*D
M$3'-Y3';%2QMTJ[)1SI03R2ZA%3@*J1Q!*]MZV9KKK)9T/)T+U'[KJ5]E7)?
M=JM*A[W,<,1'F`LC<K;^_KO=-NO;>$'<$<P)HD2#\M>(F+JW*YJRW/6(ZE3V
M'VDTCH2I"*(6*R=P@?Y5\[[C=PL@R/--<63$O@'#,&F@!4(Z.J#1"2R!+PYE
M"B0DS=[:X!HLL4O'N[!%/CR@(#$SP(EOBVU)TJ>2'G#7,E1H@'/@A.8'I)/'
M&FNI"?T'Z8[1Z4Q7!'>O<=J]W9XG-QR4I3<%IVAS:AQ1S4))]^^XJE:4KRVY
MN4T+#LKDV^1H>^@KF+*J[+:M'Q[9G,[>']R=VUW/S+F71$;I+GQ\LX61>%G^
M+5,SXW1Y2@D(V6YI*FYR5-J;^XMUD$DAX)TA(`]Z-=!334Y9]N.K^KK2W;5U
M%AO6B1:RG;]M"]RK<4MJ^HB)BI892T?[FT)R4H6T8/W109',U$KQWZP>;++[
M6\$43(.([S4,?;RRV&%"MQ]F;YW4@:W;+=-7#Y2*I)-6Z50)6VKQTC*29P$D
M@`MP)R@OQ.D[RRF7/DMO-ON0J&I'*U*2D)T*![U<B$]F?HQ%7I-M5`WKU.W1
M:K];+_=>GICN^(<CJLP?D1HK,7P$EM2C*\0I#:X\<9L4=*JENB.[6Y>'4Q#B
M'"B#UH7/\-YC$'-3%.$Q1NT:E$9YE+O9[5(1@\LDG$?)<5PLH\,`(G9+`7G$
M#@`INH4)CT]0_P!W&V$!7V)JT$)2#PKS.SC45IB,O$">C?M^ZC.MN?Y62.D;
MS+4O_P!S<+ME;AQHS;F;9=^42VE+0.L.H)T@I.+T`U0<?-+&=&#"T8,+1@PM
M&#&!]&@X,5\[Z-PV*ZIBK/>$[38"5Z]3^WZT3E7:S!4V+.WC-I2%:8PE6<K*
ME-.6(9;D3,R0(94`63'@/,&K'8+=+>F1[@TG5'3)2%4S*:442H=B:9U.7''5
M/EHZ3[WOF]ML=1K+%,O;,7=49F0IHE:XO*+<A;TE*1]QC\K4H/+(2=*AV8:V
M].,53\M::A9./,90,;X<B92*=-S',8HS%&8R4<[;"7B8!3%1)4@AZ.(#I6QD
M*W.E23_M7"#7U+SKB;\NDUM?G!CW&$Z-!N]U=;<2H?\`JIBVUI5PJ#I4E0]1
M&(Q6*$M&`<][/-K[QA+2>(7NY*&R?MOLYDW;Y"M5)+']Y+=,-ST@<HE1<4:8
MF4EH8QC#UHATFGQYD3`$JVXS<;?-NJ5!,WPQ0\GA56M!2X/Z8!"OYP)[1C<]
MIN5EZI]+^H'6AEUAG?S>SWK;?XW<09,HS87A+LRV*$IF--*3+``T2VUK]ZXD
MFR3?"GS[-]U``GU%!V^Y<*0"DYU!$U&F@`I`*',)C<>`<.W58L)(O43L_O+?
MPACD#RV+T>8/9!K1/Z56LG.@_P`8SQKE]4X->+B`7&F/.!`(;U&J/-P*!1$P
M5^/X\P``"/ITRE_XIT?](KVG&N=ZJ*MX76I)`N4JG_MUX?H>C3;%9PA_X/N?
MN:,&(@K[5\-&G[-.S$T\?MK+93R,Y`R$I'DA!DU%'4D\8E13306:+.Q=F56Y
M5"K&`"F$>SCJ9%WG!M#;:0"A-`0#6@R!]&5,JC&_&^MO4,6N%;;?&;:D0X80
MR^AIPO<L!+:5DDE*PC0$H[N@9IH:TPX#8LQ0V)BFQR=S;.']18U2O8QM#V2A
MD#`$6]5D':4*9`C=BNK<6::+:0*F406;M$P*!1`1%/Q<PEYM*#I625I`/:!3
M5VC3F17TXB1O??3RKY:(=N6B-/=E/W&,AMU0/,0$)+P45+2(BRMQ@J(*''%D
MU!PWGVV_&<],S,A9[P[L)YER+F$:.'$"P4AIM^WE&L1.MW,:W:.INS-HY^^;
MH/'8K++M3B13J`F4043<Y;;:0TV$!/$YFHR)30UH*@9"@'92N):+U>WE:[='
MB6:VMQ4QT:7E!+ZP\TA3:G62EQ2TLQE.(9<6TUH0AQ(4G05FH^J.TK;B^FJY
M:VMV4NXQ-]L,P5!W.PDA%RULFAE7$I"J(M$4Q302>/UER,4C%*4Y?P1+Q#3I
M^\7-*%,*;#>IL#@00D4`/'T"E3BTWWKMU<C6Z79'K:FVA^UL-52R\AQJ,URD
MMN@K)JHI0A!>6"2#QK0X<4C0\61-LHDVXSW`19:#/W6)IM>?LL:.&<>%E-%.
M+!5$C/(TSM5VQ-&I]%7F!VW3,)>82AV(B3,4TX@1EGF)25$<P$Z:Z3Q[:GU'
M$5$W3O:=8[G;FMKRGU72+$<EOH7<$K7X<.I8DG0X$A*^80I-.4L@&E<.U&%P
M[:SV*%;9-@';+(,_>)**1B[/&N7[Q]<*^:OVMN@"IE4ER,S\YFZ:8&`GX)N/
MH%)3DUD(6IE0+:4`U2:40=2:_P`M<0+EQZ@6,1+@[9I3<FUQ8;;A<CN)0A$5
M_GQE&E""L4"RJE>(IQQS'^`\262OSSFK7Q*#A'2#GQ9W!#4GL$V91*3:/FE%
MFKE@XCFBZ'A@F%V'(LS7`52'*8`'7M-RFLN`/-ZEUR!U`U.8X&O;PX$8?0^J
M.^[/=8K-[M:I-Q;4GEI>\2AY:W2IQD!25I<4%<RG*S0ZCN*2I)(Q\LAX1P1=
M+"@TLUY;H7"8&N5\`5G8@TU,U6NL$CH4=PW="<7S%\#Y5RJH)!>&.\$Q5`#D
MX$:?<&6M339+`JK@J@4JO?\`4>ST4&/6T^I/4W;MI4_9K:M5@CA]_)ET,M29
M#AU3$J330M&A+:4@\H):`*/?8VAVWXWC$;8S>W8X40[-%M;ZX\1K""C&*9O?
M'&4:ZMZ;)"SP\4W(5+\EWD@*HD#F$W,81\BYRE:"EO[M]B1JS-*$Z22DGCV<
M<(_YO[OFNP)$>VC])@X519"525!;JD\E;B8I6J.ZZHZN]RSI6HT`T@#Y6#`>
M+['5X2&C\E.8N.8U.1K4(Y3>UF8;C5+O,*NF:!49=H\0<"051;Q3L."Z!BD,
MD?JE`=9:N,MMY2U-54I84??#O('JI[JAV^YCU:NJ6\[/>9-QEV=#\IR<W(=!
M1):5XJ&T$J-6EI4FM.9);S0X"H+3H41C7R5B3$V1)>*AI/,(QJ]7J<?"#!I2
MM5=2)$ZQ(N6*$LZ>2+9>63,,DH=O)-S*"U?F3*FNF(DUF+-F1D*=0Q4+<)U4
M53O"M`.&0S2>(XC"NS]][[VE!?N4*P<YJ;.6]SBU)2W60A*RTE+:@T?N8"XZ
MPGF,A14VL!6"Y5XRDM)<]3<WJ)L-MKM.DX*:A6I:["+H04E(M'Z[QY6Z^BT:
MQ0)<Z1`,1-,G*?B/:;CIFZM\MAX-J2RIS4":G,`CWQX_7.*)>IFXW[>+VQ;'
MXEBEW!IYEY7/>"GFVU(2A,A\K4Y7O&A4HDIH,A3`\CL,XAAW,1<KM=&%R1I:
M+IQ`.K,YKC2$@(11A&DAD^[1J+)@LC$0\$F"3I<#'7`@J',8P<P.5SIS@4PP
MV4*6>]IJ2HU-3G4BI/`4]&+7,ZA[]N##^W]N6YVWN7%24OICID*>?>"W.<=2
MRM8+KKZM;:*)02$I`&6'E9Z=4KDD]GX7)1X%W;UV<W&3T4[@))N9K!5N1A9+
MPQO)H/&#MJM`2*XKF$IS(&X*E$HETW:?>CT0MK4E`((((XJ!%:$'B,O3PQ7K
M-N"^6!QJU7&SB4S`2IEQAQ+[:M3S[;S?,+:DN)4'VT!`!&L500H*P.7V!\"9
M*.V:L;D>3EJ%7ZQ7VKR'M+-Y(UZMPL7)IMV3XJ9E4EV<N,PL\<&<D/SK\ARB
M4"%`'8N%QB@J4BB7%J)JG)2B>/NBF0]&6+?&ZG=3]G)6])MP8@W25)?4AV,M
M+;\AUQLJ6C@4K:Y26D!LBB-2374:]]YBV`=BT)/9OGG3?*#(8R<;).ZI$)9,
M(E#NVD,G%&8QR8Q2,=$N>((Q8I)N@(4RH''CQ23+<`.F.FK)J*A1Y>8)KGG4
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M9.>@7,TP02D;*2TJ&,"Z"RR@\I>1,`*'#65W.<VZL\H(EE/>-#4`4H:').GT
MX<S^K/42TW::[\CH@;S<C%4IXM/!Y*&Z%A]+*R6XYC"A0XA`%3J54FN-V0PW
MBYG\GIBYA3:RK>S15@K$A8%Z99#61=I4&U%:-6[6=9.&CWJ1$64J:Z)>N59/
MB4_$.&L)G2U<RC)TE!"@-0TU5K-2#7B>!RSPVB]0]Z/B[)5M\KA+A.,2$,"9
M'\.%2E35*4IA:5IHZX2I"^X4JS33/$STP$I"E$>82E`!-P`.80`.(\"\"AQ'
M[79J#R'#'/*C51(R!./WHQC"T8,+1@PM&#"T8,+1@PM&#"T8,>=C_$@_1>P5
M\_J7[/+IK9'33\J2/B_VZ<?6?_A#_KIW-]%S^/1,`["'Z3^01_4/+/Q)=/YW
M]5N#^FC^3&R.I'Y&\T?YTMOM.)CYK]L]1/J190^(FM0D#YF.?'4>U..?NG7\
M/*Z?M'MWPF<42;C?9";2?K-9Z_.4KJ_V_P">$SXLS[!CZ9])/W]]]_0RR?@F
M<,O?Q]'3RM_JM+_K](Z<;>_*UU^-#X*<67RN_K:ZU?38?B3>/0;ACVP49_=V
MXL_GA=:VF?-!?YP5]MCY4=0_W!7_`-K-R^"<1)S_`/VB^?G\U&)/U#IFIF!_
M@K#]]=]JL;VZ6_-3RN?GRZ?CLK%;?FJ_H[Y<_P!3/&W\Y+JS[7_[S^.N8Z]\
MD7Y5ZM_M"N'P<$K<_P"V8P7_`$MM+_4VG:9VSYF2/<>^$YBH]%_X?&Y_O.YO
MQN7B[SRW?IR>;-\_U6_%N>J3N?\`(-G^+J^TQ\WO-W^[3T+^B\GVQ<4X/?9[
M9U_O>67QC;5S5\X(WYH^VQ]`XO[UNV?V"K^WQU-SWM_L9_/GM_\`Q(+2-M_5
M^Y]X<]B\,>C7\+2\?1F]^U[#=V(^V<SM_3>ZOXFRZ<7_`.93']&/]IB7\S?\
M/3;'Q;;7MCXM/\LKV36<_P"F-TGWI355W3\[X_N,?R8XE\Y'[\VV?B^W/[/$
M1\`?H5Y!G]><T_'S^G\OWU]^]-_!QO;JC^7_`#0?FZT?!9Q%_9E[8/=K_I;X
M/QK5J;O/S/B?]5]B,;J\Q'[@FQ/<V?[(N`CY</\`9!YI?U4YC]:S:D-T?XFU
M?'![#C8OF[^?O13Z;L_BV+E=PW_1_*'\R&&_SK#ZHD'Y^._?'?@G'SYZ4_Q3
M;I]([M^"=QPG?M*4/[K$_P"S][IPGYN_^*?V@Q)M?N@+_;9_VY&*9-B'T4?-
M*^K[6OUR>ZO%^_*MI^_GX`Q]"_,[^O'HG]*Y'XJW@A;>_8R[F/KKX<^(QKII
M-^>T;XD[]OBJ]5OXAFS?V=77VW#%_'FJ?ZMY=/UQ\,_CLM:]VK[^X?%'/8<?
M+CR1?UW5KZ`77[?%?6=OT3\^W^ON-OQ(;4];_?V/^BY\''5'3/\`+GE@_-D_
M^VQ517O9!W[Z[5._9Q(ZM[GSP1\35^$&.X;I^_M:OV<R_P#S!&+%L-?1@\D[
MZW-[_/;O5;G?E>\_%$_!..2.H/ZZ/,9]`X?X%.+L<G^U>VM?5@SW^?*MJF1/
MF?+^-M>PX^<^S/W&]Z_32R?@9.+.`_A'[^JICC3&!`>/O?>UCMP8:T51:5!2
MKR=@Z?5H:;D>H$A,14!%1TJ^!4_45!W(,VB+MQU5.!C<YQYC=H\1TLN1(=0&
MW%K4@<`5$@>T8FYVY=QW2$W;+E/FR+:U30TZ^ZXVB@H-*%**4T&0H!09##J#
ML`-)8A,<1U6JZ^CW40]@(5Y%/G)GCV,=13!Q'/'1EBN#N73)5`S9PX,X*"@G
M.4QA.`&X\0#7L.NI4%I4H+`R()K]0]F)%B\7>++1<(TJ2W/;1H0XEU:7$(H4
MA*5A04E(22-((%#2E,:$+1J76S/#5ZG56!&01[L_&%K\3%B^;_"_(/!8M$.\
MH<3#\`_,7M]&O2WY#E.:M:J<*DFGN5PYN.Y=R7?EB[7";*2TK4CG/NN:%?ZR
M-:U:3D,TT/KRQM0%4K%40<-:M6X&MMG;@73MO`1$?#H.G)OPG#A*/;MR++B`
M_AF`3>_K#CSSQ!>4I1`IWB3[<(W2]WJ^.(>O4R5,>;3I2I]U;I2G_525J40F
MO8,NW'538LTG3E\DS:I/7A$4W;Q-NB1TZ(W`Q6Y'+@A067(@4P@0#"(%`1X<
M->"I=`DDE(X#LPQ5)DN,(C..+,=LDI05$I25>^*4UHFIXT&=,ZXY$'4:K6%)
M!:MUBOU]:57[S)JPD/'12LBXXF-UWRC%L@9TKS'$>903#Q,(^[V^UO/.T#JE
M*`X5)/MX8D+E?K[>4--W>;*EH83I;#SKC@;3D-*`M2M(R&2:<!C,54ZQ!/Y*
M5A*U`0\I,J=68D8N'CX]_*J\1/SR+MJW2</#\X\>*AC#S"(^G0MYYQ(0XI2D
M)X`DD#W`<AC$Z^7JYQ68-QF2I$*.*--N.N+0T/0VA2BE&67=`RRQU6<>QCDU
M4H]DS8)+N%G:R;)L@V(L[<G%1RZ5(B0A5'#A01,<XAS'-VB(Z342HU-3E3ZG
M9]3#&1*E2U!<IQ;JTI"4E:BHA*11*05$T2D9)'`#(#''94ZIQDV^LD;5J['V
M&3*)9*>90L:TF9`H\!,#V40;$>N@,)0X\YQX\`X^C2BGGU(#:EJ+8X`DD?6K
M3$A)O]^FVYJT3)LMVTL_U;*WG%--_P!!LJ*$^J@';CZ-*G6&$T^LC"MP#*Q2
MB?2DIYI#Q[>9D$N8INF]DTFY7KHG$A1X'4$.(!]H-"G7E-AI2U%L<!4T'N#A
MCP_?+U*MS5GE3)3EH9-6V%.K4T@^E#944).?8!Q.$2J5DD^>U$KD"2T*MNYJ
M60L1'EGE&@E*46IY<K?OYD!*0`Y!4Y>``'#LT%UXM!DJ5R@?>U-/K<,"KY>E
MVL6-<R4;*%ZPP75\D*_U@UJT!5<P:5[:X<`=@<-)XBQD,9T8,+1@PM&#"T8,
M8'T:,&&[,U*K6)S&O;#6:_.O(9<'40ZF8:.DW$6Y`Q3`XCEWK9=1DN!B@/,D
M)1`0`?2`:4;>>:24MJ4E*A0@$BH]>)6WWV]VEEZ/:9DJ+'D)TNI9=<;2XG_5
M<2A20L9G)0(]6.L^CV,FV4923)I(,EN3K-'S9%VV6Z9RJ$ZB#@JB2G(H0#%Y
MBCP$`'2:2I!U))"O2..&,:5*AO)D0W'&I":T4A12H5%#122"*@D'TC'Y<Q<<
M\48K/(]BZ6C%^]1JKEHW74CW/3,CWABHJF8[1<$3B3G3$IN41#CP'60M::T)
M`(SSX^[]7'IF9,CH<;CNNH;>3I<"5%(<34'2L`C6G4`JBJBH!XX^KIHV?MG#
M)\V;O&3M%5NZ:.T4G+9RV6**:K=PW6*=)9%5,PE,4P"4P#P'B&A*E)(4G)0.
M1[?=KA-A]Z,\F1&6MN0A04E224J2H9A25`U!!S!!J,?9),B29$DR$333*5--
M-,I2)IID*!2$(0H`4I"E#@``'``UC,FIQX4I2U%:R2LDDDYDD]I/:3VX^FC'
MG"T8,0HRSM9LE]>2BU;R$WI\8_O$C<UZ^%>:24?)O9.N,(=T]>NUS!),Y)11
MLJF8S=0I#MG!RB7FX"$[#O#49*0XV5K#>G54@IH2:#L([<^T8Z+V+UML^V([
M*+S:5W":U;6XB7^>IM;2&Y"W4H0@?<UM@*2H!:20XA)!I4'K#@:YMF5$69FH
M#R1B8S),--PDW%O9"J0Z62;/7[0:1J[(Q^H9U4S5_N;$BO(`MW)^)B\.`^/E
M".I3@5S-)*""#12M"2GO'^=4$D=HPP_S/V\_)N;<@71N+(?M[K+S+B&Y+IM\
M9^-RY*Z4TR@]S7BFM'&TT!X@<2&SNY*OFJS')2IT89K%6:O+3`OI)_'9-K8R
M#>O.R*F.F1.JMHV9>)G;`!CB90H\1X:=)O;`226N\20JE`"A5*_\ZH!KBV1>
MO^WFXSC<BS@.2''8[X:T-H7;Y&A3Z"*$F2IQEHASA1)%,\)?9O:T7/=XK(::
M+%DO&6^%F7K=5S9X^^Q+56/C$4W"(-61*O$,WC@&Y>F+G@IR'4.`<=`OC)'?
M:J35)`-$E!.=>)U<*]GHICTWY@K&XSS9MJ*I+B7(KS*%!,9R$ZH+<44G4LR7
M5(1K)5R^[J2E)P_`VZV"895-K8F6+6BE,LA'K%:"K*J:\NP:T2W50DG+N79C
MKJ3CY]8$7)_2FETC\!,8P"#;Y3:;*RT7B%IH0I7`E:54`'8`*<<5@]6K3`DS
MG;2Y>W$7&&4+#\@$-+7-BR2VTE-`&4(86@<%+UIK0`@CV'VAW-2`JS><LL02
M2IL?58]K&).'K^M64("YN;$HI94SM&LD=!!)5)=DDW52,F];$ZAU$A,07+E[
M9UJ+:3H65&M`"FJ:=W.F?`DC@<ABU7#KUMY-UFNVV&^8=Q=DK4X4H1(C\^(F
M/2.=2FPHD*0\I:5!3+BM"4.:5!T4_;?<XZ#LM/FWL$2#L&/,DU`[6,.[7BDT
M[@S9Q$9&J]Y%*1<LV2+<ZY>IS'13."0*&X<=)/7..I:7D!6M+J%5-*]TU)]%
M3PQ#7_J]MV7<XFX+8W*-TBW:WR@IP(2[6*M;KC@TU;2I94E'=H%J3K*4@TPU
MV>RV;\4CY^4N;)U*,VL`:3:HHNB1-PDJ[8(+N2EF25%5XHV]4:PP0X-U4#@[
M0*<3"03%%5=]:Y:FT((;-:'M2%`^][*ZB3G7(XFY'F+MW@WK9"M[B(;BWPVI
M1278C<AA[6(Y%$!7BI#RZN)6"TLIH%4((LSMNL,D?.+U68@)A3-T>B>;A)9O
M(HPZ<U79=L%/7(HP<I.TBM:NW*V64((&%PDFKP,!1*+5NYM(Y`"5)Y!R(S-%
M`ZJ@^E6?N98J5NZOVF$G;4=J/*CHVXZ0R\TILNEF0TKQ::.)*3JDJ+B$FH"%
M*15).H#`=GN19,6,O8KW7G\VV3C8PS$D8[;Q1Z]5ES6JEL7BS0S59](0]_(F
MY5<\B76;@<O*`FT[^6H::H;;4&LS6M350T*/J!1E3.F+F.O^T8A<@VJURVK<
MLN.:RXE3G/DI\-+6@*"DH0[!U-I;JK0X0:FF/B_V-/G5;M:RUJ:O[J[;J/ZR
M18SUG4PM;BW2EL?3LZS;%\3=.'3B4.GQ(N!``PB)!'@.O2=P(#B.Z?#UHK@5
M%.D)`3V`9>C'N+YE8S%U@M(A+9VXVH(D4"%RO#"*W%0RRM7W-(2EL*S16N6H
M9X*L%AK+3.;S'-.9&GL9#)L)+$8.F:\J];0<Q+MHML<OA[ENF*[1`C54>IU@
M,<>4.4`$>#)V?"+;+8"REI0R-`2!7MKV_P`F*3<^H6Q'[;M^W,LSW(EFDME:
M5!M"GFFE.*!YB5'2LE2<M-!F:UI4*V+8K:#55]7ZI?(M`&Z3^KQ+::8/'+*1
MQZUK[MM4(*=!%P!N_P!<FW:IB+I`',T74(("/+P?-[@9YX==;.?>)%*A9/>*
M?41_I%<;$M'F9LPO;5TOML>4I2D275,K2E3<Y3Z52GF=0]Y(90@%"CDXA*@:
M5J2;[M=N]WK4,@PMD!1K"A,Y%EW@5Z/=FA8E'(<"WKC^)@4%%$S`V3C4E#"<
MY0XKKG,!2AV:;L79AAU1T*<;(0!J/>)0=6I7KKV8I^V.M.VMMWB0[*@2KE:E
M1X#2.>M/-<,%Y3Z'7B*]XK*0`DGN(`*CC5H.TNV8_C)YM%WMHY>66B25+4,\
M:'4CZL=V:(;FDJPW2(BN)9&-:J@Y1=*+%*LBB=(2@94#$F\LR5)4ILA*7`KU
MJ.9[WN$Y$4RJ,.-T==;%NJ;%>G6Q:(T.YMRQH4`N3IYJ@W(4:CN.*26UMI2=
M"W$K"J((<$EM\R2V@L;Q<'::N]E\?2,B2-LTI&.&2K>#+,%EX9D,,Q%2-=-4
MFZ9&9V_*F"0))JI'`Q1**:;G%+CJW$+"7`*I!KG2A.>=3QKVU((IB)A]5MH/
M72[SKG"FMP;LRWS([3B5@O%HM/+YJZ.)45$NA=3JU*0M)!!`5F]BF1WLRCW;
M,#)W`MJ9+TY5.0@C-7\W%V5U69F<82P1JR;7I*VRM>+@LF4%E'KQ8QQ'FXZ?
MHW!%2V:L$.%P*XY`IU`$$Y^]5IIPH!C8MM\S.T(]O5SK`XBZ+N#4H%#^I#+D
M=,AIE;7,255$:1X70HZ$LM-A(%,$N%VI6>APD.UJ,[%SDU)XXE*!>I*VNI`2
M)HNH4C*.5JJ$8D@1LTB7BK@2)+@HH9);X2AA*&FB[PS(6I3Z2E*7`M(2!V'/
M5VU.0RIGBGW#KA9=S7*0_?HS\:WL7=J=";BI1F4NE;@E%Q2BI;J`BJD$)"D]
MU("CAQ_[/N19''>.JJ>Y159E<>*K3+5TQ;&GT)"RLP:(03Q8\@W:F;(MFR2W
MPTR@ND9<1(;L[4S<XJ)+CNA2VW1I-<J)/$"G$UI];/$1_FKM*)NV[WL6]^;"
MNR0TI*U<A2(Z]2GD@(4K4I2BGNJ);4$=X"N0E@-F5_JS&#AF4]C^=A4JJ>MJ
M,K'%S#T*>XGIA[8+/)U0XNCJ*"A,/3JQ2:HD!GQ`H#RE`-.W;['=4IPI<2O5
M7(@:J`)2%>L@453CB\W3S";6O<F3<)$6Z1IZIP?"X[C2/%)9:0Q';E#0`*M(
M"9*DU+N:CWE'%C[%KW)DT9]51?NK9!OUUAYE5N@D1+JJ#[IU.7B/OCJLE6HE
M7I..1I+WB)#DB@3K654'`5-:#U#&WK&$<+C_`!:,&%HP86C!CS)>?]Y[>7/)
MYO.VRJ8TP7C_`"^USA5,B6&6>72RS\$M"+TN7K$:U:L$H5HX(X3>)SQSJ&4$
M!**8``=NC!CSU?\`/<]U/_R4X)_^(=Z_\V:,&+[_`"#//WS%YON9L[8QR3@3
M'>(X[$V.:[=HZ4I=GL,V[E'DQ85H15B\0F6B"*;=-%,#E,0>8#!P'B`]A@QZ
MD]&#'G8_Q(/T7L%?/ZE^SRZ:V1TT_*DCXO\`;IQ]9_\`A#_KIW-]%S^/1,`[
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M2ZL^U_\`O/XZYCKWR1?E7JW^T*X?!P2MS_MF,%_TMM+_`%-IVF=L^9DCW'OA
M.8J/1?\`A\;G^\[F_&Y>+O/+=^G)YLWS_5;\6YZI.Y_R#9_BZOM,?-[S=_NT
M]"_HO)]L7%.#WV>V=?[WEE\8VU<U?."-^:/ML?0.+^];MG]@J_M\=3<][?[&
M?SY[?_Q(+2-M_5^Y]X<]B\,>C7\+2\?1F]^U[#=V(^V<SM_3>ZOXFRZ<7_YE
M,?T8_P!IB7\S?\/3;'Q;;7MCXM/\LKV36<_Z8W2?>E-57=/SOC^XQ_)CB7SD
M?OS;9^+[<_L\1'P!^A7D&?UYS3\?/Z?R_?7W[TW\'&]NJ/Y?\T'YNM'P6<1?
MV9>V#W:_Z6^#\:U:F[S\SXG_`%7V(QNKS$?N";$]S9_LBX"/EP_V0>:7]5.8
M_6LVI#='^)M7QP>PXV+YN_G[T4^F[/XMBY7<-_T?RA_,AAO\ZP^J)!^?COWQ
MWX)Q\^>E/\4VZ?2.[?@G<<)W[2E#^ZQ/^S][IPGYN_\`BG]H,2;7[H"_VV?]
MN1BF38A]%'S2OJ^UK]<GNKQ?ORK:?OY^`,?0OS._KQZ)_2N1^*MX(6WOV,NY
MCZZ^'/B,:Z:3?GM&^)._;XJO5;^(9LW]G5U]MPQ?QYJG^K>73]<?#/X[+6O=
MJ^_N'Q1SV''RX\D7]=U:^@%U^WQ7UG;]$_/M_K[C;\2&U/6_W]C_`*+GP<=4
M=,_RYY8/S9/_`+;%5%>]D'?OKM4[]G$CJWN?/!'Q-7X08[ANG[^UJ_9S+_\`
M,$8L6PU]&#R3OK<WO\]N]5N=^5[S\43\$XY(Z@_KH\QGT#A_@4XNQR?[5[:U
M]6#/?Y\JVJ9$^9\OXVU[#CYS[,_<;WK]-+)^!DXLX#^$?OZJF.-,-FZ72I8Y
MJ=BOE\L<-4*948A]/6:SV!^WBX6#AHU`[A[(R3]T=-!LV;HD$1$P]H\`#B(@
M&C!@/;?]V&WK=(QL#[!.2HR\A5%8Q.R1X1=BK4_"IS;07\$^D*U;X>`L+>)G
MF)168O!:]U>)E,9%0X%-P,&.#GK>QM9VQ6&O53.F8Z[0K'9HQS.Q\,Y9S\T^
M9UID[0CW=ML:-:B)D:A36[]P1`\Q+=RC"JB)17XE-RF#$FV#]C*L64I%O6DE
M&R31N_CI!@X1>,7[%XB1PT>LG;<ZB#IHZ;J%.FH0QB'(8!`1`0'1@Q!EKYG&
MQ1[E-OAUMN(JBEN>71;&S&1&,M2>/'^14%SM%:%'Y:5@"8M?6X':9D`8HS!U
MS.2B@`"L`IZ,&)09;S5BW`]:CKCEVY1E%J\K;JE1&,Y,)OC1Y[9>IMK6ZE$+
M+,FCL&9YJ=?(M4U5NF@554H'.4!`=&#'VOF8L9XQG,:5F^W"+K4_F*Y_)[C*
M)>@Z4>W&X^"2MC/"12+1NY-UDH2$=.%%%>F@F1+X1P$Q0,8,$O1@PM&#"T8,
M#G)N6L=X=@F]DR19VE9BGLDVAXXRK:0DG\K+.P.9M&1$-#LY&8EWZI$C&!)L
MW5.!"B80`H".G,6')FN%J*@J6!4Y@``=I)(`'NG%MV;L7=G4"YKM&T(3DR<V
MRIURBD-H::20%..O.J;9:0"0-3BTIJ0*U(&.Y2;Q4LCUB(NE&GX^S5>>;`[B
MIF,5%5JZ2YC)G*('*19NX05(8BJ*I2*I*%$ARE,`@'A^.]&=4Q(24.IX@XC=
MQ[;OVT;T_M[<L5V'>HR]+C3@HI)I4<"0I)!!2I)*5)(4DD$'#4REF[%F%F<0
M]R9;F=:"P.W+*"9=RE9F9F5V3<';\8N`@&$K-OF\:V$IW*R3<R+8IRBJ8G,7
MBK$@2YQ4(J"K2*DU``KD*DD`5/"IS[,3FR>G&]>HLA^-LZ`Y,,5M*WEZVFF6
MDK5I1S'WUM,H4XKNMI4X%.$$("M)H\*?<JMD&L0MSI,]&6>JV)DG(PL[#N2.
MX^0:*"8H*(K$'L.FH0Q%"&`JB2A3$.4IBB`(OL/1GE1Y"2AY)H0<B,0&X-OW
MO:MYD;>W'%>A7N(X6WF74E*T*'80>P@A25"J5)(4DE)!+`RUN"P[@KU=#*]X
M85!6VN))K6VSAE,2;R86B&?B$H#-E"1TF[,1@S_**G$@$(4>T=.8=MFW#7X-
MLK"`"K,`"N0J20,SPQ:=B=*NH'4SQ9V-;79Z("&U2%)6TVAH.JT-ZUO.-H!6
MONI`))/9@@U&W5Z]UN(MU4D2RU=GF:;^)DBMGC0KQHKQZ:Q6S]NU>)`;@/8H
MF0WO:;/LN1G5,O#2ZDT(R-/K8JE]L5UVS=Y%AOC)8NT5PH=;*D*TJ'$:D*4@
M^ZE1'KP-<K[CL*8.?0<9E.^QU4D[(W>NX..68S4H_D&D<9(CYTBS@XR3<E;-
MCK%*90Y2D`3<./'3F';)T]*EPVRM">)J`!7W2,7#8W23J+U*C29FR;6[.B0U
MH2\X%LMH;4Y70DK><;25*`)"02:#A@JP$_$VB#B+)`NP?PL]',Y:)?%1<(`[
MCGZ!'+1R"#I)!RB"R"@&Y5"$.''@(`/9IHZVMEQ33@HM)H?41_R[,4BZVR=9
M+E(L]T1RKC%>6TZBJ5:'$**5)JDJ2:*!%4D@]A.!1DS<AA##DU&5W)60X>K3
M4LR+*-V#I"4>*-8<[T(XDW-'BV#Y&NP1WX]$KV0,V:BH!B@IQ*;@\B6N?.;+
ML5I2VP:5R&=*T%2*FF=!4XO&S>D74CJ#;GKML^U/S;<PYRU+2IM`4[HYA99#
MJT%]X([Y98#CH20=-"*FI%=%PDDNW53707336171.55%9)4H'3525()B*)J$
M,!BF`1`0'B&F!R-#QQKMQMQIQ33J5)=22""*$$&A!!S!!XCB.W$:LC[QMM>(
MI^8K&2,HQU3F:^BV<32$C!VM1K&H/"%.W6<RC.!=11$U"G#MZX@41`!X#J4C
M66Z3&TNQF2M"C04*<_J5K_HQN':/E]ZP[\M<>\[0LKLZWRU*2RI#T4*<*310
M2VM]+M00?L/<RQ(V.D64M'L96.<$=1\DT;OV+H@&!-RT=HD<-ER`<I#@15$X
M&#B`#P'MU&K2IM12L44#0^JF-1RXLB#*=A2TE$IEQ2%I-*I4DE*@:5&1!'&F
M&M8LD42IV6E4VQVF(B+5D:1D8JC5]VZ*65LSZ(BG<W)I1;,@'55(PBF*JRJ@
M@5,A2@`FYC%`56XLAYIQ]I"E,M`%9`R2"0!7ZIQ-VG:.YK[9[CN"T09$BQVA
MIMV8^A/W*.AUU++9<4:`%;BTI2D54220*`D/;TZ0Q7,+1@QC[/?T8,5JRV%]
MRMCLL]'.9^1;5]"XV)W4Y*4GY1>*4A;1:7-D5:6&*@9R&DW<=!BFBU:=-PDL
MBT,8A>P.&K0B=:VV4J"07="0H!(K5*:=TE)`)S)R()QV!`ZB='[19XLMJ*VN
MZJ@,)DMML-)<#L:,F.%,.O,NMI<>JMQVK:DK=`4<\\&:K57.+6>P9)+.I7P7
M']*AZW?&4],G6EK?(6MLYCK)(.4VRCB->.:>ZBHUZDX5.*@D,NF3G%0PZ8NN
MV\MR$@#F..$H*1DD)-0!V@*!4/K>C&OKW>^FKUKW-#;0Q\I76XO2(2V&0EJ*
MB,I+D=M)(2M"927)#*FTIT@AI:@-`P"HF@;I60R+.":SZ#&LVZ=R$C(VJV/"
MRMV?)&/&J40C5*7FVBT=-P\JY%!WU&K3KH(K=!%0G`9!4BU&G-*"5H2B@`HG
MMU5(&8(&69%:5(.-ESMU=$Y'*D7-<54F;`8@E$:,DM1$FBQ-*BTRM+C+K;>M
MK2X[H6XWS7$JJ.I!X%S_`&"5KL?:;?:(N/@8*`KWK*]M$JY=+KU\IWJUJ3C8
M29BR'FY!U)&0(+@RB1DVP"L4W8&L.7&VMH4MI""HJ*M(2`,_L<P<A2IIZ<L,
M[GU0Z66J#+E6.WPGI<J2^_R$QFDI2'Z($8N/-.$,MI;"SRPE04X0VH<<?>DU
M/,"L[A(EVA<G&1HQYF$GWSPJ\PE,2H75\^8V*0<QMZ@TDXM:!.@(.5VL@'#B
MEW<`+V^7WH8;?,=357**%*"@*0-(JDYU]!'NX2W'?]@-VS<BMMR;,'+F&GF$
M(HT6FO!H0MA"7(3Q+@>"P6T.,9]_FFN6Q:<=[K7LS>9N"F9!!.5]=+U4X`UH
M.DQ92;B.;U!EC>24%,.G&2<*W6E69T1`C2541.8X$*H4WEJ5:$MH;6!5.E*C
MIS(KJ*QZP>Z:\4@^K"5DW9T.CV^VVVY1VE+9$.%*?\,"M3:5JE*N"!7-QMU2
M8SH74NQDK`3J*2/ICW&N;!Q9DNNG;WJIVN52LS,96=N#R5<2UC?Y-DY>&L5:
M46F)`D7&Q](71;B"(-"'Y0)TQ$G-HDRX/BFG!RULBAH$@4`0`4JR%25"N=?=
MQYW9O'IP-[V>[)5;)]B85'6&V8J&@U'1;FVG6)`2TCF.+F!:ZKYI%2K715,<
M*K8FW0N[@POUUDWK%=+($U8Y>`B[!)O3%KLX.)DVD55>2<:PK(T4QA'Z:J+M
MFZ0-_*1(!3K`85'YEI2R8\<`CEA(40!F.94G(DU)3P((RQ)WO?719BP.[6VX
MRTZV;4S':><8;0.>S\IE3DFK*GE\U;K"DK:=;6*LA1*6R`3Y>IYW>US.:$LA
M(D9WH[2P5)K69AW(3\*HRF3QTE$%:KRL&"(25?9LEDV;)^V3.`+_`)4BJAN9
MHAZW)=CE!%6ZA14``:BH/`\#45*2>'9BEP+YTR8N^V78*VB_;`IB4J0TE##H
M6US&W2I+;Q46WUO(+KS+BA5O[F4(%!!-4;>.\CZ[.13$L4NA-T!=&OM[M)+R
MB4?C=5W-<DZ#U4T:1G=415C'!`575_E*1EQ4!`#"]1)LJ5*0LU[JL](`)71)
MI3.J310[,C2E<7RW;F\O\>5*MTUPOMJC3@7U0VPV5W`):JSH&LJAG3(0K2A/
MW-8:"2X1C;:83W"1E;L=Q?3UN7M,19TY6/K<3991[-6J$6?-'SR!35<SR4`V
MC&PNUA2(#<%SJ(`4%"IB!0#.MJG4,)".444*BD``T-#DG57UUIZL)/\`4?I3
M-N\3;\:+`397X1:7(=CM(:C.A*D(>(2R7U.$(0%'7H"7-6@K!."E`PN6"R.>
M9>/KMK2L]R:3`4A*T`\CH./2EI(J<2@::1N4NV3/'LW)%%"-HIHHU*B<`.J(
M?"9..1"B.A:T<E!&K30DT&>6D<?636O9BE72X[&,3;$"7+@FRV]QKQAC:7'G
M"TW5U7),1I1"UI*4ER2Z'"L$H0.`;L>+-US:OVR/%W/V"/,@E53Q<1<'+=V\
MB:I4'K2#LM5>K+LY<7EG*Y(S?@NNDL9VW3<<`,8QM/VI=H4ZA5$I5754I[5*
M!*5=E$\104H2,7^T;VZ&NW6#*Y<2+*"C)#CL4*2AV3*0IZ/)0`IK1'TJ=9T(
M4D-K4U4@)&'Y<Z%N-<M<<N,<ISL*R:MLO-',#.V]=R_KU?N,,SBZ:A./5GKQ
M><F:VY.N[0!1==1`PE3ZO$@#ILQ(M@+HDZ2L\LU"10E))50`"@5D.`Q6=O;H
MZ2,OW=K=JHLB2M=J6E]F*$H??B.J<EEE`0E++4A.AI>E"$K`*RCO9\#!6)=S
M6/Z79"6:3?35GM>,1AXXK^PRKEU#W7QYPQ5?STB^G99JH=O"O4G+9PR;-S"F
MD=,P&.!=*7"7:)#Z>4`&D.ZL@!5-*@)R';4&I/IQ*=3-]]&MU;BAFS,MQK+`
MO/-<*&&DI=A\E*PAEM#+2A5Y"FW&W7'!5:5@A)5A\2U9SS&Q6&N>#F)NRT1>
M3C7[:*L;YS!3"41(\L9)R<TM-1+U!:3K2`"+AZUDBNES&;F10,;K:;I<MRU/
M=Y(:<H14=X$@U`%",E'@"*#.II3%;@7GIC*G;ATR8\:SW-+;B%.L(2\T76R7
M&VV0RZ@AN0HT0R['+2`'4N.`<O`7F<4;UD)?P=M+"\C"TZ:KDQ8HJYR?3D%+
M#/UZ\&GH)"040<M+(RM",DR`%"@1O$+$02-R`'!^B98E(YA%%ZP0"@94!115
M.*=-#EQ4*G&P[?OCRZ.P3<'6`W,-P:?:8=B-DMAAE^'R'E-@I5'7&,=WNFKD
MI!=6-1."'6\:YNQO36K5X>[6Z7O&)).N2$=!2S^0;TJ^*LFBY)V0=SUE6=J/
M91=14BZ[4Z2)%$2`DF0#"86SLJ!*?)3H0AMX$$@#6FIRR3[<Z',XJEWWATVW
MAN%;S`ML"!;+\W(;<>:0A4R$%K!9;0S'"0AL!!0AP*64K5S%*(`PY8VEYO2Q
M1BB'IS20;35/D36ZSDN;N:K+Z:DH4[=)I!&2)9[F[>)R)EW"HIN'IF;@"$YP
M3X@4$UOP/&O+>*>6ONIT@*`!XGWJ>&7`5'9B&F;BZ;N;XOL_<"VEVZX,^%C^
M$2U(0TV\"5/5\-$2CEZ4)U-LAYLDZ2JA41%$8PW+,65-B[@PR!:U(^K$:U>:
MB[\K%R$)9YF:D)IFZO"S24;)NB4=!T#)190KHC]LD4#$XF[':Y5K4I:F2TD%
M?>!34$``'34&FLBHI2A.+[<-Y]'94BXS;"[:X*7IVN0TY"#C;T=EE#*TPPII
M2DF84EY*$EHLN*)"J#.T5BFY29-$GBI5W:;9`CI8A>4BS@J12K*%+_FE.H`B
M`?:U4U4*B4Y)KEZO5CBV0II;ZU,`I8*U%(.9"230'U@8VM8PCA>]VZ,&*1]D
M'FCY*W3>:%YC&P^S8SIU9I&S!2,3J%WAI66=62W]]F(^-/X^P>)ECFG!%[SA
MT#=A@X>CMT8,7<:,&/YW'^.%[<Q>7Y\VF>/WK1CKC^]HP8\)VC!CVW_X(_Z6
M6]#YA*)^OCO1@Q_2)T8,>=C_`!(/T7<%?/ZE^SRZ:V1TTSNL@=IC_;IQ]9_^
M$/\`KIW-]%S^/1,`["'Z3>00/_H'EGXHG\>G\W-K<'])O^3&Q^I!_P!S^:/\
MYVSVG$Q\U^V=H@_;V190^(FM0D#YF+^.M^U..?NG7\/*Z?M'MWPF<41[C1_W
M0FTCW]S6>OSG+!VZOUO/_P!83/BS/L&/IKTDS\^V_"/_`+,LGX-K#,W\?1T\
MK@?_`*6UOU^D?N:<[?RNUU/9XKV)3BQ^5PC_`#:ZU4_^]1^)-X]!F&.SS@HS
MC_\`CMQ;_/"ZUM-RV@O\X*^VQ\JNH>7D%?\`VLW+X)Q$K/\`P^43S\^W_P!U
M&)?M^Y0Z9J9@?X.P^MUWVJ&-Z]+OFGY72?\`YW=/QV7BMSS50_Y/>7/[VS/&
MW'_ODNK/M;/Y3^..8Z]\D5!=.K?[0KA\'!(W/^V8P7_2VTO]ZF4[[OHTSMOS
M,?\`<>^$[BH]%_X>^Y_O.YOQN7B[WRW?IR>;-\_U5_%N>J3N?\@VCXNK[3'S
M>\W?[M/0OZ+R?;$Q3@^]GMG7^]Y9?&M@^_JYJH=PQJ?_`"C[;'T#C9>:W;->
MWH*OV*_]..KN>]O]C/Y\\`#]P"07'C[GN:1MOS`<^\.>QS#'HT?_`/+2\_1F
M]^U[#<V(]OG-YV$/1XWNL_>1LO'3B_\`S*8_HQ_M<2_F;_AZ;8^+;:]L?%IW
MEE#_`+IK.7OS&Z3_`,J![O9JJ;HSWA'IZ&/:,<2><?/SS[9^+[<_L\1(P`/_
M`"+\@T/M7G-/QT^/WAU(3,E7SUMM_!QO?JA\X/-`.WY-M'P6<1>V9#_O@]VO
MO&WP!_V5K#[^IN\Y;/B#M_NWL1C=7F'[WD$V)3C39_LBX"?EQ!_[(/-*]';M
M3F?WK6/W=2&Y\Y5J`_\`U8]AQL7S=_/SHH?_`,W9_%L7*;AA_P#U_:'\R&&_
M<'_C6'[?\G9JB0<]^/??'?@G'SYZ4_Q3;H>S]([K^"=QPG?M*4/[K`_[/WNG
M"?FZ?SK_`&@Q)M?N@+_;9_VY&*9-A_T4?-+][;[6?W[B^U>+]^5+2?\`IS\`
M8^AGF=%>N71/Z5R/Q5&"%M[]C+N8^NOASXC&H::3LM[1OB3OV^*GU7('_$+V
M:3P'3JZ^VX8OX\U0?Y-Y=/UQ\-?:_P"O9>_PUKW:OOKB>SPCGL./ESY(J\_J
MT/\`^/[M_H"\5]YW_1+S[/Z^XW_>)">G]W4]`%'+&/YCGP<=4=,C_OSRP?FR
M?_;8JGKWL@[^/VM[5-^W[N.)'T:N#@/Z8MC_`.#5^%&.X;H?_P"^UJI_^W,O
M_P`P1BQ?#?T8/).^MS>_SV[#5:G5^5KS\43\$XY(ZA?KH\QI_P#P*'^!3BZ_
M)WM7MK7U8,]_:_X\JWOZI<0__2$L?_%M>PX^<^S/W'-[?32R?@9.+.0_A'[^
MJKCC3$?-U5KPA1\`Y'MFY&";V/!\#&QLCD:,?5-Y=XT(1"=BCDD)6ML64BN^
MBH>0!!XY/T3D;(H&6/P(F80,&*J-E%D57\TS<^Y;9AH.[)GE3;+BFW-\R8H@
MH^H57!=0JUOL##'^!)B$K<Q:J[.R%CC;&XFFTNM)^*+D04*9LBWZ8`8,/CS+
MK5A"Q0.YO"%=W"XGVC;F)_;6UF,B91RCB..LSC(NV]1KD.*]0*Q8;!*UQH\`
MMC>K)K+L%)AW!'=`<(Y51RD(&#!YQ*XR+EGRE*HCCVA36'<G6W8NI7<=4%\_
M>OIJH6,^&W-<HC1&2?M8V465.JBS6:K.$D'/(JF*I2J<W`P8@KB#=+Y<=8\J
M[;!C#(,!4,B^"U#!6'I/:-#Q$=,9K=;E:VK68FR4T^+55VUF+D."R>Q=2#YV
ML5,3&14>F7,0X*',&+<-W.`X_=%M4RWA!XR*R=7O'[I&L]\`P+5R[1B",Y1)
M8!2.(IOJS;HYFY((&$`50#TAHP8JH\OO*5F\PK<;0=P%X9N4V.Q7!(X`M46_
M;+%10WNVI5JPW#.$RKE20.\IT+5V;(BR28\`DE.4X`<2:,&+^N'OZ,&,Z,&%
MHP8@1N-D8VL;L-H%ONKQG$X_:)Y<A`FYE9)K`1M\F*]'C6BNGKDQ6;)^]9M7
M:;8Z@DXCS%*;B/`;!;$+=M$UI@$R#RS0<2D*-:`=E:5X^YCJ#I)$F7GH9OZP
M;=0X_NEPVM[DM`J?<A-/N>(*4)&M:$*4TIQ*:T%"105QWMC)T'M$S%/P?2]1
M+1N=SK8L;';(BA'NJ8_MI@0DH@O(1,T-*S"+QPU$A03%)4!+V"&O%_J)##;E
M?$(BM)<KQ"PG@?6!0'$5YEDNQ]S[?MEQK^DT+9EF8N`4:N)EHB]YMTYGFMME
MIMS4=04D@YC&ONOS=C7"UKQLX)"4J?W(VZ*ME4P^6X3<=6HNNUR04A7%XM-H
MLLD;HP5$BUV,>H_%(BCQZ<A$&Y#F$W+FSP9<UEX:EIM:"E3FD%14H5T)2!Q4
M:D"N0XDTIA?H9TWWEU$L=X:5)N,7I!`?C2;KX5E<AR1(0'DPXT:.V*O3'`M]
M+(40TR%*==4E(&HH[4:'6\<80K5=KEYA\DE<2-FLUANM>.S"`GKC;K%)6:W.
MH)I'N'3*+A23TJN1HT34-W=N0A!$Q@,(M+Q(=DSUN.MJ:R2D(5[X)2D)%2:$
MF@S-,SBD]<MSW;=W4B9=KO;7[.4,QX[$1\*YS,2*PW&BI>4M*5..EEM!==*1
MK<*E``$`1QW15VAS6Y'&$I9=TL]MYLU6PUE)[4F4?7:>DA,)R+Z$2G9]M<\@
MQ%BK2B\*R9D(ZATF0OEVBIE"+)%`1U)VER2BV.H;BIDM+?;"JJ544J0"E!2:
M&N2B:5&8.-N=%;ONBW=(+U"LVR8NZ[+-W#;4REN/RB6BA#Q895$@NQY`2\I9
M+<I3W)0ZD)4VM1P?]G61;QE;;GCB\Y%(U-:)AE)$7DV40:`9V6.CIJ0CH:W-
MH4?@Q:-IBFB+XJ)`Z9.O\``+P#4;>XT>)<W8\6H:!&5:E)(%4U[=)RKZL:L\
MP&T=L[&ZMW?;.TBL66.XV0TMT/JC..-(<=BJ>_VAC.J4R5G,Z,^]7$8]R412
MAW&6*X/]V4_M_O-8VZ*^"Q#>J4PD8K$HV&1ES3AK)D&%L<99F)91L0CZ&CD6
MCXR8%YG`%4*`2]J6_P#)B&$0TR6%2<SJ56ND"FE%"G+@I54Y\,L;FZ0S]P_Y
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MCILLA/AHY3(#27/%%]*6YJ6WS'0$-A*7M*W*6J8`E/&L%X>E2U5_12/<9TA9
M*FRCE9[(5IOZNQY6\(Z>.DT7+M5@B4J?55(150`YCE*81`*C<4%%P?3K#A#J
M^\,@K,YBF0KQH,<0]5(7R=U+W!",YJY*;O,P&6VD(1(5XA>IU*4E24A9J=*2
M4BM$D@`XC1N/:(9BW!X)VU+-6[BH*I2N=,PMCM"&"8K-!>-&E)K;U<Q>"D=+
MW=TDHX1^$"J33E,`%'4M;"85MD7.OW;)IOU%8[RAV5":T]9QN+I&^[T_Z5;F
MZQ-+6B_I4W9K4H*(Y4B:A2YDA":Y.-0TJ2VK+2IW4*D8GD1,J9")I$*FFF4I
M$TR`!2$(0`*4A"E`"D*4H<``.P/W-5XU-3VG_E7',*E*6HK625DU)/$D\2:Y
MGT^LYXKMW'XVI,;N^V4Y0;P*'K[8,L6^OR5E66>.WHP<;A"_F:Q+,KEPLVBV
M`*_#.FV(B593X2G,;MU9+;+D*LTZ(5?W9+*5!-,JEU%3D,SZ*\,=:=(MW[DE
M]`^HVRW9*_T7B6**^W'"4)1SG+Q!"G5E"4J<73NI4X5E*>ZF@Q8L'N_Y=5H9
M"F.2L9UG!C`^[[GI^S[@!K.#UXK=D\J[GI2T3M:C8^>3+!VZQ1;;P"%KT,YM
MD+)VAR[JH1=DMD'+P$._AJXV!DNJN@JBL=0%3<#=NK*B):D,I>44U4@5J20D
MZ1JJ`0H@G,`'+ACKR%LCHO"LT:\3'8I5)@1W%!]U]U,9YN,E,GFQXSS3[J'I
M"N<A"%I4D)Y8RRP6*SE;,#NR8&:NXA>:K<G2(PV9)]C``QCVUJN39RVK#EH@
M]!I+M5(N<A>F[022Z14)'J*`F"1`%H[#A<F30A+H6>6DJJ=*2-0]!J#EG6J<
MJYXHMXV/L&/9]SOM2$1KPS<G!:6%OZW%1HBDJD)4I!4TOFL/:FE*5JUQ]""L
MK40#8_<3GE%1XQCF%AOZU7NLU-WJ8CJE'HP#7'T=U8R3AH15S&U^6"7B591N
M\29JLU7XJLCI]9RBIU0?JMENR*BAO6@!(*C76:$$]Y0H<P2#3.M$D4QLJ5TE
MZ8.);DS'8EK:FVYEF$TN4LOJG.4<;>="7'VBTZ&UM+=2XEC0ZE?+9<3H/=K^
M0MU-OEJ_")+R;21:P4&SF'497*O`P2MT:%.]L$G*O+9&/5W=4!H^;(KMHX$W
MIU2'[L8.WAX<C6EEM3III*C0%14=)X`!)'>R-"<AVXC+KM7HC8(,JY*2PN(Y
M*>6TEV1(??$11T,-M(BN(")6I#BD.2"IH)*><#ECZT7/UVM,]A>)L5W?13MT
MK,0U[;QT9&UQI(W:/N;V,+".6\[0Y]RLU/#)(F*BS<1I^F?J=X$3<0Q(MT=E
MM];2`4Y%%231!36O=4,ZGB:^L4QYW+TLVW9+7N*;:+:V_';2T["4MQR0IN&N
M(APO)4Q-82E0=*@5NMR!4:>4`*85CSIN6:SE_<0U0?KUB%7N=PJ2'JLW6D[%
MCJ)CVM;3CF@$6,=O:(BVBXED@7`RC^/;F1*B854SE&[?:2VTE:QS3I2HU-$K
M/>J?2DIHDTX$U)R(QBT=,^CK]NM;-PN#2;S(3$BRCXE26V)[KBI!6NH`5&=C
M!$5100&7W`X7`&U@[6/<OYFLF,<FR458I:R7J'1LA>[S=0CF"50MB&2Y.$K]
M<8MFD##E>QKJE(H.C`N5XMV]3K\#@4/,F%!9DM!:4I844\%$ZDZ`2JM30A=1
ME3T4PCNK873RT;TLT*=$8B;9D*CG4S*6LRXJK>V\_(6I3SNAQ,LK;!;+2/L.
M55)..+5\S[E+-:V<^_A;'6*6MD"706CI&%@FL=7*2Z-B="O.+"R6A%[//IN&
MTW(KD48O&BB2SK\L(IM^4%7(5K::*$J0M_E#,$U4O[H2!G1.82,P?>Y<<2%Z
MZ>='[-8W+7%D1)FX$VMHAQMYY3DB8GY3+Z6%AY,=@I4S'20ZTZA2&_N8"G:D
MC269,KJU_/+ETPE:2TB%VDQC&U3D6W19+5PDL-?FR-%V,'9U42LE615R.7\:
MX.4\@`F1,@0#E:I@Q.9&2DA:R"%I!SU$:DUJ4CMI0*IEQKD:E#Z?;'1=-KM,
M.L7*1(2IJXQF7%*6)!:Y[)4%O1@=864*;8D-I(8(#@=7I(@E]RNXM%K`3D%0
M;PK6W,MC]$DG,5"%`;#'0RSV2R:DBSBCO7J+R7K"2IT%R$3;F=-"%;"45A(#
MQNV6M14VXXV'J+R"SD2`$5K09*XYUH<\AB^P>CO2-;\JV7*Z6U-W0Q.46VI3
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M%.N73:T1V-L0YD>+`BR76DSI;BG11005R$NN^+<;THTK[K45I2*`:UF@(=G,
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MMU?RC&:)6HNT92-`4MQ;:E:>82*XX>$LR;DW%&L5CR3#661G'^+SSM09KP<$
MFE+W@LXXA"QT)#P\!$.8=-JHLU%=M)NEU%"J@L02)`8=*7"#;`^EN*I'+#M%
M$$Y(I6I))K4<"FGU<274?I]T?;W+$M.SI$-JV-7D,REI>>):A\E+Q6\Z\\ZE
MTJ"70AR.VA*=/+5J<(P])+.&1HB#PM*V,++!2SE:1B;Q535V."R3TW`R";"6
M5&/)#R42^:+QJ9WQFC"0C%VJ2A5TE'9"BW%%-OBK=?;;TJ1D4*U=T!0R[0<C
ME4A52*$`YXKL+IMM&X7+<4*T&'*@H2V[#D\]?AV67T:VAK+K;B%)<(9#KS$E
MMU22TM#"B'0%WVXK=PQD2P#K']ECII2HSB,IWFHQ+IE6K.]L$!9*[/*.HX';
M:1@F]9D7M?2234,HLLS!RJ`*B(:>IMEF4CF!Q*D<P4[Q!4-*DE/I!*@%DG(`
MZ17&Q8W27H/(B&Z,W2&];1/9+>F4XE<B,AA^/(9"7-"D/*D(9FE2DA*4NEE!
M*`#@D0&8\S5.H,Y3)DO+QSJ\XGDIFE-YZ(KCR?/DI%@S?N&A`I]>)%1D.H@\
M*:-8ODE'J0(K`[%0_*4&SD&"Z^410E7+?`5I*M.BI'V1J>'>(R-12F*?=.G_
M`$^OM_<A;.CL/,6R^-M3%,O/H8%O*U(2K^]O<UQX*21(>94&5%3?("4U4>^T
MS/D]'%6)9RJM[9DV5>RH3F1)!BWK<J^1JT0H@E.1[A1"L4J.;I+NW?+Q:L>_
M(D0,!`5'B;21A1#*>0[H:`31`)4!J-:',J/^FF8S&(Q_IYLQ>][[;+XN#9H+
M;'(@(6J0TDR702RX`J3,<44I34AQ[DJ+@)*,A@4Q.?L^JLJ:TO$Q.5*<7JI9
M*+>1&/F[J*R99I2;D5:?%KLWU?<N6'BU=!%&1:-EF1V;LICE7Y`$#/56ZVA2
MU1TI6V%T(*S5"0.\<CG168)!!&5,7:=TNZ7(DW%[;4>-/MJ9Q;<0[.4EVW1V
MVFQ*<"T/I2OEOZE1W7$.AUHA):J<K/V"CA5DU5=I`@[4;HG=(%'F!%P=(AED
M@'W034$0^YJID`&@X8XQDH:;D.(85J8"R$GTI!R/U1GC;UC".//UYC&'O\01
M==R;N;\N;=-M[Q+ML-3:RV95'(M.HTU94KDB+WUG?KO;#BZVR!V;OBAT2@[Y
M"@!@`A1[1,&/)ML)Q/Y\$SYK_F:5?;EN:P-5-Y]>/%%W:Y$L]4HS^EWQ4TW%
M!'GI\4]QG*Q$6*;OI&'ND<P`I`,4?3P$P8]9&*</?X@B/V'[HZGE?=-M]G-^
M<]>,<.]K>2XJH41O0Z52&5LH;C)$;:8IKBQA!OW<O4V<\@V,ZC'RJ:SE,Q%$
MQ`@IF#$6?\1AY:VTG?I?]KTYN6\S7;UL#?8YI^2XJJ0.;K#C*#=Y(9V":JSR
M4EZ^6_95QRY<-Z\O&HHN!;$=$*9R3G,F(E`Q@QYMO^;K^55__1WL&_\`7_;E
M_P#=!HP8]$'^'<\L39_L1SEN`N6VSS2-N&_:;N^,*W7;%2L)V+%LW+4:,865
M>0;62:3H>6\C/D&#]R86R9ED&R0J`(<YC=@&#'K5T8,53>;1MIQ+N=PUC:IY
M@W.8\VN0=?R:2PQEMR-(5B-B[#+!5;!&A76*UIM=2:'D!:/E7(%3744Z:!AY
M.4!,%KVE<IMLF.NP8SLEU3="EL$D#4#4@(7E6@X#W<=O^17K#OSHSU!O%\V#
MLV[;UN,JS<AR+`;D..,-^)8<\0L1HTI81K0ENJD)3J6!JJ0"-\=;2<)P,OY8
MCN,W@8QGE=NM;O##%K-A)4Q0^Y!I,$`'[^A]"X.E7S>&#AU1C`DP*'X1BZ=/
MW>>MNZ)5#=`D%',)"ON)%*:^Z*5]>GCBW[MZ[=1;G`ZS,3=@WF*WNV7#7<EK
M;ECY`6U[Q$VL5(0IW/2)'AZ_8@X/N0]O^-)WS`ZUG&1W#4F`R''[=;E0VF"7
MCVMDN,C6I5&2(^OR#-Q8F\\:$B>\&,JH6/,W#I#S+%#CJ/C7"2W850DQUJCF
M0E7,H=(4""$UI34:4`KV\#C5VT^J6\;9Y5YG3:)M2Y2MIN[MB357E")'A&Y#
M1;*(2EI84QSG=("07PLZLFU&F*U,K>7YMFLNQ/!6&)GS#\(5J@4O,&3;5!9K
MDIK'"52N\S8G;Y64J<4\7R,RA%)*MJ+&*N5N^66`Q!YTR=H!9H^X;JB_2)K5
MOD&4XRVDMA*BI`32A(Y9-%=E4CW3CL+9'FGZQV?S,[FZA0.D^Y)FZ;C8+=&>
MM#;,\RX;3"4!N4ZD0%O!N0`"@K80D@C2M61QP=S?EX;7,B8HV:5JU>8W@G',
M/B?#"E2I%GG9W&K>.RW"FL[V1&X5=22R3&-7<85RL+;F:*O4>H3_`+9S<0TK
M;-Q7>/,FNL6Z2XXZ_J6D)42@T`TJHV:'*O!/'AB5Z-^;#K5M/?'4*\63I'N:
M[7"^[A$J9'99N"G+8[X9#?A)(;M[BDN%(YE'4LKH11%*'%HV/]OV-(/?FSS5
M'[B*1/7]':G2\:$PBS>5L]O7J42N!F63@:-[$O.>KLN<."*A6'=1,(\JYNP-
M5*1/DN6)4-4=Q,<R2KF4.D*S[M=--6=/?=G#CCBG=75/>5R\L3G3N7M2Y1=K
M*WQ+N!O"T2!%$IT$+MQ4J.&?$-9ZDE_F4XM)S)!N4-IN%;':_,YDY3=WC&M.
MMQ%)HL/E.*?R5.(OMR90M;@&#"9OH.;BU78-9MHR272&2+&$%)<HD,;L,,C&
MNTYMBVMIB/*3'6LMD!7W6M:A'<(-/5JSQLK9?7/J):;'T:A0MAWF8SM.XS';
M<ZVW*(ORW7WUK9A:8JDK4RI90KD&2K4@A0&8$3-ZGE_;9<N16U)M>?,-PAB!
M+&FW^HT>H.K3-XY:)Y.K\6MS-+Y71F,C0I',1+#V)F:B[;B(?!5-J7L^X+M%
M\88]OD.AV0I2]*5'03]@KN&A';6A]6-[>7;S3]9-B3-\N[9Z4;DORKSNF5,E
M)C,SUFW/N"BX3_*@/:76N*@X&G!VH&'7F/8EMRM>_P"QOFZ;W\X7J61(!_@U
M>*P;*3&/TKG/GIL!`,8-!@R=Y!93:AKJW8IKM.G'JB8C@.EU`Y1TVB7RYM6)
MR&W!D*C*#H+@"M`U%=23H([M37O?8]F>(/I_YFNK=C\K=WZ<6[I=N*?M.4U>
M4N7AMJ<8C`EOOK>4M:8*V1X12U(=U/I`+9UZ#J&+%]I."\=8OW(;X+_4,]4W
M*=ES%DZ%L5[Q[77E><3>&95IZPBA7+4C$S\M)-7[PK\X$*];LE.#8>!!'F$(
M"\3Y,JV08[T=QIIEJB5J!HX*)S35(!&5<BKCQICDKKMU+W;O3I#TVVM?]KW"
MR6;;]F>8A3GT/I9NS2^15^,76&FU(1RP267'D_=!50&G$!'.QW;TIM9R3C<V
M^[#R=5L&^MMF:3R8:6H'J_7;\040+A5ZN-\"+);5#$`2HJNDWO,/^JB'8-@-
M]N1NK4DP'^<F!RPBBM2F]5>8!H][V5I_SJXZB9\R?55'6RS[O3TROYOD3IFJ
MTMV[E3>>_!-?][H3X+FF*`:%26U-4_V]<\;^8MDFWVU^9]4=Q4SOEP_4LJ1>
M2L7V%EMPDY>B)WZ4D:X2,",KC5@[OK.R'>64&Q>[@6+.J(*_`*?X.D8EZN3>
MV56]$)]4,M+!=`5HH0JJB=!%!4U[U,NS/#;I_P"8[JK8_)A/Z2V[IKN"=L=^
MSW%A=_;:FF"TW(YG-D*6F$N/HCZCK)DA(T]Y2<\<G;5L:V[X^W_Y(S?6-^&'
M,B9$GY+-SB5P9!R]`7N,`>X$F0FVK]E&WZ2G$CTP'9Q=<\>D8O1'J]/X6E[G
M?;I)L#<)Z`^W%2EH!PI4$'3IH02@`ZJ9=X\<JX?=8?,KU9W7Y6K/TWO/3'<-
MIVG%9LZ6KR\U-$1\12UR5-K<@MLD2](Y='U`ZQHU98F?L^VZ8NQ7L>R/ARF[
MDJ)EBBS[W,JLEFBM/:PYJM>4MA783:3UU$V27@R'J0JF%T"KU/E$H]0$P[`A
M;S<I4N^M37XKC3Z>71M0(4=)RH"D'O=F7USCGCK[U:WKO;S)6??^X=H7.Q[F
MB-6D-VF0B0F2^(VGDE"78[3Q$J@#6EE501I*SF0;C+:'A"NU_P`LAC%;Q<6V
M-MMXLF0G^+WK"2IBC?<:YG5)$TA'T$S>Z.BO5X`5S%5"-/)F`"&YRE$.(.7[
MM/6;D51'@7TH"Z@_<J`BJ^X*5&8][ZLJC&RMY]>NH]VNG621.Z?WJ(_NR'!1
M<4+;EA5A2R&PVN;JB)*$OZ4E//$<&HTDC(AS;]L7VZT??AG'-%=WYX:O60;B
M;<:,]A2&EZ`M<*;Z_&G!L99=FPR!(32(8^%Z?OO68("3H#UNE\+4A<+[<GK$
MQ#=@OHB(Y.EQ05H5ITTH=`KKH-/>/'*N6-@]5/,MU9W+Y8]M=/+MTPW!;-IV
M\6#D7=YJ<(DOP(9$?E+7!;:/CM`Y6A]==8Y>O+`\VF^7UMCQE0]YL+3_`#$<
M'Y0899PC(4Z[SE<G,<.6F(X5>;[XI=;.:,R/+MFD:@OQ1,9V=DWY_2H`]FG-
MXW#=I3\-<BWR&BT^%("DJ&LTH$I^YBI^N<L6OKIYJ>LF\MS=/;C?^DVY;*_8
MMQMRH;,AFX)5='DLE`B1N9`:4IQ2>^`T'5T&2:9XGUE3;/B6R^5[6-N4MN@Q
M]6<5QN/,?P3;<G(/ZJG0I.,@G[%>/G47[JTM:P9C/'1*FD8DF8@B<.0YAX:K
MD>Y2T;D<GB,XJ4I2ZM`'4"00<M).7$]W'+FR>L>^K1YT)G5N!LNZ3-[O7::\
MK;Z$23-;<>0M*V2A,94C6R"5*"H]10ZD@8YJ^U_$1]W2>41W4X[)<2[+1Q&&
M*A?U'UC&DC5G$;\L(-AM(2WJQW50775[H++IE'^4<O$=+?*LWY)\,8KG)\;S
M-=%4UZJ\NNFFKLI6OJP\1UGWXGH.K90V1=CM\]1/E3Y2T2N0)GB4N?)6KPW*
M\1J`;T\SFZC_`%5<L0`VU^7AM=Q]A/>=4*OYC>"<AP.6L6P];O%QA)S&SB*Q
M'%-+`X?(V:TJQV2I)DT8/7!Q;@9VNR2YP'E/S=FK!<MQ7:1+A./6Z0VXRZ2@
M%*@5U332FK8J0,^"O6,=2]8?-?UJW5U'Z>WZ]])-S6FYV*].R(<5YFX)=NCJ
MF$H,>,%V]M:EH`UT:0\JA%4TSPZ\7;`]M%<\O[,&#XCS!\(6/'=JW!T*\S&=
M8Z:QVM3JE9(5*I$CZ+)/$,C/(%.;F_#$#(IK2"*YN\DY43@(<Z$B_P!U7N%B
M<Y`D"4AA:0V4JUJ2=55`<L&@!-3I/;GZ(;>GFCZR7;S3V#J3.Z5;DB;M@[4F
MPFK,XS/$N5'>,HKFMH,!#_)9+BPI2&%('+55Q)!I9QO6P7CO+R6U$MWSU3L.
MAC//E`NU1-:'=>;%RA88,S<8ZC5_QJ>A@<3$[TP!$C3O3@>;X"1NS57LLZ1$
M,KD,+>YK"DJT@]P&O>-`<A7MIPXXXR\N?4O=FPG=\*VWMBX;@-YVO.AR1&0^
MKY.8>"N9,?Y++NEIFO?+O+0*9K3B+N2MHN$;!!^9FSD]X>+:\AN&LM2D,H/'
M\E3"(;='<7W#ND=?#.+FU*P7E@1(!`D31AA`X<H"/:,I&NTYM5NI$>5R`K10
M&KH*:'1W#6G'(*^MC=.SNO/4>U7'HX_#V!>I;NU(<INW)0W+*K\EP+U.0M,1
M6L-5))8$@9&I`Q"B+\N?:LWV*6G#*/F2X%<X^DMQ,!?'6:$YW&0T^,L;&H/(
MIM0%WI<F&APFGS547A"'D"N!(0>"0DXCJ;7N*[F]HEFW2!*$<I"-*M1',"M0
M'+X5&GWO;QKCHV=YMNMKWF9@]0E](-T(W2SM-^$FT%FX>*<CKE)=5.2CY.#O
M*0L!HD,%%3FX%8E=0=F>!H3#OEX52.WK8FG(3!.=;-<\<6QG*TA2,SU/2,DL
MX<TFE*H7APT>RT:H84CD8+2*X<!YD@-Z(J1>;@N9/=7#?2MYA*5I(55L!)&I
M?<%`>/!/NXT;NGS"=3[EU`ZL7R7TZOL:Y;FVS'B3XJVI@<LK*&@E,N8##2M#
M3@[P+Z8Z/0LC%AMQQ13)7>WA?,#S+E:B+Q4L-Y-J<+AIRXARVBX0EBD89>4M
MT8V6ET9M2,KBC0B:YD62R)3*EYU""(`-?8EOHL+T)+*U1UOH47<]*2D&B:TI
M55>T]G#'*&W]\;A@^7#<6P(]BF2-MS]P6Z2]=DI=,:*ZPVZ&XKB@T60Y("BI
M`6\A9"3I0KLF,'9[O'M[?LXCJ%QS_C1E/#/#9'QON'@W<'?BOBG=_#?#.[J>
M(>(][_DHL.Z<_6ZOY/I\>;LXZ,&`E@`FV!.N3!=K8X)&I>+B:?\`D&/05:_X
MX<@GX2YJ`8\?XGT#<"@L/4*GP```H`&C!C5SFGM24>T;_:4'``2*<N93&WRV
MJX]3>C.%5:`H%,]>#D74D.N+?G*RXG$_2XAQ`FC!B09.3D)TQ+T^4O3Y.7DY
M>`<G)P^#R\.'#AV:,&(KL$]D?^T(^5BAVM_[57473D@CU,4_+YU^Z\SH7J+<
M_K^#ON`_E#*%ZG0[##R=FC!B57N^G[W'1@PQZ/\`)KR67Y-O4;I^M<QZX>H_
M@')Z\\Z?C_K+X#V>MG4Y>^=Z_EG'AU.WAHP8?.C!A:,&%HP88F1RXU/5'I<M
M#2`I)CHA(_*$:#)6.J)A[MWH]B,6,*MS\>F)A`W'\'MTXC>*#P,/F<_LT5U?
MZ,\6;:)W@F]MG8GRE^D8!Y?@0\9%/LM(8^Z$4]]3*G'+#AKGJ]X#$>J7@OJS
MW!MX#ZN]Q\!\+Z1>Y^$>&?\`@_P_H\.GT?R?+^#V:2<YO,/.U<VN=:UKVUKG
M7W<15W^5OE21\O>)^6N:KG^(U\_F5[_-YGW377WVOO5XX&>40V]BZC_EI'#?
M?.[#X3\J`TH'/<P7-S^'^M8]3NPN./'I?!Y_3VZ=1/E*A\#S]-<]&KCZ].+A
MLO\`S5Y3O^7?Z0>'UCF_)WC-.NF7,\-EJT\-6=/5AY4(,>^K#'Y+QIOJ;SN/
M#?4+P3U9ZG5-WGN/J\/A7-U^/4Z?;S<>/;IO(\1S3XK7S^W575]75GBO;H_2
MOY9=_37Y0_2&B>9XWG>(X#3KY_W3A33J[.&&]E,F%#1L2&;!Q?X1XH4T%\IY
MZL2/\9*3F+X2:TF*W&1%$.T$?R@DX@/8(Z6A_*&M7@.=KTY\O56GKT]GNXEM
MDJZC"7(/3GY:\=R3S_DX22OE$_[7PW>Y=>U?=!]>"4R!EW-IX<+7N'=D.X]R
MZ7<^Y=(G=NZ=`>CW7H<O)R?`Y>'#LTT-:G5[[M]/U?\`3BGR/$>(<\7K\5K.
MO777KJ=6NN>JM:USKQSP,,GDP:8:[\LPXKYBR`GJGREGJ93>)@9'F"!]9S%$
M[OG%/F*WXF$>7B'HT[B>/[W@>;P[VC5P]>GL]W%SV8KJ2D2_\O?EO26J2?D\
M22.70TYWA_L::J%>7OJ=N"L4"<H<HEY.`<O+PY>7@'+PX=G#APX<--%5/'CB
MCFM3JKJKG7TX$V1B8)-+U<<M&Q/XZ1R)J;\H1JB26%UUB`/JX%B,5X=7KB3B
M5MQ_*<H\.8`T\C?*`;7X/G<NG>T:J4_G4R^OB];2/4P09OZ"?+GR844E^`$H
MM::'_$<CN@:=6;GV.KLK@M<`X^G^/C^[IGGBB=F.*(5KUC],'ZW>$#P_U#UB
M\![T'-P#_P`9>$=]X<?^X]7A_G:4^[<K[+DZO7IU>RM,27^]_DG_`-Y^0>?_
M`#_#\[3_`.SYNC_GZ?5CN![W#A[VD\1ON\<<24]6^_P7C7@GBG?7'JSXIW'O
M_B7<'/>O`N]"#GOOAG5ZG=_RG0Y^/P..E$<W2KEZM%.]2M*5[>RE?3B1A_*W
MA9/R?XGP7+3XCEZ]'+UIT\[3W=',T:=?=UZ:=ZF.YI/$=A:,&,?8&C!A"'OC
MH[,&,</MC]GW1UCVX,9X>CM_X>S6<8RQCAZ>W[?W/W^.C/&<OJX7`?M_]3M]
M_P!.CLP8SP]_[.S1@/KQC@/V_LX:/;@PN'OZQC!IC/#W]&=<'LQCA[_V?NZS
MC/LPN'O_`&M&,9>K&>`_;^__`!ZQ3&<8X>__`)-9]S&,9X>__'K&1.6,X7#W
M]9->S!C'#W^WA]GNZ,&7U<9X>^.L"N#&`#W_`+/?]WT:S@PN'O\`W_X]8SP=
MN%P'[?V?NAK.#&0_A]S1@QG1@QCLX^_^_P#QZ,&*-MD&S3;;AOS7_,BW-8IW
MFXQS!E;<"RKQ,P;7*[8Z',Y"V_33.4BW+MY<64!;Y2UP[63>-2D10DXI@9(R
0W+SG^"&C!B\KW??T8,?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
